Fluorine-18 labelling of novel voltage-gated sodium channel ligands for applications in positron emission tomography (PET) imaging and oncology by Desmond, Antonia Louisa
   
  
 
Fluorine-18 labelling of novel voltage-gated sodium channel 
ligands for applications in positron emission tomography 
(PET) imaging and oncology 
 
 
 
 
A thesis submitted for the degree of 
Doctor of Philosophy 
By 
Antonia Louisa Desmond 
 
 
 
Department of Pharmacology 
UCL School of Pharmacy 
University College London 
  
   
I, Antonia Louisa Desmond confirm that the work presented in this thesis is my own. 
Where information has been derived from other sources, I confirm that this has been 
indicated in the thesis. 
 
Antonia Louisa Desmond MSci (Hons) 
  
Abstract 
Abstract 
Voltage-gated sodium channels (VGSCs) are essential for the initiation and propagation 
of neuronal impulses. Specifically, these channels initiate the rising phase of action 
potentials in electrically excitable cells, allowing the conduction of electrical 
information. There are 9 different sub-types of VGSCs, each found in different tissues, 
with a minimum 50% identical genetic code.
1
 Recently, it has been reported that some 
VGSC sub-types are over-expressed in highly metastatic tumours.
2 
Their presence 
allows the up-regulation of some key biochemical processes. In fact, the metastatic 
potential of the tumours has a positive correlation with the expression of sodium 
channels.
2-6 
This thesis focussed on developing a novel positron emission tomography 
(PET) tracer to target VGSCs. We hypothesised that a PET scan using a VGSC ligand 
may be able to highlight tumours with high metastatic potential, and assist in the 
selection of the most appropriate clinical treatment. At present, there is no known 
clinical PET tracer for imaging VGSCs.  
Our project involved the adaptation of the 3-(4-substituted-phenoxyphenyl) pyrazoles,
7
 
a known group of VGSC modulators, into novel fluorine-18 labelled PET imaging 
agents. These were chosen due to their strong affinity for VGSCs and their structural 
characteristics, which allowed multiple approches to introduce a fluorine-18 label. 
Several compounds of interest were successfully synthesised. Optimal radiolabelling 
strategies were identified and methodologies developed, to produce PET agents in good 
synthesis time, yield and purity. The fluorine-19 standards for these compounds 
underwent a full VGSC isoform selectivity screen to identify the most potent and 
selective compounds. The fluorine-18 PET agents were also put through a series of in 
vitro and in vivo studies including automated and manual electrophysiology, 
biodistribution, metabolism and autoradiography. Ultimately, we aimed to target 
specific VGSC sub-types that were highly expressed by specific aggressive tumour 
types. 
Following this study, an interesting VGSC PET agent was revealed that warrants further 
investigation.  
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An overview of voltage-gated sodium channels and medical 
imaging for applications in oncology 
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1.0 Voltage-gated sodium channel overview 
VGSCs are integral membrane proteins that allow sodium ions to permeate through the 
cell membrane in excitable cells such as neurones, myocytes and certain types of glia. 
Sodium influx is responsible for the rising phase of action potentials. VGSCs consist of 
an α-subunit of approximately 260 kDa, associated with one or more accessory β 
subunits of lower molecular mass. The α-subunit forms a Na+-selective pore spanning 
the plasma membrane. The arrangement is such that six α-helical transmembrane 
segments (TMS) are repeated on the sequence four times, creating four different 
domains (DI-IV), connected by a cytoplasmic linker. Within these four domains, there 
is a relatively short and non-helical segment between TMS five and TMS six, forming 
the pore (Figure 1.1). The fourth transmembrane helix in each domain, has a positively 
charged residue at every third position allowing for voltage sensing.
1
 A sliding helix 
model has been proposed to describe how the polar helix “unscrews” within the cell 
membrane, causing conformational changes to occur in the loop region between D III 
and IV, thus activating the channel.
1
 The β subunits typically have a large N-terminal 
domain that is extracellular and immunoglobulin-like, plus a relatively short C-terminal 
segment which has an intracellular single transmembrane region.
1
 
VGSCs exist in three conformational states: closed, open and inactivated. VGSCs in the 
closed state are blocked both intracellularly and extracellularly by the h gate and m gate 
respectively. This not only stops the influx of Na
+
 ions into the channel pore, but also 
inhibits Na
+
 ions in the channel gaining access to the cell. Activation of the channel by 
membrane depolarisation opens the m gate (extracellular) allowing further depolarsation 
of the cell during the rising phase of an action potential. The ability of the channel to 
inactivate (closure of the intracellular h gate) is due to a tethered ‘plug’ formed between 
domains III and IV of the α subunit making the h gate, and stopping Na+ ions entering 
the channel on the intracellular side thus stopping the depolarisation phase.  
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Figure 1.1: Proposed structure and topology of the voltage-gated sodium channel 1 
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1.0.0 Anatomy of neurotransmission 
Neurotransmission is the process which allows the release of neurotransmitters by the 
presynaptic neurone; subsequently they bind to and activate receptors of the 
postsynaptic neurone. Neurotransmission usually takes place at a synapse and occurs 
when an action potential (AP) (Section 1.0.1) is initiated in the presynaptic neurone.
8
 
Neurones can vary with respect to the number, length and branching on the cell body 
(soma). Each neurone has four major characteristic features namely; the soma, 
dendrites, axon and presynaptic terminals (Figure 1.2). The soma contains the nucleus 
and acts as the cells energy centre. The main activities of the soma include metabolism 
and the synthesis of macromolecules that support the execution of cellular functions and 
structural maintenance. The dendrites which extend from the soma are responsible for 
receiving synaptic input messages from other neurones. These messages can be either 
excitatory or inhibitory. Most neurones in the central nervous system (CNS) have a high 
degree of dendritic branching, resulting in multiple messages being received from a 
number of juxtaposed neurones at any one time. A cellular response is due to a 
summation of these input signals. The axon (protruding from the soma) supports the 
rapid transfer of messages received from the dendrites to the axon terminals. If the input 
message is sufficient to produce a response, the voltage difference between the inside 
and outside of the neuronal membrane at rest, is transiently modified. If the change in 
voltage reaches the threshold potential an action potential is fired and propagates along 
the axon to the presynaptic terminal. Nerve cells are not directly connected, but have a 
gap ~100 Å wide, known as the synapse, which prevents the direct propagation of an 
action potential from one nerve cell to another. The electrical signal generated from an 
action potential is translated into a chemical message in the form of a neurotransmitter, 
stored and concentrated within vesicles in the presynaptic terminal.
9-10
 
Neurotransmitter release occurs via a calcium-dependent excitation-secretion coupling 
which allows synaptic vesicles to dissociate from the network of filaments in the 
presynaptic terminal. Neurotransmitter vesicles are then free to fuse with the plasma 
membrane and participate in exocytosis. Once released into the synaptic cleft, the 
neurotransmitter can diffuse across the synapse and transmit a stimulatory or inhibitory 
message to the target cell.
9-10
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Figure 1.2: Model of neurotransmission 11 
Normally, a nerve cell releases only one type of neurotransmitter for example, 
glutamate, dopamine, serotonin etc. Neurotransmitters communicate with the 
postsynaptic cell by interacting with a specific receptor embedded in the cell membrane. 
The interaction between the neurotransmitter and the binding domain of the receptor is 
temporary with the neurotransmitter leaving unaffected, once the message has been 
passed on to the postsynaptic cell. 
Neurotransmitters need to be quickly removed from the synapse so that their actions can 
be short-lived and the postsynaptic membrane made available for further stimulation. 
This is achieved by a number of mechanisms with different kinds of neurotransmitters 
having preferred routes. Simple diffusion away from the synaptic cleft does occur but it 
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is too slow to be the principal mechanism. Free neurotransmitter can be catabolised by 
enzymes in the synaptic cleft (e.g. acetylcholinesterase) or re-uptaken by the 
presynaptic terminal, glial cells or postsynaptic processes. The synapse is responsible 
for the unidirectional flow of information, the delay and the control of message transfer 
from one nerve to another. Communication and integration of responses is essential for 
the normal working of the human body.
9-10
 
 
1.0.1 The action potential 
An AP is an all-or-nothing event in which the electrical membrane potential of a cell 
rapidly rises and falls (Figure 1.3). In neurones, they play a central role in cell-to-cell 
communication. In other cell types, their main function is to activate intracellular 
processes. In muscle cells for example, an action potential is the first step in the chain of 
events leading to contraction.
12
 
 
 
Figure 1.3: Schematic of an action potential 13 
Action potentials are initiated by VGSCs.
13
 At rest, the cell membrane potential is 
approximately -60 to -80 mV and the majority of VGSCs are closed. The channels 
rapidly open when the membrane potential becomes less negative, due to a positive 
stimulus. When the membrane potential reaches threshold (around -55 mV), the m gate 
opens, causing a net inward flow of Na
+
 ions, the membrane potential decreases towards 
the reversal potential for sodium (ENa), where ENa = +60 mV. The net inward flow of 
Na
+
 ions is known as depolarisation. The depolarisation causes adjacent channels to 
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open through charge conductance, producing a greater electric current. The rapid influx 
of Na
+
 ions causes the polarity of the plasma membrane to transiently reverse, and the 
channel then rapidly inactivates (closing of the h gate). As the Na
+ 
channel inactivates, 
Na
+ 
ions can no longer enter the neurone (and after many action potentials have been 
fired), the Na
+
/K
+
 ion pump actively transports them out of the plasma membrane. K
+
 
channels are then activated to allow a net outward flow of K
+
 ions (repolarisation), 
returning the electrochemical gradient to the resting state. Whilst K
+
 ions are leaving the 
cell, the m gate closes on the Na
+
 channel, stopping any Na
+
 ions entering the channel. 
However, the concentration of K
+
 ions leaving the cell overshoots (hyperpolarisation). 
These channels close more slowly than VGSCs, thus causing a larger K
+
 conductance 
across the membrane and therefore temporarily placing the membrane at a higher 
stimulating threshold. Thus, a greater stimulus would be required to fire an action 
potential. This period is known as the relative refractory period and is the mechanism 
that causes an action potential to travel unidirectionally. The action potential usually 
lasts for less than one millisecond.
13
 
The temporal behaviour of VGSCs can be modelled by the Hodgkin-Huxley-type 
formalism.
14
 The Na
+
 and K
+
 channels are treated as a population that are affected by 
three independent gating variables, m, h for Na
+
 and n for K
+
. Each of these variables 
can attain a value between 0 (fully impermeable) and 1 (fully permeable to ions). The 
summation of these variables yields the percentage of conducting channels.  
 
1.0.2 Overview of the Hodgkin and Huxley gating model 
The Hodgkin and Huxley (HH) model, based on their work on the giant squid axon, is a 
mathematical model addressing how an AP in neurones is intiated (Figure 1.4).
14
 The 
HH model is a set of non-linear mathematical equations developed empirically on their 
voltage-clamp data, that approximates electrical activity in excitable cells. The cell lipid 
bilayer acts as a capacitor (Cm) and the VGSC acts as a non-linear conductor (GNa), 
where the conductance has time and voltage-dependent components. 
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Figure 1.4: Schematic of the Hodgkin and Huxley model circuit 14 
The conductance is mediated by the probability that the channel will be open, which in 
turn is voltage-dependent. GL represents ‘leak’ channels (linear conductances). The 
electrochemical gradients which drive the ion flow, are represented by batteries 
(ENa/K/L). The ionic flows (INa/K/L) are represented by current sources. The time 
derivative of the potential (Vm) across the membrane is proportional to the sum of the 
currents in the circuit.  
dVm / dt = - 1/Cm (Σ Ii) 
where Ii represents the individual ionic currents of the model. Hodgkin and Huxley 
determined that each VGSC state could be defined by one or more gates responding to 
an electrical field. For a channel to be open all the gates must be open, but for the 
channel to be closed, only one gate needs to be closed. The rate at which channels open 
for any given voltage step, is dependent upon the proportion of channels already opened 
multiplied by the closing rate constant.
15
 
The model is slightly inaccurate as it over simplifies some dependencies, for example, 
the inactivation gate should not be able to close unless the activation gate is open and 
the inactivation gate, once closed, is located inside the cell membrane where it cannot 
be directly affected by the transmembrane potential. However, it is useful for gaining 
insight into activation and inactivation of VGSCs.
14-15
  
 
1.0.3 Voltage-clamp recordings of sodium currents  
The voltage-clamp technique is a method of recording the current flowing through the 
cell membrane while the membrane potential remains constant. This does not mimic 
processes found in nature, but is an important technique. When studying voltage-gated 
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channels, this technique allows the control of the voltage which determines the opening 
and closing of channels. By clamping the membrane potential, the experimenter ensures 
the current flowing through the membrane is linearly proportional to the conductance 
(G), being measured.  
Transmembrane voltage is recorded through a “voltage-electrode” relative to ground 
and a “current-electrode” passing current into the cell. In order to maintain the 
membrane potential at -80 mV, a holding voltage is set and the voltage clamp uses 
negative feedback to maintain the cell at this voltage. The electrodes are connected to an 
amplifier which measures the potential and feeds the signal into the feedback amplifier. 
The amplifier also receives a signal determining the command potential and it subtracts 
the membrane potential from this value, magnifies any differences and sends an output 
signal to the current electrode. If the cell deviates from -80 mV (holding voltage), the 
amplifier generates a signal that is the difference between the two. The feedback circuit 
passes the current into the cell to reduce this signal back to zero. Therefore, the clamp 
circuit produces a current equal and opposite to the ionic current. Figure 1.5 shows 
whole-cell voltage clamp recordings of sodium currents evoked from positive voltage 
steps of -70 to 0 mV. 
 
Figure 1.5: Whole-cell voltage clamp recording of sodium currents of mouse myenteric neurones by 
patch-clamp. Sodium currents evoked by voltage-steps from -70 to 0 mV in 5 mV increments from a 
holding potential of -80 mV. Inset shows traces between -45 and -15 mV.16 
Voltage steps of +5 mV were applied to depolarise the cell (where current is sent via the 
amplifier). On the rising phase of the step this current is equal to the capacitive current 
necessary to charge the membrane capacitance to its new value (plus leak channels). 
Since a depolarising step opens Na
+
 channels, an inward current flows through the open 
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channel after a small delay. Normally, this flowing inward current should depolarise the 
membrane but in voltage clamp experiments it does not. A current constantly equal to 
but of opposite direction is continuously sent in the circuit to compensate the sodium 
current and to clamp the membrane. Figure 1.5 illustrates those sodium currents due to 
step-wise changes in the membrane potential. 
 
1.0.4 Resolution of VGSCs into respective sub-types 
During numerous studies to understand the structure and physiology of these complex 
channels, VGSCs have now been resolved into their respective sub-types or isoforms. 
All sub-types are in the Nav 1 family e.g. Nav 1.1. This comprises channels that have 
50% identical sequence homology to each other; the subscript v denotes voltage and the 
number following the decimal place, the specific sub-type. This classifies a single 
family based on their evolutionary relationships. In total, there are nine mammalian sub-
types Nav 1.1 - Nav 1.9 (Table 1.1), which were numbered according to the order in 
which the gene was identified. VGSCs that have less than 50% sequence homology to 
each other were classed separately. The Nav x or Nav 1.10 channels were proposed to 
stem from late branch Nav 1.7, but lacked the amino acid needed for proper voltage 
gating.
17
 
Nav 1 Tissue Expressed 
Nav 1.1 Central Nervous System, Dorsal Root Ganglion, Motor Neurones 
Nav 1.2 Predominantly Central Nervous System 
Nav 1.3 Embryonic, Adult Central Nervous System, Injured Dorsal Root Ganglions 
Nav 1.4 Skeletal Muscle 
Nav 1.5 Heart, Embryonic Dorsal Root Ganglions 
Nav 1.6 Dorsal Root Ganglions, Motor Neurones, Central Nervous System 
Nav 1.7 Thyroid, Dorsal Root Ganglion (nerve terminals) 
Nav 1.8 Dorsal Root Ganglion 
Nav 1.9 Dorsal Root Ganglion, Central Nervous System 
Nav x Heart, Hypothalamus, Glial Cells, Large Dorsal Root Ganglion 
Table 1.1: The Nav 1 VGSC sub-types 
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1.0.5 Function of VGSC isoforms 
1.0.5.0 VGSCs expressed in the central nervous system  
The Nav 1.1, 1.2, 1.3 and 1.6 channel subtypes, encoded by the SCN1A, SCN2A, 
SCN3A and SCN8A genes respectively, are the primary VGSCs in the central nervous 
system (CNS).
18-19
 The SCN1A acronym stands for voltage-gated sodium channel, type 
I, alpha subunit. Nav 1.1 and 1.3 channels are primarily localised in cell bodies.
20-21
 Nav 
1.2 channels are located in unmyelinated or pre-myelinated axons and dendrites, whilst 
Nav 1.6 channels are found in myelinated axons and dendrites.
22
 These channels 
participate in generation of both somatodendritic and axonal APs.
23
 Resurgent sodium 
currents are commonly found in Nav 1.6; these are brief surges of current during 
repolarisation at voltages of -50 to -60 mV where normally VGSCs are closed and 
recovering from inactivation. The reason for resurgence is attributed to the presence of 
an endogenous open channel blocker that hastens recovery from inactivation.
23
 
Resurgent currents may be an adaptive mechanism for high frequency firing of APs in 
specific brain regions, such as cerebellum and subthalamic nucleus. 
In rodents, Nav 1.3 channels are highly expressed in the brain during embryonic life and 
their expression declines after birth as Nav 1.1 and 1.2 channels become more 
abundant.
24
 Nav 1.1 expression is the first detected VGSC isoform, measurable from 
postnatal day seven. Knockout of any of the three VGSC α subunit genes expressed 
primarily in adult brain (SCN1A, SCN2A and SCN8A) is lethal, demonstrating that 
each channel performs some essential function.
22
 
 
1.0.5.1 VGSCs expressed in skeletal muscle 
Nav 1.4 is encoded by the SCN4A gene. This channel is not well understood, however it 
is known that this channel is related to a number of channelopathies, including hyper- 
and hypokalemic periodic paralysis (episodes of extreme muscle weakness, usually 
beginning in infancy or early childhood) and paramytonia congenita (bouts of sustained 
muscle tensing that prevent muscles from relaxing normally).
25
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1.0.5.2 VGSCs expressed in cardiac cells  
Nav 1.5 is encoded by the SCN5A gene. This VGSC isoform is found primarily in 
cardiac muscle and is responsible for the initial upstroke of the action potential in an 
electrocardiogram. Mutations in the gene are associated with long Q-wave T-wave 
syndrome type 3 (LQT3), Brugada syndrome, primary cardiac conduction disease and 
idiopathic ventricular fibrillation. This channel is one of the few VGSCs found to be 
resistant to tetrodotoxin (TTX), a known VGSC toxin found in the Japanese puffer fish 
fugu. The ability of Nav 1.5 to generate physiologically effective APs is determined by 
its cellular localisation as well as its channel properties. Nav 1.5 is concentrated at 
intercalated discs (specialised sites of contact between cardiomyocytes) and are 
enriched in gap junctions. Proximity of Nav 1.5 to gap junctions, which provide rapid 
ion exchange between adjacent cells, allows efficient propagation of APs. In addition, 
Nav 1.5 is localised in cardiomyocyte T-tubules adjacent to voltage-gated Ca
2+ 
channels, 
thus is well positioned to initiate the calcium-induced calcium release that triggers 
contraction of the heart muscle.
26-28
 
 
1.0.5.3 VGSCs expressed by the peripheral nervous system  
Nav 1.7, 1.8 and 1.9 are expressed in the peripheral nervous system (PNS). Nav 1.7 is 
encoded by the SCN9A gene and plays a critical role in the generation and conduction 
of AP’s. Nav 1.7 is expressed at nociceptors (pain-sensing nerves), close to the region 
where the impulse is initiated. Stimulation of the nociceptor nerve endings produces 
‘generator potentials’; these are small changes in the potential difference across the 
neuronal membranes. Nav 1.7 amplifies these membrane depolarisations, and when the 
membrane potential difference reaches threshold, the neurone fires an AP. Nav 1.7 is 
defined by a slow transition into the inactivation state, leaving the channel active for 
longer.  
Evidence that Nav 1.7 is involved in pain transduction, originates from the observation 
that dorsal root ganglion (DRG) neurones in animal models of inflammatory pain show 
increased response to this isoform. Knockout mice also showed reduced response to 
inflammatory pain, however, response to neuropathic pain remained intact.
29-30
 
The Nav 1.8 channel encoded by the SCN10A gene, has a more depolarised activation 
threshold, producing most of the transmembrane current responsible for the depolarising 
Chapter 1  Introduction 
28 | P a g e  
 
phase of action potentials. From studies with mice deficient in Nav 1.8, reduced sensing 
of inflammatory and visceral but not neuropathic pain was seen.
29-30
 Mice that lacked 
both Nav 1.7 and 1.8 had twice the pain threshold of knockout mice lacking either 
isoform, suggesting a clear functional link between these two isoforms.
29-30
  
Nav 1.9 is encoded by the SCN11A gene; it is preferentialy expressed in nociceptive 
neurones within the DRG. Nav 1.9 is a TTX-resistant isoform; it’s unique properties 
indicate that Nav 1.9 has a significant effect on the electroresponsive properties of 
primary nocieption.  
Strickland et. al., investigated the changes in expression of Nav 1.7, 1.8 and 1.9 in a rat 
model. They showed that the DRG innervating the knee joint had increased expression 
of all three subtypes up to 28 days after the initial insult, showing a clear link between 
neuronal injury and ion channel expression.
31
 Thus these channels are an attractive 
target in the search for more effective treatments in pain. 
 
1.1 Voltage-gated sodium channels and cancer 
From oncology research, it has now become evident that VGSCs play a crucial role in 
tumour invasiveness. It has been reported that VGSCs are up-regulated in certain 
metastatic diseases, for example prostate, breast and small-cell lung carcinoma (Table 
1.2). VGSC activity appears to potentiate some metastatic cell behaviours. During the 
change from a normal epithelial cell towards cancer, a series of genetic alterations 
occur, which may also affect the expression of ion channels or cause a change in ion 
channel activity. This abnormal activity supports proliferation of the tumour cells. For 
example, expression of amiloride-sensitive VGSCs were detected in malignant glioma 
cells and non-selective cation channels have also been associated with proliferation and 
cancer.
32
 However, the mechanism of regulating functional VGSCs is not fully 
understood.
2, 33-35
 It has been shown through tissue culture experiments that it is the neo-
natal isoforms of VGSCs which are expressed in tumours.
6
 This is another example of 
oncofoetal gene expression in cancer.
36-37
 
Interestingly, Djamgoz et. al., showed in domain I, TMS 3 & 4, there are seven amino 
acid differences between neo-natal and adult VGSCs.
 38
 The most significant difference 
was the charge-reversing aspartate (adult) to lysine (neo-natal) substitution at amino 
acid position 211. Switching the lysine back to aspartate showed an overall functional 
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shift back towards the adult isoform characteristics. In fact, it is thought that the 
significant lysine residue in the neo-natal channel could alter the local electric field 
sensed by the TMS 4 voltage segment by introducing extra positive electrostatic 
potential, thereby moderately resisting the outward movement of the positively charged 
TMS 4 segment.
39-41
 This is in contrast to the adult channel, where the negatively 
charged aspartate is likely to potentiate outward TMS 4 movement by attracting 
positively charged TMS 4 residues.
38
 
Tumour Type VGSC isoform expression 
Prostate Nav 1.7 
Breast Neonatal - Nav 1.5 (82%) 
Adult - Nav 1.7 (18%) 
Colon Nav 1.5 
Leukaemia Nav 1.5, 1.6, 1.7 &1.9 
Non-small cell Lung 
Ovarian 
Cervical 
Mesothelioma 
Nav 1.7 & 1.6 
Nav 1.6 
Nav 1.6 
Nav 1.2, 1.6 and 1.7 
Table 1.2: Examples of VGSC sub-type expression in specific tumours 
 
1.1.0 Nav1.5 in breast cancer 
Breast cancer (B Ca) is the most common cancer of women and the second leading 
cause of female cancer mortality, accounting for about 10% of all cancer deaths in the 
western world.
42-43
 VGSC activity has been reported to contribute to much cellular 
behaviour integral to metastasis.
44-49
 In cell culture work, Gao et. al. functionally 
expressed Nav 1.5 in the strongly metastatic MDA-MB-231 B Ca, and normal smooth 
muscle cell lines.
50
 It was found that the type of VGSCs expressed in the normal cells, 
were genetically different to the type of VGSCs expressed in the MDA-MB-231 cell 
lines. This led them to propose that the type of VGSCs expressed in B Ca may be of the 
neo-natal and not adult form, which was independently supported by Djamgoz et. al.
51 
They hypothesised that in the cells of mature organs the neo-natal form is silenced and 
re-expressed in cancer cells. They followed on this work by studying the 
immunofluorescence of weakly metastatic MCF-7 and MDA-MB-231 cell lines. They 
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found that VGSCs were distributed on the cell membrane of MDA-MB-231 and located 
in the cytoplasm of MCF-7. It was thought that the aggressive nature of MDA-MB-231 
was due to the location of the VGSCs in the cell membrane.
50
  
In contrast to adult Nav 1.5, VGSC β1 subunit functions as a cell adhesion molecule in 
B Ca cells. Thus, VGSC α and β sub-units appear to play dynamic roles in regulating 
cell adhesion, migration and invasion. 
 
From previous studies on tumour invasiveness, MMP-9 (matrix metallopeptidase 9) 
secretion was shown to be strongly associated with invasive potential.
52-53
 MMP-9 is a 
zinc protease which degrades the extracellular matrix (first step in cancer metastasis). 
Through RT-PCR (real time-polymerase chain reaction), it was shown that expression 
levels of MMP-9 decreased by 44% when MDA-MB-231 was pre-incubated with 
tetrodotoxin (TTX) a known potent VGSC blocker for 24 hrs. It was inferred that Nav 
1.5 might control the secretion of this zinc protease and thus have an effect on invasive 
potential.
50 
More recently however, Roger et. al. confirmed that it is the neo-natal isoform of Nav 
1.5 that is expressed in the metastatic cell line MDA-MB-231 (Figure 1.6).
54-55
 1000- 
Fold higher mRNA expression of neo-natal Nav 1.5 was seen compared to adult Nav 1.5 
expression.
6
  
 
Figure 1.6: (a) RT-PCR expression of Nav  1.5, NHE 1 and 18S RNA in the cell lines, MDA-MB-231, 
MCF-7 and MCF-10A. (b) Sodium currents expressed in three cell lines to show the difference in 
excitation between strongly (MDA-MB-231) and weakly metastatic models (MCF-7)54-55 
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Some Nav 1.5 expression was reported in weakly metastatic models (MCF-7), however 
studies by Yang et. al., showed that no sodium currents could be recorded from these 
cells
56
 and no expression in healthy breast tissue. Interestingly, Chioni et al, showed 
that there is a higher expression level of β1 in MCF-7 cells.57  
Recently, the difference between the neo-natal and adult Nav 1.5 isoform has been 
identified. A key type of alternative splicing of VGSCα genes involves the presence of 
two mutually exclusive alternative exons, namely, exon 6: 5’genomic and 3’genomic 
encoding part of DI: TMS3, most of DI:TMS4, and DI:TMS3-S4. These two exon 6 
alternatives are notable by the presence (3’ genomic; adult) or absence (5’ genomic; 
neo-natal) of an aspartate residue at position seven in DI:TMS3-S4. DI:TMS3 splicing 
was thought to be developmentally regulated, as the 5’ variant is abundant at birth and 
quickly replaced by the 3’ variant within a few days. Hence, channels deemed 5’ are 
known as the neo-natal channel and 3’ adult. 58 
The neo-natal Nav 1.5 has a number of key characteristics which makes it an ideal target 
for breast cancer treatment and even diagnosis. The change in the exon variant as 
previously discussed, results in a seven amino acid change, through genomic analysis 
this amino acid sequence was revealed to be unique to the rest of the human genome. 
The most important of these amino acid changes occurring in the DI:S3 region which 
changes a negatively charged aspartate, to a positively charged lysine, causing a charge 
reversal. Neo-natal Nav1.5 also has a characteristic electrophysiological (study of 
neuronal activity) profile. This isoform activates at more depolarised voltages with 
slower activation and inactivation kinetics, potentially allowing a larger influx of Na
+
 
ions. Importantly, mutation of the lysine back to the aspartate abolished these 
characteristics. Curiously, Onkal et. al., highlighted that neo-natal Nav 1.5 is present in 
the CNS of healthy adults which correlates with  findings by Chioni et. al., in mice. 
38, 57
 
Further work on the involvement of this channel in metastatic progression, showed the 
importance of Nav 1.5 was coupled to increased cysteine cathepsin activity.
54-55
 Cysteine 
cathepsins are proteolytic enzymes with many roles in cancer metastasis.
33
 This work 
was independently supported by Gillet et. al. who published their findings on the role of 
VGSCs in cancer.
59
 It was shown that Nav 1.5 activity enhances extracellular matrix 
invasion by increasing the activity of acidic cysteine cathepsins B and S through 
acidification of the pericellular microenvironments. Na
+
/H
+
 exchanger type 1 (NHE 1) 
is the central regulator of intracellular pH and its activity is enhanced by the function of 
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Nav 1.5.
54-55
 Among all pH regulators, the ubiquitous NHE 1 allows cancer cells to 
adapt to their high metabolic H
+
 production environment.
6, 54
 
To determine all the pH regulators involved, Gillet et. al., analysed the effects of 
various inhibitors.
59
 Their results indicated H
+
 efflux was dependent upon Na
+
 not Cl
-
 
ions. Silencing NHE 1 led to a 60% reduction of H
+ 
efflux compared with the control. 
Nav 1.5 could promote H
+ 
efflux through NHE 1. TTX had no effect on regulating H
+
 
efflux from MCF-7 cell lines devoid of Na
+
 ions.
54
 It was proposed that cellular 
invasiveness is regulated by Nav 1.5 and thus allows a persistent Na
+
 ion entry. 
Inhibition of NHE 1 or Nav 1.5 produced 35% reduction in cell invasiveness. Co-
inhibition had no greater effect. This was the first study to show that Nav 1.5 and NHE 1 
channels interact to enhance H
+
 efflux, therefore, allowing acidic- dependent invasion 
of the extracellular matrix,
54
 which correlates with previous reports on MMP-9 and zinc 
protease.
50
 
To understand how Nav 1.5 and NHE 1 influences matrix degradation, Roger et. al. used 
DG-gelatin which released fluorescent activity after proteolytic cleavage by gelatinases 
in a 3D matrix of matrigel.
54
 Gelatinolytic activity was shown to be mainly distributed 
at the pericellular zone of cancer cells. When cultured with TTX, the gelatinolysis of the 
pericellular matrix was reduced by 63%. Inhibiting both NHE 1 and Nav 1.5 showed no 
additional reduction suggesting that both are involved in the same pH dependent 
pathway, furthermore, NHE 1 and Nav 1.5 were found to co-localise in the plasma 
membrane of cancer cells grown on Matrigel.
54
  
In summary, the on-going research has emphasised the key role that Nav 1.5 plays in 
keeping an acidic environment around the extracellular membrane to up-regulate the 
activity of different proteases (the first step in metastasis).  
 
1.1.1 Nav1.7 in prostate cancer 
The prostate is a compound tubular-alveolar exocrine gland, which is part of the male 
reproductive system in mammals. Prostate Cancer (P Ca), uncontrolled and abnormal 
growth of the prostate gland, continues to be a major cause of morbidity and mortality 
in ageing men worldwide.
60
 Adjacent to the on-going research in B Ca, researchers are 
also seeking to understand the pathobiological link between P Ca and VGSCs. 
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The original work by Grimes et. al. on the Dunning rat model of P Ca, showed that the 
strongly metastatic Mat-LyLu cell line expressed neo-natal VGSCs, whilst the weakly 
metastatic AT-2 cells did not.
5, 61
 Later, Bennett et. al. found that direct transfection of a 
VGSC α-subunit into the LNCaP P Ca model was “necessary and sufficient” to increase 
the in vitro invasiveness of the cells.
34
 These findings also supported that VGSC 
expression is linked to more highly metastatic tumours. 
From these studies the CELEX (cellular excitability) model was hypothesised. This 
proposes that metastatic cell membranes are ‘excitable’ and that this excitability 
determines the cells ‘hyperactive’ behaviour during metastasis.35 VGSCs in the 
metastatic model are activated at moderately depolarised potentials and exhibit ‘fast’ 
inactivation kinetics. Following on from this work, Brackenbury et. al. investigated the 
possibility of activity-dependent auto-regulation of VGSC functional expression in the 
strongly metastatic model of rat P Ca. After pre-treatment of Mat-LyLu cells with TTX 
for 24-72 hrs, they showed suppression of peak VGSC current densities without 
affecting voltage-dependence. Their hypothesis being, that the VGSC auto-regulation 
occurred via a VGSC-mediated Na
+ 
influx and subsequent
 
activation of protein kinase A 
(PKA). It was concluded that the VGSC activity in rat P Ca cells was up-regulated in 
steady-state, via a positive feedback mechanism involving PKA and this enhanced the 
cells’ migratory potential.2,35, 62,4 
At the molecular level, studies into semi-quantitative PCR analysis of rat Mat-LyLu and 
human PC-3 cell lines showed that the predominant VGSC present was Nav 1.7, at an 
mRNA expression level >1000 fold higher than the corresponding weakly metastatic 
cells (as also seen in MDA-MB-231 breast cancer cell lines).
63
 Some other minor 
VGSC sub-types were also present: Nav 1.2, 1.4 and 1.6, but their functional role if any, 
is still unknown.
64-65
 
Some VGSC blockers have been shown to inhibit P Ca cell proliferation,
66
 specifically 
the VGSC-blocking anticonvulsants phenytoin and carbamazepine were found to 
directly inhibit secretion of prostate-specific antigen (PSA) and interleukin-6 in PC-3 
cell lines.
66
 Regulation of VGSC expression by a positive feedback mechanism 
appeared to potentiate the metastatic process.
67
 Inhibiting this mechanism by 
suppressing VGSCs with long-term (48 h) TTX treatment eliminated the VGSC-
dependent component of the cells' metastatic potential.  
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From early research on the expression of VGSCs in P Ca, it was shown by Brackenbury 
et. al., that varying the levels of serum factors for example, nerve growth factor (NGF), 
had a significant effect on the VGSC current, showing that expression and activity were 
under stimulatory and inhibitory control by substances present in the serum. For Mat-
LyLu cells, NGF application improved peak VGSC current density, following a time- 
and dose-dependent relationship.
68
 High NGF levels shifted the peak voltage and the 
half-inactivation voltage to more positive potentials, and produced currents with faster 
kinetics. Through further investigations, it was shown that the effect of NGF appeared 
to be through a PKA-mediated pathway that did not affect the expression of Nav 1.7 
mRNA, but did up-regulate the total VGSC α-subunit protein level. A plausible 
hypothesis was proposed that NGF induces local synthesis of VGSCs by translating 
‘docked’ mRNA.68  
Another serum factor, epidermal growth factor (EGF) contained within the prostatic 
fluid, is known to be linked to P Ca progression, cellular invasiveness and androgen 
independence.
69,70
 Exogenous EGF up-regulated both VGSC current density in Mat 
LyLu cells and Nav 1.7 in rat and human P Ca cells in vitro.
71
 Importantly, it has been 
shown that EGF also increased the migratory potential of both MatLyLu and PC-3 cells, 
in part due to enhanced VGSC activity.
72
 It was proposed, that endogenous EGF has a 
key role in the up-regulation of Nav 1.7 expression and activity and the two could 
characterise an ‘in-built’ positive feedback mechanism accelerating the progression of P 
Ca.
73
 
 
1.1.2 Nav 1.6 in Cervical Cancer 
Cervical cancer (C Ca) is the third most common female cancer worldwide in 2008.
74
 
The main cause of C Ca is the carcinogenic human papillomavirus (HPV).
75
 A study by 
Hernandez-Plata et. al., reported that the relative expression of Nav 1.6 and 1.7b (one of 
two genetic sequences for this sub-unit) specifically, were 40- and 22-fold higher in C 
Ca tissue, respectively, than in non-cancerous tissue samples.
76
 In the C Ca tissue, the 
channels were widely distributed in the plasma membrane and cytosolic compartments, 
but in the non-cancerous tissue, the channels were limited to the cell membrane of the 
mid-zone and superficial zone of the cervical squamous epithelium. Blocking of the 
sodium current produced by Nav 1.6 (accounting for one-third of the total current), was 
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achieved by using Cn2, a B-class scorpion toxin from Centruroides noxius species. On 
average 350 nM of Cn2 decreased the sodium current amplitude by 30.3 ± 5.0% (n = 8). 
The remaining current was totally blocked with 1 µM TTX.
76
 
To explore the function of these channels in metastatic cell behaviour, in vitro assays in 
the presence and absence of TTX and Cn2 were performed. The proliferative potential 
of the C Ca primary culture cells was unchanged after exposure to TTX for 72 hrs. 
Migration was not significantly changed by the presence of the TTX or Cn2; in contrast, 
the relative invasiveness of these cells was sensitive to both toxins, showing a 
significant decrease (79.5 ± 7.6% and 78.3 ± 7.6% with TTX and Cn2 respectively) 
when compared to control conditions. Interestingly, the specific splice isoform of Nav 
1.6 and 1.7 does not correspond to any splice variant reported for humans.
76
  
There is no unanimously accepted mechanism to explain the role of VGSC in the 
metastatic behaviour. Hernandez-Plata et. al., considered two roles for the action of 
VGSCs in C Ca: the channel itself acting as an adhesion molecule and the sodium influx 
causing an electronic effect. Studies with TTX and veratridine (a VGSC agonist), had 
proved to diminish and enhance VGSC currents, however, the transient current may be 
negligible on the global sodium influx into these cells.
59, 76
  
Alternatively, VGSCs could participate in metastasis through a non-conducting function 
via direct interaction with the β-subunits of VGSCs with other plasma membrane and/or 
intracellular proteins.
58, 77
 For example, VGSC β-subunits could interact with tenascin C 
and R and participate in homophilic cell adhesion, allowing cellular aggregation and 
ankyrin recruitment.
3
 This is supported through work by Chioni et. al., who showed that 
stable expression of β1 in the breast cancer cell line MDA-MB-231 cells increased the 
VGSC activity and cell adhesion, but reduced cellular motility, suggesting that the cell 
adhesive effects might be independent of changes in cellular excitability.
57
 Overall, the 
functional expression of Nav 1.6 and to a lesser extent Nav 1.7 in C Ca might represent 
the identification of a novel molecular marker for C Ca. 
 
1.1.3 Summary of VGSCs and tumour invasiveness 
The neo-natal form of the normal adult VGSC has been identified in multiple cancers. 
Since VGSC expression is strongly linked to tumour invasiveness, it could act as a 
useful diagnostic indicator in the detection and differentiation of metastatic and non-
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metastatic tumours, thereby potentially influencing the choice of therapeutic 
intervention in cancer treatment. Thus, if the current hypothesis is correct, it could be 
said that patients not expressing VGSCs should be metastasis-free for longer than those 
expressing VGSCs. Therefore, these ion channels represent a useful biological target for 
development of new diagnostic and therapeutic agents. The main difficulty is targeting 
the specific VGSC sub-type and as the neo-natal form. 
 
1.2 Medical Imaging 
Biomedical imaging is a significant tool for cancer diagnosis, prognosis and therapy 
monitoring, but is also useful in diagnosing other diseases such as Parkinson’s Disease 
(PD) and Alzheimer’s Disease (AD).78-84 It has many advantages including real-time 
monitoring, accessibility without tissue destruction, minimal or no invasiveness, whilst 
giving information on anatomical and pathological processes.  
 
1.2.0 Types of Medical Imaging 
An X-ray image can be useful for the diagnosis of metastases in the lung and bones 
(chest or individual bone radiography), but this technique is limited as there may be 
only a small contrast between the tumour and surrounding tissues.
85
 
Computed Tomography (CT) scanning uses multiple X-ray projections from different 
angles to produce three-dimensional images. CT scans can be used to detect cancer in a 
range of tissue types (lung, bone, soft tissue, etc.). It is possible to conduct whole-body 
CT examinations, and CT images may also be enhanced with the administration of oral 
or intravenous contrast agents.
86,87
 
Ultrasound uses information from reflected high-frequency sound waves to produce 
images of tissues. More recently, contrast agents have been developed for use with 
ultrasound that enhance images.
85,88
 
Ultrasonography in oncology is commonly used in the detection of distant metastases 
and can be used to detect metastases in the liver and kidneys, but the technique relies 
upon the expertise of the operator.
85
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Bone scintigraphy uses radionuclides of technetium-99m-labelled disphosphonates for 
the identification of bone metastases.
85
 The degree of uptake into bone mainly depends 
upon blood flow and rate of new bone formation. Sites of high radio-emission may 
represent the presence of a tumour.
85
 
Magnetic resonance imaging (MRI) can visualise detailed internal structures.
85
 MRI 
makes use of the property of nuclear magnetic resonance (NMR) to image nuclei of 
atoms inside the body. MRI can provide contrast between the different soft tissues of 
the body, which makes it especially useful in imaging brain, muscle, heart and cancers 
compared with other medical imaging techniques such as CT or X-rays (Table 1.3). 
MRI contrast agents are used to improve the visibility of anatomical structures; the most 
common are gadolinium-based agents, for example ™ProHance, ™MultiHance and 
™Primovist.  
The MRI scanner produces a powerful magnetic field, which causes nuclei within the 
body to become aligned with the magnetic field. A short radiofrequency pulse is applied 
causing a brief varying electromagnetic field, which has the right frequency (resonance 
frequency) to be absorbed and ‘flip’ some nuclei (including those of the agent), known 
as ‘spinning’. Once the pulse is stopped, the nuclei then relax. During relaxation, a radio 
frequency signal is emitted which is detected by the scanner and converted into an 
image. These agents increase the relaxation time of nuclei within the body to improve 
image quality. 
Positron emission tomography (PET) and, more recently, PET/CT produce quantitative 
3D images of a radiotracer distributed within the body. PET tracers emit positrons that 
annihilate with electrons up to a few millimetres away, causing two gamma photons to 
be emitted in opposite directions. A PET scanner detects these emissions ‘coincident’ in 
time, highlighting localisation of radiation and, thus, higher resolution images. PET/CT 
has many applications in the detection of various diseases, for example, cancer and 
Alzheimer’s disease. As these multimodal technologies provide different types of data 
(PET gives functional and CT anatomical data), their combination provides greater 
diagnostic information. 
89,90
 
Single photon emission computed tomography (SPECT), is an imaging technique using 
gamma rays. SPECT is similar to PET in its use of a radioactive tracer and detection of 
gamma rays. In contrast with PET, the tracer used in SPECT emits gamma radiation 
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that are measured directly giving images with a resolution of approximately 10 mm. 
SPECT scans, however, are significantly less expensive than PET scans, in part because 
they are able to use longer-lived more easily-obtained radioisotopes than PET. The 
longer half-life allows for centralised production and generally the tracers are less 
expensive to produce per-dose. In contrast, SPECT is two to three orders of magnitude 
less sensitive than PET; thus, it is unable to detect as many emitted events as PET. 
91-92
 
Modality Spatial Resolution 
(mm) 
Concentration of 
Imaging Agents (M) 
Radiation Dose 
CT 1 10 
-4
 Yes 
MRI <1 10
-5
 No 
PET 3-10 10
-8 
- 10
-10 
Yes 
SPECT 8-20 10
-6
 Yes 
Table 1.3: Comparison of the performance of various imaging modalities 93 
 
1.2.1 Positron Emission Tomography (PET) 
Non-invasive molecular imaging of biochemical mechanisms in vivo is a promising 
interdisciplinary field of research. PET is a nuclear medicine imaging technique that 
produces a three-dimensional image or picture of functional processes in the body.
94
 
The system detects pairs of gamma rays emitted indirectly by a positron-emitting 
radionuclide (tracer), which is introduced into the body on a biologically active 
molecule. Three-dimensional images of tracer concentration within the body are then 
constructed by computer analysis. In modern scanners (Figure 1.7), imaging is often 
accomplished with the aid of a CT X-ray scan performed on the patient during the same 
session, in the same machine. This allows for attenuation correction and co-registration. 
PET is currently the most effective way to check for cancer recurrence and it offers 
significant advantages over other forms of imaging such as CT or MRI scans in 
detecting disease in many patients. In 2005, an estimated 1,129,900 clinical PET patient 
studies were performed across the UK.
95
 Of the two common nuclear medicine imaging 
modalities, SPECT and PET, PET is by far the superior in both sensitivity and 
resolution by 2 or 3 orders of magnitude (Table 1.3).
93
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Figure 1.7: A human PET scanner 
Despite the remarkable advances in PET technology, both CT and MRI still have 
superior spatial resolution. Conversely, CT and MRI have considerably lower 
sensitivity. This limits the choice of targeting agents that can be developed for imaging 
with these systems, as low sensitivity requires a higher concentration of the imaging 
agent, which may be toxic to the subject, and difficult to target biological processses. 
PET imaging offers the ability to non-invasively and quantitatively study drug targets in 
animal models and humans at low target concentrations.
96
 
 
Figure 1.8: Pictorial schematic of the action of [18F]FDG 97 
A PET ligand incorporates a radionuclide such as fluorine-18 used in the imaging ligand 
2-deoxy-2-[
18
F]fluoro-D-glucose ([
18
F]FDG). As the radionuclide β+-decays, a positron 
and neutrino are emitted (Figure 1.8) maximum positron range in water 0.02 cm.
97
 A 
positron is the anti-matter equivalent of an electron. The energy of the positron emitted 
depends on the radionuclide used. The positron encounters and annihilates with an 
electron, producing two γ photons that are emitted at almost 180° to each other. The 
photons are detected in the scanner when they reach the scintillator material in the 
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scanning device, creating an emission of light. Photomultiplier tubes in the detector 
detect the photon energy. Only photons arriving in pairs are recorded and it is possible 
to localise the annihilation point to a specific part of the body or organ, along a straight 
line of incidence known formally as the line of response (LOR). As the timing 
resolution with new scanners improves, the signal to noise ratio (SNR) of the image will 
improve. 
 
1.2.2 Types of radionuclides and their production 
Radionuclides used in PET typically have a short half-life, such as 
11
C (20 minutes), 
18
F 
(110 minutes), 
13
N (10 minutes) and 
15
O (2 minutes) and are produced on demand using 
a cyclotron. While minimisation of radiation dose to the subject is an attractive feature 
of these short-lived radioisotopes (Table 1.4), they must be produced close to the PET 
imaging facility, and ideally on-site. Limitations to the widespread use of PET arise due 
to the high costs of running and maintaining a cyclotron. 
84, 98
 
Isotope Half-life (t1/2) Preparation Positron Energy 
(MeV) 
7
Be 53 days 
7
Li(p,n) 20 
11
C 20 minutes 
14N(p,α) 15 
13
N 10 minutes 
16O(p,α) 15 
15
O 2 minutes 
14
N(d,n) 10 
18
F 110 minutes 
18
O(p,n) 15 
22
Na 2.6 years 
22
Ne(p,n) 15 
  
25Mg(p,α) 20 
28
Mg 21 hrs 
27Al(α,3p) 45 
34m
Cl
 
31.2 minutes 
34
S(p,n)
 
20 
48
V
 
16 days
 48
Ti(p,n)
 
11 
Table 1.4: Example of PET isotopes and their half-lives 84, 98 
One of the most attractive PET isotopes for clinical imaging is fluorine-18, with a half-
life (t1/2) long enough for centralised production. Fluorine-18 is a versatile isotope, 
which has been manipulated into a variety of PET ligands.
80-81, 83, 99
 Its radiosynthesis 
from oxygen-18 through proton bombardment ([
18
O]H2O (p,n) [
18
F]F), can yield up to 
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370 GBq over a 2 hr bombardment time, in a current generation cyclotron production 
system. 
 
 
1.3 Fluorine-18 PET imaging agents 
2-Deoxy-2-[
18
F]fluoro-D-glucose ([
18
F]FDG) is the most frequently used fluorine-18 
PET imaging agent.
99
 [
18
F]FDG is a glucose analogue taken up by cells such as the 
brain, kidney and cancer cells, which require high levels of glucose to function. It can 
be used for the assessment of glucose metabolism in heart, lungs and the brain but also 
has many applications within oncology. 
 
  
 
(A)                                   (B) 
Figure 1.9: (A) anterior image (B) lateral image PET [18F]FDG scan showing masses associated with 
high uptake of [18F]FDG 100 
As part of a study in 2004, Patient X was diagnosed with Hodgkin’s disease following 
an [
18
F]FDG-PET scan (Figure 1.9). The images show high activity in the prevascular 
mass (blue arrow) and in the left adrenal mass (orange arrow). Low-grade [
18
F]FDG 
activity is shown at the posterior left lung apex, likely to represent nonspecific 
inflammation or a resolving infection (green arrow). Activity present in the liver 
represents metabolised [
18
F]FDG excreted into the right kidney and passing through to 
the bladder.
100
 
The main problems associated with [
18
F]FDG as a PET radiotracer are due to the 
difficulties in differentiating between a tumour, inflammation and infection. However, 
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this ligand is still used clinically, not only in oncology but also in neurology due to its 
wide availability. For example, in (AD) which exhibits greatly decreased brain 
metabolism of both glucose and oxygen in tandem, a standard [
18
F]FDG scan of the 
brain can measure regional glucose use and successfully differentiate late stage (AD) 
from other dementia’s.101-105 
(AD) is a common neurodegenerative disorder characterised by memory dysfunction 
and pathologically as deposition of amyloid-β, neurofibrillary tangles and neuronal loss. 
There is now an emerging market of PET tracers for imaging amyloid plaques. 
([
18
F]AV-45) (Figure 1.10) studied by Lin and colleagues has shown excellent binding 
affinity (Kd=3.72 ± 0.30 nM) and good initial brain uptake in biodistribution studies.
106
 
 
Figure 1.10: Structure of ([18F]AV-45)106 
 
Figure 1.11: ([
18
F]AV-45) PET images from a patient with Alzheimer's disease (A) and a healthy control 
(B) taken at 45-55 minutes after tracer injection. All images are superimposed with sample MRI study in 
Montreal Neurologic Institute space (C) and the intensities were normalized to each cerebellar cortex for 
comparison. 106  
Ac = anterior cingulum, F = frontal cortex, P = parietal cortex, Pc = precuneus, Pu = putamen, O = 
occipital cortex, Cb = cerebellar cortex, WM = subcortical white matter. 
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During PET imaging (Figure 1.11), this ligand displayed high brain uptake and fast 
washout in primate brain. The results of the study indicated ([
18
F]AV-45) is a safe PET 
tracer for the study of amyloid beta protein distribution in the brain.
106
 Subsequently, 
this PET tracer received FDA approval in April 2012.
107
 
Over the last two decades, there has also been a concerted effort to develop PET tracers 
for imaging of N-methyl-D-aspartate-type glutamate receptors (NMDARs), ligand-gated 
heteromeric ion channels that regulate fast neurotransmission by allowing prolonged 
influx of Ca
2+
, Na
+
 and K
+
 ions into the synapse. It is one of several types of ionotropic 
glutamate receptor that is thought to be responsible for excitatory transmission in the 
CNS. A number of analogues have been radiolabelled previously, based on the use-
dependent NMDA receptor/ion channel antagonist phencyclidine (PCP); however, 
imaging studies with these tracers have given inconclusive results. These results were 
attributed to high non-specific binding, poor metabolic stability or insufficient affinity. 
Ametamey and co-workers produced ([
18
F]AFA) (Figure 1.12) an NMDA antagonist 
also binding to the PCP binding site.
108
 
 
Figure 1.12: Structure of [18F]AFA 108 
From biodistribution studies in mice, [
18
F]AFA showed high brain uptake consistent 
with good blood brain barrier (BBB) penetration. In a regional dissection study, 
elevated radioactivity concentrations were observed in the cerebellum, frontal cortex 
and in the hippocampus, regions known to contain high densities of the NMDA 
receptor.
108
 Binding of ([
18
F]AFA) to the PCP binding site was examined through non-
human primate PET imaging. 
Robins and co-workers reported the synthesis and in vitro evaluation of S-[
18
F]alkyl 
diarylguanidines (Figure 1.13), NMDA antagonists binding to the PCP binding site.
109
 
These compounds showed high affinity and selectivity in vitro as well as suitable 
lipophilicity (log D7.4 2.49 ± 0.1), indicating this class of compounds should be capable 
of crossing the BBB with good metabolic stability and low non-specific binding. 
Imaging of ion channels as targets (as opposed to neurotransmitter receptors) is a 
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relatively novel and challenging field and to date, there is still not a clinical PET agent 
available for this target, due to the difficulties surrounding specific binding, metabolic 
stability in vivo and affinity for the target.
109
 
 
Figure 1.13: The structure of S-[18F]alkyl diarylguanidines 109 
More recently, Labas et. al. developed several fluorinated ligands selective for the 
NR2B subunit containing NMDA receptors. Their antagonistic effects were measured 
by an in vitro assay. Two compounds showed high affinity and selectivity. After 
analysis of [
18
F]1a and [
18
F]2a in rats (Figure 1.14), micro PET scans showed low brain 
uptake and high bone uptake. The accumulation of radioactivity in bones, skull and 
articulations were assumed to be due to an in vivo defluorination on the 4-(4-
(
18
F)fluorobenzyl)piperidine moiety independently of the piperidinyl substituent. The 
poor brain penetration and defluorination of [
18
F]1a and [
18
F]2a slowed the evaluation 
of these radiotracers as NR2B NMDA receptor PET ligands.
110
 
 
Figure 1.14: Structure of the NR2B NMDA receptor PET ligands 
 
1.4 Voltage-gated sodium channel ligands 
VGSC ligands modulate the function of the Na
+
 channel, thereby impairing the 
conduction of Na
+ 
ions. These ligands can bind either intracellularly or extracellularly, 
depending on their mechanism of action. Some ligands act as total conductance blockers 
leading to paralysis, such as TTX; others inhibit the inactivation of the channel leading 
to over-excitation and seizures e.g. conotoxins. There are a variety of sodium channel 
ligands targeting pain pathways, epilepsy, cardiac arrhythmias and more recently, 
cancer. 
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1.4.0 Local Anaesthetics 
Local anaesthetics (LAs) are a group of chemical compounds which transiently interrupt 
the electrical process of excitation-conduction in peripheral nerve fibres and thus, 
possess the ability to reversibly block the sensation of pain with no residual effects on 
nerve fibres. 
  
 
 
 
 
Figure 1.15: The Hille model for local anaesthetic action pathway 111 
According to the classical model proposed by Hille (Figure 1.15), tertiary amine-type 
LAs are believed to diffuse through the lipophilic nerve membrane in their unioinised 
neutral form.
111
 At physiological pH (~7.4), LAs exist as tertiary amines predominantly 
in a protonated state (as a quaternary ammonium salt). It is however, the uncharged 
form that diffuses across the cell surface membrane (CSM). At the lower intracellular 
pH (~ 6.8 - 7.0), the ionised form is generated, which enters the intracellular portion of 
the Na
+
 channel in its open state and binds reversibly with the TMS IV - VI part of the 
α-subunit to block the Na+ influx. The interaction not only physically blocks the Na+ 
conductance and therefore pulse conduction, but also directly stabilises the fast 
inactivated state of the Na
+
 channel. 
The resting membrane and threshold potential of the nerve fibres are unaffected by LA 
binding. This slows the rate of depolarisation and therefore reduces the rate-of-rise of 
action potentials, which culminates in slow axonal conduction near the LA injection 
site. In addition, the unionised basic form of the LA can also partition into the 
lipid/lipoprotein matrix surrounding the Na
+
 channel, causing membrane expansion and 
therefore disrupting the channel function indirectly. It could also access the LA receptor 
within the channel via lateral movement in the membrane lipid phase. Some LAs 
exhibit use-dependent inhibition, meaning that the depth of conduction block depends 
on the action potential frequency, as LAs gain access to the channel more readily when 
the channel is open. LAs also have higher affinity for inactivated rather than resting 
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channels. Use-dependence is mainly of importance in relation to anti-arrhythmic and 
anticonvulsant effects of LAs. Voltage-dependence of block will also occur, as a greater 
proportion of VGSCs will be in the inactive state at depolarised potentials than at more 
negative potentials.
111-112
 
The first known LA agent was the naturally occuring alkaloid cocaine (Figure 1.16), 
isolated from the leaves of the bush Erythroxylum coca which grows in South America. 
There are accounts dating back to the 1500’s referring to Peruvian Indians chewing on 
the leaves for its CNS stimulating effects. Its mechanism of action was not fully 
understood until 1884, when Carl Koller, a Viennese opthalmologist demonstrated its 
usefulness as a topical anaesthetic for the eyes; it was at that time widely regarded as the 
“holy grail” of LAs.113 
 
Figure 1.16: The structure of cocaine 
Due to its effects on the mesolimbic reward pathway to prevent the reuptake of 
dopamine, cocaine is addictive. During metabolism, cocaine’s ester linkage is 
hydrolysed by plasma pseudochlolinesterase into toxic metabolites, which may cause an 
allergic reaction.
112, 114
 This observation led to efforts to discover a novel class of LA 
which did not contain an ester linkage. In 1943, Nils Lofgren synthesised lidocaine 
(lignocaine), a new amide LA which had far fewer allergic responses, no addictive CNS 
effects, and a faster onset of action. This work introduced a new class of agents which 
led on to development other agents e.g. mepivacaine, prilocaine, bupivacaine, 
amethocaine and tetracaine.  
Lidocaine is a common LA and anti-arrhythmic drug (Figure 1.17). It is characterised 
by a rapid onset of action and intermediate efficacy, making lidocaine suitable for 
topical and infiltration anaesthesia. Lidocaine is also the most important class 1B 
antiarrhythmic drug; it is used intravenously for the treatment of ventricular arrhythmias 
for acute myocardial infarction, digitalis poisoning, cardioversion or cardiac 
catheterisation. Relative insensitivity to lidocaine is genetic. 
115-116
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Figure 1.17: Structure of lidocaine 
 
1.4.1 Tetrodotoxin 
TTX is a well-known non-selective VGSC blocker from the Japanese puffer fish Fugu 
(Figure 1.18), working by binding to site 1 of the fast VGSC. TTX belongs to the 
hydrophilic heterocyclic guanidine toxins. Site 1 is located at the extracellular pore 
opening of the ion channel formed by the external loop linking TMS 5 and 6 in domains 
I-IV. The guanidine group of the TTX binds with very high affinity to the entrance of 
the channel that normally interacts with the hydrated Na
+
 ion. Whereas the hydrated Na
+
 
ion binds reversibly for nanoseconds, the TTX molecule is bound for tens of seconds. 
The binding of any molecules to this site will temporarily disable the function of the ion 
channel. Saxitoxin and several of the snail conotoxins also bind to the same site. TTX 
causes total paralysis due to its inability to distinguish one VGSC sub-type from any 
other and blocks them all extracellularly, except Nav 1.5 which is selectively TTX 
resistant. In μM concentrations, it can kill a mammal within minutes. The pharmacology 
of this drug is well understood and some research groups are currently trying to modify 
the structure of TTX to utilise the drug as a chemotherapeutic agent.
117
 
 
Figure 1.18: Structures of Tetrodotoxin, Saxitoxin and Batrachotoxin  
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Sodium channels can be classified according to their sensitivity to TTX, and use of this 
toxin as a biochemical probe has elucidated two distinct types of VGSCs present in 
humans; the TTX-sensitive and the TTX-resistant VGSCs. TTX binds to sensitive 
VGSCs with a binding affinity of 5-15 nM, while the resistant VGSCs bind TTX with 
low µM affinity. Nerve cells containing resistant Na
+
 channels are located primarily in 
the cardiac tissue (Nav 1.5), while nerve cells containing sensitive VGSCs dominate the 
rest of the body. TTX blocks the fast Na
+
 current in human myocytes (the contractile 
cells of the muscles), thereby inhibiting their contraction leading to a myocardial 
infarction. By contrast, the VGSCs in pacemaker cells of the heart are of the slow 
variety, so action potentials in the cardiac nodes are not inhibited by TTX. The 
myocytes in the atrium, which surround the main cardiac pacemaker, do express this 
fast Na
+
 current and therefore the electrical activity is blocked and the heart fails to 
beat.
118-119
 
Through binding studies, it was shown that TTX does not bind to the channel at the LA 
site, but blocks at its own site (Site 1). With this information, research was undertaken 
to discover how many different binding sites on the channel exist. It is now known that 
there are at least eight different binding sites on the sodium channel (Table 1.5), each 
binding with its own class of ligand, therefore all VGSC ligands are classified according 
to where they bind.
120-123
 
Receptor Site Ligands 
Site 1 Tetrodotoxin (TTX), Saxitoxin (STX) 
Site 2 Batrachotoxin (BTX) 
Site 3 α-Scorpion toxins 
Site 4 β-Scorpion toxins 
Site 5 Brevetoxin/Ciguatoxins 
Site 6 Conotoxins 
Site 7 DDT / Pyrethroid insecticides 
Site 8 Local Anaesthetics 
Table 1.5: Ligands and their binding sites on VGSCs 120-123 
These toxins and drugs bind to their respective sites on the channel, producing various 
effects, which all culminate in abnormal VGSC activity, whether it be over stimulation 
or total inhibition of activity. 
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1.4.2. Novel VGSC ligands 
Over the years, several groups have published the synthesis of a range of novel Na
+
 
channel ligands, with the aim of producing subtype-selective compounds for possible 
therapeutic and/or research tool purposes. WIN 17317-3 (Figure 1.19) is one such small 
molecule initially developed for inhibiting K
+
 channels but through in vitro and in vivo 
studies, was found to be a potent inhibitor of VGSCs, and is specifically selective for 
Nav 1.2 (IC50 = 3.14 nM).
124-125
 It exhibits selectivity for neuronal and skeletal muscle 
sodium channels over cardiac channel isoforms. Through in vitro studies, a ten-fold 
decrease in potency was seen as an inhibitor of adult Nav 1.5.  
 
Figure 1.19: Structure of WIN 17317-3 125 
Reported data indicated that WIN 17317-3 is a novel high-affinity probe for VGSCs, 
with the ability to differentiate between different sub-types, and this study concluded, 
that WIN 17317-3 would serve well as a template for a new generation of Na
+
 channel 
inhibitors.
125
  
Although this compound is a promising VGSC ligand which could be developed into a 
PET radiotracer, we were aware of another research group working on the development 
of the compound and therefore, we chose not to develop WIN 17317-3 within this 
project.   
Chowdhry et. al., have recently published findings on their VGSC ligand, R-(-)-2,4-
diamino-6-fluoromethyl-5-(2,3,5-trichlorophenyl)-pyrimidines (Figure 1.20). This 
compound was derived from lamotrigine, a clinical antiepileptic agent. BW202W92 
was shown to bind to a novel stereoselective drug-binding site, in the rat forebrain 
synaptosomes. It was further shown that the binding affinity for the ligand was greatly 
enhanced by doping in low concentrations of TTX. Unfortunately, the S-enantiomer 
exhibited up to 30-fold less potency and high sensitivity to increased K
+ 
concentration, 
causing an inhibitory effect.
126
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Figure 1.20: Structure of BW202W92 126 
This study revealed that there is a significant difference in H-bonding to the target for 
the R- and S-enantiomer. These structural differences are likely to reflect the different 
pharmacological behaviours in vivo.
126
  
Phenoxyphenyl pyrazoles are a class of compounds identified to be state-dependent 
blockers of VGSCs and exhibit anticonvulsant properties. These compounds have 
negligible effects at other neuroeffector sites, making them very promising for 
biological development.
7
 
 
Figure 1.21: Structure of 3-(4-substituted-phenoxy)phenyl pyrazole-1-carboxamides 
3-(4-R-phenoxy)phenyl pyrazoles (Figure 1.21) were derived from 4-(4-
fluorophenoxy)-benzaldehyde semicarbazone (V102862) (Scheme 1.1), a potent blocker 
of neuronal VGSCs that interacts selectively with inactivated states, as opposed to 
resting states of the channel. However, in vivo metabolism experiments showed that the 
semicarbazone functional group was easily metabolised to the corresponding carboxylic 
acid, a reactive species in vivo.
7, 127-128
 A quantitative structure analysis relationship 
(QSAR) study was used to afford a biologically stable alternative to the semi-carbazone 
moiety, which maintained and protected the carbon nitrogen double bond without losing 
biological activity. A pyrazole ring functionality was chosen to prevent this metabolism.  
 
Scheme 1.1: In vivo metabolism of 4-(4-substituted-phenoxy)benzaldehyde semicarbazone (V102862) 81 
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This five-membered ring allowed the same spatial arrangement between the 
carboxamide and the phenoxyphenyl moiety, while a higher affinity for VGSCs was 
seen for the pyrazole derivative (Ki = 0.031 μM ± 0.007), compared with 4-(4-
fluorophenoxy)benzaldehyde semicarbazone (V102862) (Ki = 0.18 μM ± 0.03).  
In view of their high affinity and promising characteristics, the 3-(4-R-phenoxy)phenyl 
pyrazole-1-carboxamides were chosen to develop into novel PET ligands. Their 
structure allowed much scope for potential direct and in-direct radiolabelling strategies 
to optimise [
18
F]fluoride incorporation, and to hopefully provide a PET ligand that 
proves selective towards a particular VGSC isoform. Moreover, these compounds have 
been shown to be potent and issues surrounding in vivo stability have been resolved.  
1.5 Required features of radiotracer design  
The ability to image a molecular target or in this instance VGSCs is afforded by 
delivery of the radiotracer, retention at the specific binding site and washout of any non-
specifically bound radiotracer. The chemical and pharmacological properties of the 
radiotracer exert a variety of effects on the ability to bind to the receptor. For example, 
high lipophilicity leads to greater nonspecific binding, reducing the signal-to-noise 
ratio, and therefore the ability to detect a specific signal.
129
   
When developing a small molecule into a radiotracer, the affinity of the radiotracer for 
the binding site needs to be ascertained. The affinity of the radiotracer (normally 
measured as the dissociation constant, Kd) relative to the concentration of available 
binding site (Bmax) is the most important characteristic of site-specific radiotracers.
130
 
There are additional factors that can lead to reduced specific signal, however, if 
radiotracers demonstrate poor affinity or the concentration of binding sites is too low, 
the radiotracer cannot be developed into an ideal PET agent. 
129
  
The process to develop a radiotracer follows a logical order: 
(1) Determine the concentration of receptor (Bmax)  in the target tissue 
(2) Estimate the minimum required affinity (e.g. Kd) to afford in vivo localisation 
and calculate the signal-to-noise ratio and binding potential 
(3) Determine the log P and substrate characteristics 
(4) Develop radiotracers for in vitro characterisation of affinity and binding site 
specificity using autoradiography or tissue homogenate studies. 
(5) Demonstrate specific in vivo retention in target tissue  
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When developing a novel PET agent, the following process should be considered and 
adhered to. 
Importantly, for a radiotracer to behave as a ‘tracer’, it must be injected at masses that 
do not significantly populate the receptor. The radiotracer should not produce any 
pharmacologic response. It is suggested that to remain at tracer occupancy, specific 
binding should be less than 5%.
129
  
In order to ascertain the Bmax, Kd and also bound (B) and free (F) concentration, a 
Scatchard plot (Figure 1.22) is used to combine data afforded from a radioligand 
binding assay .  
 
Figure 1.22: Example of in vitro radiotracer binding data, using a Scatchard plot to measure the Bmax 
and Kd. As the specifically bound radiotracer approaches zero, the maximum B/F approaches Bmax/Kd
129 
When specific binding reaches zero, the bound (B) to free ratio (F) (B/F) approaches the 
maximum value defined by (Bmax/Kd). The ratio of Bmax/Kd provides an estimate of the 
maximum bound to free ratio or so called binding potential, but can also be used as an 
approximation of the maximum specific to non-specific binding signal in a tissue. If 
Bmax were to equal 10 nM for example and the Kd was 1 nM, then the binding potential 
would be 10. There is currently no optimal binding potential for radiotracers, however, 
it has been agreed using experimental data from currently developed PET tracers, that a 
Bmax/Kd ≥10 should be good enough to afford a reasonable signal-to-noise ratio. 
129
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1.6 Aims 
PET is a widely utilised technique to diagnose a variety of diseases such as cancer and 
(AD). Currently, many new PET agents are being developed to target specific receptors 
expressed in different diseases to produce less ambiguous images, allowing for quicker 
and more accurate diagnosis. 
This project set out to design and synthesise novel fluorine-18 labelled PET agents to 
target VGSCs. It was hypothesised that VGSC activity in tumours could indicate 
metastatic potential, as the expression of neo-natal VGSC’s positively correlating with 
strongly metastatic cancers. At present, there is no known clinical PET agent for 
targeting VGSC’s or imaging metastatic potential in cancer; we hoped to utilise our 
novel PET agent to indicate malignant potential. 
The 3-(4-R-phenoxy)phenyl pyrazole as reported by Yang et. al., and the closely related 
3-(4-((4-R-phenyl)thio)phenyl)-pyrazoles as described by Dimmock and co-workers, 
131
 
were chosen to develop into PET agents due to their strong affinity for VGSC’s and 
their structural characteristics, which allowed multiple approaches to introduce a 
fluorine-18 label. Our aim was to identify and develop optimal radiolabelling strategies 
and methodologies to produce PET agents in good synthesis time, yield and purity. The 
fluorine-19 standards for these compounds were also synthesised and subjected to 
electrophysiological testing before under-going a full VGSC isoform selectively screen 
to identify the most potent compounds. The compounds which exhibited good potency 
were then chosen for further study. The fluorine-18 PET agents were put through näive 
biodistribution studies to assess in vivo characteristics and finally, the most promising 
PET tracer was assessed in tumour studies both in vitro and in vivo, to identify specific 
binding and give an indication of whether PET imaging of VGSCs in metastatic cancer 
was possible with our tracer. 
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2.0 General 
All reagents including anhydrous solvents were sourced from VWR, Fisher Scientific or Sigma 
Aldrich.
 1
H and 
13
C NMR spectra were recorded on a Bruker AMX at 400 MHz and 100.6 MHz 
respectively, using tetramethylsilane as the internal standard. All spectra were recorded in CDCl3 
unless otherwise stated. Mass Spectra were recorded using a HPLC-MS apparatus combining an 
Agilent Technologies 1200 and Bruker Daltonics Esquire 3000 plus ESI-MS. Low resolution 
mass spectrometry was carried out on an Agilent Technologies 6890 GC coupled to an Agilent 
Technologies 5973 mass spectrometer in electron ionisation mode (EI). The system was 
controlled by MSD productivity Chemstation software. Infrared Spectra were recorded using a 
Perkin Elmer spectrum BX FT-IR system. Thin layer chromatography (tlc) was run on Fluka 
silica gel aluminium plates with fluorescent indicator 254 nm. Column chromatography (CC) was 
run using high purity grade silica gel, pore size 60 Å, 230-400 mesh particle size. Analytical radio 
HPLC was carried out using a Gilson instrument equipped with a γ detector (Bioscan Flow-count) 
and a UV detector (Gilson UV/VIS-156) set to 254 nm with Chromeleon software (Dionex). A 
Phenomenex Luna C18(2) column (50 x 4.6 mm, 3 µm, 100 Å; flow rate 1 mL/min) was used for 
analytical HPLC. Semi-preparative radio HPLC was also carried out using a Gilson instrument 
equipped with a γ detector (Bioscan Flow-count) and a UV detector (Gilson UV/VIS-156) set to 
254 nm using Chromeleon software. A Phenomenex Luna C18 column, (250 x 10 mm, 5 µm, 100 
Å; flow rate 3 mL/min) was used for semi-preparative HPLC. Non-radioactive compounds were 
purified on a preparative Agilent 1200 HPLC using a Phenomenex Luna C18(2) column, (75 x 30 
mm, 5 µm, 100 Å; flow rate 12 mL/min). [Mobile phases used are expressed in Table 2.1]. To 
separate samples for log P calculations, a MSE Micro Centaur centrifuge apparatus was used. 
[
18
F]Fluoride was produced by a cyclotron (PET Trace, GE Medical Systems) using the 
18
O(p,n)
18
F nuclear reaction with 16.4 MeV proton irradiation of an enriched [
18
O]H2O target. 
Automated radiochemistry was performed on either a GE Healthcare Tracerlab FX-N™ module 
or a GE Healthcare FASTlab™ module.  
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Method 
A MeCN/H2O; 5-95% B over 15 minutes, 1 mL/min 
B MeCN/H2O; 10-95% B over 15 minutes, 1 mL/min 
C MeCN/H2O; 60-80% B over 25 minutes, 3 mL/min 
D MeCN/H2O; 40-80% B over 15 minutes, 3 mL/min 
E MeCN/H2O; 50–95% B over 30 minutes, 3 mL/min 
F MeCN/H2O; 50–95% B over 15 minutes, 1 mL/min 
G MeCN/H2O; 10-95% B over 15 minutes, 3 mL/min 
H MeCN/H2O; 5–80% B over 15 minutes, 1 mL/min 
I MeOH/NH4OAc; 50–80% B over 25 minutes, 3 mL/min 
J MeCN/H2O; 55–80% B over 25 minutes, 3 mL/min 
K MeCN/H2O; 20-95% B over 25 minutes, 3 mL/min 
Table 2.1: General methods and mobile phases used for reverse-phase HPLC purification 
 
2.1 Chemistry 
Synthesis of 4-(4-fluorophenoxy)acetophenone
7
 
 
 
To a stirred mixture of 4-fluorophenol (6.78 g, 40.1 mmol) in DMA (20 mL) was added potassium 
carbonate (5.55 g, 40.1 mmol) followed by 4-fluoroacetophenone (5.00 g, 44.6 mmol). The 
resultant solution was heated to 150 °C for 16 hours and monitored by tlc until reaction complete. 
The mixture was then cooled to RT, diluted with CHCl3 (10 mL) and washed with 2 M NaOH 
solution (2 x 25 mL). The organic layer was dried over MgSO4, filtered and evaporated under 
reduced pressure. The crude product was further dried under high vacuum at 60 °C for 6 hours 
giving (1) as a dark brown oil. A small sample was purified for analysis by CC (hexane/EtOAc; 
2:1) and the bulk product was used in the following step without further purification. 
1
H NMR δ 
7.98 (m, 2H, PhH), 6.98 (m, 2H, PhH), 6.79 (m, 2H, PhH), 6.77 (m, 2H, PhH), 2.49 (s, 3H, CH3); 
13
C NMR δ 197.49, 162.38, 158.38, 151.10, 131.73, 130.70, 121.89, 121.81, 116.85, 116.27, 
116.00, 26.47; m/z [M]
+
 = 230, calcd. for C14H11FO2: 230.  
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Synthesis of 4-(4-nitrophenoxy)acetophenone
7
  
 
To a stirred mixture of 4-nitrophenol (6.83 g, 44.6 mmol) in DMA (20 mL) was added potassium 
carbonate (5.55 g, 40.1 mmol), followed by 4-fluoroacetophenone (5.00 g, 44.6 mmol). The 
resultant solution was heated to 150 °C for 16 hours and monitored by tlc until the reaction was 
complete. The mixture was then cooled to RT, diluted with CHCl3 (10 mL) and washed with 2 M 
NaOH solution (2 x 25 mL). The organic layer was dried over MgSO4, filtered and evaporated 
under reduced pressure. The product was further dried under high vacuum at 60 °C for 6 hours 
giving (2) as a dark brown oil. A small sample was purified for analysis, by CC (hexane/EtOAc; 
2:1) and the bulk product was used in the following step without further purification. 
1H NMR δ 
8.20 (d, (J=9 Hz), 2H, PhH), 7.92 (d, (J=9 Hz), 2H, PhH), 7.01-6.93 (m, 4H, PhH), 2.53 (s, 3H, 
CH3); 
13C NMR δ 196.58, 162.77, 159.12, 143.5, 133.68, 130.81, 126.09, 119.52, 118.43, 26.59; 
m/z [M]
+
 = 257, calcd. for C14H11NO4: 257.  
Synthesis of 4-(2,4-difluorophenoxy)acetophenone
7
  
 
To a stirred mixture of 2,4-difluorophenol (5.80 g, 44.6 mmol) in DMA (20 mL) was added 
potassium carbonate (5.55 g, 40.1 mmol) followed by 4-fluoroacetophenone (5.00 g, 44.6 mmol). 
The resultant solution was heated to 150 °C for 16 hours. The mixture was then cooled to RT, 
diluted with CHCl3 (10 mL) and washed with 2 M NaOH solution (2 x 25 mL). The organic layer 
was dried over MgSO4, filtered and evaporated under reduced pressure. The product was further 
dried under high vacuum at 60 °C for 6 hours giving (3) as a dark brown oil. A small sample was 
purified for analysis, by CC (hexane/EtOAc; 2:1) and the bulk product was used in the following 
step without further purification. 
1
H NMR δ 7.81 (m, 2H, PhH), 7.05 (m, 1H, PhH), 6.90-6.80 (m, 
4H, PhH) 2.48 (s, 3H, CH3); 
13
C NMR δ 195.356, 160.69, 158.66, 154.83, 152.32, 137.38, 130.77, 
129.50, 122.92, 114.66, 104.86, 25.41; m/z [M]
+
 = 248, calcd. for C14H10F2O2: 248.  
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Synthesis of 3-[4-(4-fluorophenoxy)phenyl]-pyrazole
7
  
 
To a stirred solution of (1) (8.90 g, 39.0 mmol) in DMF (20 mL) was added N,N-
dimethylformamide dimethylacetal (5.00 g, 43.0 mmol). The reaction was heated to 150 °C for 16 
hours. The solution was cooled to RT and distilled H2O (30 mL) was added over 20 minutes until 
a yellow precipitate formed. This solid was collected by suction filtration and washed with 
distilled H2O (20 mL). The product was further dried by high vacuum at 25 °C for 4 hours. The 
solid was dissolved in ethanol (20 mL) and 35% aq. hydrazine (1.50 mL, 43.0 mmol) added 
dropwise. The mixture was heated to 80 °C for 90 minutes after which the solvent was removed 
by rotary evaporation. The crude product was then re-dissolved in EtOAc (20 mL) and washed 
with distilled H2O (3 x 20 mL) and brine (20 mL). The organic layer was dried over MgSO4 and 
concentrated in vacuo. The crude product was purified by CC (hexane/EtOAc; 1/1) giving (4) as a 
yellow solid (6.73 g, 68.0%). 
1H NMR δ 7.83 (m, 2H, PhH), 7.73 (d, (J=12 Hz), 1H, CH=CH-
NH), 6.97 (m, 4H, PhH), 6.88 (m, 2H, PhH), 5.62 (d, (J=12 Hz), 1H, CH-NH); 
13C NMR δ 
163.21, 154.52, 142.80, 131.88, 130.06, 127.69, 127.50, 125.98, 120.78, 117.23, 102.71; m/z 
[M+MeOH]
+
 = 286.2, calcd. for C16H15FN2O2: 286.1; mp 120.5-126.0 °C.  
Synthesis of 3-[4-(4-nitrophenoxy)phenyl]-pyrazole
7
  
 
To a stirred solution of (2) (3.30 g, 14.0 mmol) in DMF (10 mL) was added N,N-
dimethylformamide dimethylacetal (2.10 mL, 16.0 mmol) the reaction was heated to 150 °C for 
16 hours. The solution was cooled to RT and distilled H2O (20 mL) was added over 20 minutes 
until a yellow precipitate formed. This solid was collected by suction filtration and washed with 
distilled H2O (20 mL). The product was further dried by high vacuum at 25 °C for 4 hours. The 
solid was dissolved in EtOH (20 mL) and 35% aq. hydrazine (0.50 mL, 16.0 mmol) added 
dropwise. The mixture was heated to 80 °C for 90 minutes after which, the solvent was removed 
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by rotary evaporation. The crude product was re-dissolved in EtOAc (20 mL) and washed with 
distilled H2O (3 x 20 mL) and brine (20 mL). The organic layer was dried over MgSO4 and the 
solvent removed in vacuo. The crude product was purified by CC (hexane/EtOAc; 1:1) giving (5) 
as a yellow solid (982 mg, 25.0%). 
1H NMR δ 8.16-8.12 (tt, (J=3 Hz), 2H, PhH), 7.79-7.76 (tt, 
(J=2 Hz), 2H, PhH), 7.58 (d, (J=3 Hz), 1H, CH=CH-NH), 7.08-7.05 (tt, (J=2 Hz), 2H, PhH), 7.00-
6.96 (tt, (J=2 Hz), 2H, PhH), 6.56 (d, (J=3 Hz), 1H, CH-NH); 
13C NMR δ 163.21, 154.52, 142.80, 
131.88, 130.06, 127.69, 127.50, 125.98, 120.78, 117.23, 102.71; m/z [M]
+
 = 281, calcd. for 
C15H11N3O3: 281; mp = 160.0-163.2 °C.  
Synthesis of 3-[4-(2,4-difluorophenoxy)phenyl]-pyrazole
7
  
 
To a stirred solution of (3) (7.50 g, 30.0 mmol) in DMF (20 mL) was added N,N-
dimethylformamide dimethylacetal (4.40 ml, 33.0 mmol) the reaction was heated to 150 °C for 16 
hours. The solution was cooled to RT and distilled H2O (20 mL) was added over 20 minutes until 
a yellow precipitate formed. The solid was collected by suction filtration and washed with 
distilled H2O (20 mL). The product was further dried by high vacuum at 25 °C for 4 hours. The 
solid was dissolved in EtOH (20 mL) and 35% aq. hydrazine (1.10 mL, 33.0 mmol) added 
dropwise. The mixture was heated to 80 °C for 1.5 hours and the solvent removed by rotary 
evaporation. The crude product was then re-dissolved in EtOAc (20 mL) and washed with 
distilled H2O (3 x 20 mL) and brine (20 mL). The organic layer was dried over MgSO4 and the 
solvent was evaporated in vacuo. The crude product was purified by CC (hexane/EtOAc; 1:1) 
giving (6) as a yellow solid (6.36 g, 78.0%). 
1
H NMR δ 7.64-7.61 (m, 2H, PhH), 7.52 (d, (J=2 
Hz), 1H, CH=CH-NH), 7.05-6.99 (m, 2H, PhH), 6.92-6.86 (m, 3H, PhH), 6.82-6.76 (m, 1H, CH-
NH); 
13C NMR δ 157.74, 157.64, 157.52, 153.19, 153.06, 139.77, 139.72, 139.65, 139.61, 127.27, 
117.01, 105.54, 102.44; m/z [M]
+
 = 272, calcd. for C15H10F2N2O: 272; mp = 99.0 -102.2 °C. 
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Synthesis of 3-[4-(4-fluorophenoxy)phenyl]-pyrazole-1-carboxamide
7
 
 
To a stirred solution of (4) (3.50 g, 14.0 mmol) in 90% aq. AcOH (15 mL) was added sodium 
cyanate (1.10 g, 16.0 mmol) as an aq. suspension. The reaction mixture was stirred for 16 hours at 
RT. Distilled H2O (20 mL) was added until a precipitate formed and the product collected by 
suction filtration. The crude product was purified by CC, (EtOAc/hexane; 1:1) giving (7) as a 
cream solid (1.45 g, 35.0%). 
1H NMR δ 8.21 (d, (J=3 Hz), 1H, CH-N-C=O), 7.74 (m, 2H, PhH), 
6.98-6.92 (m, 6H, PhH), 6.66 (d, (J=3 Hz), 1H, CH=CH-NH); 
13C NMR δ 162.3, 158.6, 157.9, 
153.9, 152.4, 150.8, 130.1, 127.8, 126.9, 120.9, 120.8, 120.7, 118.5, 116.5, 116.3, 106.3; m/z: 
[M+H]
+
 = 298.52, calcd. for C16H13FN3O2: 298.75; HRMS [M+Na]
+
 = 320.0818, calcd. 320.2840; 
HPLC (method A), tR = 11.7 minutes, >95% purity; mp = 132.5-136.8 °C; lit. mp 141.0-143.0 
°C.
7
 
Synthesis of 3-[4-(4-nitrophenoxy)phenyl]-pyrazole-1-carboxamide
7
  
 
To a stirred solution of (5) (514 mg, 2.00 mmol) in 90% aq. AcOH (6.50 mL) was added sodium 
cyanate (156 mg, 2.40 mmol) as an aq. suspension. The reaction mixture was stirred for 16 hours 
at RT. Distilled H2O (20 mL) was added until a precipitate formed and the product collected by 
suction filtration. The crude product was purified by CC, (EtOAc/hexane; 1:1) giving (8) as a 
cream solid (157 mg, 24.2%). 
1H NMR δ 8.21 (d, (J=3 Hz), 1H, CH-N-C=O), 8.16-8.14 (m, 2H, 
PhH), 7.85-7.83 (m, 2H, PhH), 7.10-7.07 (m, 2H, PhH), 7.02-6.98 (m, 2H, PhH), 6.66 (d, (J=3 
Hz), 1H, CH=CH-N); 
13C NMR δ 162.9, 155.3, 153.3, 150.6, 143.1, 130.3, 129.2, 128.1, 126.0, 
120.8, 117.3, 106.3; m/z [M]
+
 = 324.29, calcd. for C16H12N4O4: 324.09, HRMS 324.0809, calcd. 
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324.2960; HPLC (method A), tR = 8.1 minutes, >95% purity; mp = 132.0-137.0 °C; lit. mp 145.0-
147.0 °C.
 7
 
Synthesis of 3-[4-(2,4-difluorophenoxy)phenyl]-pyrazole-1-carboxamide
7
 
 
To a stirred solution of (6) (2.40 g, 8.70 mmol) in 90% aq. AcOH (30 mL) was added sodium 
cyanate (703 mg, 10.4 mmol) as an aq. suspension. The reaction mixture was stirred for 16 hours 
at RT. Distilled H2O (20 mL) was added until a precipitate formed and the solid collected by 
suction filtration. The crude product was purified by CC (EtOAc/hexane; 1:1) giving (9) as a pure 
cream solid (2.15 g, 78.0%). 
1
H NMR δ 8.17 (d, (J=3 Hz), 1H, CH-N-C=O), 7.72 (m, 2H, PhH), 
7.08-7.02 (m, 2H, PhH), 6.92 (m, 3H, PhH), 6.81 (d, (J=3 Hz), 1H, CH=CH-NH), 5.23 (s, 1H, 
NH); 
13
C NMR δ 189.97, 158.39, 153.80, 150.52, 130.07, 127.76, 126.95, 123.15, 116.83, 111.61, 
111.38, 106.29, 105.62, 99.48; m/z [M+H]
+
 = 316.54, calcd. for: C16H12F2N3O2: 316.08, HRMS 
316.0898, calcd. 316.2881; CHN C 61.10% H 3.39% N 12.98%, calcd. C 60.95% H 3.52% N 
13.33%; HPLC (method A), tR = 11.6 minutes, >90% purity; mp = 138.6-140.2 °C; lit. mp = 
132.0-134.0 °C.
7
 
Synthesis of tert-butyl (3-(4-(4-fluorophenoxy)phenyl)-pyrazole-1-carbonyl) carbamate
7
 
 
A stirred solution of (7) (150 mg, 510 µmol) in DCM (10 mL) and triethylamine (70.0 µL, 510 
µmol) was stirred for 30 minutes. Di-tert-butyl dicarbonate (120 µL, 510 µmol) was added 
dropwise over 2 minutes and the resultant mixture stirred for 24 hours at RT. The reaction was 
washed with distilled H2O (10 mL) and extracted with DCM (3 x 10 mL). The crude product was 
purified by CC (EtOAc/hexane; 1:4) giving (10) as an colourless solid (21.0 mg, 10.0%) . 
1
H 
NMR δ 8.16 (d, (J=3 Hz), 1H, CH-NH), 7.73 (m, 2H, PhH), 6.91-6.99 (m, 6H, PhH), 6.60 (d, 
(J=3 Hz), 1H, CH=CH-NH), 5.47 (bs, 1H, NH), 1.38 (s, 9H, 3 x CH3); 
13
C NMR δ 160.27, 
158.56, 157.87, 153.86, 152.41, 150.69, 130.06, 127.78, 126.89, 120.82, 118.27, 116.55, 106.27, 
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82.42, 23.24; m/z [M]
+
 = 397.14 calcd. for C16H10FN2O2: 397.14, HPLC (method A), tR = 13.7 
minutes, >90% purity. 
Synthesis of (4-fluorophenyl)(4-(trifluoromethyl)phenyl)methanone 
132
 
 
To a stirred solution of 4-trifluoromethyl benzoyl chloride (3.40 mL, 36.0 mmol) in fluorobenzene 
(440 µL, 3.00 mmol) under N2 was added triflic acid (130 µL, 1.50 mmol) and heated to 100 °C 
for 4 days. The reaction was cooled to RT and a small amount of ice was added to decompose the 
mixture. The product was extracted into CHCl3 (20 mL), washed with brine (2 x 20 mL), dried 
with MgSO4, and the solvent removed in vacuo. The precipitate was then recrystallised from hot 
EtOH giving (15) as small off-white crystals (404 mg, 50.0%). 
1
H NMR δ 7.95-7.80 (m, 6H, 
PhH), 7.02-7.18 (m, 2H, PhH); 
13
C NMR δ 194.03, 167.04, 140.65, 134.31, 133.99, 132.82, 
129.96, 125.50, 115.90, 115.68; m/z [M+H]
+
 = 268.04, calcd. for C14H9F4O: 268.05, HRMS 
[M+Na]
+
 = 291.0406, calcd. 291.2003; HPLC (method A), tR = 13.7 minutes, >90% purity; mp 
101.0-101.3 °C; lit. mp 100.0-100.5 °C 
132
. 
Synthesis of (4-(dimethylamino)phenyl)(4-(trifluoromethyl)phenyl)-methanone 
133
 
 
To a mixture of (15) (339 mg, 1.16 mmol) in DMSO (20 mL) and distilled H2O (10 mL) was 
added dimethylamine hydrochloride (122 mg, 1.50 mmol) and potassium carbonate (417 mg, 3.02 
mmol). The resultant mixture was heated to 140 °C under N2 for 12 hours. After cooling to RT, 
the reaction was diluted with distilled H2O (20 mL) and extracted into Et2O (3 x 20 mL). The 
organic layer was extracted, dried over MgSO4 and the solvent removed in vacuo. The crude off-
white solid was purified via CC (Et2O/hexane; 1:1) giving (15) as an off-white solid (293 mg, 
86.2%). 
1
H NMR (d6-DMSO) δ 7.85-7.65 (m, 6H, PhH), 7.61-7.58 (m, 2H, PhH) 3.02 (s, 6H, 2 x 
CH3); 
13
C NMR (d6-DMSO) δ 192.78, 152.63, 141.64, 131.90, 131.79, 131.37, 129.62, 128.89, 
124.19, 109.64, 39.02; m/z [M+H]
+
 = 294.1121, calcd. for C16H15F3NO: 294.1106. 
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Synthesis of trimethyl-4-(4-(trifluoromethyl)benzoyl)-benzenaminium trifluoromethane 
sulphonate
133
  
 
A solution of (17) (281 mg, 0.884 mmol) in DCM (10 mL) was added methyl triflate (100 µL, 
0.890 mmol) under N2. The solution was stirred for 1 hour at RT, before it was cooled to 0 °C and 
hexane (10 mL) added. A colourless precipitate formed and was collected by suction filtration. 
The solid was washed with Et2O (20 mL) and dried under reduced pressure yielding (13) as a 
colourless solid (44.0 mg, 11.0%). 
1
H NMR (d6-DMSO) δ 8.20-8.15 (m, 2H, PhH), 8.04-7.92 (m, 
6H, PhH), 3.67 (s, 9H, 3 x CH3); 
13
C NMR (d6-DMSO) δ 197. 84, 142.89, 139.22, 134.73, 132.68, 
131.25, 130.44, 121.25, 121.04, 119.00, 56.40; m/z [M+H]
+
 = 308.13, calcd. for C18H17F6NO4S: 
308.12; HPLC (method A), tR = solvent front, >90% purity; mp 162.4-165.5 °C; lit. mp 167.0 °C  
133
. 
Synthesis of 1-bromo-4-iodobenzene diacetate 
134-135
 
 
A stirred solution of 1-bromo-4-iodobenzene (2.83 g, 10.0 mmol) in AcOH (100 mL) was warmed 
to 45 °C for 50 minutes resulting in a yellow solution. The reaction mixture was allowed to cool to 
RT and sodium per-borate (15.3 g, 100 mmol) was added portion-wise over 20 minutes. The 
yellow solution turned a cloudy off-white colour and was heated to 45 °C for 5 hours. After 
cooling to RT, distilled H2O (150 mL) was added to dilute the reaction and extracted into DCM (3 
x 50 mL). The organic layer was washed with brine (3 x 50 mL) and dried with MgSO4. DCM 
was removed in vacuo leaving an off-white solid. The crude product was purified by 
recrystallisation (hexane/Ac2O; 1:1) giving (18) as an off-white solid (720 mg, 18.0%). 
1
H NMR δ 
7.96 (dd, (J=2 Hz, 9 Hz), 2H, PhH), 7.63 (dd, (J=2 Hz, 9 Hz), 2H, PhH), 2.02 (s, 6H, 2 x CH3); 
13
C NMR δ 176.48, 136.45, 134.21, 126.85, 119.70, 20.24; m/z [M+H]+ = 401.88, calcd. for 
C10H11BrIO4: 401.99.  
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Synthesis of bis(4-bromophenyl)iodonium triflate 
134-135
 
 
To a solution of (17) (710 mg, 1.80 mmol) in anhy. DCM (15 mL) under N2 was added triflic acid 
(540 mg, 3.60 mmol) at -40 °C and stirred for 60 minutes at the same temperature. The solution 
was then warmed to RT for 60 minutes where a yellow solution formed. The solution was re-
cooled to -30 °C and bromobenzene (292 mg, 1.90 mmol) was added dropwise. The mixture was 
allowed to stir for a further 60 minutes at this temperature, after which, the mixture was allowed 
to warm to RT. The reaction was concentrated in vacuo to a third of the volume and 
(ether/hexane; 1/1) added until a white precipitation formed. The solid was collected by suction 
filtration and washed with hexane (20 mL). The product was recrystallised from (hexane/Ac2O; 
1:1) giving (18) as large colourless crystals (497 mg, 47.0%). 
1
H NMR (d6-DMSO) δ 8.18 (dd, 
(J=2 Hz, 9 Hz), 4H, PhH), 7.77 (dd, (J=2 Hz, 9 Hz), 4H, PhH); 
13
C NMR (d6-DMSO) δ 136.97, 
134.73, 126.35, 115.32; m/z [M]
+
 = 587.75, calcd. for C13H8Br2F3IO3S: 587.75; HPLC (method 
A), tR = solvent front, >90% purity; mp = 205.3 °C (dec.), lit. mp 210.0 °C (dec.) 
134-135
. 
Synthesis of 2-(4-fluorophenoxy)naphthalene 
136
 
 
To a solution of 1-fluoro-4-bromobenzene (87.0 mg, 500 µmol) in N-methyl-2-pyrrolidone (700 
µL) was added copper iodide (9.50 mg, 50.0 µmol), 1-naphthol (144 mg, 1.00 mmol) and caesium 
carbonate (325 mg, 1.00 mmol) under N2. The sealed vial was heated to 195 °C for 5 hours. The 
reaction mixture was first purified on a silica cartridge eluting the crude product with Et2O (10 
mL), further purification by CC (hexane) gave (22) as an off-white solid (55.0 mg, 46.0%). 
1
H 
NMR δ 7.78-7.73 (dd, (J=7, 7 Hz), 2H, PhH), 7.62 (d, (J=8 Hz), 1H, PhH), 7.41-7.31 (m, 2H, 
PhH) 7.19-7.15 (m, 2H, PhH), 7.03-6.95 (m, 4H, PhH); 
13C NMR δ 130.06, 129.97, 129.01, 
127.75, 127.08, 126.62, 125.09, 124.73, 124.45, 120.86, 120.77, 119.52, 117.84, 116.53, 116.30, 
113.25; m/z [M]
+
 = 238.08, calcd. for C16H11FO: 238.06; HPLC (method A), tR = 6.56 minutes, 
>90% purity. 
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Synthesis of 4-(4-fluorothiophenoxy)acetophenone 
 
To a stirred mixture of 4-fluorothiophenol (5.10 g, 39.8 mmol) in DMF (20 mL) was added 
potassium carbonate (4.50 g, 32.6 mmol) followed by 4-fluoroacetophenone (5.00 g, 36.2 mmol). 
The resultant solution heated to 150 
o
C for 16 hours and monitored by tlc until reaction complete. 
The mixture was then cooled to RT, diluted with CHCl3 (30 mL) and washed with 2 M NaOH 
solution (2 x 25 mL). The organic layer was dried over MgSO4, filtered and evaporated under 
reduced pressure. The product was not isolated and (23) was used as a crude product in the 
following step.  
Synthesis of 4-(4-nitrothiophenoxy)acetophenone 
 
To a stirred mixture of 4-nitrothiophenol (2.47 g, 15.9 mmol) in DMF (20 mL) was added 
potassium carbonate (1.80 g, 13.0 mmol) followed by 4-fluoroacetophenone (2.00 g, 14.5 mmol). 
The resultant solution heated to 150 
o
C for 16 hours and monitored by tlc until reaction complete. 
The mixture was then cooled to RT, diluted with CHCl3 (20 mL) and washed with 2 M NaOH 
solution (2 x 25 mL). The organic layer was dried over MgSO4, filtered and evaporated under 
reduced pressure. The product was not isolated and (24) was used as a crude product in the 
following step.  
Synthesis of 4-(2,4-difluorothiophenoxy)acetophenone 
 
To a stirred mixture of 2,4-difluorothiophenol (2.00 g, 13.7 mmol) in DMF (20 mL) was added 
potassium carbonate (1.54 g, 11.1 mmol) followed by 4-fluoroacetophenone (1.71 g, 12.4 mmol). 
The resultant solution heated to 150 
o
C for 16 hours and monitored by tlc until reaction complete. 
The mixture was then cooled to RT, diluted with CHCl3 (20 mL) and washed with 2 M NaOH 
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solution (2 x 25 mL). The organic layer was dried over MgSO4, filtered and evaporated under 
reduced pressure. The product was not isolated and (24) was used as a crude product in the 
following step.  
Synthesis of 3-[4-(4-fluorothiophenoxy)phenyl]-pyrazole  
 
To a stirred solution of (23) (8.65 g, 37.6 mmol) in DMF (20 mL) was added N,N-
dimethylformamide dimethylacetal (4.93 g, 41.3 mmol) and the reaction was heated to 150 
°
C for 
16 hours. The solution was cooled to RT and distilled H2O (20 mL) was added over 20 minutes 
until a yellow precipitate formed. This solid was collected by suction filtration and washed with 
distilled H2O (20 mL). The product was further dried by high vacuum at 25 °C for 4 hours. The 
solid was then dissolved in EtOH (20 mL) and 35% aq. hydrazine (1.32 g, 41.3 mmol) added 
dropwise. The mixture was heated to 80 °C for 90 minutes after which the solvent was removed 
by rotary evaporation. The crude product was then re-dissolved in EtOAc (20 mL), washed with 
distilled H2O (3 x 20 mL) and brine (20 mL). The organic layer was dried over MgSO4 and the 
solvent removed in vacuo. The crude product was purified by CC (hexane/EtOAc; 1:2) giving 
(26) as a yellow solid (7.83 g, 82.0%). 
1H NMR δ 7.67 (d, (J=8.1 Hz), 2H, PhH), 7.61-7.57 (m, 
1H, CH=CH-NH), 7.40 (ddd, (J=8.6, 4.6, 1.7 Hz), 2H, PhH), 7.30-7.24 (m, 2H, PhH), 7.07-7.00 
(m, 2H, PhH), 6.58 (d, (J=2.3 Hz), 1H, CH-NH); 
13
C NMR δ 163.70, 161.23, 134.52, 134.18, 
134.10, 131.57, 131.38, 130.18, 130.01, 126.57, 126.48, 116.66, 116.59, 116.37, 102.70; m/z 
[M+H]
+
 = 271.1, calcd. for C15H12FN2S: 271.1, HRMS 271. 0696, calcd. 271.3336; HPLC 
(method A), tR = 12.0 minutes, >95% purity. 
Synthesis of 3-[4-(4-nitrothiophenoxy)phenyl]-pyrazole  
 
To a stirred solution of (24) (3.96 g, 14.5 mmol) in DMF (10 mL) was added N,N-
dimethylformamide dimethylacetal (1.90 g, 15.9 mmol) the reaction was heated to 150 °C for 3 
hours. The solution was cooled to RT and distilled H2O (20 mL) was added over 20 minutes until 
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a yellow precipitate formed. This solid was collected by suction filtration and washed with 
distilled H2O (20 mL). The product was further dried by high vacuum at 25 °C for 4 hours. The 
precipitate was then dissolved in EtOH (20 mL) and 35% aq. hydrazine (510 mg, 15.9 mmol) 
added dropwise. The mixture was heated to 80 °C for 90 minutes after which the solvent was 
removed by rotary evaporation. The crude product was then re-dissolved in EtOAc (20 mL) and 
washed with distilled H2O (3 x 20 mL) and brine (20 mL). The organic layer was dried over 
MgSO4 and the solvent removed in vacuo. The crude product was purified by CC (hexane/EtOAc; 
1:2) giving (27) as a yellow solid (1.12 mg, 25.9%). 
1H NMR δ 8.11-8.06 (m, 2H, PhH), 7.89 (dd, 
(J = 6.6, 1.7 Hz), 2H, PhH), 7.68 (d, (J = 2.3 Hz), 1H, CH=CH-NH), 7.61-7.56 (m, 2H, PhH), 
7.27-7.19 (m, 2H, PhH), 6.71 (d, (J = 2.4 Hz), 1H, CH-NH); 
13C NMR δ 169.95, 147.13, 144.21, 
134.04, 128.75, 126.42, 126.09, 125.70, 122.97, 114.48, 101.99; m/z [M]
+
 = 297.2, calcd. for: 
C15H11N3O2S: 297.1, HRMS 297.0483, calcd. 297.3323; HPLC (method A), tR = 11.9 minutes, 
>95% purity. 
Synthesis of 3-[4-(2,4-difluorothiophenoxy)phenyl]-pyrazole  
 
 
To a stirred solution of (25) (1.18 g, 4.45 mmol) in DMF (10 mL) was added N,N-
dimethylformamide dimethylacetal (583 mg, 4.89 mmol) the reaction was heated to 150 °C for 16 
hours. The solution was cooled to RT and distilled H2O (20 mL) was added over 20 minutes until 
a yellow precipitate formed. This solid was collected by suction filtration and washed with 
distilled H2O (20 mL). The product was further dried by high vacuum at 25 °C for 4 hours. The 
precipitate was then dissolved in EtOH (20 mL) and 35% aq. hydrazine (157 mg, 4.89 mmol) 
added dropwise. The mixture was heated to 80 °C for 90 minutes after which the solvent was 
removed by rotary evaporation. The crude product was then re-dissolved in EtOAc (20 mL) and 
washed with distilled H2O (3 x 20 mL) and brine (20 mL). The organic layer was dried over 
MgSO4 and the solvent removed in vacuo. The crude product was purified by CC (hexane/EtOAc; 
1:2) giving (28) as a yellow solid (770 mg, 60.0%). 
1
H NMR δ 7.72-7.67 (m, 2H, PhH), 7.59 (d, 
(J=2.1 Hz), 1H, CH=CH-NH), 7.34 (dd, (J=8.4, 2.2 Hz), 2H, PhH), 6.95-6.90 (m, 3H, PhH), 6.59 
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(d, (J=2.2 Hz), 1H, CH-NH); 
13C NMR δ 162.35, 159.86, 148.95, 135.50, 133.69, 133.50, 131.34, 
131.21, 126.62, 124.35, 120.79, 112.73, 102.78; m/z [M]
+
 = 288.6, calcd. for C15H10F2N2S: 288.1. 
Synthesis of 3-[4-(4-fluorothiophenoxy)phenyl]-pyrazole-1-carboxamide 
 
To a stirred solution of (26) (1.00 g, 3.70 mmol) in 90% aq. AcOH (30 mL) was added sodium 
cyanate (289 mg, 4.44 mmol) as an aq. suspension. The reaction mixture was stirred for 16 hours 
at RT. Distilled H2O (20 mL) was added until a white precipitate formed and the product collected 
by suction filtration. The crude product was purified by CC (EtOAc/hexane; 1:2) giving (29) as a 
white solid (404 mg, 34.9%). 
1
H NMR δ 8.17 (d, (J=2.8 Hz), 1H, CH-N-C=O), 7.69-7.65 (m, 2H, 
PhH), 7.39-7.32 (m, 2H, PhH), 7.24-7.18 (m, 4H, PhH), 6.62 (d, (J=2.8 Hz), 1H, CH=CH-N), 
5.31 (s, 1H, NH); 
13
C NMR δ 189.71, 164.03, 161.32, 153.88, 150.47, 138.33, 134.70, 134.62, 
130.10, 129.59, 126.85, 116.68, 116.46, 106.39; .m/z [M+H]
+
 = 314.0, calcd. for C16H13FN3OS: 
314.1, HRMS 314.0777, calcd. 314.3587; CHN C 61.38% H 3.77% N 13.12%, calcd. C 61.33% 
H 3.86% N 13.41%. 
Synthesis of 3-[4-(4-nitrothiophenoxy)phenyl]-pyrazole-1-carboxamide
7
 
 
To a stirred solution of (27) (140 mg, 0.35 mmol) in 90% aq. AcOH (10 mL) was added sodium 
cyanate (28.0 mg, 0.42 mmol) as an aq. suspension. The reaction mixture was stirred for 16 hours 
at RT. Distilled H2O (20 mL) was added until a white precipitate formed and the product collected 
by suction filtration. The crude product was purified by CC, (EtOAc/hexane; 1:2) giving (30) as a 
white solid (70 mg, 58.8%). 
1
H NMR δ 8.31 (dd, (J=2.9, 1.1 Hz), 1H, CH-N-C=O), 8.11-8.03 (m, 
2H, PhH), 7.98-7.84 (m, 2H, PhH), 7.59 (dt, (J=6.7, 1.2 Hz), 2H, PhH), 7.29-7.19 (m, 2H, PhH), 
6.79 (dd, (J=3.0, 1.1 Hz), 1H, CH=CH-N); 
13
C NMR δ 169.49, 155.91, 154.18, 147.79, 134.74, 
133.13, 131.72, 129.67, 127.70, 127.17, 124.12, 107.49; m/z HRMS [M+H]
+
 = 341.0206, calcd. 
for C16H14N4O3S: 341.0708. 
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Synthesis of 3-[4-(2,4-difluorothiophenoxy)phenyl]-pyrazole-1-carboxamide 
 
To a stirred solution of (28) (770 mg, 2.66 mmol) in 90% aq. AcOH (20 mL) was added sodium 
cyanate (207 mg, 3.19 mmol) as an aq. suspension. The reaction mixture was stirred for 16 hours 
at RT. Distilled H2O (20 mL) was added until a pale yellow precipitate formed and the product 
collected by suction filtration. The crude product was purified by CC (EtOAc/hexane; 1:2) giving 
(31) as a pure cream solid (880 mg, 55.0%). 
1
H NMR δ 8.28–8.26 (m, 1H, CH-N-C=O), 7.81–
7.77 (m, 2H, PhH), 7.38–7.34 (m, 2H, PhH), 7.03–6.88 (m, 3H, PhH), 6.73–6.71 (m, 1H, 
CH=CH=NH), 5.45 (bs, 1H, NH); 
13
C NMR δ 162.66, 160.17, 153.56,150.94, 135.39, 134.29, 
134.14, 130.81, 130.61, 130.49, 130.13, 126.99, 124.32, 119.98, 119.80, 106.43; m/z HRMS [M]
+
 
= 331.1965, calcd. for C16H11F2N3OS: 331.3411; HPLC (method A), tR = 10.1 minutes, purity 
>95%. 
Syntheis of 3-(4-fluorophenyl)-1H-pyrazole 
 
To a stirred solution of 4-fluoroacetophessssssnone (5.00 g, 44.6 mmol) in DMF (20 mL) was 
added N,N-dimethylformamide dimethylacetal (5.79 g, 49.0 mmol) the reaction was heated to 150 
°C for 16 hours. The solution was cooled to RT and distilled H2O (20 mL) was added over 20 
minutes until a yellow precipitate formed. This solid was collected by suction filtration and 
washed with distilled H2O (20 mL). The product was further dried by high vacuum at 25 °C for 4 
hours. The precipitate was then dissolved in EtOH (20 mL) and 35% aq. hydrazine (1.57 g, 49.0 
mmol) added dropwise. The mixture was heated to 80 °C for 90 minutes after which the solvent 
was removed by rotary evaporation. The crude product was then re-dissolved in EtOAc (20 mL) 
and washed with distilled H2O (3 x 20 mL) and brine (20 mL). The organic layer was dried over 
MgSO4 and the solvent removed in vacuo. The crude product was purified by CC (hexane/EtOAc; 
1:2) giving (32) as a yellow solid (1.91 g, 32.0%). 
1H NMR δ 7.74 (dd, (J=8.5, 5.5 Hz), 2H, 2 x 
PhH), 7.61 (dd, (J=2.2, 0.9 Hz), 1H, CH=CH-NH), 7.14-7.06 (m, 2H, PhH), 6.58 (dd, (J=2.2, 0.9 
Hz), 1H, CH-NH); 
13C NMR δ 163.89, 161.44, 127.61, 127.53, 115.79, 115.57, 102.57; m/z [M]+ 
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= 162.2, calcd. for C9H7FN2: 162.1, HRMS [M+H]
+
 = 163.0678, calcd. 163.0672; HPLC (method 
A), tR = 8.1 minutes, 99% purity.  
Synthesis of 3-(4-fluorophenyl)-pyrazole-1-carboxamide 
 
To a stirred solution of (32) (1.88 g, 14.0 mmol) in 90% aq. AcOH (15 mL) was added sodium 
cyanate (898 mg, 13.8 mmol) as an aq. suspension. The reaction mixture was stirred for 16 hours 
at RT. Distilled H2O (20 mL) was added until a precipitate formed and the product collected by 
suction filtration. The crude product was purified by CC (EtOAc/hexane; 1:1) giving (33) as a 
pure cream solid (1.15 g, 45.9%). 
1
H NMR δ 8.18 (d, (J=2.8 Hz), 1H, CH-N-C=O), 7.78-7.72 (m, 
2H, PhH), 7.10-7.00 (m, 2H, PhH), 6.61 (d, (J=2.8 Hz), 1H, CH=CH=N), 5.54 (s, 1H, NH); 
13
C 
NMR δ 164.52, 162.05, 153.51, 150.65, 130.15, 128.04, 127.96, 115.89, 115.67, 106.30; m/z 
[M+Na]
+
 = 228.0, calcd. for C10H8FN3ONa: 205.1, HRMS 228.0558, calcd. 228.1824; HPLC 
(method B), tR = 7.9 minutes, > 95% purity.  
Synthesis of 3-(4-((4-nitrophenyl)sulfonyl)phenyl)-pyrazole 
 
To a solution of (27) (120 mg, 427 µmol) in AcOH (5 mL) was added hydrogen peroxide (30% 
aq. solution) (435 µL, 12.8 mmol) in DMF (2 mL). The reaction was stirred for 16 hours at RT. 
The reaction was then diluted with distilled H2O (10 mL) giving a yellow precipitate which was 
collected by suction filtration and dried on a high vacuum line. The product required no further 
purification yielding (34) as a yellow solid (99 mg, 70.5%). 
1
H NMR δ 8.32 (dd, (J=2.0, 2.0 Hz), 
2H, PhH), 8.12 (dd, 2H, PhH), 7.97 (m, 4H, PhH), 7.63 (d, (J=2.4 Hz), 1H, CH=CH-NH), 6.68 (d, 
(J=2.4 Hz), 1H, CH-NH); 
13
C NMR δ 154.46, 151.45, 150.25, 146.55, 146.47, 145.95, 140.54, 
128.91, 128.49, 126.15, 125.00; m/z [M+H]
+
 = 330.1, calcd. for C15H12N3O4S: 330.1, HRMS 
330.0530, calcd. 330.3383; IR 3426.0, 1640.2, 1521.2, 1410.6, 1347.5, 1304.0, 1155.8, 1069.7; 
HPLC (method B), tR = 9.2 minutes, > 95% purity.  
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Synthesis of 3-(4-((4-nitrophenyl)sulfinyl)phenyl)-pyrazole-1-carboxamide 
 
To a solution of (34) (99 mg, 301 µmol) in AcOH (90% aq. solution) (5 mL) was added NaOCN 
as an aq. solution (500 µL) and stirred at RT for 5 hours. A white precipitate formed which was 
collected by suction filtration and dried in vacuo. The residue was purified via CC 
(EtOAc/hexane; 2:1) to give (36) as a yellow solid (16 mg, 14.9%).
1
H NMR δ 8.33-8.21 (m, 5H, 
PhH+ CH-N-C=O), 8.11-8.05 (m, 2H, PhH), 7.99-7.94 (m, 2H, PhH), 6.73 (d (J=3.0 Hz), 1H, 
CH=CH-N); 
13
C NMR δ 168.35, 152.02, 149.41, 146.30, 138.98, 136.61, 128.89, 127.96, 127.61, 
126.60, 123.55, 106.62; IR 2852.1, 1741.9, 1602.25, 1532.0, 1423.9, 1338.9, 1306.1, 1254.2, 
1012.20 cm
-1
; HPLC (method A), tR = 12.0 minutes, purity <95%. 
Synthesis of 3-(4-((4-fluorophenyl)sulfinyl)phenyl)-pyrazole 
 
To a solution of (26) (239 mg, 884 µmol) in AcOH (5 mL) was added hydrogen peroxide (30% 
aq. solution) (30.1 µL, 884 µmol) in DMF (2 mL). The reaction was stirred for 16 hours at RT. 
The reaction was then quenched with distilled H2O (5 mL) until a pale cream precipitate formed 
which was extracted into EtOAc (3 x 5 mL). The organic layer was dried over MgSO4 and the 
solvent removed in vacuo. The crude product was purified by CC (hexane/EtOAc; 2:1) giving 
(37) as a yellow solid (93 mg, 36.7%). 
1
H NMR δ 7.90 (m, 2H, PhH), 7.68-7.60 (m, 4H, PhH), 
7.57 (dd, 1H,(J=2.6, 1.3 Hz), CH=CH-NH), 7.17-7.10 (m, 2H, PhH), 6.60 (dd, (J=2.8, 1.2 Hz), 
1H, CH-NH); 
13
C NMR δ 165.85, 163.42, 149.04, 144.33, 141.17, 136.30, 127.74, 127.65, 
127.02, 125.66, 117.22, 116.99, 103.20; m/z [M+H]
+
 = HRMS 287.0642, calcd. for C15H12FN2OS: 
287.3326; IR 3208.4, 1590.0, 1407.3, 1402.4, 1362.2, 1339.8, 1290.7, 1228.1, 1152.2, 1040.5, 
924.4; HPLC (method B), tR = 7.4 minutes, >95% purity. 
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Synthesis of 1-fluoro-2-tosyloxyethane
137
 
 
To a solution of 4-fluoroethanol (60.0 mg, 940 µmol) in anhy. DCM (2 mL) was added p-
toluenesulphonyl chloride (270 mg, 1.41 mmol), triethylamine (200 µl, 1.41 mmol) and a catalytic 
amount of DMAP (13.0 mg, 110 µmol). The reaction mixture was stirred for 2 hours at RT. The 
mixture was then partitioned between 1M aq. HCl (10 mL) and DCM (20 mL). The organic layer 
was then washed with sat. aq. K2CO3 solution (10 mL), dried over MgSO4, filtered and evaporated 
to dryness. The residue was purified by CC (hexane/EtOAc; 9:1) to give pure (38) as a colourless 
oil (200 mg, 98%). 
1H NMR δ 7.85 (d, (J=8.0 Hz), 2H, PhH), 7.38 (d, (J=8Hz), 2H, PhH), 4.66 
(dt, (J=4.0, 4.0 Hz), CH-C-F), 4.54 (dt, (J=4.0, 4.0 Hz), CH-C-F), 4.33 (dt, (J=4.0, 4.0 Hz), CH-
CH2-F), 4.27 (dt, (J=4.0, 4.0 Hz), CH-CH2-F), 2.45 (s, 3H, CH3);
13C NMR δ 145.12, 132.74, 
129.92, 127.98, 68.50, 68.29, 21.65; m/z [M+Na]
+
 = 240.9, calcd. for C9H11FO3SNa: 241.0, 
HRMS = 241.0300, calcd. 241.2321; HPLC tR = (method A), 7.6 minutes, purity > 95%. 
Synthesis of 3-(4-(2,4-difluorophenoxy)phenyl)-1-(2-fluoroethyl)-pyrazole 
 
To a stirred solution of (9) (30.0 mg, 95.0 µmol) in DMF (3 ml) was added NaH (60% dispersion 
in mineral oil, 7.00 mg, 290 µmol) portion wise at RT. After ten minutes, a solution of (38) (14.0 
mg, 67.0 µmol) in DMF (500 µL) was added to the reaction which was heated to 100 °C for 60 
minutes. The reaction was then quenched with distilled H2O (5 mL) and extracted into EtOAc (2 x 
5 mL), dried with MgSO4 and the solvent removed in vacuo. The crude mixture was then purified 
by preparative HPLC (method C), tR =16.7 minutes. The product was extracted into EtOAc (3 x 
5.00 ml) and dried with Na2SO4 giving (41) as a clear oil in (3.00 mg, 14.2%) yield, isomeric 
purity > 95%. 
1H NMR δ 7.69 (m, 2H, PhH), 7.41 (d, (J=2.4 Hz), 1H, CH-N), 7.00 (td, (J=5.5, 3.5 
Hz), 1H, PhH), 6.92-6.85 (m, 3H, PhH), 6.81-6.75 (m, 1H, PhH), 6.44 (d,(J=2.4 Hz) 1H, 
CH=CH-N), 4.78 (t,(J=4.7 Hz), 1H, CH-F) 4.67 (t, (J=4.7 Hz), 1H, CH-F), 4.40 (t, (J=4.7 Hz), 
1H, CH-CH2-F), 4.33 (t, J=4.7 Hz), 1H, CH-CH2-F); 
13C NMR δ 154.70, 152.75, 137.52, 131.60, 
127.16, 122.47, 117.29, 111.37, 105.69, 103.22, 101.68, 82.81, 81.11, 52.64, 52.43; m/z [M+H]
+
 = 
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319.3, calcd. for C17H14F3N2O: 319.1, HRMS = 319.1048, calcd. 319.3074; HPLC (method D), tR 
= 11.9 minutes, >95% purity. 
Synthesis of fluoroethylazide
137
 
 
To a solution of (38) (200 mg, 2.25 mmol) in anhy. DMF (5 mL) was added sodium azide (439 
mg, 6.75 mmol) under N2 and the reaction was stirred at RT for 24 hours. Solid sodium tosylate 
was filtered off and (42) was isolated as a pale yellow oil as a DMF solution (0.23 M). Please 
note: (42) was not isolated as it is volatile and potentially explosive.  
Synthesis of 4-(4-ethynylphenoxy)-1,2-difluorobenzene 
 
To a solution of 2,4 difluorophenol (595 mg, 4.58 mmol) in DMF (10 mL) was added potassium 
carbonate (518 mg, 3.75 mmol), shortly after, 1-ethynyl-4-fluorobenzene (500 mg, 4.17 mmol) 
was added and the solution was heated to 150 °C for 16 hours. The reaction was cooled to RT and 
diluted with DCM (20 mL). The organic layer was washed with 2M NaOH (2 x 20 mL) and brine 
(2 x 20 mL). The organic layer was dried over MgSO4 and the solvent removed in vacuo. The 
crude mixture was purified by CC (hexane/DCM; 3:1) giving (43) as a white solid (117 mg, 12.0 
%). 
1H NMR δ 7.36 (d, (J=9 Hz), 1H, PhH), 6.83-6.76 (m, 2H, PhH), 6.56-6.50 (m, 4H, PhH), 
2.95 (s, 1H, CH); 
13C NMR δ 158.90, 156.49, 141.45, 141.33, 136.58, 136.55, 132.75, 115.72, 
115.63, 115.31, 109.06, 108. 83, 103.39, 103.12; m/z [M-F]
+
 = 212.0, calcd. for C14H8FO: 212.06; 
HPLC (method A), tR = 13.8 minutes, 90% purity. 
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Synthesis of 4-(4-(2,4-difluorophenoxy)phenyl)-1-(2-fluoroethyl)-1,2,3-triazole 
 
To a charged Wheaton vial containing copper wire (diameter 0.250 mm, 100 turnings) was added 
(43) (20.0 mg, 87.0 µmol) as a DMF/H2O solution (1/1; 400 µL). To this was added (42)
 
(380 
µL,) as a 0.350 M solution in DMF. The reaction suspension was stirred for 2 hours at 130 °C. 
The reaction was then diluted with distilled H2O (100 µL) and MeCN (500 µL) and the crude 
solution was purified by preparative HPLC (method E), tR = 12.2 minutes The product was 
collected using a manual switch giving (44) in (6.60 mg, 24.0%) yield. 
1H NMR δ 7.75 (t, (J=1.1 
Hz), 1H, CH-N), 7.71 (dq, (J=8.9, 1.1 Hz), 2H, PhH), 7.07-6.98 (m, 1H, PhH), 6.95-6.85 (m, 3H, 
PhH) 6.80 (dddd, (J=6.1, 3.5, 1.2 Hz), 1H, PhH), 4.82 (ddd, (J=6.1, 3.5, 1.2 Hz), 1H, CH-F), 4.69 
(ddt, (J=9.2, 5.5, 3.7 Hz), 2H, CH-F + CH-CH2-F), 4.63-4.57 (m, 1H, CH-CH2-F); 
13C NMR δ 
157.69, 147.65, 127.29, 125.56, 123.03, 122.93, 117.04, 111.57, 111.34, 105.79, 105.55, 105.53, 
81.65, 50.63; m/z [M+H]
+
 = 320.3, cald. for C16H13F3N3O: 320.1, HRMS 320.1027, calcd. 
320.2955; CHN C 58.77%, H 3.73%, 12.79%, calcd. C 60.19% H 3.79%, N 13.16%; HPLC 
(method A), tR = 11.1 minutes, purity >95%. 
Synthesis of 2-azidoethanol 
 
To a solution of bromoethanol (2.00 g, 16.0 mmol) in distilled H2O (30 mL) was added NaN3 
(1.25 g, 19.2 mmol) and the solution was heated to 95 °C for 16 hours. The reaction was cooled to 
RT and diluted with DCM (20 mL). The organic layer was washed with distilled H2O (2 x 20 mL) 
prior to drying over MgSO4 and the solvent removed in vacuo. The product was not isolated as it 
is volatile and potentially explosive, therefore (45) was used as a crude product in the following 
step.  
 
 
Chapter 2  Materials and Methods 
75 | P a g e  
 
Synthesis of 2-azidoethyl 4-methylbenzenesulfonate 
 
A solution of (45) (1.39 g, 16 mmol) in pyridine (1.94 mL) was cooled to 0 °C prior to addition of 
TsCl (4.57 g, 24 mmol). The solution was then warmed to RT and reaction was stirred for 3 hours 
before re-cooling to 0 °C. The reaction was diluted with ether (20 mL) prior to neutralising with 
aq. 2M HCl (5 mL). The product was extracted into ether (2 x 20 mL), dried over MgSO4 and the 
solvent removed in vacuo. The crude mixture was purified by CC (ether/EtOAc; 5:1) giving (46) 
as a yellow oil (3.474 g, 90%). 
1H NMR δ 7.73 (d, (J=8 Hz), 2H, PhH), 7.33 (d, (J=8 Hz), 2H, 
PhH), 4.12 (t, (J=5 Hz), 2H, CH2-O), 3.45 (t, (J=5 Hz), 2H, CH2-N), 2.36 (s, 3H, CH3); 
13
C NMR 
δ 145.47, 132.41, 130.13, 127.97, 68.54, 49.59, 21.73; m/z [M]+ = 241.00, calcd. for C9H11N3O3S: 
241.05; HPLC (method A), tR = 6.7 minutes, 90% purity. 
Synthesis of 2-(4-(4-(2,4-difluorophenoxy)phenyl)-1,2,3-triazol-1-yl)ethyl-4-methylbenzene-
sulfonate 
 
To a charged Wheaton vial containing copper wire (diameter 0.250 mm, 100 turnings) was added 
(43) (25.0 mg, 105 µmol) as a DMF/H2O solution (1/1; 400 µL) and (46)
 
(25 mg). The reaction 
suspension was stirred for 2 hours at 130 °C. The reaction was then diluted with distilled H2O 
(100 µL) and MeCN (500 µL) and the crude solution was purified by preparative HPLC (method 
K), tR = 22.5 minutes The product was collected using a manual switch giving (47) in (3 mg, 
13.5%) yield. m/z [M+H]
+
 = 472.19, calcd. for C23H19F2N3O4S: 471.11; HPLC (method A), tR = 
12.5 minutes, 95% purity. 
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2.2 Radiochemistry 
General procedure for manual drying of [
18
F]fluoride 
[
18
F] fluoride (aq.) was dispensed into a Wheaton vial containing potassium carbonate (1M, 13.0 
µmol), Kryptofix (10.0 mg, 30.0 µmol) and anhy. acetonitrile (1 mL). The mixture was 
azeotropically dried at 110 °C under a stream of nitrogen (0.4 mL/min). Two subsequent portions 
of anhy. acetonitrile (500 µL) were added and sequentially dried to give no-carrier-added 
[
18
F]fluoride/Kryptofix
®
2.2.2./carbonate-complex as a white semi-solid residue.  
Radiochemical yields 
Radiochemical yields are all isolated non-decay corrected (n.d.c) values, calculated either from 
[
18
F]fluoride or from a previous step (as indicated). Where yields are not given due to a product 
not being isolated, these reactions are measured as percent radiochemical purity using analytical 
HPLC.   
 
Synthesis of ((4-
18
F)fluorophenyl)(4-(trifluoromethyl)phenyl)methanone 
 
[
18
F]Fluoride (aq.) (330-370 MBq) was dried as according to the general procedure and the vial 
cooled to RT. A solution of (14) (2.0 mg) in DMSO (200 µL) was added and stirred at 130 °C for 
10 minutes before diluting with distilled H2O (1.50 mL). The product was purified by trapping to 
a 
t
C18 light Sep-pak cartridge pre-conditioned with EtOH (1 mL) and distilled H2O (3 mL). The 
cartridge was dried over a stream of nitrogen for 15 minutes and the product was eluted off the 
cartridge with MeCN (100 µL) to afford ([
18
F]15) (132-167 MBq, 40-45% n.d.c. radiochemical 
yield in 70 minutes from [
18
F]fluoride, n = 12). Analytical HPLC: (method A), tR = 12.5 minutes, 
RCP > 99%.  
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Synthesis of (1-
18
F)fluoro-4-bromobenzene 
 
[
18
F]Fluoride (aq.) (330-370 MBq) was dried as according to the general procedure and the vial 
cooled to RT. A solution of (19) (22.0 mg, 90.0 mmol) in DMF (200 µL) was added followed by a 
solution of TEMPO (10.0 mg, 60.0 µmol) in DMF (200 µL). The reaction was heated under 
microwave irradiation at 90 °C, 40 W for 30 secs. The reaction was diluted with distilled H2O 
(300 µL) and MeCN (300 µL) prior to purification by semi-preparative HPLC, (method E), tR = 
10.2 minutes. The product was collected via a manual switch and diluted with distilled H2O to a 
total volume of 20 mL, prior to loading to a 
t
C18 light Sep-pak cartridge pre-conditioned with 
NMP (1 mL) and distilled H2O (3 mL). The cartridge was dried over a stream of nitrogen for 20 
minutes. The product was eluted off the cartridge with NMP (1 mL) to afford ([
18
F]20) (50-93 
MBq, 15-25% n.d.c. radiochemical yield in 75 minutes from [
18
F]fluoride, n = 19). Analytical 
HPLC: (method F), tR = 10.2 minutes, RCP >99%.  
Synthesis of 3-(4-((4-
18
F)fluorophenyl))sulfinyl)phenyl)-1H-pyrazole 
 
[
18
F]Fluoride (aq.) (80-100 MBq) was dried as according to the general procedure and the vial 
cooled to RT. A solution of (36) (2.00 mg) in DMSO (200 µL) was added and the reaction was 
stirred at 150 °C for 20 minutes. The reaction was purified by semi-preparative HPLC: (method 
G), tR = 14.8 minutes and the product isolated via manual switch to afford ([
18
F]37) (0.8-1 MBq, 
1.0% n.d.c. radiochemical yield in 80 minutes from [
18
F]fluoride). Analytical HPLC: (method B), 
tR = 7.1 minutes, RCP > 99%. 
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Synthesis of (1-
18
F)fluoroethyl tosylate 
 
Manual: [
18
F]Fluoride (aq.) (300-400 MBq) was dried as according to the general procedure and 
the vial cooled, to this was added a solution of ethyl ditosylate (5.00 mg, 100 µmol) in MeCN 
(500 µL). The reaction was stirred at 100 °C for 15 minutes. The reaction was then diluted with 
distilled H2O (1.50 mL) and purified by semi-preparative HPLC: (method D), tR = 13.2 minutes. 
The product was collected using a manual switch, diluted with distilled H2O to a total volume of 
20 mL, and loaded on to a 
t
C18 light Sep-pak cartridge, pre-conditioned with DMF (1 mL) and 
H2O (3 mL). The cartridge was dried over a stream of nitrogen for 15 minutes. The product was 
eluted off the cartridge with DMF (60.0 µL) to afford ([
18
F]38) (120-160 MBq, 30-40% n.d.c. 
radiochemical yield in 70 minutes from [
18
F]fluoride, n = 13). Analytical HPLC: (method H), tR = 
11.0 minutes, RCP > 99%. 
Automated synthesis via Tracerlab™ FX-N: [18F]Fluoride (aq.) (2-4 GBq) was dried 
azeotropically in the reaction vessel using the same method as described in the general procedure 
section using the set-up as shown in Figure 2.1. To the dried [
18
F]fluoride was added ethylene 
ditosylate (5.00 mg, 100 µmol) in MeCN (500 µL) through the manifold and the reaction was 
heated to 100 °C for 10 minutes before purifying via semi-preparative HPLC, (method I), tR = 9.8 
minutes. The product was collected via a manual switch and diluted with distilled H2O to total 
volume of 20 mL and loaded on to a 
t
C18 light Sep-pak cartridge, pre-conditioned with DMF (1 
mL) and distilled H2O (3 mL). The cartridge was dried over a stream of nitrogen for 15 minutes. 
The product was eluted off the cartridge with DMF (60 µL) to afford ([
18
F]38) (0.6 – 1.2 GBq, 20-
30% n.d.c. radiochemical yield in 70 minutes from [
18
F]fluoride, n=6). Analytical HPLC: (method 
H), tR = 11.0 minutes, RCP > 99%. 
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Figure 2.1:GE Healthcare Tracerlab™ set-up for [18F]fluoroethyl tosylate synthesis 
Synthesis of 3-(4-(2,4-difluorophenoxy)phenyl)-1-(2-
18
F)fluoroethyl))-pyrazole 
 
A solution of (9) (2.00 mg, 6.35 µmol) in anhy. DMF (100 µL) was added to a Wheaton vial 
followed by addition of NaH (60% dispersion in mineral oil, 1.50 mg, 62.5 µmol) at RT and 
stirred for 10 minutes. ([
18
F]38) (400 MBq) in DMF (approx. 300 µL) was added dropwise to the 
vial and subsequently heated at 100 °C for 15 minutes. The reaction was diluted with distilled 
H2O (1.50 mL) and purified by reverse phase semi-preparative HPLC: (method J), tR = 9.80 
minutes. The product was collected using a manual switch, diluted with distilled H2O to a total 
volume of 20 mL, and loaded on to a 
t
C18 light Sep-pak cartridge, pre-conditioned with EtOH (1 
mL) and distilled H2O (3 mL). The cartridge was dried over a stream of nitrogen for 15 minutes. 
The product was eluted off the cartridge with EtOH (approx. 100 µL) to afford ([
18
F]41) (120 – 
140 MBq, 30-35% n.d.c. radiochemical yield in 70 minutes from ([
18
F]38), n = 8). Analytical 
HPLC: (method D), tR = 9.8 minutes, >99% RCP. Specific activity: 3.48 GBq/µmol. 
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Synthesis of (1-
18
F)fluoroethylazide  
 
Automated synthesis via FASTlab™ module: [18F]Fluoride (1-1.5 GBq) in [18O]H2O (0.1-1 mL) 
was trapped on to a QMA cartridge and eluted using a solution of Kryptofix 2.2.2 (10.0 mg, 27.0 
µmol) and potassium hydrogencarbonate (5.00 mg, 60.0 µmol), in distilled H2O (500 µL) and 
MeCN (1 mL) (Figure 2.2). [
18
F]fluoride was then dried in the reaction vessel at 100 °C for 15 
minutes. (46)
 
(15.0 µL) in MeCN (2 mL) was added to the reactor through the central line and 
heated to 100 °C for 30 minutes. As the reaction progressed, the product was distilled from the 
cassette manifold to an external vial charged with DMF (100 µL) to trap ([
18
F]42) (300-450 MBq, 
20-30% n.d.c. radiochemical yield in 60 minutes from [
18
F]fluoride, n = 10). Analytical HPLC: 
(method A), tR = 6.3 minutes, RCP >99%. 
 
 
Figure 2.2: A prepared GE Healthcare FASTlab™ cassette set-up for synthesising [18F]fluoroethyl azide 
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Synthesis of 4-(4-(2,4-difluorophenoxy)phenyl)-1-((2-
18
F)fluoroethyl)-1,2,3-triazole  
 
To a Wheaton vial was added distilled H2O (100 µL) followed by copper (II) sulphate (4 eq.), 
sodium L-ascorbate (4.4 eq) and bathophenanthrolinedisulphonic acid disodium salt (4.4 eq.). The 
vial was purged with N2 for 2 minutes prior to addition of (43) (2 eq.) in DMF (50 µL) followed 
by further N2 purging for 2 minutes. A solution of ([
18
F]42) in MeCN (300-400 MBq, 200-300 
µL) was added and the reaction proceeded at 130 °C for 15 minutes. The reaction was then cooled 
to RT and diluted with distilled H2O (1.50 mL) before purification by semi-preparative HPLC: 
(method K), tR = 23.4 minutes. The HPLC fraction was then collected via a manual switch and 
diluted with distilled H2O to a total volume of 20 mL and loaded onto a 
t
C18 light Sep-pak, which 
was subsequently dried over a stream of N2 and the product eluted with EtOH (100 µL) affording 
formulated ([
18
F]44) (90-160 MBq, 30-40% n.d.c. radiochemical yield in 60 minutes from 
([
18
F]42). Overall ([
18
F]44) was achieved in 10% n.d.c. e.o.s. radiochemical yield from 
[
18
F]fluoride (n=7) in 110 minutes with specific activity 0.2-16 GBq/µmol. Analytical HPLC: 
(method A), tR = 11.3 minutes, RCP >99%. 
 
2.3 Log P determination 
The octanol/H2O partition coefficients were determined using the shake flask method. Both 
solvents were presaturated with each other by shaking together for 5 minutes. To a solution of 0.5 
mL of both octanol and distilled H2O was added 1.0 mg of test compound. The mixture was 
shaken in a rotamixer for 5 minutes. After reaching equilibrium, the mixtures were centrifuged (5 
minutes at 10,000 rpm) to achieve good separation. Samples from each layer (25 µL) were taken 
and dissolved in 25 µL of MeCN. Analytical HPLC of both the aqueous and octanol layers was 
performed to measure the UV absorbance region of interest (ROI). The absorbance was correlated 
to a calibration curve of known concentrations. Two further samples were prepared of the same 
concentration, and all samples analysed by analytical HPLC. Log P was calculated according to 
the formula: 
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log P = log (ROI in octanol layer / ROI in H2O layer) 
 
2.4 In vitro biology 
2.4.0 Sharp intracellular microelectrode electrophysiology 
Preparation and storage of brain slices. 
Experiments were carried out using transverse, rostro-caudal slices of olfactory (piriform) cortex 
(450 µm thick; 6–10 slices per animal) prepared from adult male Wistar rats (150–200 g; either 
sex). Animals were sacrificed in accordance with the UK Animals (Scientific Procedures) Act 
1986 by overdose with inhaled isoflurane, decapitated, hemisected and placed into ice-cold (4 °C) 
oxygenated Krebs’ solution. Serial slices were then sectioned using a Campden Vibroslice/ tissue 
cutter (Campden Instruments, U.K.), and stored in oxygenated Krebs solution at 30 °C for at least 
30 minutes, before transferring to a Perspex recording chamber, where they were superfused 
continuously (held completely submerged) at ~ 10 mL/min with pre-warmed oxygenated Krebs 
solution at 29–30 °C. The composition of the normal Krebs solution was (in mM): NaCl 118, KCl 
3, CaCl2 1.5, NaHCO3 25, MgCl2 6, H2O 1, NaH2PO4 2, H2O 1.25 and D-glucose 11 (bubbled 
with 95% O2 – 5% CO2, pH 7.4). 
138
 
 
Intracellular recording 
Intracellular current-clamp recordings were made from the CA1 region of the hippocampus or 
periamygdaloid area of the piriform cortex slices within the piriform cortical cell layers II–III, 
using glass microelectrodes filled with 4M potassium acetate (tip resistances 60–80 MΩ) coupled 
to an Axoclamp 2B sample-and-hold preamplifier (2–3 kHz switching frequency, 50% duty cycle; 
Axon Instruments,CA, U.S.A.). Membrane input resistance and firing behaviour were assessed by 
injecting positive or negative current pulses of varying intensities (~ 0.25–3 nA; 160 ms), and the 
resulting electrotonic potentials or evoked action potentials recorded, respectively. First spike 
amplitudes were always measured (from baseline level) under ‘bridge’ recording mode to avoid 
sampling limitations of the discontinuous sample-and-hold preamplifier. In all experiments, the 
membrane potential was usually maintained at –70 mV (near firing threshold) by applying a 
steady depolarising current. The steady voltage level recorded at the soma following current step 
commands were always used to construct current–voltage (I–V) curves. Acceptable recordings 
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typically remained stable for periods of 1–5 hours. Sampled membrane voltage signals were 
monitored on a storage oscilloscope and a Gould TA240 Easygraf 2 channel chart recorder and 
also fed directly to a computer (Viglen Ltd, U.K.) via a Digidata 1322A analogue-to digital 
interface (Axon Instruments, CA, U.S.A.), using pCLAMP 10 software (Axon Instruments) for 
hard disk recording and off-line analysis. All measurements were made before, during and after 
bath superfusion (bath-exchange time 30 seconds) of pharmacological agents, so that each 
neurone served as its own control. Unless otherwise stated, each experimental sequence described 
below was repeated at least twice on different cells. Data are expressed as means ± s.e.m. 
 
Compound applications 
Research compounds were prepared as a 10 mM stock solution in either DMSO or EtOH, and 
were stored for up to 4 weeks at 4 °C without apparent loss of activity (analytical HPLC tested for 
decomposition). Compound solutions were subsequently diluted in Krebs solution immediately 
before use; the final bath concentrations of DMSO (up to 0.5%) or ethanol (0.1%) had no 
deleterious effects on membrane properties. The results presented in this thesis are based on 
recordings obtained from both pyramidal and cortical neurones in the hippocampus and piriform 
cortex respectively. 
 
Data analysis 
Electrophysiological traces of all recordings are reported to allow a qualitative report of the spike 
inhibition effects of each research compound at differing concentrations in each brain slice 
preparation. 
 
2.4.1 Automated patch-clamp electrophysiology 
Cell culture 
Chinese hamster ovary (CHO) cells were stably transfected with specific Na
+
 ion channel subtype 
cDNAs. Cells were cultured in Ham’s F-12 supplemented with 10% fetal bovine serum, 100 
U/mL penicillin G sodium, 100 μg/mL streptomycin sulphate, and the appropriate selection 
antibiotics. Before testing the cells, culture dishes were washed twice with Hank’s Balanced Salt 
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Solution and treated with accutase for approximately 20 minutes. Immediately before use in the 
IonWorks QuattroTM system, the cells were washed with HB-PS to remove the accutase and re-
suspended in approximately 3 mL of HB-PS. 
 
Formulation of test articles 
Chemicals used in solution preparation were purchased from Sigma-Aldrich (St. Louis, MO) 
unless otherwise noted and were of ACS reagent grade purity or higher. Stock solutions of test 
articles and the positive control (lidocaine.HCl, 3 mM) were prepared in dimethyl sulfoxide 
(DMSO) at 10 mM and stored frozen, unless otherwise specified. Test article and positive control 
concentrations were prepared fresh daily by diluting stock solutions into a HEPES-buffered 
physiological saline (HB-PS) solution (composition in mM): 137 NaCl, 4.0 KCl, 1.8 CaCl2, 1 
MgCl2, 10 HEPES, 10 Glucose, pH adjusted to 7.4 with NaOH, which was prepared weekly and 
refrigerated until use. Since previous results have shown that ≤ 0.3% DMSO and 0.05% pluronic 
F-127 do not affect sodium channel currents, all test and control solutions contained 0.3% DMSO 
and 0.05% F-127. The test article formulations were loaded in a glass-lined 384-well compound 
plate, and placed in the plate well of IonWorks Quattro™ (Molecular Devices Corporation, Union 
City CA). 
 
Test article treatment 
All experiments were performed at ambient temperature. Each test article (TA) concentration was 
applied to naïve cells (n ≥ 2, where n = the number cells/concentration) via steel needles of a 48-
channel pipettor. Each application consisted of addition of 6 μL of 2 x concentrated test article 
solution to the total 12 μL of final volume of the extracellular well of the Population Patch 
Clamp™ (PPC) planar electrode. The addition was followed by mixing (3 times) of the PPC well 
content. To prevent test article cross-contamination where necessary, the pipettor was washed 
with 0.1 M NaOH (3 cycles) and PBS (3 cycles). Duration of exposure to each test article 
concentration was at least five minutes to cells expressing specific ion channels (n ≥ 6, where n = 
the number cells). To verify the sensitivity of the assay to block, the positive control was applied to 
cells for five minutes (n ≥ 2, where n = the number cells).  
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Electrophysiology recordings 
In preparation for a recording session, intracellular solution comprising of as mM: KCl 130, 
MgCl2 4, EGTA 0.5, HEPES 10 was loaded into the intracellular compartment of the PPC planar 
electrode. Cell suspensions were pipetted into the wells of the PPC planar electrode. After 
establishment of a whole-cell patch-clamp configuration, membrane currents were recorded using 
the patch clamp amplifier within the IonWorks Quattro™ system. Before digitisation, the current 
records were low-pass filtered at one-fifth of the sampling frequency. Block of each Nav channel 
sub-type was measured using a stimulus voltage pattern shown in Figure 2.3 (voltage potentials 
are indicated in Table 2.2). The pulse pattern was repeated twice: before and 5 minutes after TA 
addition and peak current amplitudes at three test pulses was measured (ITP1, ITP11 and ITP12 [or 
TP13 or TP14]). 
 
Figure 2.3: Voltage protocol Type I for hNav1.x test procedure 
 
Table 2.2: Voltage-protocol parameters for hNav 1.x channels 
Data analysis 
Data were stored on the ChanTest computer network (and backed-up nightly) for off-line analysis. 
Data acquisition and analyses were performed using the IonWorks Quattro™ system operation 
software (version 2.0.2; Molecular Devices Corporation, Union City, CA). Data were also corrected 
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for leak currents. The decrease in current amplitude after TA application was used to calculate the 
percent block relative to control. 
The tonic block was calculated as:  
% Block (Tonic) = (1 – ITP1, TA / ITP1, Control) x 100%,  
where ITP1, Control and ITP1, TA are the inward peak Na
+
 currents elicited by the TP1 in control 
and in the presence of a test article, respectively.  
The frequency-dependent block at stimulation frequency 10 Hz was calculated as:  
% Block (10 Hz) = (1 – ITP11, TA / ITP11, Control)) x 100%,  
where ITP11, Control and ITP11, TA are the inward peak Na
+
 currents elicited by the TP11 in 
control and in the presence of a test article, respectively.  
We define the inactivation state block as decrease in test pulse (TP12 [or TP13 or TP14]*) current 
amplitude due to the conditioning depolarizing pulse (TP11). The inactivation state block was 
calculated as:  
% Block (inactivation state) = (1 – (ITP12, TA / ITP12, TA) x 100%,  
where ITP12, Control and ITP12, TA are the inward peak Na
+
 currents elicited by the TP12 in 
control and in the presence of a test article, respectively.  
*TP13 or TP14 currents was analyzed instead of TP12 if insufficient current (<0.1 nA) at TP12.  
Concentration-response data for the blocks will be fit to an equation of the following form:  
% Block = % VC + {(100 - % VC) - (100 -% VC) / [1 + ([Test] / IC50)N]},  
where [Test] is the concentration of test article, IC50 is the concentration of the test article 
producing half-maximal inhibition, N is the Hill coefficient, % VC is the percentage of the current 
run-down (the mean current inhibition at the vehicle control) and % Block is the percentage of ion 
channel current inhibited at each concentration of the test article. Non-linear least squares fits was 
solved with the XLfit add-in for Excel 2003 (Microsoft, Redmond, WA). 
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2.4.2 Manual patch-clamp electrophysiology 
Assay set-up 
HEK-293 cells stably expressing Nav 1.4 and 1.5 were cultured according to Scottish Biomedical 
standard operating system. They were plated onto 15 mm plastic dishes and incubated for 1-3 days in 
a 5% CO2 incubator prior to cell perforated whole-cell patch clamp experiments. Cells were 
superfused at RT with a standard physiological solution containing (in mM) NaCl (140), KCl (4), 
CaCl (2), MgCl2 (1), glucose (10), HEPES (10), pH 7.35 with NaOH. Patch pipettes were pulled 
from borosilicate glass and exhibited tip resistances of 2-5 MΩ when filled with the above 
solution. Internal (pipette) solution contained (in mM): NaCl (10), CsCl (50), CsF (60), MgCl2 
(2), EGTA (20), HEPES (10), (gramicidin) (0.1) pH 7.25 with CsOH, was used to study sodium 
channels without the interference of potassium currents. 
 
Whole-cell patch clamp 
Perforated patch-clamp technique (see Section 3.5.2) was carried out using an Axon 200B 
amplifier (Axon Instruments™) using the antibiotic gramicidin, to allow pore formation in the 
cell’s membrane without rupturing the membrane, minimising cell’s dialysis and allowing longer 
recording times (up to 60 minutes). The software program pClamp (version 10) was used to 
stimulate and record electrical activity using the two-pulse state-dependent protocol. A P/4 leak 
subtraction method was used for all experiments. Capacitative transients were compensated 
electronically from the recordings, however the voltage drop across the series resistance was 
generally less than 10 MΩ (n=76 cells), with a mean cell capacity of 30 ±5 pF. A two test pulse 
protocol was used to measure inhibition at rest and in an inactivated state (Figure 2.4). Starting 
from a holding potential of -90 mV, a test pulse was evoked for 10 ms pulses to 0 mV (P1; 
resting). Then, a 4 second pulse was applied to maintain the holding potential at -75 mV (P2; 
inactivation of channels). Prior to the assay, compounds were dissolved in 10 mM DMSO stock 
solution and then subsequently diluted in physiological solutions without exceeding 0.1% DMSO 
in the final solution of 0.1, 1, 10 and 30 µM. Perfusion of compounds only commenced when run-
down of cells was <10% (within a 120 second control period for both P1 and P2). Cells with 
higher run-down were usually excluded from further analysis.  
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Figure 2.4: Two-pulse IV protocol to assay state-dependent inhibition of hNaV 1.5 and 1.4. Typical current traces 
evoked by 10 ms test pulses to 0 mV from a holding potential of –90 mV. The 2 pulse protocol is applied every 15 s. 
Peak 1 (P1) represents all channels available from the resting state, and Peak 2 (P2) evokes current after a 4 s 
prepulse to -75 mV, which inactivates ~50% of the channels. 
Incubation time ranged from 2-5 minutes for control period, followed by 40 minutes incubation 
for each concentration. The effect of each compound on each channel was constantly monitored 
(for example, every 10 s), so that observation of steady-state inhibition was seen before 
experiment termination (40 minutes incubation time required).  
Figure 2.5 shows an example of the hNav 1.4 currents evoked by the I-V protocol as well as the 
average I-V curve and voltage-dependent parameters calculated from up to 6 cells. Inactivation 
and activation curves were always adequately fitted with single Boltzmann equations, indicating 
the presence of a single major sodium conductance. The rapid and complete inactivation of the 
currents were in line with published data. Currents begun to activate at -40 mV and typically 
reached a peak during test pulses to -10 mV, before reversing positive to +60 mV.  
 
 
Figure 2.5: Voltage –dependent properties of hNav 1.4 HEK-293 cell line. (A) example of current traces during an I-V 
protocol (50 ms test pulses from –90 mV in 10 mV increments). The -90 mV voltage pulse is highlighted by the red 
trace. (B): averaged activation and inactivation current data was used to plot the steady-state activation and 
inactivation curves, which are fit with single Boltzmann equations with values for Vh1/2 of -26±2 mV and V1/2 of -
61±2 mV; slope factors were 6±2 and 8±2, respectively. 
(A) (B) 
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An example of the hNaV 1.5 currents evoked by the I-V protocol is shown in Figure 2.6 below, as 
well as the average I-V curve and voltage dependent parameters calculated from up to 11 cells. 
Inactivation and activation curves were always adequately fitted with single Boltzmann equations, 
indicating the presence of a single major sodium conductance. 
 
Figure 2.6: Voltage-dependent properties of hNaV 1.5 HEK-293 cell line. (A) example of current traces during an I-V 
protocol (50 ms test pulses from –90 mV in 10 mV increments). The –90 mV voltage pulse is highlighted by the red 
trace. (B): averaged activation and inactivation current data was used to plot the steady-state activation and 
inactivation curves, which are fit with single Boltzmann equations with values for Vh1/2 of -35 ±1 mV and V1/2 of -69 ±1 
mV; slope factors were 3 ±1 and 5 ±1,respectively. 
TTX was used as positive control for both hNav 1.4 (Figure 2.7) and 1.5 (Figure 2.8). A calculated 
IC50 of 15 nM and 5 µM was obtained, respectively. hNav1.4 is regarded as the TTX sensitive 
channel and hNav 1.5 as the TTX resistant channel. The IV relationships recorded identified the 
correct expressed channel.  
 
Figure 2.7: Block of hNaV 1.4 by TTX on manual patch-clamp.(A): I-V relationships of INa expressed in terms of 
absolute current (pA), in the absence (open circles) and in the presence of TTX at 100 nM (solid circles; n=6).Values 
are means, with error bars denoting SEM. The holding potential was -90 mV up to+80 mV. (B): Concentration-
dependent effects of TTX (0.1 nM-10 µM) on INa currents (pA) obtained from HEK-293 cells stable transfected with 
hNaV. 1.4. Cells were stimulated from a holding potential of -90 mV to +80 mV with 50 ms pulses at 1 Hz. The mean 
data points were fitted by a variable slope sigmoidal curve using the Hill equation. 
 
(A) (B) 
(A) (B) 
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Figure 2.8: Block of hNaV 1.5 by TTX on manual patch-clamp.(A): I-V relationships of INa expressed in terms of 
absolute current (pA), in the absence (open circles) and in the presence of TTX at 100 nM (solid circles; n=11) and at 
100 μM (solid squares; n=3). Values are means, with error bars denoting SEM. The holding potential was -90 mV up 
to + 80 mV. (B): Concentration-dependent effects of TTX (1 nM -100 μM) on INa currents (pA) obtained from HEK-
293 cells stable transfected with hNaV 1.5. Cells were stimulated from a holding potential of -90 mV to -10 mV with 50 
ms pulses at 1 Hz. The mean data points were fitted by a variable slope sigmoidal curve using the Hill equation. 
 
Data analysis 
Activation curves were created by transforming I-V current into conductance and normalising to 
the peak (G/Gmax). Single Boltzmann equations were used to fit the data by varying the V50 
potential and slope (k) factors. The GraphPad Prism (version 5) software calculates the IC50 value 
and Hill slope co-efficient using a least squares regression algorithm, and constrained to allow 
100% block at a large but unknown concentration and fixing 0% inhibition to the hNav peak 
current value in pre-drug control periods (0.1% DMSO throughout). The concentration of 0.1% 
DMSO did not lead to significant effects on the amplitude of either the fully activated (P1) or 
half-inactivated (P2) of each of the hNav channels tested, which generally remain stable during the 
duration of a typical manual whole-cell recording control period (up to 5 minutes). Concentration-
response data for the effect of drugs on peak currents was fitted iteratively using a variable slope 
sigmoidal concentration-response curve and the calculated IC50 values were reported for the 
inactivation state.  
 
2.4.3 In vitro autoradiography 
Rat brains and hearts from naïve male Sprague Dawley rats were carefully removed and 
immediately frozen in 2-methylbutane cooled with dry ice. Briefly, coronal sections (10-15 μm 
thick) were cut in 3 regions of the brain (Regions 1, 2 and 4, see Figure 2.9) and 1 region of the 
heart (Figure 2.10). Frozen sections were thawed and pre-incubated for 20 minutes with 50 mM 
(A) (B) 
Chapter 2  Materials and Methods 
91 | P a g e  
 
TRIS buffer, pH 8.0, containing 138 mM NaCl and 2.7 M KCl, at RT. For determination of total 
binding, sections were incubated with a ~1.2 μM solution (100 μL containing 160 KBq) of 
([
18
F]44) in the same buffer at RT for 60 minutes. Non-specific binding was determined in the 
presence of ~1.2 mM of cold (44). After incubation, sections were washed twice for 2 minutes 
with 50 mM TRIS-HCl, pH 7.0, dipped briefly in ice-cold deionised water (5 seconds) and dried 
in a stream of cold air. Sections were exposed for 10-20 minutes to Kodak™ photographic film, 
which was developed using an Amersham Biosciences, Hyperprocessor™. One brain section 
(region 2) and one heart section (coronal) were imaged using a Biospace Mesures, Microimager™ 
for 2 hours. Images were digitised using a Photometrics CoolSnap™ and interpreted using MCID 
Elite™ 7.0 software. 
 
Figure 2.9: Slicing scheme. Abbreviations used in the above images: Ac: anterior commissure, C: cerebellum, Cc: 
cerebral cortex, Cca: corpus callosum, H: hypothalamus, Hc: hippocampus, Mo: medulla oblongata, O: optic 
chiasm, P: pons, Sr: striatum, T: thalamus. 
 
 
 
Figure 2.10: Schematic of rodent heart (left) and longitudinal section through both ventricles (right). Rv: right 
ventricle, Ra: right auricle, Ao: aorta, La: left auricle, Cv: conoventricular vein, Lv: left ventricle, At: atrium  
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2.4.4 Cell-culture of human breast cancer cell lines 
MDA-MB-231 and MCF-7 cell lines 
MDA-MB-231 cells obtained from ATTC (approx 1 x 10
6
 cells) were thawed in a 37 °C water 
bath and then sprayed (70% EtOH) into a pre-cleaned category II tissue culture fumehood. The 
contents of the flask was added to a T75 flask (passage 0) containing 25 mL of fresh media RPMI 
media (developed by Roswell Park Memorial Institute), containing 5% FBS, 0.5% sodium 
pyruvate, 0.5% L-glutamine). Cells were cultured at 37 °C in a 5% CO2 incubator. After 3 days 
the confluency of the flask had reached >70%. The flask was sprayed into a pre-cleaned category 
II tissue culture fumehood as before and the media removed prior to cell washing with 10 mL 
PBS. Trypsin (6 mL) was added to the flask and placed temporarily into the incubator (5 minutes). 
The cell suspension was then aliquoted into three T175 flasks (2 mL; passage 1) containing 50 mL 
of media and placed into the incubator. Subsequently, the cells were split on average every 3 days 
into T175 flasks; the split number depended upon the confluency of the flasks. After 5/6 passages, 
the cultured cells were used for in vivo inocculations.  
MCF-7 cells were also obtained from ATTC and cultured using minimum essential amino acid 
media (containing 5% FBS, 0.5% minimum essential amino acid, 0.5% L-glutamine) following 
the same method as described above. 
 
2.4.5 Radioligand cell binding assay 
2.4.5.0 Seeded-cell assay 
MDA-MB-231 and MCF-7 cells were separately harvested prior to seeding in flat-bottomed 96-
well plates (following a similar method as described for cell culturing). The media was removed 
from each flask and all cells washed with PBS (5 mL) before addition of trypsin (6 mL per flask). 
The flasks were placed in a 37 °C incubator with 5% CO2 for 5 minutes before being pooled into 
falcon tubes. The falcon tubes were placed in a centrifuge and spun for 5 minutes at 1000 rpm. 
The supernatant was removed and new media was added to the cell pellet to give a total 
concentration of: MDA-MB-231 cells: 1x10
5
 cells/mL and MCF-7 cells: 5x10
5
 cells/mL. To each 
of the wells was added 100 µL of each solution. The cells were seeded overnight in the incubator 
to attach to the plate. 
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Initially, 0.6 mL of PBS was added to ten eppendorf tubes (per cell line). Thereafter, 0.3 mL of 
prepared radiotracer (approx 1 µM) was added to tube one and then a 1:3 serial dilution produced 
nine different concentrations for testing. 
Concentration µM 
1 1.6 
2 0.53 
3 0.18 
4 0.059 
5 0.019 
6 0.0065 
7 0.0022 
8 0.00073 
9 0.00027 
Table 2.3: Serial dilutions of radiotracer for binding study 
To measure block for specific binding, a 10 µL solution of cold standard (1 mM) was added to 
eighteen wells (per plate) prior to addition of radiotracer. Of each concentration (Table 2.3), 90 
µL was added to each well containing cold standard, starting with the most dilute concentration in 
duplicate. In the remaining wells, 100 µL of each concentration was added in triplicate. Each 96-
well plate was incubated for 60 minutes in a lead box at RT. The plates were washed with PBS 
twice to remove unbound radiotracer. Then, trypsin (100 µL) was added to each well and left for 5 
minutes at RT to loosen the cells from the plate. Each plate was then transferred to a Micro 96 
Harvester™. A printed glass fibre filter was moistened with PBS prior to removal of the cells 
from the plate and trapped to the filter using a standard washing cycle. The filter corresponding to 
each well was separated out and placed on a gamma counter. 
   
2.4.5.1 Cell suspension assay 
MDA-MB-231 and MCF-7 cells were separately harvested by trypsination and centrifuged for 5 
minutes at 1,000 rpm prior to suspending in PBS (5 x 10
5
 cells/mL). The cells were divided into 
16 eppendorf tubes (0.5 mL) per cell line to give an initial starting number of 2.5 x 10
5 
cells. 
Initially, 5 µL of (44) (1 mM) was added to 6 eppendorf tubes per cell line to give an overall 
concentration of 10 µM for “blocking”. The cells were incubated for 5 minutes at RT. To two of 
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the “block” tubes was added ([18F]44) (50 µL) and then the same amount was added to two blank 
tubes, giving concentration one as 100 nM. Then, to two of the “block” tubes was added ([18F]44) 
(5 µL) and then the same amount was added to two blank tubes, giving concentration two as 10 
nM. All the cells were incubated for 60 minutes at RT. The tubes were then centrifuged for 5 
minutes at 1,000 rpm. The supernatant was carefully removed and the cell pellet resuspended in 
PBS (0.5 mL) before further centrifugation (5 minutes, 1,000 rpm). The supernatant was carefully 
removed and further PBS (0.5 mL) was added. Again, all samples were centrifuged as before and 
cells resuspended in PBS (0.5 mL). Finally, all the samples were transferred to a Wallach™ 
counter for recording. To monitor cell viability, cells with just “block” and blank cells which 
underwent the assay were tested. Tryphan blue (200 µL) was added to an aliquot of cells (200 µL) 
and counted using a haemocytometer, cells which showed active removal of the chemical were 
counted. 
 
2.5 In vivo biology 
2.5.0 Biodistribution study 
The [
18
F] sodium channel tracer was injected intravenously as a bolus via the tail vein of non-
anaesthetised mice, in a volume of no more than 5 mL/kg. Each animal was injected with between 
1-3 MBq. Following injection of the “labelled substance” the animals were placed in short-term 
metabolism cages as appropriate. All voided urine and faeces were collected. At the appropriate 
time points, animals were anesthetised and killed by cervical dislocation (non-schedule 1). 
Inhalational isoflurane anaesthetic was used for all the biodistribution experiments (2% alveolar 
concentration). Key tissues (as decided for each study) were dissected, weighed, counted and 
expressed as % ID and % ID/g. Each study was performed at n ≥1 (see each study for more exact 
details). 
For näive studies, tracer concentrations were sampled at 2, 15, 20, 60 and 120 minutes. For 
tumour-bearing mice, see each study for exact details.  
Biodistribution studies were kindly performed by the in vivo biology team, GE Healthcare, 
Amersham.  
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2.5.1 Metabolism study 
Initially, [
18
F] sodium channel tracer was injected intravenously as a bolus via the tail vein of non-
anaesthetised mice, in a volume of no more than 5 mL/kg. Each animal was injected with between 
1-3 MBq. Following injection of the “labelled substance” the animals were placed in short-term 
metabolism cages as appropriate. All voided urine and faeces were collected. Animals were 
anesthetised and killed by cervical dislocation (non-schedule 1) at 2, 15 and 60 minutes. 
Inhalational isoflurane anaesthetic was used for all the biodistribution experiments (2% alveolar 
concentration). Plasma, brain and heart tissue was extracted at each time point and the protein 
precipitation method was used to extract parent and non-parent radiotracer from each tissue 
sample.  
Initially, the 2 minute plasma sample was selected and a 100 µL aliquot of plasma was extracted 
and added to an eppendorf tube in duplicate (for measuring on the Wallach counter at the end of 
the study). To the remaining plasma sample was added 5 mL of ice-cold acetonitrile and 
centrifuged for 3 minutes at 1000 rpm. The supernatant was removed and collated in a 100 mL 
round bottom flask. The total volume of supernatant was recorded and 100 µL aliquoted into an 
eppendorf tube for measuring at the end of the study in duplicate. The plasma pellet was also 
placed onto the Wallach counter to measure the efficiency of the centrifugation step. The 
remaining supernatant was put on the rotary evaporator to remove the acetonitrile and 
resuspended in 2 mL (40% MeCN and 60% H2O) mobile phase. A 100 µL aliquot of the mobile 
phase solution was taken for counting in duplicate. Of the remaining mobile phase solution, 1 mL 
was injected onto a semi-preparative HPLC. The eluent was collected to ascertain the efficiency 
of the HPLC purification. This procedure was then repeated for each sample over the three time 
points.  
This study was kindly assisted by the in vivo biology team, GE Healthcare, Amersham.  
 
2.5.2 Inoculations of  MDA-MB-231 and MCF-7 cells 
MDA-MB-231 cells 
MDA-MB-231 tumour cells in PBS (100 µL; 1 x 10
7
 cells/mL) were inoculated subcutaneously 
into the right second mammary fat pad area of up to six anaethetised SCID female mice and the 
tumours allowed to grow for up to six weeks or until they reached a maximum size of 12.5 mm.  
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A secondary group of SCID female mice were also inoculated, 5 x 10
7
 cells/mL in 1/1 
PBS/Matrigel™ (100 µL), subcutaneously into the right second mammary fat pad area and 
allowed to grow over the same time scale.  
Inoculations studies were kindly performed by Dr S Hoppmann, GE Healthcare, Amersham. 
  
MCF-7 cells 
MCF-7 tumour cells were implanted at 1x10
7
 cells/mL in PBS (100 µL) subcutaneously into the 
inner right thigh of up to six anaesthetised female mice and the tumours allowed to grow for up to 
six weeks or until they reached a maximum size of 10 mm. As MCF-7 cells are oestradiol 
dependent, mice were implanted subcutaneously into the nape of the neck with a 60-day slow 
release pellet (17β-oestradiol, 1.7 mg/pellet) obtained from Innovative research of America (cat 
number, SE-121). 
Inoculations were kindly performed by Dr S Hoppmann and Ms R Lear, GE Healthcare, 
Amersham.  
 
2.5.3 PET/CT imaging  
Each animal was placed in a warming box at 37 °C to ensure the tail vein was visible to aid 
injection. Animals were placed in a humane perspex restrainer and injected with 100 µL of the 
radiotracer (5-10 mBq). The animal was then placed on the imaging bed and maintained under 
inhalation anaesthesia (isoflurane) throughout the duration of the study (60 minutes). 
Immediately, DYNAMIC PET scanning was commenced using a MicroPET-P4 scanner (Siemens 
Inc). Respiration and body temperature was monitored using the BioVET system. Following the 
emission acquisition a transmission scan was acquired. The imaging bed was then transferred to a 
MicroCT II (Siemens) scanner and a CT scan acquired. The animal was either recovered for use in 
a further study or sacrificed by cervical dislocation (non-Schedule 1).  
PET/CT imaging was kindly carried out by the in vivo biology team, GE Healthcare, Amersham.  
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3. Results and Discussion 
 
 
 
 
 
Design, synthesis and bioevaluation of 3-(3-(4-R-
phenoxy)phenyl)-pyrazole-1-carboxamides 
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3.0 Synthesis of 3-(4-R-phenoxy)phenyl pyrazoles 
3-(4-R-Phenoxy)phenyl pyrazoles, first reported by Yang and co-workers (Scheme 3.1), 
were shown to be potent state-dependent VGSC ligands through in vitro studies.
7
 They 
reportedly gave good efficacy in animal models of neuropathic pain. In-fact, they were 
shown to be nearly 10 times as efficacious as carbamazepine (a known anti-convulsant). 
Inhibition of VGSC currents were recorded in HEK-293 cells stably expressing hNav 
1.4. The inhibitory effects of these compounds were reported to be highly sensitive to 
the holding voltage, indicating that they bind more efficiently to VGSCs in their 
inactivated states (measured as Ki), and show ~100 times weaker potency towards 
resting states (measured as Kr). This class of compounds were chosen as a platform to 
develop a novel fluorine-18 labelled PET ligand targeting VGSCs. They were selected 
due to their good binding affinity and its structure amenable to multiple potential 
radiolabelling strategies.
7
  
Initially, the three most potent compounds were selected from the library of 3-(4-R-
phenoxyphenyl) pyrazoles ((7) – (9), Scheme 3.1). These compounds were synthesised 
following a three step procedure.  
 
Scheme 3.1: Synthesis of 3-(4-substituted-phenoxy)phenyl pyrazoles 
7
 
The first step followed a Williamson ether synthesis (Scheme 3.2). Deprotonation of the 
phenol allowed for nucleophilic attack on 4-fluoroacetophenone with loss of KF. 
Following reaction completion as monitored by tlc, each reaction was quenched with 
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2M NaOH and the product was extracted into EtOAc. The crude products were 
continued onto the following step without further purification. However, a small sample 
from each reaction ((1)-(3)) was purified by CC (1:1; hexane:EtOAc) for product 
identification by nuclear magnetic resonance spectroscopy (NMR) and gas 
chromatography mass spectrometry (GCMS). 
 
 
Scheme 3.2: Formation of ether bridge 
The pyrazole ring was formed by a one-pot two-step ring closure (Scheme 3.3). 
Addition of N,N dimethylformamide dimethylacetal (N,N DMF DMA) allowed carbon-
carbon bond formation through a base catalysed aldol reaction. Attack at the terminal 
carbonyl gave a reactive enolate intermediate, which then reacted with the carbonyl of 
dimethylacetal dimethylformamide giving an α,β-unsaturated ketone intermediate as a 
yellow precipitate. The addition of hydrazine drove the ring closure through a 1,4 
Michael addition. 
  
Scheme 3.3: Pyrazole ring closure 
In the final step, addition of sodium cyanate in AcOH (90% aq.), allowed for formation 
of the terminal carboxamide through nucleophilic attack on the pyrazole (Scheme 3.4). 
The product precipitated out of solution without further purification. (7), (8) and (9) 
were isolated in 68%, 25% and 78% yield respectively. 
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Scheme 3.4: Formation of terminal carboxamide 
Product identity was confirmed by 
1
H, 
13
C, COSY and NOSEY NMR and liquid 
chromatography mass spectrometry (LCMS) under electrospray ionisation. Data was 
consistent with the structures shown, and with literature reports.
7 
  
 
Figure 3.1: 1H NMR spectrum of (7) in CDCl3  
The three literature compounds were produced in variable yields with purity > 95%. 
The NMR spectrum of (7) (Figure 3.1) was compared to the data reported by Yang et. 
al., and showed to be consistent with literature characterisation. 
The next steps were to ascertain a reproducible radiolabelling process to produce a 
fluorine-18 labelled analogue of the 3-(4-R-phenoxy)phenyl pyrazoles. Thereafter, these 
potential radiotracers were going to be used in radioligand binding studies to afford the 
Bmax and Kd values and ultimately the binding potential (Bmax/Kd). As discussed 
previously (Section 1.5), this would need to be ≥10 to afford a good signal to noise 
ratio. Tritiation of the compounds could have allowed these radioligand binding studies 
to be achieved earlier; unfortunately, funds were not available to allow this, so the 
(6) 
(1) 
(2) 
(3) 
(4) 
(5) 
(7) 
Chapter 3  Results and Discussion 
101 | P a g e  
 
compounds were evaluated for radiolabelling studies with fluorine-18 in the first 
instance.  
3.1 General [
18
F] radiolabelling strategies 
Fluorine-18 produced from a proton accelerator cyclotron was delivered as an aqueous 
solution by irradiation of an [
18
O] H2O liquid target. In aqueous solution, [
18
F]fluoride is 
relatively unreactive, due to being highly diluted and strongly solvated, thus steps are 
taken to provide a reactive nucleophilic reagent.
139-140
 Firstly, a large organic soluble 
cation is added. Caesium and tetralkylammonium salts have been used, but more 
commonly a potassium salt complexed by a cryptand such as Kryptofix (2.2.2)™ 
(4,7,13,16,21,24-hexaoxa-1,10-diazabicyclo[8.8.8]-hexacosane). This step is often 
performed by adsorbing the target water containing [
18
F]
-
 on a short anion exchange 
resin cartridge and eluting with a solution of the chosen cation in a water/solvent 
mixture, e.g. an aqueous solution of potassium carbonate with Kryptofix™ (Figure 3.2). 
Secondly, [
18
F]
-
 has to be dried. This step is completed by azeotropic distillation of the 
aqueous solution with a solvent, commonly acetonitrile. The azeotropic drying of [
18
F]
-
 
typically takes from 10 to 30 minutes in an automated radiosynthesis process.
141
 
 
Figure 3.2: Diagram to represent the purification of [18F]fluoride on a QMA cartridge 
There are two established methods for radiolabelling compounds with fluorine-18: 
Direct labelling incorporates fluorine-18 in a one-step method through nucleophilic 
aromatic substitution (SNAr) for example, or other displacement reactions. This type of 
labelling allows for short synthesis times, but has limitations with molecules that do not 
allow for direct labelling due to incompatible functionalities present on the molecule.
142-
143
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Indirect labelling makes use of synthon chemistry; the molecule is broken down into 
“fragments” through disconnecting certain bonds following the rules for retrosynthetic 
analysis. Initially, a small “fragment” is labelled, and subsequently bound to the 
remainder of the target molecule.
144
 
In the context of PET radiochemistry, it is important to minimise reaction times, to 
avoid unnecessary decay of the radioisotope. [
18
F] has a half-life of 110 minutes and 
[
18
F]-labelled tracers for PET are therefore ideally synthesised and purified within one 
half-life. It is also important to note that the concentration of fluorine-18 present is so 
low, that it is not possible to incorporate fluorine-18 into multiple positions. 
 
Figure 3.3: Structure of ([18F]7) 
Of the three VGSC ligands, ([
18
F]7) (Figure 3.3) was selected to be the first PET tracer 
of this class to be prepared. 
  
3.1.0 Direct fluorine-18 labelling 
There is much information in the literature about devising radiolabelling strategies and 
problems which may arise due to side and competition reactions; this knowledge 
allowed for different radiolabelling routes to be planned and implemented. For direct 
labelling to proceed, any base labile functional groups on the molecule require 
protecting first, as [
18
F]fluoride can act as a base. The carboxamide group is a base 
labile functional group, where [
18
F]fluoride could de-protonate and cleave the whole 
functional group, stopping the desired SNAr reaction from occurring. The protecting 
group used needed to be base stable but acid labile to remove the group at the end of the 
synthesis. Di-tert-butyl dicarbonate (Boc) is a common protecting group used, as it is 
base stable but cleaved easily with concentrated trifluoroacetic acid (TFA).  
To produce ([
18
F]7), (10) was synthesised as labelling precursor via a boc protection of 
the terminal carboxamide of (7). This was carried out in the presence of TFA and boc in 
anhydrous DCM at rt for 24 hrs. The product was purified by CC (4:1; hexane: EtOAc) 
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giving (10) in 10% yield. Characterisation was achieved via 
1
H and 
13
C NMR and high-
resolution mass spectroscopy (HRMS).  
Fluorine-19 for fluorine-18 isotopic substitution of (10) (Scheme 3.5) was assessed as a 
high-risk radiolabelling strategy to model whether direct labelling of this compound was 
possible. As discussed in section 2.1, the concentration of fluorine-18 in comparison to 
the concentration of precursor is so low that there will always be a significant amount of 
fluorine-19 compound remaining, giving low specific activity (amount of activity 
divided by the mass of material, usually expressed in GBq/µmol). Although 
radiolabelling by isotopic exchange gives poor specific activity, it does allow for an 
indication of whether radiolabelling is possible. Blom et. al., reported using isotopic 
exchange for radiolabelling a series of compounds including fluorobenzophenones, 1-
(4-fluorophenyl)ethanone and various activated and deactivated fluoro benzenes. They 
reported the best general conditions for isotopic exchange to be: DMSO, 150 °C, 25 
minutes giving an average specific activity of 0.58 GBq/µmol.
145
  
Initially the isotopic exchange of (10) was performed using the conditions in Table 3.1 
and Table 3.2. 
 
Scheme 3.5: Attempted radiolabelling of (10) through isotopic exchange 
Solvent Temperature 
(°C) 
Reaction Time 
(minutes) 
Radiochemical 
Purity (%) 
DMSO 150 45 0 
DMSO 150 75 0 
MeCN 100 25 0 
MeCN 110 15 0 
DMF 110 30 0 
DMF 140 15 0 
Table 3.1: Attempted isotopic exchange of (10) via conventional heating 
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Solvent Set Temperature 
(°C) 
Power 
(W) 
Reaction Time 
(seconds) 
Radiochemical 
Purity (%) 
DMSO 80 50 30 0 
DMF 100 50 60 0 
Table 3.2: Attempted isotopic exchange of (10) via microwave irradiation 
Though many different reaction conditions were tested, no labelling of (10) was 
observed. From the HPLC radio chromatograms, it was seen that the activity remained 
as unreacted [
18
F]fluoride. Despite the literature precedent for this reaction, we could 
not replicate isotopic exchange on our compounds.
145
 Interestingly, when comparing 
UV chromatograms (Figure 3.4), (5) was identified as a side-product of this reaction. It 
was surprising that cleavage of the boc and carboxamide group was seen, as the boc 
group had been added to protect this type of reaction from occurring. El Kazzouli et. al., 
however published results showing that bases can in fact cleave boc groups.
146
 Their 
findings were that boc is very labile in the presence of sodium carbonate. It was 
therefore concluded that the presence of potassium carbonate required in the azeotropic 
drying of [
18
F]fluoride, was causing deprotection of (10).  
 
 
Figure 3.4: HPLC (a) radio and (b) UV chromatogram of radiolabelling of (10) 
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As protection of the carboxamide had shown to be ineffective, the synthetic route was 
altered to add the carboxamide with sodium cyanate after fluorination to afford ([
18
F]7). 
Therefore, radiolabelling of (5) was subsequently tested through a nucleophilic aromatic 
substitution reaction of the para-nitro group with fluorine-18. This compound contains 
no labile terminal carboxamide and as the NH is only weakly acidic, we initially did not 
protect this group (Scheme 3.6). The results under various conditions are shown in 
Table 3.3. 
 
Scheme 3.6: Attempted radiolabelling of (5) 
Solvent Temperature 
(°C) 
Reaction Time 
(minutes) 
Radiochemical 
Purity (%) 
MeCN 90 30 0 
MeCN 110 45 0 
DMF 145 20 0 
Table 3.3: Attempted radiolabelling of (5) via conventional heating 
Once again SNAr chemistry, for directly labelling proved unsuccessful. The main reason 
was thought to be due to the electron donation from the oxygen atom (forming the ether 
bridge), causing de-activation of the ring towards SNAr chemistry. To activate 
radiolabelling, additional electron withdrawing groups for example CF3 and NO2 were 
investigated. It was proposed that addition of the electron withdrawing groups would 
stabilise the positively charged ring intermediate, thus drive the [
18
F]
- 
nucleophilic 
attack and SNAr reaction forward. Therefore, based on the reported information that (9) 
is the most potent of the three compounds by 6 nM, and that isotopic exchange does not 
occur, we proposed the modification of (8) by adding in a fluorine meta to the nitro 
(Scheme 3.7; (11)). Although electron withdrawing groups in the meta position would 
not directly activate this ring for SNAr chemistry, it was thought that adding the extra 
electron withdrawing group into the ortho positon might change some pharmacological 
properties of the molecule. By adding the fluorine in the meta position, we were able to 
maintain the structure of (9). Also, the terminal carboxamide was added to protect the 
NH group to avoid concerns over deprotontation with fluorine-18.  
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Scheme 3.7: Proposed synthesis of ([18F]9) 
The synthesis of (11) was undertaken using the same procedure as described in (Scheme 
3.1). 2-Fluoro-4-nitrophenol in the presence of base was added 4-fluoroacetophenone to 
undergo a Williamson reaction (Scheme 3.8). Following thin layer chromatography (tlc) 
monitoring, no product was seen, even after 16 hours at 140 °C.  
 
Scheme 3.8: Attempted synthesis of (12) 
The reaction was worked-up and the crude mixture purified by CC (4:1; hexane: 
EtOAc) to identify whether any undesired side-products had formed. An NMR 
spectrum of each product was taken, and only starting materials (2-fluoro-4-nitrophenol 
and 4-fluoroacetophenone) and DMF (presumably polymerised) were identified. This 
was unexpected, as (9) was successfully synthesised which also has two electron-
withdrawing groups on the phenolic starting material in the same positions. Stronger 
base was used encase the limitation was deprotonation of the phenol. Potassium 
hydroxide was used under the same reaction conditions but also after 16 hours at 140 
°C, no product was seen. Again, the reaction mixture was purified by CC (4:1; 
hexane:EtOAc) and following NMR of each fraction, only starting material and DMF 
were found. 
It was unusual that this reaction did not work even after the addition of a stronger base. 
We hypothesised that perhaps the phenol was being deprotonated by both bases, (in 
accordance with previous results (compounds (1) – (3)), but the anion formed, was 
stabilised by delocalising the charge into the benzene ring, thereby inhibiting the 
Williamson reaction.  
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Scheme 3.9: Stability of 2,4 difluorophenol under basic conditions by inductive effect 
The presence of the second fluorine, as in 2,4-difluorophenol is likely to increase 
stability of the phenolate formed during deprotonation of the phenol by stabilising the 
electron density over the ring (Scheme 3.9). 
We proposed that the combination of ortho-fluorine and para-nitro group stabilised the 
anion better than the other phenols previously used. This could also be one reason why 
the yields were so low for previous reactions. Also, nitro is a better electron-
withdrawing group than fluorine, and could better stabilise an anion intermediate, hence 
why this reaction did not proceed, but the synthesis of (3) did. To test this hypothesis, 
we used 2,4 dinitrophenol under standard Williamson conditions (Scheme 3.10) to 
afford (13). We also found this reaction was unsuccessful. The reaction was monitored 
hourly by tlc, but after 9 hours no reaction was occurring. Tlc showed only starting 
material in the crude reaction mixture and the reaction was subsequently abandoned. 
We proposed that the anion of 2,4-dinitrophenol and 2-fluoro-4-nitrophenol were too 
stable to undergo a Williamson reaction due to the stabilising effect of the nitro group. 
 
Scheme 3.10: Attempted synthesis of (13) 
Finally, the use of iodonium salts was proposed to afford a precursor for use in a one 
step labelling process. An iodonium salt of (7) was initially sought (Figure 3.5), 
utilising a modified Koser’s reagent to afford a 4-methoxy moiety on the terminal 
phenyl ring. It was hoped that the p-methoxy moiety would direct fluorination onto the 
opposite ring and leave 1-iodo-4-methoxy benzene as the by-product, together with 
([
18
F]7)  
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Figure 3.5: Proposed iodonium salt of (7) 
The initial synthesis of the modified Koser’s reagent (Figure 3.6) however, proved 
challenging and was not achievable. Previous reports have shown that modifying the 
traditional Koser’s reagent is difficult to do and only exothermic decomposition is 
seen.
147-148
  
 
Figure 3.6: 4-methoxy derivative of Koser’s reagent 
We set out to develop an iodonium salt to afford a precursor for use in a one-step 
labelling process. However, it was not possible to find a reliable procedure to undertake 
this work and as such, this route was discarded in favour of following an indirect 
labelling process.  
 
3.1.1 Indirect fluorine-18 labelling 
As fluorination via direct radio-fluorination proved unsuccessful, multi-step routes were 
investigated to produce ([
18
F]7). Firstly a retrosynthetic analysis was used to identify 
possible synthons for indirect labelling protocols.  
 
3.1.1.0 Retrosynthetic analysis  
Through retrosynthetic analysis two synthons were identified, (4-
18
F)fluorophenol and 
(1-
18
F)fluoro-4-bromobenzene (Scheme 3.11).
133, 149-150
 Both synthons have literature 
precedent for their synthesis and could be conjugated to the rest of the molecule in a 
short synthetic pathway.  
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Scheme 3.11: Retrosynthetic analysis of target molecule 
The two strategies outlined show feasible pathways to produce the desired compound 
([
18
F]7). Following the synthesis of (1-
18
F)fluorophenol, a Williamson reaction would 
complete the synthesis of the target molecule (Scheme 3.12). Following route two,     
(1-
18
F)fluoro-4-bromobenzene would undergo a copper catalysed Ullmann coupling to 
afford ([
18
F]7).  
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3.1.1.1 Synthesis of (1-
18
F)fluorophenol 
 
Scheme 3.12: Proposed scheme to afford ([18F]7) using a Williamson reaction with 4-[18F]fluorophenol 
Coenen and co-workers reported the synthesis of (1-
18
F)fluorophenol in 60% 
radiochemical yield (RCY) from [
18
F]fluoride (Scheme 3.13). Starting from the diaryl 
ketone (14), they carried out their radiolabelling to give ([
18
F]15) and performed a 
Baeyer-Villiger oxidation to prepare ([
18
F]16). Lastly, hydrolysis of the ester with 
sodium hydroxide, yielded n.c.a. [
18
F]4-fluorophenol and trifluoromethyl benzoic 
acid.
133
 
 
Scheme 3.13: Proposed synthesis of (1-18F)fluorophenol133 
This procedure was followed to synthesise (1-
18
F)fluorophenol. To synthesise the 
radiolabelling precursor (14), a three step procedure by the same group was used. 
Initially a Friedel-Crafts acylation between 4-fluorobenzene and 4-(trifluoromethyl)-
benzoyl chloride afforded (15). In the first instance, 1 equivalent of AlCl3 was used to 
catalyse the reaction, however no desired product was observed by 
1
H NMR. Literature 
searches showed the original procedure published by Pews et. al. followed a similar 
procedure but used an excess of AlCl3.
151
 After adding 1.2 equivalents of AlCl3, the 
reaction, still proved unsuccessful. An improved method published by Noriyuki et. al., 
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used 0.5 equivalents of TfOH instead of AlCl3, as they stated that “CF3-bearing aryl 
fluorophenyl ketones are rarely obtained using AlCl3”. After 6 days at 100 °C, the 
Noriyuki group reported yields of 64%.
132
 In my hands, (15) was obtained in 56% yield 
after 4 days as tlc monitoring showed no further reaction occurring. The synthesis of 
(17) (Scheme 3.14), returned to the literature procedure by Coenen and co-workers. The 
displacement of fluorine with dimethyl amine hydrochloride, afforded (17) in 86% yield 
with no purification required. Lastly, the trimethylammonium group was produced via a 
methylation reaction with methyl triflate. The triflate salt precipitated out of solution 
after 1 hour and was recrystallised from hot ether giving (14) in 85% yield.  
 
Scheme 3.14: Synthesis of (4-(trifluoromethyl)phenyl)benzoyl-4-trimethylammonium triflate (14) 
Radiolabelling of (14) was tested as shown in Scheme 3.15 following the procedure by 
Coenen and co-workers.
133
 
 
Scheme 3.15: [18F] radiolabelling (14) 
The synthesis of ([
18
F]15) in acetonitrile at 90 °C for 15 minutes, gave 40% non-decay 
corrected (n.d.c.) radiochemical yield from [
18
F]fluoride after purification by semi-
preparative HPLC. This procedure was not optimised further due to the adequate yield 
produced. After formation of ([
18
F]15), the acetonitrile was removed by distillation 
prior to the oxidation step. The procedure by Coenen and co-workers used hydrogen 
peroxide in the presence of acetic acid, acetic anhydride, and sulphuric acid, generating 
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per-acetic acid in-situ for the Baeyer-Villiger oxidation step (Scheme 3.16). The 
oxidation was further investigated using mCPBA (Table 3.4 and Table 3.5).  
 
Scheme 3.16: Attempted synthesis of ([18F]16) 
Per-acid 
H2O2 (60% aq.) (0.5 mL) 
m-CPBA (40 mg) 
Temperature 
(°C) 
Reaction Time 
(mins) 
Radiochemical 
Purity (%) 
H2O2 80 45 0 
H2O2 90 45 0 
H2O2 100 45 0 
H2O2 120 60 0 
m-CPBA 85 15 0 
m-CPBA 90 30 0 
m-CPBA 130 60 0 
m-CPBA (100 mg) 130 30 0 
Table 3.4: Attempted Baeyer-Villiger oxidation of ([18F]15) via conventional heating 
 
Table 3.5: Attempted Baeyer-Villiger oxidation of ([
18
F]15) via microwave irradiation 
After multiple attempts, the Baeyer-Villiger oxidation did not proceed. 
Per-acid 
H2O2 (60% aq.) (0.5 mL) 
m-CPBA (40 mg) 
Temperature 
(°C) 
Power 
(W) 
Reaction 
Time 
(secs) 
Radiochemical 
Purity (%) 
H2O2 90 50 90 0 
m-CPBA 60 60 130 0 
m-CPBA (100 mg) 60 60 30 0 
m-CPBA (150 mg) 100 50 120 0 
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Figure 3.7: HPLC (a) radio and (b) UV chromatogram of oxidation of ([18F]15) 
From the HPLC UV chromatogram of the reaction mixture (Figure 3.7), there was a 
high residual concentration of (17) (the decomposition product of (14). It was 
hypothesised that perhaps this was oxidising preferentially over the reaction with 
([
18
F]15). However, after evaluating HPLC chromatograms, the peak corresponding to 
(17) never diminished whilst under oxidation conditions. Thus it was concluded that 
neither compound was reactive towards a Baeyer-Villiger oxidation under these 
conditions. To determine the progression of oxidation in the absence of (17), (15) was 
used to model the radiochemistry (Scheme 3.17). Again, the different per-acids were 
used (in-situ per-acetic acid and m-CPBA). Analytical HPLC chromatograms were 
acquired to monitor the progress of each reaction. 
 
Scheme 3.17: Attempted synthesis of (16) 
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After 12 hours of heating each reaction under reflux, (15) was still present with no peak 
corresponding to (16) observed. It was therefore concluded that (15) was unreactive 
towards oxidation. 
In conclusion, the synthesis of (1-
18
F)fluorophenol initially seemed straightforward, 
however, the Baeyer-Villiger oxidation did not proceed as expected and this pathway 
was consequently abandoned. Other pathways to afford (1-
18
F)fluorophenol were 
investigated.  
Independently Gouverneur et. al, published a manual synthesis of (1-
18
F)fluorophenol 
starting from 4-tert-butylphenol in the presence of [
18
F]TBAF, using the oxidant p-
iododiacetoxy benzene under acidic conditions in dichloromethane at RT for 20 
minutes. They reported an integrated analytical HPLC yield of 4-6% (or as it should be 
known, radiochemical purity).
19 
Due to the low radiochemical purity and no isolated 
yield reported, we chose not to reproduce this work.  
The synthon (1-
18
F)fluoro-4-bromobenzene (Section 3.1.1.2) was pursued. This synthon 
can in principle be conjugated in a similar manner as (1-
18
F)fluorophenol, using a 
copper catalysed Ullmann coupling to produce ([
18
F]7). 
 
3.1.1.2 Synthesis of (1-
18
F)fluoro-4-bromobenzene 
Different methods were considered for the synthesis of (1-
18
F)fluoro-4-bromobenzene 
as discussed by Ermert et al., who compared various pathways.
152
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Scheme 3.18: One-step reactions to n.c.a (1-18F)fluoro-4-bromobenzene 
The Wallach reaction (Scheme 3.18, pathway A), even using a wide variety of 
conditions (temperature, concentration of precursor, 
19
F carrier, solvent, different 
sulfonic acids for decomposition), only provided 3-4% radiochemical yield.  
Pathway B followed a direct nucleophilic aromatic substitution reaction using 
18
F-for-
halide exchange.
153-154
 The bromines simultaneously act as weak activating and leaving 
groups. However, only 1-2% radiochemical yield was reported.  
In pathway C, 1-bromo-4-nitrobenzene was used for halogen activated 
18
F / NO2 
exchange. Only 0.5% radiochemical yield was reported.
155
 The major product was 
[
18
F]1-fluoro-4-nitrobenzene in > 40% radiochemical yield.
155
 
Pathway D used trimethyl ammonium substitution for [
18
F] weakly activated with a 
para bromo, leading to only 8-15% radiochemical yield.
156-157
 
Pathway E and F both made use of diaryl iodonium salts. They react with nucleophiles 
by interacting with, in this case [
18
F]fluoride, to form a trigonal bipyramidal complex 
which undergoes syn elimination to give an [
18
F]fluoroaryl and iodoaryl species.
158
 
Numerous diaryliodonium salts have been synthesised and radiolabelled with [
18
F].
159-
161
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In pathway E the synthesis of (1-
18
F)fluoro-4-bromobenzene is preferred to the 
formation of (1-
18
F)fluorobenzene, as labelling is directed to the more electronegative 
arene. Unfortunately however, this pathway only allows a maximum 50% yield. In 
comparison, pathway F offers a higher yielding reaction (50-60% radiochemical yield), 
due to both arenes possessing an electron-withdrawing para-bromine.
152
  
Consequently pathway F was selected as it allowed the highest possible yields of [
18
F]1-
bromo-4-fluorobenzene. Consequently, 1-bromo-4-iodobenzene was acetylated to give 
(18) in 17% yield, followed by acidic coupling with bromobenzene via an iodoso 
species giving (19) in 47% yield (Scheme 3.19).
134-135
 
 
Scheme 3.19: Synthesis of (19) 
Radiolabelling of (19) yielded (1-
18
F)fluoro-4-bromobenzene ([
18
F]20) (Scheme 3.20; 
Table 3.6 and Table 3.7), which was characterised by comparing retention times with 1-
bromo-4-fluorobenzene on analytical HPLC. Reaction concentration was calculated 
based on amount of (19) and isolated yields are given after purification by semi-
preparative HPLC.  
 
Scheme 3.20: Proposed radiolabelling of dibromodiphenyliodonium triflate (19) 
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Table 3.6: Radiolabelling of (19) via conventional heating 
*[
18
F]Fluoride purified with a QMA pre-drying step 
**[
18
F]Fluoride purified with a QMA pre-drying step plus addition of TEMPO  
Table 3.7: Radiolabelling of (19) via microwave irradiation (concentration 90 mmol/L) 
 0:00 10:00 20:00 mm:ss
0.0
20000.0
40000.0
60000.0
cps
Solvent 
Concentration 
(mmol/L) 
Temperature 
(°C) 
Reaction Time 
(minutes) 
Radiochemical 
Yield n.d.c (%) 
MeCN 25 90 15 0.2 
MeCN 25 95 30 0.3 
DMF 90 130 30 3.1 
DMSO 90 140 30 0 
Solvent 
Temperature 
(°C) 
Power 
(W) 
Reaction Time 
(seconds) 
Radiochemical 
Yield n.d.c (%) 
DMF 100 40 50 2.0 
DMF 130 50 100 3.5 
DMF 120 50 60 2.6 
DMF 100 40 35 7.0 
DMF 90 40 30 6.4 
*DMF 90 40 30 3.0 
**DMF 90 40 30 19.8 
**DMF 90 40 30 20.7 
[
18
F]
-
 ([
18
F]20) 
(A) 
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Figure 3.8: Semi-preparative HPLC (a) radio and (b) UV chromatogram of the synthesis of ([18F]20) 
Initial radiolabelling of (19) showed little incorporation of fluorine-18. This was 
possibly due to decomposition of (19) from free radical reactions and metal impurities 
from the cyclotron source. To reduce the likelihood of side reactions, [
18
F]fluoride was 
purified prior to use. Fluorine-18 in aqueous solution was trapped to a quaternary 
ammonium cartridge, allowing cations, water and other impurities to pass through the 
cartridge. Thereafter, [
18
F]
-
 was cleanly eluted with kryptofix™, K2CO3 and MeCN, and 
azeotropically dried. TEMPO, a radical scavenger was added to the precursor to prevent 
side reactions.
162
 Subsequent reactions after purification of fluorine-18 and addition of 
TEMPO gave n.d.c. radiochemical yields of approximately 20% after purification by 
semi-preparative HPLC. This satisfactory yield allowed progression onto the Ullman 
coupling to prepare the target molecule (Scheme 3.21). 
 
Scheme 3.21: Proposed synthesis of 3-[4-(4-[18F]fluorophenoxy)phenyl]-1H-pyrazole-1-carboxamide 
([
18
F]7) 
The classic copper-catalysed Ullman coupling allows for synthesis of both symmetrical 
and unsymmetrical biaryls. As a model to test reaction conditions for radiochemistry, 2-
napthol was coupled with (20) (Scheme 3.22), following the procedure by Sperotto and 
co-workers.
136
 The reaction was catalysed by ligand free CuI in low catalytic amount 
(3.5 mol% wrt to the phenol).  
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Scheme 3.22: Synthesis of 2-(4-fluorophenoxy)naphthalene (22) 
This reaction was monitored by analytical HPLC and after five hours (22) was isolated 
following CC (n-hexane) purification in 47% yield. As this proof-of-concept reaction 
proceeded in moderate yield, radiolabelling studies with ([
18
F]20) commenced (Scheme 
3.23; Table 3.8 and Table 3.9) using the same reaction conditions. 
 
Scheme 3.23: Proposed synthesis of ([18F]22) through an Ullman coupling reaction 
Solvent Temperature 
(°C) 
Reaction Time 
(mins) 
Radiochemical 
Purity (%) 
NMP 195 40 0 
NMP 195 70 0 
NMP 195 80 0 
Table 3.8: Ullmann coupling via conventional heating 
Solvent Temperature 
(°C) 
Power 
(W) 
Reaction Time 
(secs) 
Radiochemical 
Purity (%) 
NMP 180 60 180 0 
Table 3.9: Ullmann coupling via microwave irradiation 
Initial radiochemistry showed no coupling. One explanation for this could be the 
presence of a large amount of the by-product 1-bromo-4-iodobenzene co-eluting with 
([
18
F]20) upon semi-preparative HPLC purification. This by-product exhibited the same 
retention time as ([
18
F]20) making it difficult to separate even using various gradients 
and mobile phase conditions. 1-Bromo-4-iodobenzene can react with copper iodide, 
thus it was believed, that this competing reaction prevented the radiochemical reaction 
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([
18
F]20) 
from progressing. A strategy to overcome this problem was to add a higher 
concentration of copper iodide and heat prior to the addition of napthol and caesium 
carbonate. It was thought this should allow a complex to form between ([
18
F]20) and 
copper iodide. 
 
 
Figure 3.9: HPLC (A) radio chromatogram after 40 minutes heating and (B) radio chromatogram after 
90 minutes heating during the synthesis of ([18F]20) 
The HPLC radio chromatogram showed a new radiochemical peak (Figure 3.9A) that 
did not correlate to the correct retention time for the product nor any previously 
identified side-products. It was hypothesised that this peak might be a copper 
complexed intermediate. Heating was continued for a further 50 minutes after the 
addition of napthol and caesium carbonate, but no peak corresponding to ([
18
F]22) was 
seen (Figure 3.9B) only the relative ratio of the new peak to ([
18
F]20) changed. 
Subsequently, microwave irradiation was used but this proved unsuccessful also. 
Despite the Ullmann reaction showing promising results with the fluorine-19 analogue 
to produce (22), this reaction could not be reproduced radiochemically. 
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After attempting numerous routes to produce ([
18
F]7) both directly and in-directly, 
radiolabelling proved unsuccessful. It was demonstrated that these molecules have a 
cleavable site and are unreactive towards a variety of chemistries. Alternative 
compounds were therefore pursued.  
 
3.2 Synthesis of 3-(4-((4-R-phenyl)thio)phenyl)-pyrazoles 
The closely related (arylthiooxy)aryl semicarbazones (Figure 3.10),
163
 were reported by 
Dimmock et. al., during their quantitative structure activity relationship (QSAR) study 
of the arylsemicarbazones. They reported that the optimum linker between the phenyl 
rings to maintain binding to VGSCs could be either an oxygen or sulphur, however, if 
the linker were changed beyond this, the effects were detrimental. The thioether linker 
was also attractive as sulphur is less electron donating than oxygen, thus it was hoped 
this structural alteration would remove the previous problems with SNAr chemistry for 
radiolabelling. Furthermore, there is literature precedent that by oxidising the thioethers 
to aromatic sulphones and sulphoxides, the system may be sufficiently activated for 
fluorination. The semi-carbazone moiety was replaced with the pyrazole ring as 
previously discussed (Section 3.0). 
 
Figure 3.10: Structure of 3-(4-((4-R-phenyl)thio)phenyl)-pyrazoles-carboxamides  
The synthesis of these compounds followed the same procedure as (Scheme 3.1; Section 
3.0), to afford compounds (29), (30) and (31) (Scheme 3.24). 
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Scheme 3.24: Synthesis of 3-(4-((4-R-phenyl)thio)phenyl)-pyrazoles 
Compounds (23) – (25), the products of the Williamson reaction, were not isolated and 
carried onto the next step as crude material.  
The pyrazole ring closure gave mixed yields with (25) produced in the lowest yield 
(26%). The subsequent carboxamide formation gave generally moderate yields to afford 
(29), (30) and (31) (35-55%). All compounds were characterised by NMR and HRMS. 
Subsequently this class of compounds were evaluated for radiolabelling with fluorine-
18. 
 
3.3 General [
18
F] radiolabelling strategies 
Compound (30) was selected for radiolabelling initially, to determine whether our 
hypothesis was correct: is a thioether linker less deactivating towards SNAr chemistry 
than an ether. Nitro was used as the leaving group and the carboxamide group was used 
to protect the secondary NH. 
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3.3.0. Direct fluorine-18 labelling 
 
Scheme 3.25: Attempted radiolabelling of (30) 
Different reaction conditions were tested for labelling of (30) and incorporation of 
fluorine-18 was monitored by analytical HPLC (Table 3.10). ([
18
F]26) was the assumed 
product, due to previous results showing efficient cleavage of the amide under 
radiolabelling conditions. 
Solvent Temperature 
(°C) 
Reaction Time 
(mins) 
Radiochemical 
Purity (%) 
DMSO 150  40 0 
MeCN 100  40 0 
Table 3.10: Attempted radiolabelling of (30) via conventional heating 
Many different radio peaks were seen in the HPLC radio chromatogram; however, 
following co-injection of (26), no correlation was seen. We considered the thioether 
bridge may have been a site of cleavage caused by attack of [
18
F
-
], but comparison with 
HPLC standards (32) and (33), showed that neither was the radiolabelled product 
(Figure 3.11).  
 
Figure 3.11: Structure of (32) and (33) 
Unfortunately, we were unable to identify any of the radioactive species. It was 
presumed that under the radiolabelling conditions, the molecule was unstable and 
decomposed.  
Subsequently, the thioether bridge moiety was oxidised using hydrogen peroxide to 
afford a sulphone (Scheme 3.26) linker.
164
 It was proposed this would stabilise the 
thioether bridge allowing incorporation of fluorine-18 and following reduction using 
sodium borohydride, cede the desired product ([
18
F]26). There is precedent for this 
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method in the literature, Elmaleh et. al., reported using a sulphone to initiate labelling of 
their molecule in MeCN at 140 
o
C, followed by reduction of the sulphone to the 
thioether.
165
 A yield was not reported for this; as this step was the first of a multiple step 
pathway.  
 
Scheme 3.26: Synthesis of (34) 164 
Following the procedure by Liu et. al., oxidation of (27) was achieved using 29 
equivalents of hydrogen peroxide in glacial acetic acid at RT. After 16 hours the 
reaction was quenched by addition of water which followed precipitation of the crude 
product and collection via suction filtration. Compound (34) was isolated and observed 
via NMR and HRMS before following onto the next step. To complete the synthesis of 
the precursor (35), (34) was reacted with sodium cyanate in acetic acid (90% aq.), 
allowing for formation of the terminal carboxamide (as described in section 3.0).  
 
Scheme 3.27: Attempted synthesis of (35) 
Compound (35) was not identified as the product of the reaction (Scheme 3.27). From 
1
H NMR, the terminal carboxamide was seen, characterised by the upfield shift in the 
pyrazole CH adjacent to the carboxamide. Infrared spectroscopy (IR) spectroscopy 
confirmed that a sulphoxide, rather than a sulphone had been formed. The S=O stretch 
band for sulphoxides was identified at 1012 cm
-1
, whereas bands at 1325 ± 25 and 1140 
±20 cm
-1
, characteristic of sulphones, were absent. It was not possible to characterise 
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this compound further. Although high resolution mass spectroscopy (HRMS) spectra 
were compared, (35) did not ionise very well under electro spray ionisation. 
Presumably, the acidic reaction conditions caused reduction of the sulphone affording 
(36) as the by-product in 15% yield. Although we were unable to produce a 
radiolabelling precursor possessing the sulphone moiety, we used (36) as a platform to 
investigate radiolabelling of sulphoxides with fluorine-18, as to the best of our 
knowledge there was no literature precedent for this reaction. 
 
Scheme 3.28: Radiolabelling of (36) 
Labelling of (36) commenced using similar conditions to the work reported by Elmaleh 
et. al. (Scheme 3.28). DMSO instead of MeCN was used as heating the reaction 50 °C 
above the boiling point of MeCN might cause pressure problems within the sealed 
reactor. The reaction was monitored via analytical HPLC and a new product was seen, 
following co-injection of (37), the product was identified as ([
18
F]37). After 15 minutes 
no further reaction was observed, the product was purification and isolated by semi-
preparative HPLC (10-95% using MeCN/H2O over 25 minutes) affording ([
18
F]37) in 
1.0 % n.d.c. yield.  
The low isolated yield meant that using ([
18
F]37) as a synthon for subsequent 
modifications to yield (7) was not feasible. Very harsh conditions had been required to 
produce even this low yield. As a result of this work radiolabelling of the 3-(4-((4-R-
phenyl)thio)phenyl)-pyrazole-carboxamides was abandoned. 
 
3.4 Conclusion of radiolabelling studies 
Following an in-depth look into the chemistry of the 3-(4-R-phenoxy)phenyl pyrazole-
1-carboxamides, these compounds were shown to be difficult to label for a variety of 
reasons. It was proposed that SNAr chemistry with fluorine-18 was inhibited due to the 
electron donating ether bridge. Secondly, we found the terminal carboxamide labile to 
cleave under basic conditions, even when protected with base stable protecting groups.  
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Consequently radiolabelled synthons such as (1-
18
F)fluorophenol and (1-
18
F)fluoro-4-
bromobenzene (which the latter was successful) was produced, for use in in-direct 
labelling strategies, but were unable to utilise these synthons to produce the desired 
products. 
Lastly, we modified the molecule to contain a thioether link between the two phenyl 
rings to reduce electron donation into the aromatic ring. However, this caused further 
problems; the molecule became so unstable that multiple radiolabelled products formed. 
Only one product was identified in minimal yield. 
In summary, we were unable to produce a PET tracer using the given structures by 
Yang et. al., and Dimmock et. al.
7, 131
  
 
3.5. In vitro electrophysiological characterisation 
Although we were unable to produce a fluorine-18 labelled PET tracer of 3-(3-(4-R-
phenoxy)phenyl)-pyrazole-1-carboxamides and its thio derivative (Section 3.0 and 3.2), 
it was still important to improve our knowledge of the physiological properties of these 
compounds. The report by Yang et. al., described limited electrophysiological data, 
therefore by studying these compounds in more detail, we were able to more fully 
characterise their biological properties. Moreover, by studying these compounds using a 
quantified technique, we were then able to compare with analogues produced later on 
(Chapter 4 and 5) in this thesis. 
 
3.5.0. Overview of sharp microelectrode electrophysiology   
Electrophysiology is the study of the electrical properties of biological cells and tissues. 
It involves measurements of changes in voltage or current in response to stimuli. In 
neuroscience, it includes measurements of the electrical activity of neurones, and 
particularly action potentials through commonly whole-cell patch clamp or sharp 
microelectrode electrophysiology.  
The sharp microelectrode technique uses a thin tipped micropipette allowing the pipette 
to pierce the membrane, thereby recording the potential inside the cell. Due to the 
thinner tip (<0.5 μm), there is little ion exchange between the intracellular fluid and the 
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electrolyte in the pipette. The resistance of the micropipette is normally in the range of 
80-100 MΩ, allowing small currents to be measured and applied. 
 
3.5.0.0 Results  
Sharp microelectrode electrophysiology was performed by Dr Andrew Constanti (UCL 
School of Pharmacy). This was intended to be a preliminary screen of compounds in 
order to provide a basis for further quantitative evaluation of potency and sub-type 
selectivity using automated and manual patch clamp assays. Each result presented here 
was confirmed in at least two neurones in different brain slice preparations. Compound 
(9) (Figure 3.12) was chosen as a “reference standard” for the development of further 
analogues, moreover, Yang et. al., showed this compound to be the most potent with a 
Ki of 25 nM.
12 
 
Figure 3.12: Structure of (9) 
Initially, recordings were taken from the hippocampus region of the brain. The 
hippocampus is located in the medical temporal lobe of the brain; it is part of the limbic 
system and plays a role in the consolidation of information in the short-term to long-
term memory and spatial navigation. It contains two main interlocking parts; Cornu 
Ammonis (CA) and the dentate gyrus (DG). This area of the hippocampus is thought to 
contribute to the formation of new memories. The DG receives excitatory input from the 
entorhinal cortex; this activates pyramidal cells among the CA. CA4 and CA3 
pyramidal cells via the Schaffer collaterals contact CA1 pyramidal cells, allowing the 
DG to control the flow of information within the hippocampus.
23
  
The electrophysiological characterisation of (9) was initiated within the CA1 region of 
the hippocampus, an area known to be densely populated with neurones and has been 
reported to express Nav 1.6.
166
 The pyramidal cells were chosen as they are larger and 
more able to be impaled for sharp electrophysiology studies. Brain slices were obtained 
from Sprague-Dawley rats as previously described by Whalley et. al.
167
 Briefly, The 
brain was rapidly removed following decapitation, hemisected and placed in ice-cold 
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oxygenated Kreb’s solution at 4 °C. Transverse slices were cut 450 μm thick using a 
vibrating tissue slicer in ice-cold Kreb’s medium. Once the slices had been cut, they 
were transferred to a Kreb’s solution (as described in Materials and Methods) warmed 
to 29 °C for 1 hour to recover.  
A pyramidal cell of the CA1 region was impaled and held at -70 mV (Figure 3.13). 
Control recordings were taken and a solution of (9) at 1 µM was applied for 60 minutes. 
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(A) 
(B) 
(C) 
(D) 
 
Figure 3.13: Hippocampal CA1 neurone held at -75 mV (maintained by steady current injection). (A): 
Control IV relationship (± 0.2 nA steps, duration 160 ms). (B): Control positive/negative step in control 
(± 0.5 nA step, duration 160 ms). (C) Control long sweep (+ 0.8 nA / -0.5 nA step, duration 1.5 s). (D) 
Stretch of control long sweep recording from (C). (E) IV relationship (± 0.2 nA steps, duration 160 ms) 
showing no change in neuronal firing with (9) (1 µM; 15 minutes). (F) Positive/negative step (± 0.5 nA 
step, duration 160 ms) showing no change in neuronal firing with (9) (1 µM; 15 minutes). (G) Long 
sweep (+ 0.8 nA / -0.5 nA step, duration 1.5 s) with (9) (1 µM; 15 minutes). (H) Stretch of long sweep 
recording from (G). (I) IV relationship (± 0.2 nA steps, duration 160 ms) after 30 min washout.(J): 
Stretch of long sweep recording after 30 min washout. (K): Positive/negative step (± 0.5 nA step, duration 
160 ms) after 30 min washout. 
In total, neuronal activity was recorded over 1 hour (30 minute traces shown; Figure 
3.13), during which, no obvious changes in neuronal firing patterns nor resting 
membrane potential was seen.  
(E) 
+ (9), 1µM, 15 minutes 
(F) 
(G) 
(H) 
Control 
(I) 
(J) 
(K) 
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Recording of pyramidal cells in the CA1 region was then repeated with a ten-fold 
higher concentration of (9) (Figure 3.14). A pyramidal cell of the CA1 region was also 
impaled and held at -70 mV. Control recordings were acquired before applying (9) at 10 
µM for 45 minutes. 
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Figure 3.14: Hippocampal CA1 neurone held at -70 mV (maintained by steady current injection). (A): 
Control IV relationship (± 0.2 nA steps, duration 160 ms). (B): Control positive/negative step (± 0.5 nA 
step, duration 160 ms). (C) Control long sweep (+ 1.0 nA / -0.5 nA step, duration 1.5 s). (D) Stretch of 
control long sweep recording from (C). (E) IV relationship (± 0.2 nA steps, duration 160 ms) showing 
inhibition of later action potentials with (9) (10 µM; 45 minutes). (F) Positive/negative step (± 0.5 nA 
step, duration 160 ms) showing clear inhibition of spikes with (9) (10 µM; 45 minutes). (G): Long sweep 
(+ 0.8 nA / -0.5 nA step, duration 1.5 s) after 45 minutes showing a change in the neuronal firing pattern. 
(H): Stretch of long sweep recording from (G) showing noticeable diminishing in the spike amplitude and 
considerable decline in the number of spikes. (I): Stretch of long sweep recording after 45 min washout. 
(J): Positive/negative step (± 0.5 nA step, duration 160 ms) after 45 min washout. 
(J) 
Control 
(A) 
(B) 
(C) 
(E) 
(F) 
(G) 
(I) 
(D) (H) 
+ (9), 10 µM, 45 minutes 
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At 15 minute intervals, recordings were taken to monitor the drug effect. At 45 minutes 
the drug effect peaked (Figure 3.14E-H). The number of action potentials and the peak 
spike amplitude after the first spike decreased dramatically. For example, the amplitude 
of the 4
th
 spike decreased by 12 mV from 65 mV in control (Figure 3.14D) to 53 mV 
after application of (9) (Figure 3.14H). After 45 minute washout, the spike amplitude 
showed some recovery, returning to 60 mV. The time between spikes also increased due 
to the longer spike after-hyperpolarizations (AHPs), most likely due to opening of more 
calcium channels and subsequent activation of Ca
2+
 activated K
+
 channels. The time 
between action potentials 4 and 5 is 20 milliseconds in control (Figure 3.14D), whereas 
after application of (9) at 10 µM for 45 minutes, this gap doubled to 40 milliseconds 
(Figure 3.14H). After washout, this time did not change remaining at 40 milliseconds 
(Figure 3.14I), indicating (9) had not washed out after 45 minutes. Meanwhile, the 
resting membrane potential remained steady and there was no change in slow inward 
rectification currents or input resistance. Having raised the drug concentration 10-fold, 
(9) had now exhibited reversible binding to the pyramidal cells of the CA1 with some 
slow washout seen after 45 minutes. 
To compare these results with VGSC inhibition elsewhere in the brain, recordings were 
taken from pyramidal cells within layers II- III of the piriform cortex (PC). The PC lies 
to the posterior of the hippocampus and is associated with the generation and 
propagation of forebrain (limbic type) seizures.
168
 To begin with, a 1 µM solution of (9) 
(1:99 EtOH/Kreb’s) (Figure 3.15) was tested. The piriform cortex was studied due to 
good neuronal activity in this area. A pyramidal cell of the PC was impaled and held at 
a membrane potential of -70 mV (Figure 3.15). Control recordings were then taken, 
followed by application of (9) at 1 µM for 15 minutes. 
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Figure 3.15: Piriform cortex neurone held at -70 mV (maintained by steady current injection). (A): 
Control current/voltage (IV) relationship (± 0.2 nA steps, duration 160 ms). (B): Control 
positive/negative step (± 0.4 nA step, duration 160 ms). (C) IV relationship (± 0.2 nA steps, duration 160 
ms) showing no change in neuronal firing with (9) (1 µM; 15 minutes). (D) Positive/negative step (± 0.4 
nA step, duration 160 ms) showing no change in neuronal firing with (9) (1 µM; 15 minutes). 
On comparing the control recordings with recordings after application of (9) over 15 
minutes, no change in neuronal firing was seen, whilst resting membrane potential 
remained steady and no change in input resistance occurred. No washout was recorded 
due to the lack of effect. Unfortunately, no data are reported about VGSC isoform 
expression in the PC. It was hypothesised however, that there is a difference in the 
isoform expression between the PC and CA1 to explain these results. 
With (9) at 1 µM having no obvious efficacy in the PC region, we increased the 
concentration ten-fold to see the effect this higher concentration would have. 
A pyramidal cell of the PC was impaled and held at a membrane potential of -70 mV. 
Control recordings were then taken, followed by application of (9) at 10 µM for 30 
minutes. Still, no change in neuronal firing was seen (traces not shown), so the 
concentration of (9) was increased to 20 µM (Figure 3.16) whist stimulating the same 
pyramidal cell. 
  
(D) 
Control + (9), 1µM, 15 minutes 
(C) 
(B) 
(A) 
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Figure 3.16: Piriform cortex neurone held at -70 mV (maintained by steady current injection). (A): 
Control current/voltage (IV) relationship (± 0.2 nA steps, duration 160 ms). (B): Control 
positive/negative step (± 0.5 nA step, duration 160 ms). (C) Control long sweep (+ 0.8 nA / -0.5 nA step, 
duration 1.5 s). (D) IV relationship (± 0.2 nA steps, duration 160 ms) showing no change in neuronal 
firing with (9) (20 µM; 15 minutes). (E) Positive/negative step (± 0.5 nA step, duration 160 ms) showing 
no change in neuronal firing with (9) (20 µM; 20 minutes). (F) Long sweep (+ 0.8 nA / -0.5 nA step, 
duration 1.5 s) after 20 minutes showing no change in the neuronal firing pattern. 
After increasing the concentration of (9) to 20 µM, there was still no strong change in 
neuronal firing frequency nor resting membrane potential. When comparing traces from 
Figure 3.16C and F showing the long sweep, there is a slight diminishing of the spike 
amplitude. The lack of effect was anticipated to be an indication of VGSC subtype 
selectivity. No further concentrations were tested; having concluded this drug is inactive 
within the low micromolar concentration range in this brain region. 
Upon completion of intial testing of (9), (25) was studied using the same procedure and 
in the same brain region for direct comparisons. Subsequently, (25) was tested also 
beginning in the CA1 region of the hippocampus. A pyramidal cell of the CA1 region 
was impaled and held at -70 mV. Control recordings were taken and a solution of (25) 
at 10 µM was applied for 30 minutes (traces not shown). During this time, no change in 
neuronal firing nor membrane potential was seen. The concentration of (25) was then 
increased to 20 µM whilst stimulating the same pyramidal cell. However, the neuronal 
firing pattern remained steady (traces not shown) even at this increased concentration. 
Control + (9), 20 µM, 20 minutes 
 
(A) 
(B) 
(C) 
(D) 
(E) 
(F) 
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(C) 
(D) 
Finally, the drug concentration was increased to 30 µM and the same pyramidal cell was 
stimulated for a further 70 minutes (Figure 3.17). 
 
 
Figure 3.17: Hippocampal (CA1) neurone held at -70 mV (maintained by steady state injection). (A) 
Control positive/negative step (± 0.5 nA step, duration 160 ms). (B) Control long sweep (+ 0.8 nA / -0.5 
nA step, duration 1.5 s). (C) Positive/negative step (± 0.5 nA step, duration 160 ms) showing no change in 
neuronal firing with (25) (30 µM; 70 minutes). (D) Long sweep (+ 0.8 nA / -0.5 nA step, duration 1.5 s) 
after 70 minutes showing no change in the neuronal firing pattern. 
At this highest concentration, (25) showed minimal effect in the CA1 region (maximum 
concentration 30 µM; 70 minutes incubation). Upon comparison of the control and drug 
traces, traces with drug showed a slightly faster firing rate. Currently, (25) has not been 
assessed in the PC region.  
 
3.5.0.1 Discussion  
Initially, (9) was studied in both the CA1 region of the hippocampus and in the PC. This 
compound showed a good effect in the CA1 region of the brain (up to 10 µM) to reduce 
spike amplitude and repetitive firing, whereas in the PC little effect was noticed (only 
slight reduction in the spike amplitude up to 30 µM). It has been reported that there is a 
high expression of Nav 1.6 in the hippocampus, with respect to Nav 1.1, 1.2 and 1.3 also 
found in the brain. 
166
 However, nothing could be found on the relative expression of 
VGSCs in the PC, thus it was difficult to tell whether Nav 1.6 was also found in the PC 
or not. It was inferred from the electrophysiology that perhaps there is a lack of this sub-
type expressed in this region. Thus, it was proposed that (9) was showing some 
selectivity for Nav1.6.  
Control + (25), 30 µM, 70 minutes 
 
(B) 
(A) 
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Subsequently, (25) was studied to ascertain whether the alternative thioether link 
increased or decreased potency towards VGSCs. After testing at numerous 
concentrations in the CA1 (up to 30 µM), no change in neuronal firing was exhibited, 
nor was there any change to the resting membrane potential. Thus, (25) was shown to be 
inactive at the concentrations tested (30 µM maximum concentration). It was concluded 
that the introduction of the thioether link was the most likely cause of the lack of 
potency. Although, Dimmock et. al., described these compounds as potent VGSC 
blockers, our studies showed them to be inactive.
131
  
As a result of initial data, (9) was evaluated further in an automated patch clamp study 
using cultured cells expressing Nav 1.1 to 1.7 (Section 3.5.1) to ascertain if any, VGSC 
subtype selectivity. (25) was also included as a negative control to moderate the results 
between the two electrophysiological studies, but also to see if (25) showed binding to 
any non-CNS expressed VGSC.  
 
3.5.1 Overview of automated electrophysiology  
Compounds (9) and (25) were screened to highlight VGSC sub-type selectivity 
following some initial positive electrophysiological evaluation on brain tissue. As only 
certain VGSC isoforms are expressed in different tumours, we also needed to ascertain 
which VGSCs (if any), this family of compounds were selective for. These two 
compounds were screened by ChanTest® US, using their automated IonWorks 
Quattro™ patch clamp system on transfected CHO (Chinese hamster ovary) cells 
stabling expressing Nav1.1 – 1.7 from the organism Cricetulus griseus. They screened 8 
different concentrations (0.01-30 µM) to obtain a dose-response relationship and 
lidocaine (3 mM) was used as the positive control drug to block all sodium currents at 
the end of each experiment. The IC50 of both (9) and (25) was evaluated in three 
experiments: tonic block (no stimulation applied), frequency-dependent block 
(following 10 Hz frequency stimulation) and inactivated state block (following a 
conditioning depolarising pulse). 
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Figure 3.18: Voltage step protocol for hNav1.x test procedure 
Three protocols were used to study binding to Nav 1.1-1.7; tonic, frequency dependent 
block and inactivated state block.  
Tonic block was ascertained by measuring binding at -80 mV (resting membrane 
potential), the measurement was calculated as follows: 
Tonic block (%) = (1-ITP1,TA/ITP1,control) x 100% 
Where ITP1, control and ITP1, TA are the peak inward sodium currents elicited by the 
test pulse (TP1) in control and in the presence of each compound. 
Frequency dependent block was ascertained by increasing the stimulation frequency to 
10 Hz, this protocol highlighted whether the compounds were only binding to the 
channels under a strong stimulation. Frequency dependent block was calculated as 
follows: 
10 Hz block (%) = (1-ITP11,TA / ITP11,control) x 100% 
Where ITP11, TA and ITP11,control are the peak inward sodium currents elicited by the 
TP11 in control and in the presence of a test article. 
Inactivated state block, was measured by holding 500 ms stimulation to 0 mV, this 
established all the channels in the inactivated state. Inactivated block was calculated as 
follows: 
Inactivation state block (%) = (1- ITP12,TA / ITP12,control) x 100% 
Where ITP12, TA and ITP11, control are the peak inward currents elicited by the TP12 in 
control and in the presence of the test article. 
Concentration-response data with standard error for the blocks was fit to an equation of 
the following form: 
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Block = % VC + {(100 - % VC) - (100 - % VC) / [1 + ([Test] / IC50)
N
]} 
where [Test] was the concentration of test article, IC50 was the concentration of the test 
article producing half-maximal inhibition, N was the Hill coefficient, % VC is the 
percentage of the current run-down (the mean current inhibition at the vehicle control) 
and % Block is the percentage of ion channel current inhibited at each concentration of 
the test article. Nonlinear least squares fits were solved with the XLfit, (model 201) 
add-in for Excel 2003 (Microsoft, Redmond, WA). In case of maximal blocking effect 
less than 50% or minimal blocking effect greater than 50%, the IC50 value was not 
calculated. 
 
3.5.1.0 Results  
Following automated patch clamp experiments on Nav 1.1-1.7 in CHO cells, (9) was 
shown to be a state-dependent blocker of VGSCs. In particular (9) was shown to be 
most potent for Nav 1.5 (IC50 = 0.78 ±0.29 µM) followed by Nav 1.4 (IC50 = 1.26 ± 0.29 
µM) and then Nav 1.2 (IC50 =1.53 ± 0.49 µM). (25) however, was shown not to block 
VGSCs over the concentrations tested (maximum concentration tested 30 µM) in any 
isoform. Results are detailed in Table 3.11.  
In each block, the test pulse (Figure 3.18) was repeated twice; before and 5 minutes 
after compound addition. Peak current amplitudes at three test pulses were measured 
(ITP1, ITP11 and ITP12). 
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No 
Type 
of 
block 
IC50 (µM) 
Nav 1.1 Nav 1.2 Nav 1.3 Nav 1.4 Nav 1.5 Nav 1.6 Nav 1.7 
(9) 
Tonic >30 >30 >30 >30 >30 >30 >30 
10 Hz >30 >30 >30 >30 
6.37 
± 2.71 
>30 >30 
Inact. 
5.46 
± 0.49 
1.53 
± 0.49 
6.82 
± 3.3 
1.26 
± 0.29 
0.78 
± 0.29 
2.84 
± 0.95 
>30 
(25) 
Tonic >30 >30 >30 >30 >30 >30 >30 
10 Hz >30 >30 >30 >30 >30 >30 >30 
Inact. >30 >30 >30 >30 >30 >30 >30 
Table 3.11: Summary of (9) and (25) IC50 values with Nav 1.1-1.7 
3.5.1.1 Discussion  
This study highlighted the sub-type selectivity of (9) and confirmed that (25) is not a 
VGSC blocker under these test conditions used. Upon comparison of these results with 
Yang and co-workers reported findings on (9), this compound appeared to be less 
potent. They showed (9) to have a Ki of 25 nM in human skeletal muscle (hSkM) tissue 
(expressing Nav 1.4) but our study found the IC50 for Nav 1.4 to be 1.26 ± 0.29 µM. 
This automated study did not measure binding kinetics of (9) and (25), only IC50 values 
were afforded. Thus, we cannot directly compare Ki to our IC50 data, although one 
would expect the values to be similar. These results were unexpected, but the protocol 
used only stimulated the channels twice and each compound was only allowed to 
superfuse for 5 minutes (this protocol was not changeable). Through sharp 
microelectrode electrophysiological recordings reported in Section 3.4.0.1, we showed 
that it took at least 20 minutes for (9) to have a full effect on neuronal activity. In 
conclusion, our study indicated that (9) binds to all Nav 1.1 -1.6 at <7 µM. It was most 
selective for Nav 1.5, while potency for Nav 1.4 and Nav 1.6 were in the same order of 
magnitude. 
The next step was to identify a more accurate IC50 value for both Nav 1.4 and Nav 1.5 
for comparison with analogues of (9) (Chapter 4 and 5) and with literature reported 
values. As a result of these data, (25) however, was not incorporated into further 
studies. 
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3.5.2 Overview of patch clamp electrophysiology 
Patch clamp techniques allow the study of single or multiple ion channels in cells under 
current clamp. There are different variations of patch clamp techniques, for example 
cell-attached recordings, whole-cell recordings, outside-out patch, inside-out patch and 
perforated patch clamp. These techniques use a glass micropipette with an open tip of 
diameter (0.5-1 µm), a size enclosing a membrane surface area or “patch” that often 
contains just one or a few ion channels. This technique requires the micropipette to seal 
onto the surface of the cell membrane rather than insert through it, as in traditional sharp 
microelectrode recordings. The interior of the pipette is filled with a solution matching 
the ionic composition of the cell interior. A chlorided silver wire is placed in contact 
with this solution and conducts electric-current to the recording amplifier. The 
micropipette is pressed against a cell membrane and suction is applied to assist in the 
formation of a high resistance seal between the glass and the cell membrane. This is 
known as a “gigaohm seal” (109 Ω), since the electrical resistance of the seal is in 
excess of a gigaohm. The high resistance of this seal makes it possible to electronically 
isolate the currents measured across the membrane with little noise competing, as well 
as providing mechanical stability for the recordings.  
Perforated patch clamp was used in the proceeding study. In this variation of whole-cell 
recordings, a gigaohm seal forms, but no suction is required to rupture the patch 
membrane. Instead, the electrode solution contains small amounts of an antifungal or 
antibiotic agent, such as amphothericin-B, nystatin, or gramicidin. As the molecules 
diffuse into the membrane patch, they create small perforations in the membrane, 
providing access to the cell interior. This technique reduces the dialysis of the cell that 
occurs in whole-cell recordings allowing longer drug incubation time. This method also 
has several disadvantages associated with it. First, the access resistance is higher (access 
resistance being the sum of the electrode resistance and the resistance at the electrode-
cell junction). The high resistance decreases electrical access and thus current 
resolution, which increases recording noise, and magnifies any series resistance error. 
Secondly, it can take a significant amount of time for the antibiotic to perforate the 
membrane (10–30 minutes, though this can be reduced with thin tipped electrodes). 
Thirdly, the membrane under the electrode tip is weakened by the perforations formed 
by the antibiotic and can rupture. If the patch ruptures, the recording is then in whole-
cell mode, with antibiotic contaminating the inside of the cell. 
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Patch-clamp studies were undertaken on Nav1.4 and 1.5 channels only, due to earlier 
results highlighting (9) as binding preferentially to these channels (Section 3.5.1.0). The 
I-V relationship was used to calculate half-inactivation potential (IC50), and 500 
milliseconds pre-pulses used to create inactivation curves for estimation of channel 
availability (hα); all experiments were conducted using a holding potential of -90 mV to 
ensure maximum channel availability and block of the resting state; and half-
inactivation between -80-60 mV was used to ensure block of the inactivated state. The 
rapid kinetics and complete inactivation of the currents were in line with published data. 
18
 
 
3.5.2.0 Results  
hNav1.4 and 1.5 were stably expressed in HEK-293 cells, (9) was tested at 4 
concentrations (0.1, 1, 10 and 30 µM) to ascertain an accurate IC50 value. These 
concentrations were chosen based on previous electrophysiological work which 
indicated an approximate IC50 in the low micromolar range. Using the resting and 
inactivated state protocol (Section 2.4.2), (9) showed a preference for binding to the 
inactivated state.  
Following testing in hNav 1.4, (9) had approximately 5000-fold higher affinity for P2 
(inactivated) compared to P1 (resting), with an IC50 2 nM vs 10 µM, respectively. The 
maximal inhibitory response (Imax) of (9) was approximately 98% total block at the 
maximal concentration of 30 µM in P2, whilst only 62% was seen in P1. No standard 
error is reported for the IC50 value. The dose-response curve (Figure 3.19) indicated that 
all concentrations tested gave >50% block. Therefore, the IC50 value quoted was 
reported using a non-linear regression fit algorithm (GraphPad Prism version 5.0) to 
extrapolate the data. The graph below shows the trough of a standard inhibition dose 
response curve.  
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Figure 3.19: Dose response curve of hNav 1.4 of (9) (0.1-30 µM) under P1 and P2 conditions.  
Following testing on hNav 1.5, (41) also showed a higher affinity for P2 compared to P1 
(Figure 3.20). The IC50 for P2 was calculated as 41 nM, however, an IC50 for P1 at the 
highest concentration of 30 µM could not be afforded, due to its limited inhibitory 
activity at resting state. The maximal inhibitory response (Imax) of (9) on hNav 1.5 
current was approximately 94% of control for P2 and 14% of control for P1 at the 
maximum concentration tested of 30 μM. 
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Figure 3.20: Dose response curve of hNav 1.5 of (9) (0.1-30 µM) under P1 and P2 conditions.  
The dose-response curve for these results (Figure 3.20) is similar to that seen for hNav 
1.4. It also highlights the trough section of a dose response curve. Block saturation was 
seen at 10 µM and but all concentrations again afforded >50% block. No standard error 
is given as described for hNav 1.4 due to the high variance with extrapolating data. The 
value afforded is the best estimate of the IC50 according to the non-linear regression best 
fit algorithm.  
 
Chapter 3  Results and Discussion 
143 | P a g e  
 
3.5.2.1 Discussion  
This assay showed (9) to be highly selective for the skeletal muscle sodium channel 
(Nav 1.4; IC50 = 2 nM vs Nav 1.5; IC50 = 41 nM). Whereas in the previous assay, there 
was approximately equal selectively between the two channels (when including error 
variance). The estimated IC50 values quoted for each channel here, indicated that (9) is 
far more potent than was initially established (Section 3.5.1.0). Moreover, the 
concentrations tested were based on those previous results, but it appeared that the 
automated electrophysiological screen was inaccurate in indicating likely IC50 values. 
The values quoted here, are three orders of magnitude more potent. Although there is a 
high margin of error associated with these extrapolated values, this study showed that 
(9) has an IC50 around the low nanomolar range on both channels.  
The most likely reason for the difference in potency between these results and the 
automated electrophysiology results is the incubation time allowed. When developing a 
protocol for the automated electrophysiology, the incubation time used was not 
changeable. Therefore all compounds were screened for 5 minutes in each state (resting, 
frequency dependent and inactivated). The main concern about the inaccuracy of those 
data, was that the maximum effect at each concentration was not being seen within 5 
minutes. This study aimed to minimise that error by incubating the cells until a steady 
state effect was reached (approximately 20-30 minutes). Therefore these results are 
more precise. Unfortunately it could not be foreseen that the potency of these 
compounds would be quite so different from that indicated previously. The dose 
response curves shown, gives a true indication of inhibition at each concentration, but 
future work will require lower concentrations being tested to get an exact determination 
of the IC50 value. Overall, (9) is more potent than previously established and these data 
appear to corroborate to the potency values reported by Yang et. al.  
Following electrophysiology studies undertaken, a binding study would normally be the 
next step to afford values of Bmax, Kd and ultimately binding potential using [
3
H](9) (as 
it was not possible to label with fluorine-18). This would have allowed an estimation of 
whether (9) was worth pursuing in further radiochemical studies, and also, whether an 
analogue of this compound would be suitable as a radiotracer for VGSCs. After 
consulting numerous companies who perform trituration and radioligand binding 
assays, we were unable to find a company which could perform binding assays on cell 
lines expressing Nav 1.4 and 1.5. 
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Although it was not ideal that binding studies had not been performed on these 
compounds, the electrophysiology data suggested that this class of compounds could 
serve as a good basis for future analogue development.  
However, to allow an approximation of the binding potential of (9) to Nav 1.5, data 
from [
3
H]BTX studies on cardiomyocytes was used, to give an approximation of VGSC 
Bmax. Sheldon and co-workers reported that the Bmax for [
3
H]BTX in cardiomyocytes 
was 6.6 µM. We assume, as BTX is a potent VGSC ligand, that this Bmax value could be 
used as an approximate indication of the VGSC expression in the heart. In order to 
afford an estimation of the binding potential for (9), the approximate IC50 value for Nav 
1.5 (41 nM) was used as a substitute for Kd.
169
  
Therefore: 
Binding Potential = Bmax / Kd 
     = 6.6 µM / 41 nM 
     = 160 
Whilst it is noted that the assumptions made in the above calculation only allow for a 
very approximate indication of binding potential, this figure is ten times greater than the 
suggested minimum value. Thus, (9) appears to be a promising compound and it is 
unfortunate that a labelling pathway could not be found. Additioanlly though, this value 
does highlight that pursuing this class of compound is warranted.  
 
3.6 In vivo characterisation  
3.6.0 Naive biodistribution 
In previous work conducted by Arstad,
170
 (9) was tritiated by GE Healthcare, 
Amersham and studied through naive mouse biodistribution. 
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3.6.0.0 Results  
This naive biodistribution (Figure 3.21) is the only historical in vivo data reported to 
show the behaviour of (9) in an animal model. Therefore we show here for comparison 
with data presented in Chapters 4 and 5. Unfortunately as this biodistribution used low 
energy tritium [
3
H] and not [
18
F], it was not possible to directly compare these data with 
fluorine-18 labelled analogues. However, it is interesting to note the uptake and 
clearance trend of ([
3
H]9) for general comparison. 
 
Figure 3.21: Naive biodistribution graph for ([3H]9) 
Good uptake was seen in the (whole) brain (total brain; 6.65% id/g) and heart (2.96% 
id/g) at 2 minutes which decreased to (whole) brain (total brain; 3.02% id/g) and heart 
(1.09% id/g) by 40 minutes, consistent with reversible uptake. Little uptake was seen in 
the muscle (0.4% id/g), which was surprising as Yang et. al., and recent data showed 
this compound to have good efficacy for Nav 1.4 (expressed in the skeletal muscle) 
7
. 
High uptake was seen in the kidney (4.59% id/g), lung (5.13% id/g) and liver (6.48% 
id/g) at 2 minutes whilst after 20 minutes levels in the kidney (2.39% id/g) and liver 
(3.80% id/g) remained high, suggesting the compound is metabolised in the liver and 
cleared through the renal system. 
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Although the brain biodistribution was separated into right, cortex and hippocampus, 
here, the % id/g is quoted as total brain. In subsequent studies, the brain was not 
separated in this way, so the values of total brain are more important here.   
 
3.6.0.1 Discussion  
It was difficult to draw too many conclusions from these data as this was the first 
indication of the compounds behaviour in vivo. It appears that there was good uptake of 
([
3
H]9) and this was reversible within 40 minutes. However, in vivo stability cannot be 
inferred as with fluorine-18 labelled compounds, where fluorine uptake in the bone can 
indicate in vivo stability (with respect to de-fluorination). In summary, this 
biodistribution has given an insight into the uptake profile of this compound for use as a 
general trend for comparison with analogues of (9) labelled with fluorine-18, presented 
later.  
 
3.7 Conclusions of chapter 3 
In summary, (9) was shown to be a potent sub-type selective VGSC blocker. Following 
numerous pathways to radiolabel this compound with fluorine-18, we were unable to 
find any success in our pursuits. Subsequently, we were able to offer a more detailed 
characterisation of (9) through both sharp electrode and patch-clamp electrophysiology. 
We showed that (9) selectively binds to the cardiac sodium channel (Nav 1.5) and SkM 
sodium channel (Nav 1.4). This result was interesting, as previously reported work had 
only been carried out on Nav 1.4, our work allowed for a more detailed and wider 
analysis of (9).
7
 
Following on, (25) showed no binding to any VGSC subtype over the concentrations 
tested, this was in contrast to previous reports.  
As (9) had shown to be a promising VGSC ligand through initial evaluation, analogues 
of (9) were pursued to overcome the problems of radiolabelling. 
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4. Results and Discussion 
 
 
Design, synthesis and bioevaluation of [
18
F]3-(4-(2,4-
difluorophenoxy)phenyl)-1-(2-fluoroethyl)-pyrazole 
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4.0 Rationale for novel tracer  
Due to the difficulties surrounding the labelling of the 3-(4-(4-R-phenoxy)phenyl)-
pyrazole-1- carboxamides with fluorine-18 (chapter 3), strategies were developed to 
generate analogues of the 3-(4-phenoxyphenyl)pyrazole-1-carboxamides, to provide 
more reliable radiolabelling pathways. A well known reaction for introducing fluorine-
18 is the base activated fluoroalkylation with [
18
F]fluoroethyltosylate ([
18
F]38) (Scheme 
4.1). [
18
F]Fluoroethyl tosylate is a reliable radiochemical synthon and has been used in 
the synthesis of many PET ligands and reactions generally proceed in high yields.
171-175
 
 
4.1 Synthesis of 3-(4-(2,4-difluorophenoxy)phenyl)-1-(2-fluoroethyl)-
pyrazole  
In initial studies, we proposed a fluoroalkylation of the terminal carboxamide of (9) 
with fluoroethyl tosylate (38) to afford (39) (Scheme 4.1). Various bases and conditions 
were employed to optimise this chemistry (Table 4.1). 
 
Scheme 4.1: Proposed fluoroalkylation of (9) 
Base Temperature (°C) Reaction Time (hrs) Product 
Cs2CO3 55 12 (6) 
DIPEA 100 2 (6) 
NaH rt/50 1 (6) + (40) + (41) 
DBU Rt 1 (6) 
KHCO3 50 4 (6) 
Table 4.1: Conditions for fluoroalkylation of (9) 
During our testing of reaction conditions using various bases, total cleavage of the 
carboxamide was seen without any product formation. Production of (6) and remaining 
(38) however, was seen in high concentration. 
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Scheme 4.2: Cleavage of carboxamide during fluoroalkyation of (9) 
As shown in Table 4.1, only the mild base potassium bicarbonate did not cause cleavage 
of the carboxamide, but no product was obtained either. It was serendipitously found 
through using sodium hydride, that alkylation does proceed on the pyrazole NH 
following cleavage of the carboxamide. Two products were found during HPLC 
purification in the ratio of approximately 9:1. Subsequently, NOESY and COSY NMR 
studies identified that the major product was the isomer (41) in 27% yield. It was 
proposed that the minor product was (40). 2D NMR studies on (40) were unable to 
determine the structure due to minimal compound isolated (<5% yield). When scaling 
up this reaction to isolate a larger amount, HPLC purification became unable to separate 
the two isomers and CC was also unable to separate the stereo isomers.  
 
Scheme 4.3: Unexpected products of the fluoroalkylation reaction 
Although the terminal carboxamide of (9) was cleaved during the course of this 
reaction, the biological properties and radiochemistry of (41) was still of interest. In 
particular, whether the same mixture of isomers would be formed and in what ratio. 
Yang et. al., reported replacing the carboxamide with a methyl group and they afforded 
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a Ki of 0.69±0.18 µM. Hogenkamp et. al., reported the use of aryl substituted pyrazoles 
for use as VGSC ligands, finding the IC50 values of their compounds to be 
approximately 100 µM or less in hSkM VGSCs expressed in HEK 293 cells .
176
 These 
previously reported data were used as a basis to further investigate (41) as a potential 
novel VGSC ligand. 
 
4.2 Synthesis of ([
18
F]41) 
Using the conditions as outlined in Scheme 4.3 we investigated the radiolabelling of (9) 
with ([
18
F]38).  
To generate ([
18
F]38) we started from commercially available ethylene di(p-
toluenesulfonate). 
 
Scheme 4.4: Synthesis of ([18F]38) 
([
18
F]38) was synthesised following the procedure by Block and co-workers (Scheme 
4.4).
177
 Ethylene di(p-toluenesulfonate) was added to a solution of pre-dried 
[
18
F]fluoride in acetonitrile at 100 °C for 10 minutes. The reaction mixture was then 
cooled to RT and purified by preparative HPLC (40-80% MeCN/H2O over 25 minutes), 
([
18
F]38) was isolated in 30% n.d.c. yield from [
18
F]fluoride.  
 
Figure 4.1: HPLC radio chromatogram of ([18F]38) 
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Using the conditions employed in Scheme 4.5, sodium hydride was added to a solution 
of (9) in DMF (100 µL) shortly followed by addition of ([
18
F]38) as a DMF solution 
(200-300 µL). The reaction was then heated to 50 °C for 15 minutes. Following 
analytical HPLC analysis, some ([
18
F]38)
 
remained, but after heating the reaction to 100 
°C for a further 15 minutes all ([
18
F]38)
 
was consumed. Consequently, the crude 
product was purified by semi-preparative HPLC (40-80% MeCN/H2O over 25 minutes). 
([
18
F]41) was identified to be the major isomer in 30% isolated n.d.c. yield from 
([
18
F]38). Overall, ([
18
F]41) was produced in 11% isolated e.o.s. n.d.c. yield from 
[
18
F]fluoride within 2.5 hrs, in 90-95% radiochemical purity (n=10). Whilst ([
18
F]40) 
was produced minimally owing to < 1% n.d.c. yield (Scheme 4.5 and Figure 4.2).  
 
Scheme 4.5: Synthesis of ([18F]40) and([18F]41) 
 
Figure 4.2: Analytical HPLC chromatogram of ([18F]40) and ([18F]41) 
This two-step reaction to yield ([
18
F]41) was repeated a number of times to assess its 
reproducibility. Following numerous experiments (n=10) which all showed good yields, 
([
18
F]40)
] 
([
18
F]41) 
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this chemistry was applied to an automated module. This allowed a higher starting 
activity of [
18
F]fluoride to be used, whilst minimising personal dose. Initially, the 
synthesis of ([
18
F]38) was automated using a Tracerlab™ FX F-N module (GE 
Healthcare) with HPLC purification. The azeotropic drying of [
18
F]fluoride followed the 
same method as mentioned in Section 3.1 and the labelling of ethylene di(p-
toluenesulfonate) was performed under the same conditions. After the preparation of 
([
18
F]38), the crude product was purified by semi-preparative HPLC (50-80% 
ammonium acetate / methanol over 25 minutes). The isolated product was then diluted 
in water (20 mL) and trapped to a reverse phase silica gel cartridge (C-18 Sep-Pak; 
Waters). The cartridge was dried over a stream of nitrogen and the product was eluted  
with DMF (300-400 µL). The automated synthesis of ([
18
F]38) afforded on average 
25% n.d.c. isolated yield from [
18
F]fluoride (n = 4).  
The fluoroalkylation step however, was unable to be automated due to the harsh 
conditions required. Namely, using sodium hydride produced a pH 9 reaction solution; 
this basic solution is unsuitable to be used on an automation module.  
Following the successful development of ([
18
F]41) and semi-automated synthesis, the 
next steps were to characterise the fluorine-19 standard (41), to ascertain whether this 
compound behaves as a potent VGSC ligand. 
  
4.3 In vitro electrophysiological characterisation 
Evaluation of (41) commenced with ‘sharp’ intracellular microelectrode and patch-
clamp electrophysiology studies (as outlined in section 3.5). These results were 
compared with the literature compound (9) and other analogues (Chapters 3 and 5).  
 
4.3.0 Sharp microelectrode electrophysiology 
For a general overview of sharp electrode electrophysiology, see Section 3.5.0. 
 
4.3.0.0 Results 
As depicted in Section 3.5.0.0, sharp microelectrode electrophysiology was performed 
by Dr Andrew Constanti (UCL School of Pharmacy). This was intended to be a 
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preliminary screen of compounds in order to provide a basis for further quantitative 
evaluation of potency and sub-type selectivity using automated and manual patch clamp 
assays. Each result presented here was confirmed in at least two neurones in different 
brain slice preparations. Evaluation of (41) began in the CA1 region of the hippocampus 
as discussed previously for (9). A pyramidal cell in the CA1 region was impaled and 
held at -70 mV membrane potential with steady positive current (Figure 4.3); control 
recordings were taken and a 10 µM solution of (41) in Kreb’s medium was bath-applied 
for 30 minutes. During this time, no obvious reduction in spike amplitude or evoked 
firing was seen, and the resting membrane potential remained steady at -70 mV (traces 
not shown). Consequently, the concentration of (41) applied was increased to 20 µM 
and the same pyramidal cell was stimulated (traces not shown). Still, no change in 
neuronal firing was seen. Finally, the concentration was increased to 30 µM and the cell 
was monitored further (Figure 4.3).  
 
 
Figure 4.3: Hippocampal CA1 pyramidal cell held at -70 mV (maintained by steady current injection). 
(A): Control current/voltage (IV) relationship (± 0.2 nA steps, duration 160 ms). (B): Control 
positive/negative step (± 0.5 nA step, duration 160 ms). (C) Control long sweep (+ 0.8 nA / -0.5 nA step, 
duration 1.5 s). (D) IV relationship (± 0.2 nA steps, duration 160 ms) showing no change in neuronal 
firing with (41) 30 µM; 30 minutes). (E) Positive/negative step (± 0.5 nA step, duration 160 ms) showing 
no change in neuronal firing with (41) (30 µM; 30 minutes). (F) Long sweep (+ 0.8 nA / -0.5 nA step, 
duration 1.5 s) after 30 minutes showing a reduction in the after hyperpolarisation slow bursting 
(A) 
(B) 
(C) 
(D) 
(E) 
(F) 
Control + (41), 30 µM, 30 minutes 
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After increasing the drug concentration to 30 µM for 40 minutes, the neuronal firing 
pattern showed a small change (Figure 4.3E) indicated by a decrease in the number of 
spikes initiated by the short depolarising current pulse step (8 spikes reduced to 7). 
Interestingly, when a longer (1.5 second) and larger ((+ 0.8 nA / -0.5 nA) current step 
was injected, a reduction in the slow afterhyperpolarisation following a spike burst, 
resulted in an apparent increase in the firing frequency (Figure 4.3F). However, this 
increase in neuronal firing is not well represented in the IV traces or positive/negative 
current step. 
  
4.3.0.1 Discussion  
Compound (41) was shown through sharp microelectrode electrophysiology to be 
mostly inactive in the CA1 region of the hippocampus. It was only at higher 
concentrations (30 µM) (Figure 4.3E) that a slight effect on firing rate was seen with no 
apparent change in spike amplitude or duration. Reduction of the slow 
afterhyperpolarisation was also seen, which resulted in an increase in the neuronal firing 
frequency during the longer current step in Figure 4.3F.  
Normally, the repolarisation phase of an action potential increases the membrane 
potential, due to opening of slow-inactivating (delayed rectifier) potassium channels. 
Also, slow calcium-activated potassium channels (SK channels), open in response to the 
influx of calcium ions during the action potential burst. The permeability to potassium 
causes the membrane potential to be driven closer to the potassium equilibrium 
potential, causing an undershoot of the resting membrane potential (after-
hyperpolarisation). It is possible that (41) was having an inhibitory effect on these slow 
inactivating potassium channels and/or on cell calcium entry, but this was not 
confirmed. However, it was shown that (41) was not behaving like a classical VGSC 
blocker in this brain region at the concentrations tested. 
Due to this compound showing minimal effect in the hippocampal slices, (41) was not 
selected for further testing in the CNS. Nevertheless, (41) went on to be tested in a 
VGSC isoform selectivity screen to ascertain its full potential as a VGSC ligand. 
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4.3.1 Automated electrophysiology  
For details on the protocol used for this study, see Section 3.5.1. The results described 
in this section were provided by Chantest
®
, US. 
 
4.3.1.0 Results 
The same conditions and measurements were used as first detailed (Section 3.5.1), but a 
ten-fold higher concentration of (41) was tested (Table 4.2) than previously used, due to 
this compound appearing to have lower potency towards VGSCs than (9), following 
sharp microelectrode studies. 
No 
Type 
of 
block 
IC50 
Nav 1.1 Nav 1.2 Nav 1.3 Nav 1.4 Nav 1.5 Nav 1.6 Nav 1.7 
(41) 
Tonic >300 >300 >300 >300 >300 >300 >300 
10 Hz >300 >300 >300 >300 
75.9 
± 27.2 
>300 >300 
Inact 
138 
± 56.7 
113 
± 28.9 
189 
± 74.6 
44.2 
± 3.50 
15.1 
± 6.6 
193 
± 81.5 
>300 
Table 4.2: Summary of IC50 values with (41) on Nav 1.1-1.7  
Firstly, it should be noted that (41) seemed to have the same binding characteristics as 
(9), namely, that it bound preferentially to the inactivated state of the Na
+
 channels. 
These data indicated preferential binding to specifically Nav 1.5 (IC50 = 15.1 ± 6.6 µM) 
and Nav 1.4 (IC50 = 44.2 ± 3.5 µM). Although (9) showed higher potencies for Nav 1.5 
(IC50 = 0.78 ± 0.29 µM) and Nav 1.4 (IC50 = 1.26 ± 0.29 µM), (41) emerged to be more 
selective, 2.9 times more selective for Nav 1.5 compared with (9), showing 1.6 times 
selectivity. Poor potency was seen in the tonic and frequency dependent block 
protocols, with no IC50 value established at the concentrations tested, except Nav 1.5, 
where an IC50 of 75.9 ± 27.2 µM was determined (maximum concentration 300 µM). 
Although the overall binding profile appeared similar to (9), (41) was one order of 
magnitude less potent in these tests.  
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4.3.1.1 Discussion 
Compound (41) was highlighted as a semi-potent sub-type selective VGSC blocker. 
Although the potency of this compound was revealed to be less than (9), this study only 
allowed for an indication of potency. As (41) along with (9) is a state-dependent 
blocker, with preferential affinity for the inactivated state, it was likely to require more 
time under stimulation to see the maximum effect, than was allowed in the protocol. 
Furthermore, a longer stimulation period would have been more in-line with 
physiological conditions. In conclusion, this assay showed our compound to be sub-type 
specific but was unable to accurately depict the potency within the confines of this 
assay. (41) was therefore also screened through manual patch clamp experiments 
(courtesy of Scottish Biomedical
®
) specifically testing for inactivated state block in 
expressed Nav 1.4 and 1.5 channels.  
 
4.3.2 Patch-clamp electrophysiology  
The results described in this section were provided by Scottish Biomedical
®
, UK. 
hNav1.4 and 1.5 were stably expressed in HEK-293 cells, (41) was tested at 4 
concentrations (0.1, 1, 10 and 30 µM). Incubation time of drug varied depending on 
time taken to reach maximum inhibition at each concentration. 
 
4.3.2.0 Results 
Using the P1-P2 protocol (see Section 2.4.1), (41) showed a preference for binding to 
the inactivated state, inducing a significant reduction in control response across both 
cell lines.  
Following testing in hNav 1.4, (41) had approximately 160-fold higher affinity for P2 
(inactivated) compared to P1 (resting), with an estimated IC50 40 nM vs 6 µM, 
respectively. The maximal inhibitory response (Imax) of (41) was approximately 93% 
total block at the maximal concentration of 30 µM in P2, whilst 67% was seen in P1. 
Figure 4.4 shows the trough of a dose response curve. At -5 log [M] (10 µM), the rising 
part of the curve is beginning to show.  
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Figure 4.4: Dose response curve of hNav 1.4 of (41) (0.1-30 µM) under P1 and P2 conditions  
Following testing in hNav 1.5, (41) had approximately 145,000-fold higher affinity for 
P2 (inactivated) compared to P1 (resting), with an estimated IC50 0.2 nM vs 29 µM, 
respectively. The maximal inhibitory response (Imax) of (41) was approximately 94% 
total block at the maximum concentration of 30 µM in P2, whilst 54% was seen in P1.  
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Figure 4.5: Dose response curve of hNav 1.5 of (41) (0.1-30 µM) under P1 and P2 conditions 
The dose-response curves for (41) indicated that all concentrations tested gave >50% 
block across both cell lines. The IC50 value was therefore reported using a non-linear 
regression fit algorithm (GraphPad Prism version 5.0) to extrapolate the data.  
 
4.3.2.1 Discussion 
The estimated IC50 values quoted for both channels indicated that (41) is more potent 
than was initially established (Section 4.3.1.0). Applying each concentration of (41) for 
longer, showed a marked difference in the reported inhibition values. All concentrations 
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tested gave >50% block. These results mirror that seen with (9). The IC50 values quoted 
here, are four orders of magnitude more potent when comparing Nav 1.5 IC50 (0.2 nM) 
with the IC50 value obtained for Nav 1.5 (15.1 µM) in the automated electrophysiology 
screen. As described previously, there is a high margin of error with these results, but it 
is likely that (41) has an IC50 around the low to sub nanomolar range. Interestingly, 
these results also indicated a higher degree of selectivity between the two channels (40 
vs 0.2 nM; 1.4 vs 1.5) than was seen before.  
Overall, the potency of (41) has been shown to be much higher in this study. In order to 
gain confidence in these values, lower concentrations are needed to be tested, but it was 
not possible within the confines of the research grant to commission a further external 
study.  
In order to put these values in context, calculations were carried out using the same 
approximate Bmax (6.6 µM) as mentioned in Section 3.5.2.1. To indicate the binding 
potential, the calculation used the approximate IC50 of 0.2 nM as Kd (41) giving a 
binding potential of 33,000. Again, caution must be used when interpreting this value as 
this should be used as a guide only. However, this value does imply that the binding 
potential is possibly much higher than the minimum recommended value of 10. 
In vitro work showed (41) to be a promising VGSC ligand, more work was needed to 
establish its exact efficacy and binding kinetics but it was important to identify the in 
vivo characteristics of ([
18
F]41). A näive biodistribution of ([
18
F]41) was carried out to 
ascertain whether this radiotracer was able to show uptake, retention and then clearance 
in key tissues.  
 
4.4 In vivo characterisation 
All in vivo studies described in this section were kindly performed by the in vivo 
biology team, GE Healthcare, Amersham.  
4.4.0 Log P determination 
Lipophilicity can indicate compound properties such as non-specific binding and 
metabolic stability.
130, 178-179
 Therefore, before any in vivo work was carried out, the lop 
P of (41) was determined. 
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The distribution coefficient (Log-P) was measured experimentally using the shake-flask 
method (see Section 2.3). Briefly, known concentrations of (41) were added to a 
mixture of octanol and water (0.5 ml; 1/1) in an eppendorf tube. The tube was vortexed 
for 10 minutes to allow for even distribution of (41) before being centrifuged for 5 
minutes at 10 000 xg. The amount of (41) in the octanol and water layer was measured 
using HPLC and the area of the solute was evaluated against a calibration curve of 
known concentrations run on the same day. (Ideally, known concentrations of ([
18
F]41) 
would have been used but access to fluorine-18 was not available at that time).  
The Log P was found to be 2.03 which is within the range 2 < logP < 3.5 typically 
identified as optimal.  
 
4.4.1 Näive biodistribution 
([
18
F]41) was assessed through a näive biodistribution study to determine whether this 
tracer could show uptake and retention in key tissues and clear from these tissues within 
2 hours. 
 
4.4.1.0 Results 
([
18
F]41) was delivered in 11% n.d.c. e.o.s. yield from [
18
F]fluoride at 30.3 MBq/mL, as 
a phosphate buffer /ethanol solution (9:1), with specific activity 3.48 GBq/µmol. 3.3 
MBq (100 µL) was injected i.v. via the tail vein to each CD1 näive male mouse. The 
radiotracer was sampled at five time points over 2 hours and three animals were 
sacrificed at each time point (Figure 4.6 and Table 4.3).  
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Figure 4.6: Näive biodistribution graph for ([18F]41) 
Tissue 2 minutes 15 minutes 30 minutes 60 minutes 120 minutes 
Mean %ID/G ±SD (n=3) 
Bone 1.70 ±0.62 0.65 ±0.19 1.19 ±0.14 1.07 ±0.05 2.53 ±0.54 
Muscle 2.98 ±0.87 1.11 ±0.36 1.31 ±0.09 0.68 ±0.04 0.95 ±0.09 
Blood 1.64 ±0.28 2.07 ±0.99 1.89 ±0.17 1.42 ±0.40 1.47 ±0.11 
Lung 5.74 ±1.39 1.95 ±0.67 1.92 ±0.17 0.96 ±0.09 1.13 ±0.01 
Liver 8.15 ±2.21 6.57 ±1.03 3.99 ±0.32 3.90 ±1.04 3.07 ±0.24 
Heart 5.86 ±1.17 1.23 ±0.15 1.89 ±0.22 1.14 ±0.40 1.21 ±0.09 
Skin 0.81 ±0.01 1.70 ±0.17 2.04 ±0.05 1.87 ±0.14 1.39 ±0.14 
Brain 6.29 ±1.25 1.57 ±0.29 1.53 ±0.12 0.77 ±0.18 1.07 ±0.02 
Table 4.3: Näive biodistribution data of ([18F]41) in key tissues 
In general, the biodistribution indicated little retention of radioactivity in most tissues; 
clearance was primarily through the hepatobiliary system (39.84% id at 120 minutes). 
In more detail, the biodistribution showed initial brain uptake at 2 minutes to be 6.3 ± 
1.3% id/g and heart at 2 minutes, 5.9 ± 1.2% id/g. The radioactivity cleared rapidly from 
these tissues, (brain: 1.5 ±0.1% id/g; heart: 1.8 ±0.2% id/g) within 30 minutes. Little 
retention of radioactivity was seen in the muscle. Initial uptake of 2.98 ± 0.9% id/g at 2 
minutes within the muscle rapidly cleared to (1.11 ± 0.4% id/g) after 15 minutes. 
Lowest blood levels were seen at 2 minutes (1.64 ± 0.3% id/g), whilst subsequent time 
points showed higher levels, consistent with rapid uptake of radiotracer into tissues and 
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later, diffusion of radioactivity out of tissues and into the systemic system. For example, 
the muscle level dropped from 2.98 ± 0.9% id/g to 1.11 ± 0.4% id/g from 2 to 15 
minutes. Interestingly, the skin level (skin known not to contain VGSCs), although low 
at 2 minutes at 0.81 ±0.01% id/g, increased to 2.04 ± 0.05% id/g within 30 minutes 
before decreasing. This could be due to contamination from blood, which appeared to 
follow a similar pattern. The lung showed uptake comparable to the heart and brain at 2 
minutes (5.75 ± 1.4% id/g) and sharply decreased by 15 minutes to 1.95 ± 0.2% id/g. 
Uptake in the lung is likely to be consistent with dispersion of radioactivity which 
quickly diffuses back into the blood. Bone level remained low throughout the time 
course of the study (average 1.15 ± 0.3% id/g in the first 60 minutes) until the last time 
point at 120 minutes, the radioactivity level increased to 2.53 ± 0.5% id/g. All three 
animals were consistent (2.56 ±0.6% id/g) so it was not thought that the sudden increase 
was due to contamination, but more likely, free [
18
F]fluoride binding which has been 
released during metabolism of the tracer. 
4.4.1.1 Discussion 
The näive biodistribution study for ([
18
F]41) showed somewhat unpredicted results. In 
vitro data suggested this compound would show greater binding to Nav 1.4 (expressed 
in skeletal muscle) and Nav 1.5 (expressed in the heart), although uptake was seen in 
these tissues it was not retained, suggesting little specific uptake. In vitro data also 
showed less selectivity towards Nav 1.1-1.3 and 1.6 (found in the brain), but higher 
uptake of ([
18
F]41) was seen in the brain (than in the heart or muscle) at the initial time 
point (6.29 ± 1.3% id/g; 2 minutes).  
Overall, the biodistribution profile showed little retention of ([
18
F]41) in all tissues, 
implying minimal binding, whilst most of the radioactivity was cleared through the 
hepatobiliary system. 
Although there was not a known fluorine-18 labelled VGSC PET tracer to compare our 
biodistribution data with, it was important to put our figures into context in terms of 
indicating whether uptake, retention and clearance were noteworthy.  
The NMDA receptor (as first mentioned in Section 1.4) is an ionotropic glutamate 
receptor distributed widely within the brain, which also exhibits voltage-dependent 
activation, allowing the flow of sodium and calcium ions into the cell and potassium out 
of the cell. PET tracers to target the NMDA receptor have now been developed.
180
 The 
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NMDA PET tracer [
18
F]memantine was studied through a näive mouse biodistribution. 
Samnick et. al., reported initial brain uptake of 2.50% id/g ± 0.13 at 5 minutes, 
subsequently this increased to 3.76% id/g ± 0.45 at 30 minutes before decreasing.
180
 
Using these data as a rough guideline of uptake for comparison, our tracer appeared to 
have greater initial uptake in our expressing tissue (heart; 5.86 ±1.17% ID/g), but not as 
good retention. Although no strong comparisons can be drawn, it was interesting to 
understand what percentage uptake in a key tissue (high expression of receptor) is 
common for an ion channel PET tracer. 
It is also important to consider the low specific activity afforded. To-date, it has not 
been possible to determine accurate values of Bmax (and Kd). Without this, we are not 
sure if the concentration of available receptors for binding is high or low. It could be 
that the administered mass of (41) or (an unidentified compound which elutes at the 
same retention time) is blocking the an unknown amount of VGSCs and therefore, 
inhibiting the binding of ([
18
F]41). Currently, not enough is known regarding the 
concentration of sodium channels or more accurately the Bmax. However, the low 
specific activity afforded here, will need to be improved, if later studies confirm that 
there is a high VGSC saturation at this concentration.  
4.5 Conclusions of Chapter 4  
Initial in vitro data (Section 4.1) highlighted (41) as a semi-potent sub-type selective 
VGSC ligand. It was further investigated through a näive biodistribution study to 
characterise its in vivo biodistribution profile. It was known that removing the terminal 
carboxamide might have an effect on the compound’s affinity for VGSCs, but it was not 
known to what extent and therefore still important to ascertain how this compound 
behaved in vivo. Moreover, as Yang et. al., had not performed in vivo studies on their 
compounds, our study was adding to the field of knowledge. It was important to note, 
that after injecting ([
18
F]41) into näive CD1 mice for the biodistribution study, all 
animals suffered no measurable ill effects from this tracer. Although it showed little 
retention in key tissues, initial uptake was good, in vivo stability was inferred from the 
low bone uptake and the tracer showed signs of clearing within 2 hours. As a result of 
this work ([
18
F]41) was not selected for further development. Using the data from this 
chapter, our next analogue of the 3-(4-(4-R-phenoxy)phenyl)-pyrazole-1- carboxamides 
was developed. 
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5. Results and Discussion  
 
 
 
Design, synthesis and bioevaluation of [
18
F]4-(4-(2,4-
difluorophenoxy)phenyl)-1-(2fluoroethyl)-triazole 
 
 
  
Chapter 5  Results and Discussion 
164 | P a g e  
 
5.0 Rationale for novel tracer  
Following on from work described in Chapter 4, ([
18
F]41) was highlighted to have some 
efficacy for VGSCs, but it’s in vivo characteristics indicated that it was not suitable for 
use as a PET tracer. Moreover, the biodistribution appeared to indicate that the terminal 
carboxamide was indeed important for binding. However, due to this group’s lability 
towards cleavage under basic conditions as discussed in Chapter 3, a bioisostere was 
sought to replace the terminal amide. A 1,4-substituted triazole produced by the 
Hüisgen 1,3-cycloaddition reaction between an azide and a terminal alkyne had been 
previously reported to act as a bioisostere for an amide.
181
 The Hüsigen 1,3-
cycloaddition, a so called “click chemistry” reaction is well reported with [18F]2-
fluoroethylazide and a variety of terminal alkynes, whilst the copper (I)-catalysed 
reaction gives exclusively the 1,4-product.
182
 Subsequently, the structure was altered 
further with the removal of the pyrazole ring (Figure 5.1). The purpose of this ring as 
reported by Yang et. al., was simply to conjugate the second phenyl ring to the terminal 
amide whilst being metabolically stable. There was no other rationale for its presence.
181
 
The exclusion of the pyrazole ring also reduced the molecular weight and size of the 
molecule, making it closer to the original 3-(4-phenoxyphenyl) pyrazole-1-
carboxamides. 
 
Figure 5.1: Structure of (43) 
 
5.1 Click chemistry  
Over the last decade there has been an ever increasing demand for pharmaceutically 
active molecules to be produced in high purity and yield. A powerful synthetic tool that 
fulfils these requirements is click chemistry. The term was first coined by Sharpless in 
1999 at the 217
th
 American Chemical Society annual meeting. He then followed on this 
work with his 2001 review defining click chemistry as a group of reactions that “... must 
be modular, wide in scope, give very high yields, generate only inoffensive by products 
that can be removed by nonchromatographic methods, and be stereospecific. The 
Chapter 5  Results and Discussion 
165 | P a g e  
 
required process characteristics include simple reaction conditions, readily available 
starting materials and reagents, the use of no solvent or a solvent that is benign, 
allowing easy product isolation. Purification, if required, must be by non-
chromatographic methods, such as crystallisation or distillation, and the product must 
be stable under physiological conditions”.183 These reactions include cycloadditions; 
primarily this refers to 1,3-dipolar cycloadditions including hetero Diels-Alder 
cycloadditions.
184
 Other reactions also come under the umbrella of click chemistry, for 
example, nucleophilic ring-openings,
184
 carbonyl chemistry involving non-aldol 
chemistrys and addition to C-C multiple bonds.
184-185
 
 
5.1.0 The Hüisgen 1,3 cycloaddition 
The Hüisgen 1,3-cycloaddition has found much synthetic utility since it is extremely 
reliable and easy to use. The reaction is very atom economic as the combined formula of 
the reactants equals the formula of the product. No σ-bond connection is broken during 
the reaction, therefore the solvent is not coordinated to the starting material during 
product formation, allowing the reaction to be solvent independent. The reaction 
exclusively forms a 1,4-substituted product when copper catalysed, making it 
regiospecific and the catalysed route significantly improves the rate of reaction (> 10
7
 
times faster). It can be performed in a wide range of solvents including aqueous. Azides 
and terminal alkynes are fairly easy to install and are tolerant to a range of conditions 
commonly encountered in synthesis. Aliphatic azides may decompose in a 
thermodynamically favoured reaction. However, in the cycloaddition reaction, a kinetic 
barrier to decomposition allows them to form a stable complex.
184-187
  
 
 
Figure 5.2: General mechanism for Hüisgen 1,3-cycloaddition 
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This cycloaddition proceeds via a stepwise reaction pathway based on Cu(I) insertion 
into terminal alkynes. It seems most likely that the first step of the reaction is the π-
complexation of a Cu(I) dimer to the alkyne via a Cu2L2 complex.
184-185
 After this, the 
deprotonation of the terminal alkyne occurs to form a Cu-acetylide.
184-185
 There are 
many forms of this complex that exist; only one is shown above. The π-complexation of 
Cu(I) reduces the pKa of the terminal alkyne by nearly 10 units allowing the 
deprotonation to occur in aqueous solution without the need for a base (if the reaction 
were to be performed in an organic solvent then a suitable base such as N,N-
diisopropylethylaminutes (DIPEA) would need to be added). In the following step the 
internal nitrogen of the azide attaches to the free copper (not bonded to the acetylide) 
forming an “activated” metallo complex. The external nitrogen on the azide now acts as 
a nucleophile and can attack the adjacent alkyne carbon due to the close proximity and 
electronic factors. The metallocycle contracts when the lone pair on the nitrogen attacks 
the alkyne forming the respective triazole ring. Once this complex has been formed the 
copper dimer then dissociates from the triazole and complexes to a second terminal 
alkyne. This occurs via protonation of the triazole.
184-187
 
The general method for the formation of the Cu(I) catalyst is mixing copper (II) 
sulphate with a reducing agent such as sodium ascorbate, although this is not the only 
reducing agent that can be used. The production of the catalyst using this method is very 
cheap and can be performed in aqueous solution. The only drawback to this method is 
that Cu(II) can be reduced to Cu(0) from Cu(I) in a disproportionation reaction.
184-187
 
However, recently the use of copper wire and copper powder has been reported, which 
overcomes this problem.
188
 
 
5.2 Synthesis of 4-(4-(2,4-difluorophenoxy)phenyl)-1-(2-fluoroethyl)-
triazole  
(44) was produced through a Hüisgen 1,3-cycloaddition between (42) and (43) (Scheme 
5.3). Initially, (42) was afforded in a 2-step procedure (Scheme 5.1). Treating 2-
fluoroethanol with tosyl chloride (TsCl) under basic conditions with triethylamine 
(TEA) catalysed by dimethylaminopyridine (DMAP) afforded (38) in 98% yield. The 
tosyl group was displaced using sodium azide in DMF to yield (42). Due to the 
instability of (42), it was kept as a solution in DMF with concentration 0.23 M. 
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Scheme 5.1: Synthesis of (42) 
Subsequently, (43) was produced by reaction of 2,4-difluorophenol with 1-ethynyl-4-
fluorobenzene undergoing a Williamson reaction, giving (43) in 15% yield (Scheme 
5.2). The low yield was perhaps related to the stability of 2,4-difluorophenol under 
basic conditions as discussed in Section 3.1.1. 
 
Scheme 5.2: Synthesis of (43) 
The subsequent Hüisgen 1,3-cycloaddition reaction between (42) and (43) was 
catalysed using copper wire (where copper (I) is present on the surface) in DMF, 
affording (44) as the exclusive isomer in 24% yield ( 
Scheme 5.3). Copper wire was introduced as catalyst instead of using the reduction of 
copper sulphate to minimise any disproportionation reactions.  
 
Scheme 5.3: Synthesis of (44) via a Huisgen 1,3 cycloaddition 
The low yield was attributed to precipitation of starting materials under reaction 
conditions. However, using a more dilute reaction solution did not improve the yield of 
the rate of reaction.  
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5.3 General [
18
F] radiolabelling strategies  
Following on from the successful synthesis of (44), radiolabelling studies commenced 
incorporating fluorine-18 by using ([
18
F]42) (Scheme 5.5). 
5.3.0 Indirect fluorine-18 labelling 
The precursor for ([
18
F]42) was produced in a two-step synthesis. 2-Bromoethanol 
underwent an SN2 reaction with sodium azide in DMF at RT for 24 hrs affording (45) 
(Scheme 5.4). Due to the volatile nature of (45), this compound was not isolated. 
Subsequently, pyridine and tosyl chloride were added at 0 °C and the reaction 
proceeded at RT to yield (46) in 90% yield.  
 
Scheme 5.4: Synthesis of (45) via an SN2 reaction 
The synthesis of ([
18
F]42) was carried out using an automated manifold. Recently, its 
synthesis on a GE Healthcare FASTlab™ was reported by Iddon et. al., who distilled 
the product in 30-40% n.d.c. yield starting from (46).
188
 
 
Scheme 5.5: Automated synthesis of ([18F]42) on a FASTlab™ 
A FASTlab™ cassette was assembled (Section 2.2). Initially a solution of KHCO3 and 
kyrptofix® in MeCN was used to elute [
18
F]fluoride from the QMA cartridge in the first 
processing step. Following drying of [
18
F]fluoride in the reactor vessel, (46) in MeCN 
was added and heated at 100 °C for 30 minutes to yield ([
18
F]42). Owing to the 
volatility of ([
18
F]42), it was distilled out of the central manifold into an external vial 
charged with 100 µl of DMF as a simple and effective purification. As the labelling 
proceeded, ([
18
F]42) was trapped in DMF affording this synthon in 20-30% n.d.c. yield.  
Following on from the successful synthesis of ([
18
F]42), the Hüisgen 1,3-cycloaddition 
was attempted under manual labelling conditions (Scheme 5.6). 
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Scheme 5.6: Manual synthesis of ([18F]44) 
Instead of using copper wire to catalyse the reaction as previously discussed, copper (I) 
was produced under the classic reduction of copper(II)sulphate with sodium ascorbate 
in water. Copper wire was reported by Iddon et. al., to be unsuccessful in catalysing the 
Hüisgen 1,3-cycloaddition in reactions with fluorine-18 using alkyne functionalised 
peptides.
188
 Following reduction of copper sulphate by sodium ascorbate in a Wheaton 
vial under aqueous conditions; the copper ligand bathophenanthroline (BPDS) was 
added to enhance the rate of reaction as reported by Glaser et. al.
137
 The vial was purged 
with nitrogen to prevent oxidation of copper and thereafter (43) was added as a DMF 
solution. The solution was again purged with nitrogen and left to complex with the 
copper for 5 minutes. Lastly, ([
18
F]42) as a MeCN solution was added and the reaction 
was heated to 130 °C for 20 minutes. ([
18
F]44) was purified by semi-preparative HPLC 
(10-95%; MeCN/H2O over 25 minutes) and isolated in 37% n.d.c yield, giving ([
18
F]44) 
overall in 10% e.o.s n.d.c. yield from [
18
F]fluoride (n=7). 
A one-step synthesis of ([
18
F]44) was attempted using a fluorine-18 for tosylate 
displacement using (47) as precursor (Scheme 5.7). (47) was produced through a copper 
catalysed Hüisgen 1,3-cycloaddition between (46) and (43) in the presence of copper (I) 
to yield (46) in 12.5%. Due to the minimal yield, (47) was characterised by low 
resolution MS only. 
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Scheme 5.7: Synthesis of (46) and attempted radiolabelling of ([18F]44) 
Subsequently, [
18
F]fluoride was dried manually as per normal procedure (Section 3.0.1) 
and (47) was added as a DMF solution and heated to 130 °C for 20 minutes (Scheme 
5.7). The reaction mixture was subsequently purified by semi-preparative HPLC (10-
95%; MeCN/H2O over 25 minutes) to identify ([
18
F]44). 
From the radiochemical chromatogram, most of the activity remained as “free” 
[
18
F]fluorine while 2 minor peaks were seen each accounting for <0.5% integrated 
yield, but neither were product. Unfortunately, it was not possible to identify these 
peaks. 
The next step was to trial this radiochemistry using the FASTlab™ module, as 
previously introduced. To date, the total automation to synthesise ([
18
F]44) has not been 
achieved due to laboratory time constraints and synthesis of (47) has not been scaled up 
as yet. For more details see Future Work (Section 8). 
 
5.4 Conclusion of radiolabelling experiments 
A new tracer ([
18
F]44) was successfully produced in a two-step semi-automated 
procedure using click chemistry. An alternative one-step procedure was attempted 
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manually which had so far proved unsuccessful. The two-step procedure was used 
herein to prepare this tracer for a series of in vitro and in vivo studies. 
5.5 In vitro electrophysiological characterisation 
Initially, (44) was assessed through a series of electrophysiological studies and 
compared with the literature compound (9) and other analogues.  
 
5.5.0 Sharp microelectrode electrophysiology 
For a general overview of sharp microelectrode electrophysiology, see Section 3.5.0. 
5.5.0.0 Results 
As depicted in Section 3.5.0.0, sharp electrode electrophysiology was performed by Dr 
Andrew Constanti (UCL School of Pharmacy). Classification of (44) commenced with a 
10 µM solution (1:99; EtOH/Kreb’s) (Figure 5.3) applied to pyramidal cells of the CA1 
hippocampal region in vitro. This region and concentration was first studied to see 
whether there was a similar effect in this area, as shown with (9). 
A CA1 pyramidal neurone was impaled and held at -70 mV membrane potential. 
Control recordings were taken and the drug solution bubbled with oxygen 95% / CO2 
5% applied via the bathing medium. Neuronal activity was monitored and recorded.  
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Figure 5.3: Hippocampal CA1 neurone held at -70 mV (maintained by steady positive current injection). 
(A): Control IV relationship (± 0.2 nA steps, duration 160 ms). (B): Control positive/negative step (± 0.5 
nA step, duration 160 ms). (C) Control long sweep (+ 0.8 nA / -0.5 nA step, duration 1.5 s). (D) Stretch of 
control long sweep recording from (C). (E) IV relationship (± 0.2 nA steps, duration 160 ms) showing 
inhibition of later action potentials after (44) was applied (10 µM; 60 minutes). (F) Positive/negative step 
(± 0.5 nA step, duration 160 ms) showing clear inhibition of spikes with (44) (10 µM; 60 minutes). (G): 
Long sweep (+ 0.8 nA / -0.5 nA step, duration 1.5 s) showing a change in the firing pattern after (44) 
applied (10 µM; 60 minutes). (H): Stretch of long sweep recording from (G) showing slight diminishing 
in the spike amplitude. (I) IV relationship (± 0.2 nA steps, duration 160 ms) after 30 min washout. (J) 
Stretch of long sweep (+ 0.8 nA / -0.5 nA step, duration 1.5 s). (K) Positive/negative step (± 0.5 nA step, 
duration 160 ms) after 30 min washout.  
 
+ 10 µM (44); 60 minutes 
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After 60 minutes, very little effect was seen on neuronal activity. It was anticipated that 
(44) might be less potent than (9) due to the structural modifications made. From 
(Figure 5.3E), it can be seen that some later action potentials were dropping out. This is 
quantified in Figure 5.3D and H. The time between the third and fourth spike in control 
was 12 ms (Figure 5.3D) which increased to 19 ms after application of (44) (Figure 
5.3H). Interestingly, the peak amplitude of the spikes was not changed, remaining at 65 
mV throughout (Figure 5.3D and H). After 30 minutes washout (Figure 5.3K), those 
action potentials recovered and thus the gap decreased to 15 ms. The drug concentration 
was then doubled to 20 µM and recordings repeated using the same cell. 
A CA1 pyramidal neurone was held at -70 mV, control recordings taken before and 
after (44) was applied (Figure 5.4). A 20 µM solution of (44) (2:98; EtOH/Kreb’s) 
bubbled with oxygen 95% / carbon dioxide 5% was applied to the system and neuronal 
activity was monitored. 
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Figure 5.4: Same hippocampal CA1 neurone as in Figure 5.3, held at -70 mV (maintained by steady 
current injection). (A): Control IV relationship (± 0.2 nA steps, duration 160 ms). (B): Control 
positive/negative step (± 0.5 nA step, duration 160 ms). (C) Control long sweep (+ 0.8 nA / -0.5 nA step, 
duration 1.5 s). (D) Stretch of control long sweep recording from (C). (E) IV relationship (± 0.2 nA steps, 
duration 160 ms) showing some inhibition of action potentials with (44) (20 µM; 15 minutes). (F) 
Positive/negative step (± 0.5 nA step, duration 160 ms) showing total neuronal block with (44) (20 µM; 
20 minutes). (G): Long sweep (+ 0.8 nA / -0.5 nA step, duration 1.5 s) showing little neuronal firing with 
(44) (20 µM; 20 minutes). (H): Stretch of long sweep recording from (G) showing diminished spike 
frequency. (I) IV relationship (± 0.2 nA steps, duration 160 ms) after 20 minutes washout. (J) Stretch of 
long sweep (+ 0.8 nA / -0.5 nA step, duration 1.5 s) after 30 min washout. (K) Positive/negative step (± 
0.5 nA step, duration 160 ms) after 20 minutes washout showing some recovery of neurones. 
CONTROL + 20 µM (44); 20 minutes 
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Recordings were taken 20 minutes after drug application. After 7 minutes, a clear drop 
in the number of action potentials fired was observed. It is interesting to note that only a 
very slight drop in the spike amplitude was seen (65 mV to 60 mV) (Figure 5.4 D and 
H), whilst spike AHPs were again increasing due to opening of calcium channels. 
Within 20 minutes, total block of all action potentials were seen (Figure 5.4F). When 
applying the long pulse (1.5 seconds) some action potentials were seen (Figure 5.4G) 
indicating reversible binding with longer stimulation. Figure 5.4 proved that (44) had 
affinity for blocking neuronal firing in the pyramidal cells of the CA1 region at 20 µM, 
however, it is not as potent as previously reported (9). Interestingly, a different onset of 
action for (44) at 20 µM, than was seen with (9) at 10 µM.  
Consequently, recordings were taken from pyramidal cells of the PC to monitor any 
differences in action and therefore indicate any subtype selectivity  
 
 
Figure 5.5: PC neurone held at -70 mV (maintained by steady current injection). (A) Control IV 
relationship (± 0.2 nA steps, duration 160 ms). (B) Control positive/negative step (± 0.5 nA step, duration 
160 ms). (C) IV relationship (± 0.2 nA steps, duration 160 ms) showing no inhibition of action potentials 
after application of (44) (1 µM; 15 minutes). (D) Positive/negative step (± 0.5 nA step, duration 160 ms) 
after (44) (1 µM; 20 minutes) applied, showing no inhibition of spikes. 
 
The recordings with (44) applied at 1 µM in PC corroborated with the results of (9) 
(Section 3.5.0.0.) at the same concentration. The traces appeared virtually identical 
between drug and control. Due to no effect seen, no washout was recorded. These 
results further suggested that these compounds have a lack of binding affinity for the PC 
neurones at this concentration.  
 
(C) (A) 
(B) (D) 
CONTROL + 1 µM (44); 15 minutes 
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5.5.0.1 Discussion 
Compound (44) appeared to act like a traditional Na
+
 channel pore blocker; inhibiting 
action potentials without causing an effect on the spike amplitude. This is reminiscent 
of the site 1 blocker tetrodotoxin (TTX). Compound (9) in contrast, showed use-
dependent characteristics (Section 3.5.0.0). Compound (44) may thus be a novel 
inhibitor of neuronal firing exhibiting TTX-like characteristics, although not as potent. 
Moreover, as exhibited with (9), (44) showed a good inhibitory effect in the 
hippocampal CA1 region but no effect was shown in the PC, possibly indicating some 
neurone type/brain area selectivity. (44) was thus considered to be an interesting 
compound warranting further investigation, therefore, it was also tested in the VGSC 
selectivity screen. 
 
5.5.1. Automated electrophysiology  
For a general background to the study performed see Section 3.5.1. The results 
described in this section were provided by Chantest®, US. 
 
5.5.1.0 Results 
Following automated patch clamp experiments on Nav 1.1-1.7 channels expressed in 
CHO cells, (44) was shown to be a state-dependent blocker of VGSCs (Table 5.1). 
Type of 
block 
IC50 
Nav 
1.1 
Nav 
1.2 
Nav 
1.3 
Nav 
1.4 
Nav 
1.5 
Nav 
1.6 
Nav 
1.7 
Tonic >30 >30 >30 *>100 *>100 >30 >30 
10 Hz >30 >30 >30 *74.6 ± 21.7 *52.0 ± 17.05 >30 >30 
Inactivated >30 >30 >30 *34.3 ± 12.6 *15.6 ± 16.3 >30 >30 
*Maximum concentration tested was 100 µM to ascertain accurate IC50 values 
Table 5.1: IC50 values of (44) with Nav 1.1-1.7 provided by Chantest® 
In particular, (44) was shown to be most potent for Nav 1.5 (IC50 = 15.6 ± 16.3 µM) 
followed by Nav 1.4 (IC50 = 34.3 ± 12.6 µM) in the inactivated state. Higher 
concentrations of (44) were tested in these cell lines only to more accurately measure 
the IC50. At the increased concentrations, the IC50 for frequency dependent block (10 
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Hz) was also afforded. Although, it was shown that (44) did not bind as well under 
these conditions, when comparing the raw data, Nav 1.1-1.3 and 1.6-1.7 sodium currents 
showed minimal inhibition of sodium currents at up to 30 µM. Therefore, it was felt that 
testing higher concentrations in these cell lines was not necessary as these 
concentrations adequately demonstrated the lack of potency toward these channels.   
 
5.5.1.1 Discussion 
Compound (44) was shown from the automated electrophysiology assay to be a cardiac 
sub-type selective VGSC blocker in the low µM range. It was also shown to be 
somewhat less potent than (9), but it was recognised in Section 3.5.1.1 that automated 
electrophysiology does not give an accurate representation of potency, because of the 
limitations in the procedure (low incubation time) and thus the potency of (44) was 
expected to be higher than reported. On comparison with (41), (44) was shown to be 
equally potent for the cardiac sodium channel. (44) then went on to be studied in a 
manual patch-clamp study to afford a more accurate IC50 for Nav 1.4 and 1.5 channels.   
 
5.5.2 Patch-clamp electrophysiology 
For information of the procedure used for this study, see section 2.4.2. The results 
described in this section were provided by Scottish Biomedical®, UK. As described 
earlier, hNav1.4 and 1.5 stably expressed in HEK-293 cells were tested at 4 
concentrations (0.1, 1, 10 and 30 µM) of (44) to ascertain an IC50 value. (These 
concentrations were chosen based on previous electrophysiological work which 
indicated an approximate IC50 in the low micromolar range.) 
 
5.5.2.0 Results 
Compound (44) showed a preference for binding to the inactivated state, inducing a 
significant reduction in control response.  
Following testing in hNav 1.4, (44) had approximately 30,000-fold higher affinity for P2 
(inactivated) compared to P1 (resting), with an IC50 4 nM vs 126 µM, respectively. The 
maximal inhibitory response (Imax) of (44) was approximately 98% total block at the 
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maximal concentration of 30 µM in P2, whilst only 30% was seen in P1. Figure 5.6 
shows the trough of the dose response curve only. 
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Figure 5.6: Dose response curve of hNav 1.4 of (44) (0.1-30 µM) under P1 and P2 conditions  
Following testing in hNav 1.5, (44) had a higher affinity for P2 (inactivated) compared 
to P1 (resting), with IC50 3 nM. No IC50 could be calculated for P1 at the maximum 
concentration tested due to its limited inhibitory activity. The maximal inhibitory 
response (Imax) of (44) was approximately 69% total block at the maximal concentration 
of 30 µM in P2, whilst only 22% was seen in P1. The data points from Figure 5.7 show 
the trough of the dose response curve only. 
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Figure 5.7: Dose response curve of hNav 1.5 of (44) (0.1-30 µM) under P1 and P2 conditions 
 
5.5.2.1. Discussion 
The estimated IC50 values quoted for each channel indicated that (44) is far more potent 
than was initially established (Section 5.5.1.0). The values quoted here, are four orders 
of magnitude more potent (comparing Nav 1.5, IC50 3 nM vs 15.6 µM). Although there 
is a high margin of error associated with these values. Interestingly, these results 
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highlighted a narrower degree of selectivity between the two channels (4 vs 3 nM; 1.4 vs 
1.5), than was seen before, highlighting (44) to be equally potent for Nav 1.4 and 1.5. As 
mentioned previously, there is a high error associated with this assay. All concentrations 
showed maximal blocking as was seen in results from (9) and (41).  
Overall, this second assay has allowed for a better insight into the potency of this novel 
VGSC ligand, but due to the unexpected high potency of this compound, only an 
approximate IC50 was afforded. This compound will require further testing at lower 
concentrations, but it was not possible within the confines of the research grant to 
commission a further external study.  
To give an indication of the possible binding potential of (44) (as calculated previously 
for (41) and (9)) the IC50 of 3 nM for Nav 1.5 was used as an approximation of the Kd. 
Again, 6.6 µM was taken as an indication of the Bmax. Therefore, the estimated binding 
potential for (44) is 2,200. Again, caution must be applied to this value; however, it is 
above the minimum recommended value of 10. 
The next steps were to establish the in vivo characteristics of ([
18
F]44) through a 
biodistribution study. Namely, to ascertain whether this compound was able to show 
uptake, retention and clearance in key tissues.  
 
5.6 In vivo studies 
All in vivo studies were kindly performed by the in vivo biology team, GE Healthcare, 
Amersham.  
5.6.0 Log P determination 
As outlined in Section 4.4.0, Log P was measured using the shake-flask method to 
indicate potential lipophilicity and infer some metabolic stability. The measured value 
was 3.05, which is inside the range 2 <logP< 3.5 typically identified as optimal.  
 
5.6.1 Näive mouse biodistribution 
We initially characterised ([
18
F]44) through a näive mouse biodistribution study (Figure 
5.8) to ascertain whether the triazole moiety (which replaced the amide), offered a more 
suitable in vivo profile then ([
18
F]41) (Chapter 4). 
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5.6.1.0 Results 
([
18
F]44) was delivered in 10% n.d.c. e.o.s. yield from [
18
F]fluoride, as a phosphate 
buffer /ethanol solution (9:1; 1/1) at 25.0 MBq per ml, with specific activity 16.8 
GBq/µmol. 2.5 MBq (100 µl) were injected via the tail vein to each CD1 näive male 
mouse. The radiotracer concentration was sampled at 2, 15, 30, 60 and 120 minutes, 
three animals were sacrificed at each time point. 
 
Figure 5.8: Naive biodistribution graph of ([18F]44) 
Tissue 2 minutes 15 minutes 30 minutes 60 minutes 120 minutes 
Mean %ID/G ± SD (n=3) 
Bone 2.98 ± 0.16 1.88 ± 0.15 2.35 ± 0.44 3.19 ± 0.12 7.24 ± 0.98 
Muscle 4.32 ± 0.53 2.49 ± 0.33 2.66 ± 0.43 2.71 ± 0.34 2.36 ±0.15 
Blood 2.87 ± 0.34 3.56 ± 0.25 3.48 ± 0.18 3.59 ± 0.28 4.26 ± 0.27 
Lung 7.02 ± 1.32 7.02 ± 0.45 5.60 ± 0.96 4.21 ± 0.33 4.22 ± 0.77 
Liver 10.52 ± 2.38 15.35 ± 1.83 11.87 ± 1.96 8.60 ± 1.45 6.65 ± 0.55 
Heart 7.77 ± 0.82 6.99 ± 0.72 5.12 ± 0.81 4.36 ± 0.24 3.80 ± 0.40 
Skin 2.11 ± 0.19 4.07 ± 0.32 3.95 ± 0.02 3.94 ± 0.41 3.28 ± 0.19 
Brain 8.20 ± 0.87 5.89 ± 1.02 4.06 ± 0.27 4.98 ± 0.15 3.76 ± 0.10 
Table 5.2: Näive biodistribution data of ([18F]44) in key tissues 
The radiotracer showed good initial uptake in the brain (8.2 ± 0.9% ID/g, 2 minutes) 
and heart (7.8 ± 0.8% ID/g, 2 minutes) unlike ([
18
F]41), where clearance from these 
organs was almost complete after 30 minutes. Here, after 30 minutes there was a much 
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higher degree of radiotracer retention in the brain (4.0 ± 0.3% ID/g) and heart (5.1 ± 
0.8% ID/g) whilst after 120 minutes the tracer appeared to have potentially cleared 
(brain: 3.8 ± 0.1% ID/g vs heart: 3.80% ID/g). Clearance of the tracer was mainly 
through the hepatobiliary system (27.7 ± 0.2% ID; 120 minutes) and some through the 
renal system (7.2 ± 0.4% ID; 120 minutes). Muscle also showed some retention 
although not much initial uptake was seen (4.3 ± 0.5% ID/g, 2 minutes vs 2.4 ± 0.2% 
ID/g 120 minutes). As mentioned in Section 4.4.1.0, uptake in the muscle was presumed 
to be consistent with binding to Nav 1.4 (known to be expressed in the muscle). Lowest 
blood levels were seen at 2 minutes (2.9 ± 0.3% ID/g); subsequent time points showed 
higher levels, which may indicate diffusion of radiotracer or its metabolite into the 
systemic system. Interestingly, the skin level (skin known not to contain VGSCs) 
although low at 2 minutes at 2.11 ± 0.2% ID/g, increased to 3.95 ± 0.02% ID/g within 
30 minutes. This could be reasoned by contamination from blood which also followed a 
similar pattern. The lung showed uptake consistent with dispersion of radioactivity into 
the tissue which quickly diffuses back into the blood. Bone level remained low 
throughout the time course of the study (average 2.60 ± 0.3% ID/g in the first 60 
minutes) until the last time point at 120 minutes, the radioactivity level increased to 
7.24 ± 1.0% ID/g. All three animals were fairly consistent, so it was not thought that 
this was due to contamination from other tissues, but more likely, free [
18
F]fluoride 
binding which has been released during metabolism of the tracer. 
 
5.6.1.1 Discussion 
This biodistribution showed good initial uptake in both the brain and heart, with 
enhanced retention seen in the heart suggesting some specific binding here. Although 
([
18
F]44) was shown to be less selective towards Nav 1.1-1.3 and 1.6, good initial 
uptake in the brain was seen, but less of this uptake was retained, therefore, 
corroborating in vitro results that this tracer is not particularly active in the CNS.  
On comparing ([
18
F]44) and ([
18
F]41), it appears that ([
18
F]44) shows a more positive 
uptake and retention profile, whilst showing some clearance from major organs within 
120 minutes. Without having (9) radiolabelled with fluorine-18, it was difficult to assess 
whether this biodistribution profile was better or worse than ([
3
H]9).  
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On comparison of ([
18
F]44) with the CNS expressing NMDA receptor PET tracer 
[
18
F]memantine (as first discussed in Section 4.4.1.0), this tracer showed much higher 
initial uptake in the heart (2 minutes, 7.8 ± 0.8% ID/g) (where our channel is 
expressed), compared with 2.50 % ± 0.13% ID/g in the brain at 5 minutes reported for 
[
18
F]memantine.
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In addition, it is important to note the specific activity of 16.8 GBq/µmol. As discussed 
in the previous chapter, the relative concentration (Bmax) of VGSCs in each tissue is still 
unknown. Therefore, it is difficult to appreciate whether there is a saturation of VGSCs 
from binding of (44). Future work will require the Bmax of VGSCs to be determined in 
all expressing tissues to allow a greater understanding of how much VGSC binding is 
occurring from ‘cold’ by-products, and how many VGSCs are still available for 
([
18
F]44) to bind to.   
5.6.1 Näive mouse metabolism  
To complement the results of the biodistribution, a metabolism study was performed to 
demonstrate the stability of ([
18
F]44) in vivo (2-60 minutes). Cellular protein was 
removed by precipitation using ice-cold acetonitrile (see Section 2.5.1).  
Before the metabolism study was performed, an extraction efficiency test was executed 
using a 0.6 mL plasma sample with 6 MBq of ([
18
F]43). The percentage recovery of 
radiotracer associated with this method was checked at each step (Table 5.3). Each 
percentage reported is with respect to the previous step.  
Sample % Recovery (n.d.c.) 
Post centrifugation supernatant 96 
Post centrifugation pellet 4 
After removal of solvent 86 
After filtration of HPLC sample 64 
HPLC eluent waste 100 
Table 5.3: Percent recovery (n.d.c.) from protein precipitation method 
This method gave good recovery of the radiotracer into the supernatant with little 
([
18
F]44) remaining in the pellet (4% recovery) and washes. However, some radiotracer 
was retained during filtration of samples prior to the HPLC injection, so this step was 
omitted in the subsequent metabolism study. Each sample was quickly injected onto a 
semi-preparative HPLC system and co-injection of (44) was performed. All solvent 
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waste from the HPLC was collected and measured, showing that all radiotracer was 
efficiently eluted from the column. Having shown this method to afford good 
recoveries, this procedure was used to carry out the metabolism study. 
 
5.6.1.0 Results 
([
18
F]44) was delivered in 7.3% n.d.c. e.o.s. yield from [
18
F]fluoride at 104 MBq/mL as 
a phosphate buffer /ethanol solution (9:1; 1/1), with 0.187 specific activity GBq/µmol. 
10.4 MBq (100 µl) was injected via the tail vein to each C57BL/6 näive male mouse. 
Unfortunately, the specific activity was not as high as normal, but as interest was only 
in the metabolism of ([
18
F]44) and not of the cold impurities, it was thought this would 
not affect any results. The radiotracer concentration was sampled at three time points (2, 
15 and 60 minutes) in the heart and plasma and at 15 minutes only in the brain. One 
animal was sacrificed at each time point (except 60 minutes, where two animals were 
sacrificed and their tissue combined due to little activity remaining at later time points). 
Once the tissue was extracted at each time, the tissue samples were cleaned, 
homogenised and separated using the protein precipitation method as discussed 
previously. Table 5.4 shows the percentage parent vs non-parent for each time point in 
the heart and plasma. A 15 minute brain sample was taken to see whether the uptake 
shown in the brain during the biodistribution was due to uptake of parent or non-parent. 
Tissue Time 
(min) 
% Parent 
Compound 
Parent 
%ID 
Parent 
%ID/G 
Non-parent 
%ID/G 
Heart 
2  100 0.98 7.77 - 
15  93 0.85 6.5 0.49 
60  56 0.33 2.44 1.92 
Brain 15  94 3.81 5.54 0.35 
Plasma 
2  100 5.61 2.87 - 
15  71 4.57 2.53 1.03 
60  14 0.94 0.5 3.09 
Table 5.4: Raw data of percent metabolite and percentage injected dose as parent (n=1) 
([
18
F]44) showed good overall in vivo stability. It is interesting to note that percentage 
parent in the brain (94%) (Figure 5.9A) and in the heart (93%) (Figure 5.9B) was very 
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similar at 15 minute time point. While in the plasma (Figure 5.9C), less parent was seen 
(71%) at the same time point. 
 
 
 
Figure 5.9: Radio chromatogram of labelled parent molecule and labelled metabolites at 15 mins post iv 
injection (red trace) in (A) brain, (B) heart and (C) plasma overlaid with UV chromatogram with “cold” 
(44) co-injected (blue trace). 
After 60 minutes, further metabolism of the tracer was observed. A hydrophilic 
metabolite was observed in the heart and plasma (Figure 5.10). In the plasma, the 
percentage non-parent was much larger than in the brain and heart. 
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Figure 5.10: Radio chromatogram of labelled parent molecule and labelled metabolites at 60 mins post iv 
injection (red trace) in the (A) heart and (B) plasma overlaid with UV chromatogram with “cold” (44) 
co-injected (blue trace),  
In order to give an indication of the possible active metabolite(s), the structure of (44) 
was analysed using Meteor™ software (Lhasa limited). This software produces 
structures of the most plausible metabolites using reasoning from phase I and II 
metabolism processes and published reports of metabolites based on similar structures. 
Meteor™ inferred a 5-hydroxylation of the trisubstituted distal phenyl ring as a possible 
phase I metabolism product. However this is not a plausible structure as the 
metabolite(s) eluted from the HPLC in the solvent front. Therefore, the metabolite(s) are 
hydrophilic species. From the naive biodistribution, the bone uptake remained low at 60 
minutes, thus, it is unlikely that one of the metabolites was [
18
F]fluoride. One possible 
suggestion is cleavage of the triazole ring, either re-forming (1-
18
F)fluoroethyl azide or 
potentially (1-
18
F)Fluoroethane. The metabolites will need to be determined in future 
work. 
 
5.6.1.1 Discussion 
Overall, the study showed that uptake in the heart and brain is mainly parent radiotracer 
(at 2 and 15 minutes) and not a metabolite (Table 5.4). While after 60 minutes the 
amount of parent radiotracer decreases and more metabolite is seen, which is consistent 
with the biodistribution data, as the signal in these tissues decreases after 60 minutes. It 
is likely that the metabolite would not be an active VGSC ligand, which may explain 
why the signal from the brain and heart decreases. Although not as many time points 
were studied here as in the biodistribution (due to laboratory time constraints and tracer 
decay), this metabolism study indicates adequate in vivo stability of ([
18
F]44) and 
allowed for further investigations of this tracer in a disease model. 
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5.7 Conclusions of Chapter 5  
In summary, this chapter has shown that ([
18
F]44) was successfully synthesised in 
moderate yield through a copper catalysed Hüisgen 1,3-cycloaddition. Thereafter, (44) 
was characterised through a series of electrophysiological studies to ascertain its 
potency and selectivity for VGSC sub-types. These studies showed (44) to be both 
potent and sub-type selective, but an accurate IC50 value was not determined. 
Automated electrophysiology results showed (44) to have less than ideal affinity, with 
IC50 15.6 µM for Nav 1.5. Manual patch clamp results indicated the potency to be rather 
lower, with all concentration (100 nM lowest) showing >50% inhibition of sodium 
currents. Further work is now required to test this compound at <100 nM in both Nav 
1.4 and 1.5.   
Consequently, we evaluated this tracer in vivo through a näive biodistribution and 
metabolism study. The data showed ([
18
F]44) to have good uptake in key tissues while 
clearance was seen through the hepatobiliary system over the 2 hour time course 
studied. The metabolism study corroborated that uptake seen in the biodistribution 
during early time-points (2-15 minutes) was consistent with parent rather than non-
parent uptake. Whereas at 60 minutes, metabolised product was seen in higher 
concentration, especially in the plasma. Overall, early näive pre-clinical studies 
highlighted this tracer as a promising candidate for PET imaging. As a result of this 
data, ([
18
F]44) was selected for studying in two types of breast cancer, metastatic 
(MDA-MB-231 cell lines) and non-metastatic (MCF-7 cell lines) (Chapter 6). 
Autoradiography was performed on brain and heart slices (Appendix 5.8) to ascertain 
specific binding using a 1000-fold higher concentration of (44) vs ([
18
F]44) for 
blocking. However, these results were inconclusive. At the time of this study, we 
received electrophysiology data from Chantest, US that confirmed there was no or little 
binding in the tonic (resting) state. Although some specific binding had been inferred 
for these data, it was then highlighted that binding of our compound occurs in a 
physiological dependent state, so the data shown was not be a fair representation of the 
possible specific binding that may occur in vivo. For interest, these images are disclosed 
but are not put forward as evidence of specific binding. Following the termination of 
this study, literature research was undertaken to outsource a binding study. Studies 
available to screen novel potential VGSC ligands centred around automated and patch-
clamp electrophysiology as previously performed (Section 5.5), with binding studies 
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available on homogenised cerebral cortex (site of Nav 1.1-1.3 and 1.6 expression) tissue. 
Moreover, it was not possible to find a study which used homogenised heart tissue to 
measure specific binding. Additionally, as this tracer was hoped to potentially target the 
neo-natal splice variant of the cardiac sodium channel (expressed in B Ca), it was 
thought it would be more beneficial to measure specific binding in that variant. There 
are seven amino acids differences between the neo-natal and adult channel affecting DI: 
TMS3, most of DI:TMS4, and DI:TMS3-S4. As it was not known how, or if binding of 
(44) would be altered in the neo-natal splice variant, the next study was invaluable.  
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5.8 Appendix 
Autoradiography was performed on brain and heart slices. ([
18
F]44) was delivered in 6 
MBq/mL as a PBS/EtOH solution (9:1; v/v), with specific activity 3.53 GBq/µmol.  
Frozen heart and brain tissue were sliced (10-15 microns) and placed on glass 
microslides. All slices were incubated with ([
18
F]44) (100 µL) for 60 minutes at RT. In 
order to perform a blocking study, a 1000-fold concentration of (44) was added to one 
set of slices, prior to addition of ([
18
F]44). All slices were then washed with PBS three 
times to remove all non-bound radiotracer, and then exposed to Kodak™ film for 20 
minutes before developing the films. The films were digitised and interpreted using 
MCID software to measure radiotracer uptake. Specific binding (sb) was measured by 
using digitised non-blocked slices and subtracting total uptake from digitised blocked 
slices (see Section 2.4.3).  
As mentioned previously, this study was not included in the main chapter, as during this 
work, results received showed that (44) binds in a physiological dependent state 
(Section 5.5.1). Nevertheless, the images were analysed to complete this section of 
work.  
Brain 
   
   Olfactory bulbs   Frontal cortex     Dorsal hippocampus  
     (sb 30-40%)    (sb 30-40%)   (sb 50-60%) 
   
Ventral hippocampus   Mid-brain   Cerebellum 
 (sb 60-70%)            (sb 50-60%)            (sb 30-40%) 
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   Dorsal Hippocampal slice imaged on a Microimager™ (no sb measured) 
Figure 5.11: Autoradiography images of brain slices  
These images highlighted some specific binding in the brain, particularly in the 
hippocampal region. Possibly this is due to some binding to Nav 1.6 (expressed in the 
hippocampus) in the resting state.  
 
Heart  
  
                  Mid-heart (sb 20-25%)                      Mid-heart (sb 20–30%) 
Figure 5.12: Autoradiography of heart slices 
Little specific binding was seen in the cardiac tissue, presumably due to the tracer being 
unable to bind to the tissue.  
In summary, this study did not allow for accurate measurement of specific binding. 
Additionally, a cell binding assay was used to monitor specific binding (Section 6.1.0).  
  
Chapter 6  Results and Discussion 
190 | P a g e  
 
 
 
 
 
 
 
6.  Results and Discussion 
 
 
 
 
 
Preliminary application of [
18
F]4-(4-(2,4-difluorophenoxy)-
phenyl)-1-(2-fluoroethyl)-triazole in PET imaging of breast 
cancer 
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6.0 Rationale for metastatic breast cancer study 
After the successful synthesis and initial näive bioevaluation of ([
18
F]44), the next steps 
were to apply this potential PET radiotracer for in vitro and in vivo assessment in a 
tumour model. The aim of this study was to assess if ([
18
F]44) could image highly 
metastatic tumours. 
As described in chapter 1, high VGSC expression is associated with increasing 
metastatic potential of various tumours. Importantly, it was shown that neo-natal Nav 
1.5 is associated with the strongly metastatic model of breast cancer MDA-MB-231, 
showing 1800-fold higher mRNA expression than the weakly metastatic model (MCF-
7), which shows little or no expression.
54, 59, 189-190
 In vitro work (Chapter 5), highlighted 
([
18
F]44) as a moderately selective VGSC ligand with highest affinity for Nav 1.4 and 
1.5. Crucially, there was good uptake in the heart during näive biodistribution studies 
and the in vivo characteristics were similar to that required for a PET radiotracer.
191-193
 
Namely, the radiotracer requires good uptake in key tissues above background, with 
pharmacokinetics that allow reversible binding and clearance within 2 hours.  
In order to obtain an understanding of the binding of this tracer to the neo-natal cardiac 
sodium channel, cultured MDA-MB-231 cells (stably expressing neo-natal Nav 1.5), 
were used to undertake a radioligand binding assay. Cultured MCF-7 cells were used as 
a negative control. The autoradiography described in Chapter 5 was not useful in 
providing accurate binding data due to (44) binding in a state-dependent manner. 
Cultured cells however, are dynamic systems, with functionally active sodium channels. 
We wanted to identify binding specifically to the neo-natal isoform of Nav 1.5 
expressed in metastatic breast cancer. There is however, significant sequence similarity 
between the adult and neo-natal isoforms, with only seven amino acids differing 
between the two. It is currently thought that these differences do not affect binding site 
1, the most likely binding site for our tracer as briefly described in Section 5.5.0. 
 
6.1 In vitro biology 
Following previous findings by Djamgoz et. al., that MDA-MB-231 cells display neo-
natal Nav 1.5 expression and MCF-7 cells low or no expression,
190
 these cells were 
cultured for cell binding studies. Two variations of a standard radioligand binding assay 
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were carried out. Initially, a seeded-cell method was used, where cells were cultured in 
96-well plates 24 hours prior to assay, and secondly, a cell suspension method. For 
more details see section 2.4.5. 
Work described in this section was aided by the in vitro biology team at GE Healthcare, 
Amersham. 
 
6.1.0 Cell binding study in MDA-MB-231 and MCF-7 cell lines 
6.1.0.0 Results  
Initially, MDA-MB-231 and MCF-7 cells (approx 1 x 10
4 
cells) were seeded onto 96 
well plates 24 hrs before assay commenced to create a monolayer of cells in the 
corresponding media (100 µL).  
([
18
F]44) was delivered in 6.0 MBq/mL as a phosphate buffer /EtOH solution (9:1; v/v), 
with specific activity 4.2 GBq/µmol.  
Nine serial dilutions of ([
18
F]44) was prepared to give a wide concentration range 
(Table 6.1). A 10.6 µM solution of (44) (100-fold excess concentration of ([
18
F]44)), 
was prepared for the blocking study and added to a set of cells (for each tracer 
concentration), in duplicate. These cells were left for 5 minutes at RT to incubate prior 
to addition of each tracer concentration. ([
18
F]44) was added to all cells giving n=2 for 
the blocking study and n=3 for the binding study, at each concentration, per cell line. 
All cells were left to incubate for 60 minutes at RT. The cells were then washed with 
PBS and subjected to cleavage with trypsin for 5 minutes at RT. These cells were then 
washed, harvested and trapped to a printed glass fibre filter. The washed 96 well plates 
were monitored under a microscope to check that all cells were removed from the wells. 
The filter paper corresponding to each well was removed and activity counted using a 
gamma counter.   
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Dilution Number Concentration (nM) 
1 1600 
2 530 
3 180 
4 59 
5 19 
6 6.5 
7 2.2 
8 0.73 
9 0.27 
Table 6.1: Concentrations of (
18
F]44) to measure specific binding 
Following completion of the assay the activity observed on the filters was found to be 
within background levels. Assessment of the 96 well plates with a beta counter detector 
showed significant activity, suggesting that the activity and by extension the tracer, 
remained on the plates. This indicated a high degree of non-specific binding to the 
plastic composite. Due to this issue, this assay method was not repeated.  
To overcome this problem, a cell suspension radioligand binding assay was undertaken. 
([
18
F]44) was delivered in 5.0 MBq/mL as a phosphate buffer/EtOH solution (9:1; v/v), 
with specific activity 3.7 GBq/µmol.  
MDA-MB-231 cells (2.5 x 10
5 
cells) and MCF-7 cells (2.5 x 10
5
 cells) were aliquoted 
into twelve eppendorf tubes per cell line. Figure 6.1 details the assay set-up per cell line. 
Briefly, two concentrations (100 nM and 10 nM) of ([
18
F]44) were prepared from a 
stock solution, to measure binding. To estimate specific binding, a 10 µM concentration 
of (44) was applied to block VGSCs prior to addition of ([
18
F]44). After addition of 
([
18
F]44), all cells were incubated for 60 minutes at RT. Cells were pelleted by 
centrifugation (1000 rpm, 5 minutes) and supernatant removed. To wash the cells, PBS 
(0.5 mL) was added and cells pelleted. This wash procedure was carried out twice. After 
washing, the cells were re-suspended in PBS (0.5 mL) for counting. In order to remove 
contamination due to non-specific binding associated with the eppendorf tubes, the cell 
suspensions were added to fresh tubes before counted overnight (Wallac counter). 
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([
18
F]44) 
(100 nM) 
([
18
F]44) 
(10 nM) 
Blank 
(44) (10 µM) + 
([
18
F]44) (100 nM) 
(44) (10 µM) + 
([
18
F]44) (10 nM) 
(44) 
(10 µM) 
([
18
F]44) 
(100 nM) 
([
18
F]44)  
(10 nM) 
Blank 
(44) (10 µM) + 
([
18
F]44) (100 nM) 
(44) (10 µM) + 
([
18
F]44) (10 nM) 
(44) 
(10 µM) 
Figure 6.1: Radioligand binding assay set-up, per cell line 
Two controls were used to measure cell viability in the assay: cells without any 
([
18
F]44) (media only), and cells with only (44) applied (block control). These cells 
underwent the whole procedure and cell viability was monitored at the end using a 
standard tryphan blue test to give an indication of active cell numbers (Table 6.2). 
 MCF-7 cells MDA-MB-231 cells 
 Average cell viability (%) 
Blank 52 (61, 42) 52 (40, 63) 
Block 40  44 (47, 42) 
Table 6.2: Cell viability after assay (n=1/2) 
Following cell viability test of the two cell lines, both gave approximately 52% viability 
on the blank cells (n=2), whilst slightly higher viability was seen in the MDA-MB-231 
cells (44 vs 40%) incubated in 10 µM (44), implying some toxicity at this concentration.   
Following counting of all cell samples, all results were decay-corrected (d.c.) back to 
formulation time and expressed as a function of cell viability (Table 6.3).  
Concentration of 
([
18
F]44) 
MCF-7 cells MDA-MB-231 cells 
 Average d.c. cpm/viable cell (n=2) 
100 nM 921 (995, 849) 1084 (989, 1180) 
10 nM 93 (104, 82) 243 (456, 30) 
100 nM +(44) (10 µM) 1183 (1044, 1323) 1898 (2186, 1611) 
10 nM +(44) (10 µM) 129 (141, 119) 329 (342, 440) 
Table 6.3: Decay-corrected values of cpm/cell (per cell line). 
These results suggested slightly increased binding of ([
18
F]44) to the MDA-MB-231 
cells when compared to the MCF-7 cells, on average 1084 vs. 921 cpm/viable cell, 
respectively. Furthermore, the data from the MCF-7 cells suggested that the difference 
in cpm/viable cell was proportional to the two tracer concentrations tested (100 vs 10 
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nM). The MDA-MB-231 cells did not show this proportional correlation, which could 
be attributable to a saturation effect.  
The blocking study showed no reduction in cpm for either cell line, implying a high 
degree of non-specific binding. In fact, when ([
18
F]44) (100 nM) was combined with 
(44) (10 µM) in the MDA-MB-231 cells, there was a 75% increase in cpm/viable cell 
(1898 vs 1084). However, at the lower concentration of 10 nM, this was not apparent 
(within error). The MCF-7 cells displayed a similar profile, but higher cpm/viable cell 
was seen at both concentrations.  
6.1.0.1 Discussion 
Initially, a standard seeded-cell radioligand binding study was performed to measure 
binding to the neo-natal channel in high and low expressing cell lines. Unfortunately, no 
binding was observed above background in either cell line and thus no difference was 
seen between the cells with block applied. A high degree of non-specific binding was 
observed to the well plate itself. These 96 well plates are made of a polystyrene 
composite treated with an enhanced cell binding surface, to aid cell attachment by 
incorporating more oxygen into the cell culture surface, rendering it more hydrophilic 
and with better surface stability. The plate washes were not extracted for counting, so it 
was not possible to determine whether there was no possible binding or whether no 
binding was due to no access of ([
18
F]44) to the cells. 
Non-specific binding of highly lipophilic radiotracers to plastic is common and method 
validation to produce an optimised binding assay is time consuming and highly labour 
intensive. In order to overcome this issue in a timely manner, a cell-suspension 
radioligand assay was undertaken.  
In contrast, the cell suspension assay afforded some useful information. Importantly, the 
assay was performed with little binding to the eppendorf tubes themselves. Although 
some activity remained bound to the eppendorf tubes, much of the activity was 
associated with the cell suspension.  
Importantly, this assay highlighted uptake in the MDA-MB-231 cells to be 15% higher 
than the MCF-7 cells (n=2). This indicated a binding differential between the VGSC 
expressing (MDA-MB-231 cells) and non-expressing (MCF-7 cells). Also, a potential 
saturation effect was noted with the MDA-MB-231 cells over the two concentrations 
tested (Table 6.3). Where the concentration of ([
18
F]44) was increased 10-fold (10 nM 
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to 100 nM), a ten-fold increase in binding was not seen. Due to the minimal 
concentration range tested here, further investigations are warranted to assess this effect 
over a greater concentration range. The blocking study however, did not show expected 
results. The addition of a 100 and 1000-fold block of (44) did not inhibit binding of the 
radiotracer and in fact, these data suggested binding was slightly enhanced. This high 
non-specific binding indicated that perhaps ([
18
F]44) is not suitable as a PET tracer for 
targeting VGSCs in tumour cells. Another possible explanation for these data could be 
due to the low cell viability encountered. The cell viability test showed that only 50% of 
cells (approximately) were still functional at the end of the assay. This high cell death 
showed that the conditions employed were not able to maintain a high level of living 
cells. Cell death was probably due to permealisation of the cell membrane causing 
release of cellular debris. It is plausible that excess cell debris gave rise to non-specific 
interactions with both (44) and ([
18
F]44). In order to discount this reasoning, an 
improved assay method is required which affords higher cell viability. It would also be 
interesting to see if a higher concentration of (44) would make any difference to the 
blocking effect, or whether the concentration used was having a toxic effect. 
Nevertheless, this study was the first time a novel VGSC PET tracer was assessed for 
specific binding to metastatic tumour cells. This tracer is highly lipophilic, so some non-
specific binding was anticipated. The next step would be to repeat this assay using a 
variety of conditions and with a greater range of concentrations of both (44) and 
([
18
F]44). Due to the time constraints of this study and increasing personal radiation 
dose, it was not possible to develop this assay further. To summarise, this assay 
provided useful results over two concentrations and most importantly, a difference 
between uptake in the MCF-7 and MDA-MB-231 cells was shown.  
Although it was not possible to fully complete this assay and obtain the required 
binding data, an estimation of the required sodium channel density (Bmax) can be 
calculated, if the binding potential is set to the generally accepted minimum value of 10. 
Using the approximate IC50 for (44) (Nav 1.5; 3 nM) as the Kd, the approximate required 
Bmax of Nav 1.5 in breast tumour cells to give appropriate signal to noise ratio is ≥30 
nM. Future work on VGSCs in breast cancer will require the relative expression of 
VGSCs to be determined.  
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6.2 In vivo biology 
Alongside in vitro study, MDA-MB-231 and MCF-7 cells were inoculated into immune 
compromised mice to allow growth of tumours with high and low expression of neo-
natal Nav 1.5, respectively.
54, 59, 189-190
 Full details see section 2.5.2  
Initially an immunohistochemistry study (IHC) of the tumour tissue was planned using 
a non-commercial neo-natal Nav 1.5 antibody to measure relative expression of the 
channel in our model prior to any further studies. Sourcing of the antibody through an 
academic collaboration however, proved unsuccessful. Thus this study was altered to an 
imaging and biodistribution study to ascertain in vivo uptake of ([
18
F]44) in a disease 
model.  
Following reported work on neo-natal Nav 1.5 expression levels by Djamgoz et al., on 
MDA-MB-231 and MCF-7 cell lines,
190
 and clinical evidence of channel expression in 
metastatic breast tissue,
194
 tumours were grown with an assumed but not determined 
expression level.  
Both MDA-MB-231 and MCF-7 tumours were grown post-inoculation for six weeks 
after which imaging and biodistribution studies were carried out to determine if 
([
18
F]44) could detect metastatic breast cancer. Tumours grown from MCF-7 cells were 
imaged as a negative control experiment, as this cell line is associated with little or no 
VGSC expression.
190
  
All in vivo data described in this section was kindly carried out by the in vivo biology 
team at GE Healthcare, Amersham. 
 
6.2.0 Tumour growth and PET imaging of metastatic breast tumours  
Briefly, MDA-MB-231 cells (1 x 10
6
 cells in PBS; 100 µL) were inoculated into the 
mammary fat pad of six female severely combined immunodeficiency (SCID) mice. 
Following slow tumour growth over an initial six week pilot study, only five mice 
displayed tumours (average weight 42.3 ± 19.7 mg, post-dissection). [From herein, 
these animals are referred to as group #1 for imaging and biodistribution studies]. 
To increase tumour growth, an adjustment to the protocol was sought. Colleagues at 
Stanford University reported faster and larger tumour growth using a higher 
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concentration of cells.
195
 Thus, 5 x 10
6
 cells in PBS and Matrigel™ (100 µL; v/v) were 
injected into the mammary fat pad of SCID mice. Following a six week growth period, 
four tumours grew. They were slightly larger using this method (average weight 53.6 ± 
38.4 mg, post-dissection), however they were not so consistent in size. [From herein, 
these animals are referred to as group #2]. 
Group 
Number 
PET/CT imaging 
(number of studies) 
Biodistribution 
(number of studies) 
Group #1 2 3 
Group #2 1 3 
Table 6.4: MDA-MB-231 study outline 
 
6.2.0.0 Results - study #1 / group #1 
A tumour bearing mouse was selected for PET/CT imaging. ([
18
F]44) was delivered in 
8.5% n.d.c. e.o.s. yield from [
18
F]fluoride in 180 minutes at 59.0 MBq/mL, as a 
phosphate buffer /ethanol solution (9:1; v/v), with specific activity 0.68 GBq/µmol. 100 
µL was iv injected via tail vein to a MDA-MB-231 tumour bearing SCID female mouse 
(tumour size approx. 4.7 mm x 3.6 mm, measured 6 hrs pre-imaging).  
The animal was placed on a microPET scanner bed after tail-vein radiotracer injection. 
PET imaging commenced 6 minutes pi and ended 66 minutes pi. The animal was 
maintained under inhalation anaesthetic during the imaging and respiration rate 
monitored.  
Imaging was assessed in three planes: transverse, coronal and sagittal to give an 
overview of binding and clearance.  
A microCT scan was performed post PET imaging. CT images were used to determine 
anatomical information. During analysis, ROIs were positioned over key tissues with 
PET data overlaid to give functional data. 
During the first 2 minutes of the PET imaging, the animal regained consciousness from 
anaesthetic producing motion distortion of the images. This made it difficult to overlay 
the PET and CT data accurately, therefore, images from 6-11 minutes pi were not 
analysed. The first PET imaging was analysed at 12 minutes pi (Figure 6.2). 
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Figure 6.2: Dynamic PET image 12-14 minutes pi: ROIs for tumour (coronal view, red arrow), brain 
(sagittal view, blue arrow), heart (transverse and sagittal view, white arrow) and liver (coronal and 
sagittal views, yellow arrow). (A) CT image (B) PET/CT image. PET calibration bar indicating 0-7.1% 
ID/g 
 
Radiotracer uptake was apparent in the liver and brain, with the heart showing no 
radiotracer uptake above background (Figure 6.2). Some motion distortion still affected 
these images, so the alignment of the PET and CT data was not exact, hence why the 
tumour imaged by CT does not overlay with the PET data. 
(A) 
(B) 
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Figure 6.3: Dynamic PET image 31-32 minutes pi: ROIs for tumour (coronal view, red arrow), brain 
(sagittal view, blue arrow), heart (sagittal view, white arrow) and liver (coronal and sagittal views, 
yellow arrow). (A) CT image (B) PET/CT image. PET colour indicating 0-7.1% ID/g 
 
The latter time points of the imaging (31-32 minutes pi) showed more exact overlay 
between the PET and CT images. Radiotracer concentration in the brain appeared to 
decrease and uptake in the heart is now apparent (Figure 6.3), but could not be resolved 
from radiotracer concentrations in the liver.  
  
(A) 
(B) 
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Figure 6.4: Dynamic PET image 65-66 minutes pi: ROIs for tumour (coronal view, red arrow), brain 
(sagittal view, blue arrow), heart (sagittal view, white arrow) and liver (coronal and sagittal views, 
yellow arrow). (A) CT image (B) PET/CT image. PET colour indicating 0-7.1% ID/g 
 
The last minutes of the imaging (Figure 6.4) showed high levels of radioactivity in the 
liver and bladder while radioactivity seen earlier in the heart and brain had cleared. 
During the last minute of the PET image. The animal’s respiration deteriorated without 
recovery. It was not clear what caused this effect. The PET radiotracer was examined 
and the solution had turned slightly cloudy (90 minutes post formulation). The 
precipitate likely to be an impurity co-eluting with ([
18
F]44). Although no ill effects 
were seen during radiotracer administration, the radiotracer was discarded and an 
improvement to the purification of the radiotracer was sought.   
Compounds used in the synthesis of ([
18
F]44) were analysed as possible contaminants 
using analytical HPLC. Alkyne (42), 2,4-difluorophenol and 4-fluorophenylacetylene 
were checked for co-registration of retention times with the unknown contaminant. 
Following analytical HPLC, 4-fluorophenylacetylene was shown to have the same 
retention time as ([
18
F]44) (gradient: 5-95% MeCN / H2O over 15 minutes), tR = 11.3 
minutes. However, this compound was not present in the alkyne starting material (42). 
Overall, it was not possible to identify the contaminant. 
(A) 
(B) 
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A time course of the PET data was plotted to monitor the biodistribution of ([
18
F]44) 
commencing from 12 minutes pi (Figure 6.5). Activity concentrations from ROIs of key 
tissues were measured from the PET data and converted to %ID/mL. Earlier time points 
were not plotted as motion distortion (when the animal regained consciousness) made it 
difficult to assign accurate ROIs. Alongside the PET imaging, radiotracer 
concentrations from a biodistribution study (section 6.2.1) using three tumour bearing 
mice from the five that grew [group #1], were also carried out to measure radioactivity 
levels at 15 minutes (n=3) and an animal was also imaged 74 minutes (n=1) after 
administration of ([
18
F]44). Biodistribution studies measured radiotracer concentration 
in % ID/g whereas the PET time curve was measured in % ID/mL, it was assumed that 
the ratio of g:mL was one, so the biodistribution and PET data could be compared. 
 
Figure 6.5: PET imaging time course (12-66 minutes pi) in key tissues (lines) and biodistribution data 
(points) 
Overall, the PET imaging time course showed some clearance of radiotracer from the 
liver and heart, while uptake in other tissues (brain and muscle) appeared not to reverse. 
More specifically, highest uptake was seen in the liver, which started to clear over the 
first 30 minutes of the imaging to give a consistent 6.5 ± 0.3% ID/mL in the later time 
points. The heart however, showed continual clearance of radiotracer over the 60 minute 
imaging. The kidney gave a consistent level of radiotracer (5.9 ± 0.3% ID/mL) until 
approximately 38 minutes pi where an increase was seen and then some clearance in the 
final 20 minutes of the imaging. In contrast, the muscle, brain and tumour were quite 
consistent in their concentration of radiotracer indicating little clearance over the 60 
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minute time course, with tumour uptake the low throughout the imaging. The uniform 
theoretical distribution line and blood data points (biodistribution data) were used to 
indicate background radiotracer concentration. The theoretical distribution line (from 
PET data) assumes there is no specific uptake of the tracer and that instead the tracer 
distributes evenly throughout the body. Of course usually this is not the case, even for a 
non-binding compound clearance through specific organs starts straight away, giving an 
uneven distribution. This marker therefore, is a crude threshold for targeted binding. 
Here, ([
18
F]44) does appear to distribute evenly throughout the body so the uniform 
distribution is indicated, to allow comparison against this “surrogate” background level.  
The liver, kidney and heart were all above the distribution line at early time points with 
the muscle, brain and tumour remaining below at all time points. When comparing with 
the blood level however, (which itself remained consistent at the two time points, 15 
and 74 minutes, pi) then all tissues except muscle fall above background. 
The imaging results showed little consistency with the biodistribution results at 15 
minutes pi. A significant difference in tumour uptake was seen (4.5 vs 0.7% ID/mL; 15 
minutes), with the imaging indicating the lower value. The brain also showed lower 
uptake in the imaging than the biodistribution. In contrast, the imaging indicated higher 
levels (than the biodistribution) in both the muscle and heart (NB: biodistribution point 
masked by tumour point). Almost exact alignment was seen in the kidney. The liver 
point (25.5% ID/mL; biodistribution 15 minutes pi) was not plotted as it was 
significantly higher than the 0-12% ID/mL range.  
The biodistribution results at 74 minutes pi also highlighted a different pattern to that 
seen at the end of the imaging (66 minutes). The biodistribution showed higher levels of 
radiotracer in the liver, brain, heart, kidney and tumour than was reported at the end of 
the imaging. However, the muscle showed a very similar level. 
  
6.2.0.1 Discussion 
In summary, the first PET images of the MDA-MB-231 tumours gave no evidence that 
([
18
F]44) is able to highlight ion channel activity in metastatic breast tumours.  
Firstly, it is important to note that the tumours themselves were slow to grow over a six 
week period, which indicated these tumours probably were not aggressive in their 
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nature. It is well established that the metastatic potential and aggressiveness of these 
tumours is directly correlated to the expression of VGSCs; therefore its likely these 
tumours expressed little neo-natal Nav 1.5. Moreover, it was not possible to determine 
the relative expression of VGSCs within the tumour cells due to the neo-natal Nav 1.5 
antibody not being available.  
The time course of the PET imaging was plotted and overlaid with results from a 
biodistribution study of MDA-MB-231 tumour bearing mice. This indicated the 
accuracy of using ROI points to infer actual radiotracer uptake. Little correlation was 
seen. For example, there was little uptake in the tumour throughout the imaging, while 
actual tumour uptake in the biodistribution (15 minutes pi), showed levels to be 
somewhat higher. Similar inconsistencies were seen throughout all tissues studied.  
In summary, the PET imaging showed below background (using theoretical uniform 
distribution) uptake in the tumour throughout the imaging. It was unclear whether other 
factors to do with the morphology and growth of the tumour tissue were the key 
limitations or more over, whether our radiotracer was not binding to the neo-natal 
VGSCs. 
Only two time points were studied in the biodistribution. A greater breadth of time 
points are needed for overlaying with the imaging data, before any firm conclusions 
regarding how inaccurate assigning of ROIs is for interpreting radiotracer uptake. 
Following this initial study, another tumour bearing mouse was selected for imaging. 
 
6.2.0.2 Results - study #2 / group #1 
A second tumour bearing mouse was selected for PET/CT imaging. ([
18
F]44) was 
delivered in 8.0% n.d.c. e.o.s. yield from [
18
F]fluoride in 120 minutes at 61.0 MBq/mL, 
as a phosphate buffer / ethanol solution (9:1; v/v), with specific activity 0.98 GBq/µmol. 
100 µl was iv injected via the tail vein to a MDA-MB-231 tumour bearing SCID female 
mouse (tumour size approx. 6.4 x 5.2 mm, measured 6 hrs pre-imaging).  
The animal was placed on a microPET scanner bed after tail-vein radiotracer injection. 
PET imaging commenced 6 minutes pi and ended 66 minutes pi. The animal was 
maintained under inhalation anaesthetic during the imaging and respiration rate 
monitored.  
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Figure 6.6: Dynamic PET image 6-7 minute pi: ROIs for tumour (coronal view; red arrow), liver 
(coronal view; yellow arrow), throat (coronal and sagittal view; orange arrow), front leg muscle 
(coronal view; purple arrow) and heart (transverse, coronal and sagittal view, white arrow). (A) CT 
image (B) PET/CT image. PET colour indicating 0-6.6% ID/g 
 
Uptake of ([
18
F]44) was evident in the heart, brain and liver at 6-7 minutes pi (Figure 
6.6; first minute of PET imaging). Uptake in the tumour however, was not above 
background; but it was difficult to resolve tumour uptake from the high uptake 
spreading from the liver. Radiotracer concentration in the front leg muscle appeared to 
be within background level. Interestingly, these images showed high uptake in the 
throat area, which had not been seen previously (Figure 6.6).  
(A) 
(B) 
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Figure 6.7: Dynamic PET image 15-16 minute pi. ROIs for tumour (coronal view; red arrow), liver 
(coronal view; yellow arrow), throat (coronal and sagittal view; orange arrow), front leg muscle 
(coronal view; purple arrow) and heart (transverse, coronal and sagittal view, white arrow). (A) CT 
image, (B) PET/CT image. PET colour indicating 0 - 6.6% ID/g 
 
The 15
th
 minute of the imaging showed uptake in the heart and brain to have cleared to 
within background levels (Figure 6.7). Radiotracer concentration in the throat had 
decreased from earlier time points, while uptake in the liver appeared to be increasing. 
Although it was difficult to distinguish radiotracer levels in the tumour from increasing 
liver uptake, it appears there was not uptake above background in the tumour.  
(A) 
(B) 
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Figure 6.8: Dynamic PET image 65-66 minute pi. ROIs for tumour (coronal view; red arrow), liver 
(coronal view; yellow arrow), throat (coronal and sagittal view; orange arrow), front leg muscle 
(coronal view; purple arrow) and heart (transverse, coronal and sagittal view, white arrow). (A) CT, (B) 
PET/CT image. PET colour indicating 0 - 9.0% ID/g 
 
The last minute of the imaging (65-66 minutes pi; Figure 6.8) showed ([
18
F]44) to be 
present mainly in the liver and bladder. Previous uptake in the throat had now reversed 
to background levels. The PET calibration was decreased to improve resolution (0–
9.0% ID/g) between the bladder, kidneys and liver. Overall, the imaging study was 
completed with no measurable ill effects to the animal. Post imaging this animal 
underwent a biodistribution study to afford a late time point data set (74 minutes pi).  
A time course of the PET data was plotted as described in the previous section and data 
points from a biodistribution study were overlaid as before (15 and 74 minutes pi).  
(A) 
(B) 
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Figure 6.9: PET imaging time course (6-74 minutes, pi) in key tissues (lines) and biodistribution data 
(points). All tissues are colour coded the same between the PET and biodistribution data. 
The PET imaging time course showed highest early (6 minutes, pi) uptake in the liver 
(10.4% ID/mL) which increased before reaching a plateau at 20 minutes, and then 
decreased over the remaining 40 minutes imaged. Strangely, the throat showed 
significant (9.0% ID/mL; 6 minutes pi) uptake at early times points, which cleared 
rapidly to below the theoretical distribution line but remained above blood level 
(indicated at 15 and 74 minutes pi). The kidney also showed high uptake (7.7% ID/mL); 
6 minutes pi) which was quick to clear. The same initial uptake in the kidney was seen 
in the brain, which also displayed a similar clearance profile (to kidney), throughout the 
imaging. Radiotracer uptake in the heart appeared early on to fluctuate above and below 
the theoretical distribution line, but after 30 minutes the % ID/mL remained consistent. 
The muscle and tumour uptake was the lowest across the tissues sampled and remained 
below the theoretical distribution throughout. In muscle, an initial decrease from 4.7-
4.0% ID/mL was reported over 6-13 minutes. Thereafter, a consistent level of 4.1% 
ID/mL was seen. Interestingly, there was a slight increase in tumour uptake from 6-16 
mins of 3.2-4.3% ID/mL which plateaued, leaving a consistent level of uptake which 
overlapped with the time curve for muscle for the remaining time points. 
Overall, the PET imaging time curve showed some uptake and clearance of radiotracer 
at early time points (6-20 minutes), after which levels remained consistent for all tissues 
sampled (except the liver). This suggested little clearance of radiotracer from these 
tissues (brain, heart, muscle and tumour) within 66 minutes pi. Using blood level from 
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the biodistribution data points as background, all tissues were above this level at 15 
minutes and then at end of the time course, all tissues except the liver were nearing this 
background level. The theoretical distribution level co-registered with the blood level 
almost exactly. 
Upon comparison of the imaging and biodistribution data, it was evident that the PET 
data appeared to indicate slightly higher radiotracer concentrations (in most tissues) 
than was actually sampled (biodistribution data) at the earliest time point (15 minutes 
pi).  
Initial biodistribution data from the liver (15 minutes pi) was not plotted on this graph, 
due it being significantly higher than this scale (25.5% ID/mL). At the latest time point, 
the PET imaging data for the liver (8.3% ID/mL; 66 minutes) correlated well to the 
biodistribution data at 74 minutes (8.5% ID/mL). Alignment of PET data and 
biodistribution data was seen in the kidney (15 minutes pi), while the 74 minute pi data 
point (biodistribution) showed higher radiotracer concentration than was indicated by 
the last PET data point (66 minutes; 6.4 vs 5.4% ID/mL), respectively. In the heart, PET 
data showed higher uptake than was sampled (15 minutes biodistribution) but it is not 
possible to see the data point due to masking by data from the brain and tumour. The 
radiotracer concentration seen at end of the PET imaging (66 minutes pi) was shown to 
be slightly higher at 74 minutes pi (biodistribution). Again, the PET data overestimated 
the uptake in the brain at 15 minutes pi and then underestimated at the 75 minutes pi 
(compared to biodistribution). In contrast to this, good alignment was seen in the muscle 
and tumour tissues with just the muscle biodistribution data point (15 minutes pi), 
showing some lower radiotracer concentration. Throat tissue was not sampled in the 
biodistribution; it was felt that the uptake here was unlikely to be repeated.   
 
6.2.0.3 Discussion 
These images of a second mouse bearing a slightly larger tumour (6.4 x 5.2 mm), 
correlated well to our previous data (Section 6.2.0.1). A time course of the imaging was 
reported and overlaid with data from a later biodistribution study. The time course 
clearly showed lowest levels in the tumour and muscle with higher uptake in the brain 
and heart. The biodistribution data also supported these findings. The higher uptake in 
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the brain was quick to clear suggesting little retention of radiotracer, while the heart 
showed little clearance of radiotracer suggesting binding was not reversed.  
The differences seen when overlaying the PET time course and the biodistribution data 
is likely to be due namely, to the low n numbers used in these studies providing no error 
bars associated for this data. Importantly, the PET data is dependent upon the efficiency 
of the detector and also the manipulation of the data to afford an accurate time course. 
For example, bleeding of radioactivity between tissues, makes it difficult to distinguish 
between different tissues. Importantly, the accurate assignment of voxels when 
manipulating the PET data is vital in order to get a precise time course. In the 
biodistribution however, all the tissues are separated quickly but some contamination 
can occur. Therefore, although there are differences in tracer concentration between the 
biodistribution and PET data, without an understanding of the associated error, it is not 
clear if the differences seen are significant or not. 
This study indicated ([
18
F]44) was not able to highlight metastatic breast cancer tissue 
above background levels. These data corroborate with data from study #1 (Section 
6.2.0.0). It is likely our compound is not able to bind to the VGSCs but also the 
morphology of the tumour tissue was questioned. Moreover, due to their slow growth, 
suggesting little aggressive or metastatic behaviour it was inferred that the level of 
VGSC expression was low. It was not possible to determine the VGSC expression level 
so the next steps were to use tumour bearing mice from [group #2] which grew slightly 
larger tumours for the following imaging and biodistribution study. 
 
6.2.0.4 Results - study #3 / group #2 
After imaging two of five MDA-MB-231 tumour bearing mice [group #1], our studies 
then turned to imaging of a slightly larger tumour from the second group of SCID mice 
inoculated with MDA-MB-231 cells.  
([
18
F]44) was delivered in 3.7% n.d.c. e.o.s. yield in 150 minutes from [
18
F]fluoride at 
7.0 MBq/mL, as a phosphate buffer /ethanol solution (9:1; v/v), with specific activity 
4.0 GBq/µmol. 100 µL was injected iv via the tail vein to a MDA-MB-231 tumour 
bearing SCID female mouse (size approx. 7.89 x 6.44 mm). As before, PET imaging 
was performed over 60 minutes with CT imaging afterwards.  
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At 6 minutes pi, PET imaging commenced and the image acquired from the first minute 
was analysed (Figure 6.10).  
 
 
Figure 6.10: Dynamic PET image 6-7 minute pi: ROIs for tumour (transverse and coronal view, red 
arrow), heart (coronal view, white arrow), liver (coronal and sagittal views, yellow arrow) and muscle 
(coronal view, purple arrow). (A) CT image (B) PET/CT image. PET colour indicating 0.1-7.0% ID/g 
 
The tumour from this animal grew on the right shoulder allowing improved resolution 
of tumour tissue. The tumour is clearly visible in the CT scan but with the PET data 
overlaid, the tumour has decidedly low uptake, well below background. Initial high 
uptake was seen in the heart, brain and liver, with little activity in the muscle (Figure 
6.10). 
(A) 
(B) 
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Figure 6.11: Dynamic PET image 16-18 minute pi: ROIs for tumour (transverse and coronal view, red 
arrow), heart (coronal view, white arrow), liver (coronal and sagittal views, yellow arrow) and muscle 
(coronal view, purple arrow). (A) CT image (B) PET/CT image. PET colour indicating 0.1-7.0% ID/g 
 
At 16 minutes pi, uptake in the tumour appeared to show some increase, although it 
seemed not above background (Figure 6.11). As previously seen (study #1 and #2; 
group #1), early uptake in the brain cleared rapidly, while concentration of radiotracer 
in the heart was retained. The uptake in the liver and kidneys is shown to be bleeding 
into each another causing a large central mass of radiotracer concentration and some 
clearance via the bladder is now evident. 
(A) 
(B) 
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Figure 6.12: Dynamic PET image 63-65 minute pi: ROIs for tumour (transverse and coronal view, red 
arrow), heart (coronal view, white arrow), liver (coronal and sagittal views, yellow arrow) and muscle 
(coronal view, purple arrow). (A) CT image (B) PET/CT image. PET colour indicating 0.1-7.0% ID/g 
 
At 63-65 minutes, (Figure 6.12) activity in the heart, kidney and liver cleared to the 
intestines and bladder. These high levels in the intestine and bladder are indicative of 
hepatobiliary and urinary excretion. The tumour level, although appearing to increase 
during the time course, remained within background levels. 
A time course of the PET data was plotted as described in the previous section and data 
points from a later biodistribution study were overlaid as before (15 minutes pi). A 74 
minute post-imaging data point was not afforded for this biodistribution study. The 
animal imaged here, was recovered for studying in the biodistribution study at 15 
minute pi, due to it exhibiting the largest tumour in this group of animals (however this 
animal was removed from the study a short time later, as discussed below).  
(A) 
(B) 
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Figure 6.13: PET imaging time course (6-74 minutes, pi) in key tissues (lines) and biodistribution data 
(15 minutes pi, points). All tissues are colour coded the same between the PET and biodistribution data. 
The PET time curve (Figure 6.13) indicated increasing uptake of radiotracer in tumour 
and kidney tissue throughout the time course, whilst the liver, heart, brain and muscle 
all showed clearing of tracer.  
More specifically, the tumour showed a large increase in uptake over the 60 minutes 
imaged (1.7-4.5% ID/mL) equating to a 265% increase. Although this increase 
remained below theoretical distribution and blood level (taken from the biodistribution 
at 15 minutes; 4.45% ID/mL). Due to overlap of data points the blood point cannot been 
seen. 
The high liver uptake (17.4% ID/mL, 16 minutes pi), continued to clear over the 60 
minute imaging, whilst in the kidney, increasing uptake was seen (2.2-7.5% ID/mL, 6-
66 minutes pi). The brain, heart and muscle remained consistent across all time points 
indicating little clearance of tracer. The heart and brain remained above theoretical 
distribution and blood level, whilst the muscle and tumour uptake remained below these 
thresholds.  
In terms of accuracy of PET data with respect to biodistribution values, the imaging 
overestimated uptake in the heart, brain and muscle, whilst the actual tumour uptake 
was higher than imaging indicated. 
This animal was recovered post-imaging for a later biodistribution study, however, 16 
hours post-imaging, the animal was found unwell and was removed from the study. The 
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remaining radiotracer solution remained clear and HPLC analysis of the decayed 
radiotracer did not show a change in the UV profile.  
 
6.2.0.5 Discussion 
A modification to the procedure for inoculating the MDA-MB-231 cells into animals of 
group #2 was made to produce larger tumours. However, this was found not to be the 
case. The tumours were only slightly larger by weight and only four tumours grew from 
six inoculated, whereas before [group #1], five tumours grew. While tumour growth 
was limited, the imaging of these tumours was important to corroborate our previous 
results (Study #1 and #2), as only low uptake in the tumours was seen before.  
The tumour imaged from this study (tumour size 7.89 x 6.44 mm) was located on the 
right shoulder which aided in resolution between the cardiac and tumour tissue, whereas 
previously, the tumour had grown more centrally. The PET/CT images for this study 
(Figure 6.10, Figure 6.11, Figure 6.12) allowed for a more accurate picture of tumour 
uptake. These data showed low initial tumour uptake but a high increase (265%) 
throughout the imaging time course. Interestingly, patch-clamp electrophysiology 
results showed that it took a minimum of 30 minutes for (44) to have a maximum effect 
at each concentration tested. As this tracer is a state-dependent VGSC blocker, binding 
to the channel in the inactivated state nearly exclusively, the channels are not available 
for binding instantly. This increasing uptake over 60 minutes could be aligned to the 
fact that this tracer requires a long incubation period to afford maximum effect.  
As seen before, rapid uptake in the brain and heart was evident and clearance of the 
radiotracer was through the hepatobiliary system and renal system. These results were 
co-registered with a biodistribution study (Figure 6.13) and correlation of PET imaging 
to actual levels was shown to be less accurate than data produced in study #1, group #1. 
The difference in tracer concentration when overlaying the PET time course and the 
biodistribution data is likely to be due namely, to the low n numbers used in these 
studies (as mentioned in the previous section). The low n numbers afforded no error 
bars, therefore, although there are differences in tracer concentrations between the 
biodistribution and PET data, without an understanding of the associated error, it is not 
clear if the differences seen are significant or not. Importantly, the PET data is 
dependent upon the efficiency of the detector and also the manipulation of the data to 
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afford an accurate time course. For example, much bleeding of radioactivity was seen in 
the PET images making it difficult to distinguish between different tissues. In the 
biodistribution however, all the tissues are separated quickly but some contamination 
can occur. Future work will need to study more biodistribution time points to give 
greater overlay with PET data, thus affording firmer conclusions to be drawn when 
comparing the two techniques. 
 
6.2.1 Biodistribution of MDA-MB-231 tumour bearing mice 
Biodistribution studies were carried out using remaining tumour bearing mice from each 
group [group #1 and #2]. These animals were studied at 15 minutes pi. From group #1, 
one animal was also studied post PET/CT imaging to afford a 74 minute pi data point. 
These results were briefly described earlier when overlaying with PET data, but a fuller 
discussion is given in this section.  
 
6.2.1.0 Results - study #1 / group #1 
([
18
F]44) was delivered in 10% n.d.c. e.o.s. yield from [
18
F]fluoride in 180 minutes at 
61.0 MBq/mL as a phosphate buffer /ethanol solution (9:1; v/v), with specific activity 
0.98 GBq/µmol. 100 µL was injected via the tail vein to each MDA-MB-231 tumour 
bearing mouse (n = 3). The animals were sacrificed at 15 minutes pi and tissues 
dissected for analysis. This preparation of ([
18
F]44) is the same as used in study #2, 
group #1 PET imaging, where the 74 minute pi time point was afforded post-imaging.  
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Time p.i. 
[min] 
15 (n=3) 15 (n=3) 74 74 
 Mean % ID ± SD Mean % ID/g ± SD  % ID % ID/g 
Bone 2.0 ± 0.2 2.1 ± 0.3 4.1 4.3 
Muscle 26.1 ± 1.0 3.3 ±0.3 34.9 4.3 
Blood 5.4 ± 0.6 3.8 ±0.6 6.0 4.1 
Kidneys 1.6 ± 0.2 6.2 ± 0.9 1.7 6.4 
Bladder/urine 0.8 ± 0.2 - 1.6 - 
Lung 1.8 ± 0.0 12.9 ± 0.9 0.9 5.7 
Liver 22.8 ± 1.9 25.5 ± 0.3 7.9 8.5 
Heart 0.4 ± 0.1 4.7 ± 0.5 0.6 5.6 
Brain 1.9 ± 0.2  4.9 ± 0.6 2.4 6.1 
Skin 12.9 ± 0.3 4.7 ± 0.3 16.9 5.9 
Tumour 0.2 ± 0.1 4.7 ± 1.5 0.4 4.2 
Table 6.5: Biodistribution data of MDA-MB-231 tumour bearing mice at 15 minutes (n=3) and 74 
minutes (n=1; post PET/CT scan) pi [group #1]. 
The 15 minute biodistribution of the MDA-MB-231 tumour bearing mice showed 
similar uptake in the tumour and heart (heart 4.7 ± 0.5% ID/g vs tumour 4.7 ± 1.5% 
ID/g; 15 minutes), however binding to the cardiac tissue appeared to be preferred (as the 
SD error is smaller). Uptake in the brain was approximately comparable (4.9 ± 0.6% 
ID/g; 15 minutes). ([
18
F]44) was also present in the lung in high level (12.9 ± 0.9% 
ID/g; 15 minutes) and a large part of the radioactivity was found in the liver (25.5± 
0.3% ID/g; 15 minutes). Interestingly, uptake in the skin (4.7 ± 0.3% ID/g; 15 minutes) 
was higher than seen previously (4.07 ± 0.32% ID/g; näive biodistribution) and bone 
uptake remained the lowest (2.1 ± 0.3% ID/g; 15 minutes), comparable to levels seen 
previously (1.88 ± 0.15% ID/g; näive biodistribution). Blood uptake was used as 
background (3.8 ± 0.6% ID/g). These data showed for this study, only muscle and bone 
exhibited below background concentration of radiotracer. 
At 74 minutes post-imaging, radiotracer concentration in the brain (6.1% ID/g), muscle 
(4.3% ID/g) and heart (5.6% ID/g) showed higher uptake than seen at 15 minutes. 
Whilst uptake in the liver (8.5% ID/g), lung (5.7% ID/g) and tumour (4.2% ID/g) had 
all decreased. No standard error was calculated for these results (n=1 only). (Please 
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note: these data from the 74 minute pi was afforded from an animal not included at 15 
minutes pi.) 
 
6.2.1.1 Discussion 
Overall this study showed uptake in the tumour and heart above blood background (15 
minutes pi). Unfortunately as with the PET data, these results showed that ([
18
F]44) 
does not bind to the neo-natal sodium channel in high concentration. Moreover this 
compound is better at interacting with the adult cardiac sodium channel.  
Clearance of the tracer was seen from the liver, but most tissues exhibited little or no 
clearance showing binding is not reversible.  
 
6.2.1.2 Results - study #2 / group #2 
In the next study, ([
18
F]44) was delivered in 3.7% n.d.c. e.o.s. yield in 150 minutes from 
[
18
F]fluoride, at 57.0 MBq/mL as a phosphate buffer /ethanol solution (9:1 v/v), with 
specific activity 4.0 GBq/µmol (same radiotracer as used for imaging study #3 / group 
#2). 100 µL was injected via the tail vein to each MDA-MB-231 tumour bearing mouse 
(average weight: 54 ± 38 mg) (n = 3). 
Time p.i. [min] 15 (n=3) 15 (n=3) 
 Mean % ID ± SD  Mean % ID/g ± SD  
Bone 1.8 ± 0.3 1.8 ± 0.4  
Muscle 26.8 ± 2.6 3.2 ± 0.4  
Blood 6.8 ± 0.3 4.5 ± 0.3 
Kidneys 1.9 ± 0.1 6.5 ± 0.2 
Bladder/urine 0.9 ± 0.1 - 
Lung 1.5 ± 0.3  9.4 ± 0.8  
Liver 21.5 ± 1.9 23.0 ± 1.9 
Heart 0.6 ± 0.1  5.0 ± 0.3 
Brain 1.9 ± 0.1 5.1 ± 0.2 
Skin 11.7 ± 0.3  4.0 ± 0.2 
Tumour 0.2 ± 0.1 4.3 ± 1.6 
Fat 6.8 ± 2.3 5.0 ± 1.8 
Table 6.6: Biodistribution data of MDA-MB-231 tumour bearing mice at 15 minutes (n=3 / group #2)  
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These biodistribution data showed uptake in the tumour (4.3 ± 1.6% ID/g) to be 
approximately comparable to uptake in the heart (5.0 ± 0.3% ID/g). Uptake in the brain 
was similar (5.1 ± 0.2% ID/g), whilst the radiotracer was concentrated mostly in the 
liver and lung (23.0 0 ± 1.9% and 9.4 ± 0.8% ID/g), respectively. Blood levels were 
used as background (4.5 ± 0.3% ID/g) which indicated that uptake in the skin, bone and 
muscle were below background. 
Time p.i. [min] 15 (n=3) 
Ratio Mean ± SD 
Tumour : Muscle 1.29 ± 0.42 
Tumour : Skin 1.03 ± 0.35 
Tumour : Fat 0.85 ± 0.21 
Table 6.7: Table of tissue ratios at 15 minutes pi 
To gain a better understanding of the significance of radiotracer concentration in the 
tumour, uptake was compared with muscle, skin and fat tissue (Table 6.7). The level of 
radiotracer concentration in the muscle and skin was shown to be lower than the 
tumour, but fat had a higher concentration and with the lowest standard deviation, likely 
to be consistent with non-specific binding.  
6.2.1.3 Discussion 
This biodistribution study afforded radiotracer concentration values at 15 minutes only 
(n=3). A 74 minute time point was not achieved (as was in study #1), as only three 
animals remained for this study. 
These data gave good agreement with the previous biodistribution study (study #1). 
Uptake in the tumour was similar (4.7 ± 1.5% vs. 4.3 ± 1.6% ID/g; study #1 vs study #2) 
while uptake in Study #1 was above blood background (3.8 ± 0.6% ID/g), this study 
showed uptake to be comparable to blood background (4.5 ± 0.3% ID/g). Uptake in the 
tumour (4.3 ± 1.6% ID/g) was higher than levels in the skin (4.0 ± 0.2% ID/g) and 
muscle (3.2 ± 0.4% ID/g), indicating some targeted binding, (as Nav 1.5 is not expressed 
in skin nor muscle tissue). The increased uptake in the fat was likely to be consistent 
with non-specific binding of ([
18
F]44) as it is a particularly lipophilic radiotracer. 
Uptake in the brain (5.1 ± 0.2% ID/g) was higher than the tumour (4.3 ± 1.6% ID/g) but 
comparable to the heart (5.0 ± 0.3% ID/g). High uptake was seen in the liver (23.0 ± 
1.9% ID/g) and lung (9.4 ± 0.8% ID/g) as seen previously at 15 minutes pi. All of these 
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results appear to be common across all the studies, supporting the conclusion that 
([
18
F]44) does not appear to be a good PET tracer for targeting neo-natal Nav 1.5. 
 
6.2.2 Tumour growth and PET imaging of non-metastatic breast tumours  
MCF-7 cells 1 x 10
6
 cells (100 µl) in PBS were inoculated into the inner right thigh of 
six female nude mice. Shortly after, a 60-day slow release estradiol pellet was co-
administered into the nape of the neck (as tumour growth in this model is estradiol 
dependent).
196
 Tumours were allowed to grow for up to six weeks and a maximum size 
of 10 mm. In fact, four tumours grew ranging from 9.0 by 8.1 mm - 5.8 by 3.5 mm. The 
largest tumour was chosen for imaging.  
 
6.2.2.0 Results  
([
18
F]44) was delivered in 3.7% n.d.c. e.o.s. yield from [
18
F]fluoride in 150 minutes at 
57.0 MBq/mL as a phosphate buffer /ethanol solution (9:1 v/v), with specific activity 
2.4 GBq/µmol. 100 µL was injected via the tail vein to a MCF-7 tumour bearing nude 
mouse. 
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Figure 6.14: Dynamic PET image 6-7 minutes pi: ROIs for heart (transverse, coronal and sagittal view, 
white arrow), muscle left and right (coronal view, purple arrow), brain (sagittal view, blue arrow) and 
liver (coronal and sagittal views, yellow arrow). (A) CT image (B) PET/CT image. PET colour indicating 
0.1-7% ID/g 
 
Upon analysis of the PET images, it was seen that the field of view of the PET camera 
was not wide enough to image the thigh (tumour location) and whole body. So the 
tumour image was not captured. It was not possible to see image captures during the 
scanning, so this was not apparent until data analysis. The images of the näive tissues 
are included here for comparison with data from the MDA-MB-231 tumour bearing 
mice.  
At 6-7 minutes pi (Figure 6.14), uptake of ([
18
F]44) was seen in the brain with high 
uptake in the liver. Little uptake is apparent in the heart and muscle. The radiotracer 
appears to have been distributed evenly among most tissues.  
(A) 
(B) 
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Figure 6.15: Dynamic PET image 16-17 minutes pi: ROIs for heart (transverse and coronal view, white 
arrow), muscle left and right (coronal view, purple arrow), brain (sagittal view, blue arrow) and liver 
(coronal and sagittal views, yellow arrow). (A) CT image (B) PET/CT image. PET colour indicating 0.1-
7% ID/g 
 
At 16-17 minutes pi (Figure 6.15), the images appeared similar to those seen at 6-7 
minutes pi. Radiotracer concentration is no-longer present above background in the 
brain, and uptake in the heart remains low. Some clearance from the liver is seen with 
uptake of radioactivity in the bladder appearing (ROI not indicated). 
  
(A) 
(B) 
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Figure 6.16: Dynamic PET image 65-66 minutes pi: ROIs for heart (transverse and coronal view, white 
arrow), muscle left and right (coronal view, purple arrow), and liver (coronal and sagittal views, yellow 
arrow). (A) CT image (B) PET/CT image. PET colour indicating 0.1-7% ID/g 
 
At 65 minutes pi (Figure 6.16), the radiotracer had cleared to the intestines and bladder. 
No activity was seen above background in other tissues.  
An imaging time course (Figure 6.17) was plotted and overlaid with points from a later 
biodistribution study (15 minutes, n=3, Section 6.2.3).  
 
Figure 6.17: PET imaging time course (6-66 minutes, pi) in key tissues (lines) and biodistribution data 
(75 minutes pi; points) of MCF-7 tumour bearing mice. 
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Overall the PET time curve showed clearance from the liver and brain over the 60 
minute imaging, whilst the heart and muscle showed little clearance, indicating little 
reversible uptake. Moreover, the 2 muscle ROIs highlighted, generally showed minimal 
uptake (<3% ID/mL) across all time points. The tumour (3.1% ID/g, 15 minute pi) also 
showed low uptake. Heart uptake (3.9%, 15 minutes pi) was higher than tumour level, 
at the same time point.  
The time course highlighted some similarity with the biodistribution data. For instance, 
the imaging showed uptake in the brain to be higher than in the heart, which 
corroborated well with the biodistribution data. In terms of accuracy of ROIs with 
respect to biodistribution values, the muscle and brain is aligned almost perfectly, while 
the liver and heart level (in the biodistribution) was markedly higher than obtained from 
PET data.  
 
6.2.2.1 Discussion  
The MCF-7 PET images allowed for comparison of radiotracer uptake with the MDA-
MB-231 images (tumour not included). Overall, the images showed a similar profile to 
that seen in the previous imaging study. ([
18
F]44) was concentrated in the brain and 
some heart uptake at early time points, while high uptake is evident in the liver 
throughout the time course. Radiotracer uptake in the liver and brain reverses 
throughout the time course of the imaging, while uptake in the heart and muscle appears 
not to reverse.  
Due to the small field of view of the PET camera which did not allow for imaging of the 
tumour, no further animals were studied via PET/CT imaging.  
The PET time course allowed clearance from tissues to be visualised. Little clearance of 
radiotracer was seen by the heart and muscle, whilst clearance was apparent in the brain 
and liver. Overlay of PET and biodistribution results allowed for comparison of data, 
which showed good corroboration across most tissues.  
  
Chapter 6  Results and Discussion 
225 | P a g e  
 
6.2.3 Biodistribution of MCF-7 tumour bearing mice 
6.2.3.0 Results 
([
18
F]43) was delivered in 3.7% n.d.c. e.o.s. yield from [
18
F]fluoride in 150 minutes at 
57.0 MBq/mL as a phosphate buffer /ethanol solution (9:1 v/v), with specific activity 
2.4 GBq/µmol. 100 µL was injected iv via the tail vein to each MCF-7 tumour bearing 
mouse. The animals were sacrificed at 15 minutes pi and tissues dissected for analysis 
as described in section 2.5.0. An animal was also sacrificed post PET imaging to afford 
a 75 minute time point. 
Tissue 15 mins pi 15 mins pi 75 mins pi 75 mins pi 
 
Mean % ID ± SD Mean % ID/g ± SD % ID % ID/g 
Bone 1.90 ± 0.37 1.46 ± 0.27 3.86 3.00 
Muscle 29.15 ± 1.64 2.61 ± 0.18 31.38 2.83 
Blood 7.08 ± 0.44 3.49 ± 0.18 6.91 3.44 
Kidneys 2.21 ± 0.13  6.70 ± 0.33 2.02 5.24 
Bladder/Urine 0.78 ± 0.08 - 0.63 - 
Lung 1.12 ± 0.04 6.09 ± 0.33 0.76 4.07 
Liver 13.05 ± 1.68 9.55 ± 1.50 7.28 5.3 
Heart 0.60 ± 0.01 4.79 ± 0.26 0.51 4.4 
Brain 2.23 ± 0.38 5.17 ± 0.65 2.13 4.8 
Skin 16.29 ± 0.31 4.18 ± 0.03 18.62 4.82 
Tumour 0.35 ± 0.27 3.07 ± 0.48 1.74 3.8 
Table 6.8: Biodistribution of MCF-7 tumour bearing mice at 15 minutes (n=3) and 75 minutes (n=1; post 
PET/CT scan) 
This study highlighted radiotracer uptake in both the heart and tumour, with the tumour 
showing significantly lower uptake (tumour 3.07 ± 0.48% ID/g vs heart 4.79 ± 0.26% 
ID/g). Interestingly, the animal studied at 75 minutes highlighted an increase in 
radiotracer concentration in the tumour by 0.74% ID/g, whereas some clearance from 
the heart was reported 0.39% ID/g (although there is no standard error reported; n=1). 
The brain had high uptake (5.17 ± 0.65% ID/g) at 15 minutes, which reversed somewhat 
(4.8% ID/g; 75 minutes). Using blood level as background (3.49 ± 0.18% ID/g), 
radiotracer concentration in the muscle and tumour fell below. Interestingly, initial 
uptake in the liver (9.55 ± 1.5% ID/g) was lower than seen in the previous disease 
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model (MDA-MB-231 tumours) which also decreased at the 75 minute time point 
(7.28% ID/g).  
 
6.2.3.1 Discussion 
The low uptake in the tumour with respect to the heart is an encouraging indication. 
Previously, the MDA-MB-231 tumours showed similar or in some data, lower uptake 
compared to the heart, suggesting little difference in binding to the adult and neo-natal 
splice variant. It appears the radiotracer is equally able to bind to both splice variants. It 
was thought that these MCF-7 tumours would show a marked decrease in radiotracer 
uptake compared to the MDA-MB-231 tumours due to low/no expression of the target 
channel (MCF-7 tumour 3.07 ± 0.48% ID/g vs MDA-MB-231 tumour 4.3 ± 1.6% ID/g), 
as was found. The lower uptake in the MCF-7 tumours suggests lower expression of the 
neo-natal Nav 1.5 channel as reported in the literature. Whereas the concentration of 
radiotracer in the heart decreased from 15 to 75 minutes (4.79 ± 0.26% ID/g to 4.4% 
ID/g; in the tumour, a slight increase was reported (3.07 ± 0.48% ID/g to 3.8% ID/g). 
Unusual patterns were also seen during the biodistribution of the MDA-MB-231 
tumours, again it is difficult to tell if these are true increases or whether these values 
would be within error if the study were repeated at this time point. 
  
6.3 Conclusions of Chapter 6 
In summary, this preliminary study into ([
18
F]44) as a PET tracer for imaging sodium 
ion channel activity in metastatic breast cancer, has delivered some interesting, but 
mixed results. Firstly, the cell binding assay indicated some higher binding to the MDA-
MB-231 cells than the MCF-7 cells, as was expected. The specific binding results were 
not encouraging; these data showed there was high non-specific binding. This could 
imply that the concentration of (44) was not high enough, or high binding to cell debris 
was inhibiting blocking. Developing assays is a time consuming process and requires a 
prolonged radiation dose to be received during development, therefore, assay validation 
was not continued and was put forward for future considerations.  
Alongside in vitro work, in vivo inoculations allowed for growth of the two tumour 
types. Initially, this study was for model validation of sodium ion channel expression in 
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IHC experiments, but later developed into an imaging and biodistribution study to 
quantify in vivo uptake in a disease model. Again some mixed but hopeful results were 
produced here. Some tracer uptake was seen in the MDA-MB-231 tumours during 
imaging, however, it was difficult to note uptake above background. Moreover, the 
combined biodistribution studies allowed for quantified uptake in the tumour to be 
recorded. Using blood as background, some uptake in the tumour was noteworthy but 
mainly uptake was below background. 
In comparison with the MCF-7 tumours, the biodistribution here, showed lower uptake 
in the tumours, potentially suggesting a lower expression of target. It would have been 
beneficial to have the tumour images of these animals alongside the MDA-MB-231 
tumour bearing mice, but due to equipment limitations (small camera field of view), it 
was not possible. Encouragingly though, the biodistribution allowed for a positive 
quantitative comparison of the two tumour models.  
Overall, these studies into PET imaging of VGSCs in breast cancer highlighted some 
interesting results. Although ([
18
F]44) was not able to image the MDA-MB-231 
tumours, it was able to highlight the heart, in most images. This suggested that this 
radiotracer is able to bind to the inactivated-state of Nav 1.5 in vivo. Recent studies into 
the sodium currents produced by neo-natal Nav 1.5 in MDA-MB-231 cells, have sought 
to determine which type of sodium current is expressed by these cells. Since 
undertaking this work, Yang et. al., have reported that it is the persistent component of 
the sodium current likely to be predominant in these cells.
56
 The persistent sodium 
current corresponds to the delayed inactivation of Nav 1.5.
197
 VGSCs typically 
inactivate within a few milliseconds of opening following depolarisation, and remain 
inactivated until the membrane repolarises.
198
 Several subtypes, including Nav 1.5, do 
not inactivate completely, they continue to carry a small steady-state persistent sodium 
current at depolarised potentials.
199
 Furthermore, it has been shown that cancer cells 
typically have a more depolarised membrane potential than normal epithelial cells or 
neurones.
200
 Also, the persistent sodium current is more prevalent in hypoxic cells.
201
 
Thus, it has been proposed that the persistent component of the sodium current is likely 
to be predominant in MDA-MB-231 cells.  
When the findings from this report are considered, it now seems likely that ([
18
F]44) 
was not able to bind to neo-natal Nav 1.5, due to the channel remaining activated. It was 
demonstrated that (44) binds preferentially to the inactivated state of the channel, 
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therefore this literature report corroborates our results, that an inactivated state-
dependent VGSC ligand, is not a good ligand for neo-natal Nav 1.5. Importantly, this 
report has highlighted that a fluorine-18 labelled VGSC ligand binding to the activated 
state, would likely be a better VGSC PET tracer. Further work is required to support 
this hypothesis and also determine whether the channels ever inactivate. If it is 
supported that the channels cannot inactivate, then (44) and the 3-(4-R-phenoxy)phenyl 
pyrazoles in general, cannot be used to highlight neo-natal Nav 1.5 in metastatic breast 
cancer.  
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7. Thesis conclusion 
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Overall, this thesis has described some interesting and novel work. This project set out 
to develop a VGSC PET tracer which could highlight sodium channels in metastatic 
cancer. In order to achieve this, the 3-(4-R-phenoxy)phenyl pyrazoles were initially 
studied. Numerous radiolabelling strategies were studied and implemented, but 
unfortunately, these studies could not produce a PET tracer. The main problem was 
identified to be the ether bridge linking the two phenyl rings causing inactivation of the 
ring toward any SNAr substitution for fluorine-18. To overcome this, an ether bridge 
was changed to a thioether bridge. The thioether bridge was oxidised to a sulphone and 
sulphoxide prior to radiolabelling. This change to the structure showed vastly different 
reaction kinetics under radiolabelling conditions. Many products were found but 
unfortunately, no desired product could be identified and the unwanted products could 
not be determined either. Although the 3-(4-((4-R-phenyl)thio)phenyl)-pyrazoles had 
been reported to be potent VGSC ligands, our subsequent electrophysiology studies on 
(25) showed apparent no affinity for VGSCs. Moreover, (9) was shown to be highly 
potent for Nav 1.4 and 1.5, as reported, so analogues of these compounds were prepared 
consequently to these data.  
Thereafter, ([
18
F]41) was afforded by replacing the terminal carboxamide with a 
fluoroethyl chain produced via [
18
F]fluoroethyl tosylate. In vitro electrophysiology 
showed (41) to be a potent state-dependent VGSC ligand. The radiochemistry followed 
a reproducible 2-step procedure where the synthesis of [
18
F]fluoroethyl tosylate was 
afforded using a FX-N Tracerlab™. Following in vivo assessment however, this PET 
tracer was shown to clear within 15 minutes from nearly all tissues. This tracer was not 
studied further following these results. Although in vivo work was not promising, it may 
be interesting to develop this tracer in the future, with a view to improve in vivo 
stability.  
Finally, ([
18
F]44) was produced also in a two-step reproducible procedure. Click 
chemistry was employed to produce high yields and the synthesis of [
18
F]fluoroethyl 
azide was carried out via a GE Healthcare FASTlab™. In vitro assessment of (44) 
identified this compound to be a potent state-dependent VGSC ligand, binding 
specifically to Nav 1.4 and 1.5, with equal potency. In vivo assessment of this compound 
looked promising, high uptake was seen in the heart with good retention and some 
clearance within 2 hours. Little uptake was monitored in the skeletal muscle 
highlighting this compound to more selective for Nav 1.5 (cardiac sodium channel), than 
was expressed by in vitro data. Thereafter, a metabolism study was carried out which 
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showed this PET tracer to have some stability up to 60 minutes with high parent uptake 
apparent in the heart. These näive data were used as a basis for further investigations in 
a disease model.  
The metastatic and non-metastatic cell lines for B Ca were studied. A cell binding assay 
was performed alongside in vivo inoculation of cells into small animals. The cell 
binding assay highlighted a positive difference between binding to the MDA-MB-231 
cells (positive control; express Nav 1.5) and MCF-7 (negative control; little/no 
expression of Nav 1.5). The tumour bearing mice were both PET/CT imaged and 
underwent a biodistribution study to assess uptake in the tumours. In both studies, these 
data did not look promising. Little uptake was seen in the positive control tumours and 
more importantly uptake was not seen above background. The negative control tumours 
did show lower uptake, but the difference was so small it was difficult to infer it as 
significant. During these studies, a report was published to indicate that sodium 
channels in tumour cells exhibit a persistent current causing slow or no inactivation of 
the channels as a result. Our negative results could be explained by this report as our 
compound binds nearly exclusively in the inactivated state. However, further work is 
required to identify these results in more detail and indicate whether there is still some 
inactivation of the channels. 
In summary, this project bordered on a series of different research areas. Chemistry and 
radiochemistry research lead to the generation of two novel potential VGSC PET 
tracers. A series of electrophysiological studies were implemented to identify the 
potency and selectivity of these compounds prior to in vivo assessment. ([
18
F]44) 
appeared the more promising and this PET tracer allowed the project to diversify into 
many areas of in vivo biology. Näive data looked interesting and it was hoped that 
results in our B Ca model would appear the same, but little uptake was reported. 
Nevertheless, this thesis describes the first study into developing a PET tracer for 
imaging sodium ion channels in cancer. VGSCs in cancer although recognised, is still at 
a discovery phase. The kinetic behaviour of these VGSCs for example, is only just 
being established. It now appears that they exhibit a characteristic current which slows 
inactivation. Therefore the key in designing subsequent VGSC PET tracers could be to 
target the persistent current using an activated state-dependent VGSC ligand.  
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This project carried out a number of preliminary studies which require further 
investigations. (44) will need to undergo manual patch clamp studies at much lower 
concentrations than those already tested in order to gain confidence in the IC50 values 
afforded. For completeness and for comparison, the remaining compounds (9) and (41) 
will need to be added to this study. Moreover, the binding studies which we were unable 
to commission will need to be carried out to determine the Bmax and Kd, therefore 
confirming whether the binding potentials for each of the three compounds are indeed 
≥10. This would complete the näive characterisation of these compounds. 
Current reports suggest neo-natal Nav 1.5 exhibits prolonged activation. A study into the 
kinetics of this channel will be required to confirm what state the channel 
predominantly resides in. If that study shows there is no inactivation, then our 
compounds will not be able to bind and a study into activation-dependent ligands will 
be required. If inactivation is present, then completion of ([
18
F]44) studies will be 
necessary.  
In order to complete work in the disease model; the cell binding assay of ([
18
F]44) with 
MDA-MB-231 and MCF-7 cells will need to be repeated with modified conditions, to 
give a reproducible assay with high cell viability count. If these results look interesting, 
then a tumour growth study will need to be commissioned to produce both tumour types 
in good size and over a reasonable time-frame. These tumours will need to undergo IHC 
studies with the neo-natal Nav 1.5 antibody before any further studies could proceed, to 
determine relative expression level of the channel. Previously, an academic 
collaboration was sought, but was not successful in obtaining the anti-body. Therefore, 
the growth of the anti-body would need to be generated in-house. Once the antibody is 
available and the relative expression of neo-natal Nav 1.5 known, PET imaging studies 
could be repeated. For comparison, these animals would need to undergo an [
18
F]FDG 
screen as a control scan to check the tumours could be highlighted.  
In summary, there is still work needed to investigate this area further and moreover, 
determine fully whether ([
18
F]44) is able to highlight metastatic breast cancer.  
 
  
  References 
234 | P a g e  
 
 
 
 
 
 
 
 
 
 
 
 
 
9. References 
  
  References 
235 | P a g e  
 
1. Chanda, B.; Bezanilla, F., J Gen Physiol 2002, 120 (5), 629-645. 
2. Brackenbury, W. J.; Djamgoz, M. B. A., The Journal of Physiology 2006, 573 
(2), 343-356. 
3. Brackenbury, W. J.; Djamgoz, M. B.; Isom, L. L., Neuroscientist 2008, 14 (6), 
571-83. 
4. Bennett, E.; Smith, B.; Harper, J., Pflügers Archiv European Journal of 
Physiology 2004, 447 (6), 908-914. 
5. Grimes, J. A.; Fraser, S. P.; Stephens, G. J.; Downing, J. E. G.; Laniado, M. E.; 
Foster, C. S.; Abel, P. D.; Djamgoz, M. B. A., FEBS Letters 1995, 369 (2-3), 
290-294. 
6. Roger, S.; Besson, P.; Le Guennec, J. Y., Biochim Biophys Acta 2003, 1616 (2), 
107-11. 
7. Yang, J.; Gharagozloo, P.; Yao, J. C.; Ilyin, V. I.; Carter, R. B.; Nguyen, P.; 
Robledo, S.; Woodward, R. M.; Hogenkamp, D. J., J Med Chem 2004, 47 (6), 
1547-1552. 
8. Iversen, L. L., Br J Pharmacol 1971, 41 (4), 571-91. 
9. Ames, A.; Pollen, D. A., Journal of Neurophysiology 1969, 32 (3), 424-42. 
10. Thomas, E. A.; Bornstein, J. C., Neuroscience 2003, 120 (2), 333-351. 
11. Williamson, B. http://www.brianwilliamson.id.au/cit/level1/substance-
K/images/Neurotransmission.gif. 
12. Macdonald, P. E.; Rorsman, P., PLoS Biol 2006, 4 (2), e49. 
13. Barnett, M. W.; Larkman, P. M., Practical Neurology 2007, 7 (3), 192-197. 
14. Hodgkin, A. L.; Huxley, A. F., J Physiol 1952, 117 (4), 500-44. 
15. Mccormick, D. A.; Shu, Y.; Yu, Y., Nature 2007, 445 (7123), E1-E2. 
16. Osorio, N.; Delmas, P., Nat. Protocols 2011, 6 (1), 15-27. 
17. Kyle, D. J.; Ilyin, V. I., Journal of Medicinal Chemistry 2007, 50 (11), 2583-
2588. 
18. Catterall, W. A., Neuron 2000, 26 (1), 13-25. 
19. Goldin, A. L., Annual Review of Physiology 2001, 63, 871-894. 
20. Westenbroek, R. E.; Merrick, D. K.; Catterall, W. A., Neuron 1989, 3 (6), 695-
704. 
21. Westenbroek, R. E.; Noebels, J. L.; Catterall, W. A., Journal of Neuroscience 
1992, 12 (6), 2259-2267. 
  References 
236 | P a g e  
 
22. Caldwell, J. H.; Schaller, K. L.; Lasher, R. S.; Peles, E.; Levinson, S. R., 
Proceedings of the National Academy of Sciences of the United States of 
America 2000, 97 (10), 5616-5620. 
23. Khaliq, Z. M.; Raman, I. M., J Neurosci 2006, 26 (7), 1935-1944. 
24. Gordon, D.; Merrick, D.; Auld, V.; Dunn, R.; Goldin, A. L.; Davidson, N.; 
Catterall, W. A., Proc Natl Acad Sci U S A 1987, 84 (23), 8682-6. 
25. Sasaki, R.; Takano, H.; Kamakura, K.; Kaida, K.; Hirata, A.; Saito, M.; Tanaka, 
H.; Kuzuhara, S.; Tsuji, S., Arch Neurol 1999, 56 (6), 692-696. 
26. Mohler, P. J.; Rivolta, I.; Napolitano, C.; Lemaillet, G.; Lambert, S.; Priori, S. 
G.; Bennett, V., Proceedings of the National Academy of Sciences of the United 
States of America 2004, 101 (50), 17533-17538. 
27. Cohen, S. A., Circulation 1996, 94 (12), 3083-6. 
28. Scriven, D. R.; Dan, P.; Moore, E. D., Biophysical Journal 2000, 79 (5), 2682-
91. 
29. Nassar, M. A.; Stirling, L. C.; Forlani, G.; Baker, M. D.; Matthews, E. A.; 
Dickenson, A. H.; Wood, J. N., Proceedings of the National Academy of 
Sciences of the United States of America 2004, 101 (34), 12706-12711. 
30. Laird, J. M.; Souslova, V.; Wood, J. N.; Cervero, F., Journal of Neuroscience 
2002, 22 (19), 8352-6. 
31. Beneng, K.; Renton, T.; Yilmaz, Z.; Yiangou, Y.; Anand, P., BMC Neuroscience 
2010, 11 (1), 71. 
32. Bubien, J. K.; Keeton, D. A.; Fuller, C. M.; Gillespie, G. Y.; Reddy, A. T.; 
Mapstone, T. B.; Benos, D. J., Am J Physiol Cell Physiol 1999, 276 (6), C1405-
1410. 
33. Sloane, B. F.; Mohamed, M. M., Nat. Rev. Cancer 2006, 6 (10), 764-775. 
34. Bennett, E. S.; Smith, B. A.; Harper, J. M., Pflugers Arch 2004, 447 (6), 908-14. 
35. Grimes, J. A.; Fraser, S. P.; Stephens, G. J.; Downing, J. E. G.; Laniado, M. E.; 
Foster, C. S.; Abel, P. D.; Djamgoz, M. B. A., FEBS Letters 1995, 369 (2-3), 
290-294. 
36. Monk, M.; Holding, C., Oncogene 2001, 20 (56), 8085-91. 
37. Boyerinas, B.; Park, S. M.; Shomron, N.; Hedegaard, M. M.; Vinther, J.; 
Andersen, J. S.; Feig, C.; Xu, J.; Burge, C. B.; Peter, M. E., Cancer Res 2008, 68 
(8), 2587-91. 
38. Onkal, R.; Mattis, J. H.; Fraser, S. P.; Diss, J. K. J.; Shao, D.; Okuse, K.; 
Djamgoz, M. B. A., Journal of Cellular Physiology 2008, 216 (3), 716-726. 
  References 
237 | P a g e  
 
39. Sheets, M. F.; Hanck, D. A., Biophys J 2002, 82 (6), 3048-55. 
40. Henrikson, C. A.; Xue, T.; Dong, P.; Sang, D.; Marban, E.; Li, R. A., J Biol 
Chem 2003, 278 (16), 13647-54. 
41. Chen, T.; Inoue, M.; Sheets, M. F., Am J Physiol Heart Circ Physiol 2005, 288 
(6), H2666-76. 
42. Parkin, D. M.; Pisani, P.; Ferlay, J., Int J Cancer 1999, 80 (6), 827-41. 
43. Wingo, P. A.; Ries, L. A.; Rosenberg, H. M.; Miller, D. S.; Edwards, B. K., 
Cancer 1998, 82 (6), 1197-207. 
44. Fraser, S. P.; Ding, Y.; Liu, A.; Foster, C. S.; Djamgoz, M. B., Cell Tissue Res 
1999, 295 (3), 505-12. 
45. Fraser, S. P.; Salvador, V.; Manning, E. A.; Mizal, J.; Altun, S.; Raza, M.; 
Berridge, R. J.; Djamgoz, M. B., J Cell Physiol 2003, 195 (3), 479-87. 
46. Djamgoz, M. B. A.; Mycielska, M.; Madeja, Z.; Fraser, S. P.; Korohoda, W., J 
Cell Sci 2001, 114 (Pt 14), 2697-705. 
47. Smith, P.; Rhodes, N. P.; Shortland, A. P.; Fraser, S. P.; Djamgoz, M. B. A.; Ke, 
Y. Q.; Foster, C. S., FEBS Letters 1998, 423 (1), 19-24. 
48. Fraser, S. P.; Salvador, V.; Manning, E. A.; Mizal, J.; Altun, S.; Raza, M.; 
Berridge, R. J.; Djamgoz, M. B. A., Journal of Cellular Physiology 2003, 195 
(3), 479-487. 
49. Djamgoz, M. B. A.; Krasowska, M.; Grzywna, Z. J.; Mycielska, M. E., Eur 
Biophys J Biophy 2004, 33 (6), 535-542. 
50. Gao, R.; Wang, J.; Shen, Y.; Lei, M.; Wang, Z., J Huazhong Univ Sci Technolog 
Med Sci 2009, 29 (1), 64-7. 
51. Djamgoz, M. B. A., Febs J 2006, 273, 9-9. 
52. Roger, S.; Potier, M.; Vandier, C.; Besson, P.; Le Guennec, J. Y., Curr Pharm 
Des 2006, 12 (28), 3681-95. 
53. Roger, S.; Rollin, J.; Barascu, A.; Besson, P.; Raynal, P. I.; Iochmann, S.; Lei, 
M.; Bougnoux, P.; Gruel, Y.; Le Guennec, J. Y., Int J Biochem Cell Biol 2007, 
39 (4), 774-86. 
54. Roger, S.; Brisson, L.; Gillet, L.; Calaghan, S.; Besson, P.; Le Guennec, J. Y.; 
Gore, J., Oncogene 2011, 30 (17), 2070-2076. 
55. Fraser, S. P.; Pardo, L. A., Embo Rep 2008, 9 (6), 512-515. 
56. Yang, M.; Kozminski, D. J.; Wold, L. A.; Modak, R.; Calhoun, J. D.; Isom, L. 
L.; Brackenbury, W. J., Breast Cancer Res Treat 2012, 134 (2), 603-15. 
  References 
238 | P a g e  
 
57. Chioni, A. M.; Brackenbury, W. J.; Calhoun, J. D.; Isom, L. L.; Djamgoz, M. B., 
Int J Biochem Cell Biol 2009, 41 (5), 1216-27. 
58. Diss, J. K.; Fraser, S. P.; Djamgoz, M. B., Eur Biophys J 2004, 33 (3), 180-93. 
59. Gillet, L.; Roger, S.; Besson, P.; Lecaille, F.; Gore, J.; Bougnoux, P.; 
Lalmanach, G.; Le Guennec, J. Y., J Biol Chem 2009, 284 (13), 8680-91. 
60. Jemal, A.; Siegel, R.; Ward, E.; Murray, T.; Xu, J.; Smigal, C.; Thun, M. J., CA: 
A Cancer Journal for Clinicians 2006, 56 (2), 106-130. 
61. Laniado, M. E.; Lalani, E. N.; Fraser, S. P.; Grimes, J. A.; Bhangal, G.; 
Djamgoz, M. B.; Abel, P. D., Am J Pathol 1997, 150 (4), 1213-21. 
62. Fraser, S. P.; Diss, J. K. J.; Chioni, A.-M.; Mycielska, M. E.; Pan, H.; Yamaci, 
R. F.; Pani, F.; Siwy, Z.; Krasowska, M.; Grzywna, Z.; Brackenbury, W. J.; 
Theodorou, D.; Koyutürk, M.; Kaya, H.; Battaloglu, E.; De Bella, M. T.; Slade, 
M. J.; Tolhurst, R.; Palmieri, C.; Jiang, J.; Latchman, D. S.; Coombes, R. C.; 
Djamgoz, M. B. A., Clinical Cancer Research 2005, 11 (15), 5381-5389. 
63. Diss, J. K.; Archer, S. N.; Hirano, J.; Fraser, S. P.; Djamgoz, M. B., Prostate 
2001, 48 (3), 165-78. 
64. Diss, J. K.; Stewart, D.; Fraser, S. P.; Black, J. A.; Dib-Hajj, S.; Waxman, S. G.; 
Archer, S. N.; Djamgoz, M. B., FEBS Lett 1998, 427 (1), 5-10. 
65. Diss, J. K. J.; Archer, S. N.; Hirano, J.; Fraser, S. P.; Djamgoz, M. B. A., 
Prostate 2001, 48 (3), 165-178. 
66. Anderson, J. D.; Hansen, T. P.; Lenkowski, P. W.; Walls, A. M.; Choudhury, I. 
M.; Schenck, H. A.; Friehling, M.; Höll, G. M.; Patel, M. K.; Sikes, R. A.; 
Brown, M. L., Molecular Cancer Therapeutics 2003, 2 (11), 1149-1154. 
67. Fidler, I. J., Nature Reviews Cancer 2003, 3 (6), 453-458. 
68. Brackenbury, W. J.; Djamgoz, M. B., J Cell Physiol 2007, 210 (3), 602-8. 
69. Russell, P. J.; Bennett, S.; Stricker, P., Clin Chem 1998, 44 (4), 705-23. 
70. Gann, P. H.; Klein, K. G.; Chatterton, R. T.; Ellman, A. E.; Grayhack, J. T.; 
Nadler, R. B.; Lee, C., Prostate 1999, 40 (4), 248-55. 
71. Uysal-Onganer, P.; Djamgoz, M. B., Mol Cancer 2007, 6, 76. 
72. Ding, Y.; Brackenbury, W. J.; Onganer, P. U.; Montano, X.; Porter, L. M.; 
Bates, L. F.; Djamgoz, M. B., J Cell Physiol 2008, 215 (1), 77-81. 
73. Montano, X.; Djamgoz, M. B., FEBS Lett 2004, 571 (1-3), 1-8. 
74. Ferlay, J.; Shin, H. R.; Bray, F.; Forman, D.; Mathers, C.; Parkin, D. M., Int J 
Cancer 2010, 127 (12), 2893-917. 
75. Roden, R.; Wu, T. C., Nat Rev Cancer 2006, 6 (10), 753-63. 
  References 
239 | P a g e  
 
76. Hernandez-Plata, E.; Ortiz, C. S.; Marquina-Castillo, B.; Medina-Martinez, I.; 
Alfaro, A.; Berumen, J.; Rivera, M.; Gomora, J. C., Int J Cancer 2012, 130 (9), 
2013-23. 
77. Diss, J. K.; Fraser, S. P.; Walker, M. M.; Patel, A.; Latchman, D. S.; Djamgoz, 
M. B., Prostate Cancer Prostatic Dis 2008, 11 (4), 325-33. 
78. Lin, X. A.; Ren, J. L.; Huo, J. F.; Zhang, J. B.; Wang, X. B., Nucl Med Biol 
2010, 37 (6), 702-702. 
79. Lin, Y.; Yang, W. J.; Zhang, X. Z.; Zhang, J. B.; Tang, Z. G., Nucl Med Biol 
2010, 37 (6), 701-702. 
80. Fowler, J., J Nucl Med 2002, 43 (1), 20N-+. 
81. Fowler, J. E.; Bigler, S. A.; Farabaugh, P. B., Cancer 2002, 94 (6), 1661-1667. 
82. Fowler, J. S.; Ido, T., Semin Nucl Med 2002, 32 (1), 6-12. 
83. Fowler, J. S.; Volkow, N. D.; Wang, G. J.; Logan, J., Abstr Pap Am Chem S 
2002, 223, B151-B151. 
84. Hao, G. Y.; Singh, A. N.; Liu, W.; Sun, X. K., Curr Top Med Chem 2010, 10 
(11), 1096-1112. 
85. Love, C.; Din, A. S.; Tomas, M. B.; Kalapparambath, T. P.; Palestro, C. J., 
Radiographics 2003, 23 (2), 341-58. 
86. Schnall, M.; Rosen, M., J Clin Oncol 2006, 24 (20), 3225-33. 
87. Hayes, D. F., Ann Oncol 1993, 4 (10), 807-19. 
88. Barentsz, J.; Takahashi, S.; Oyen, W.; Mus, R.; De Mulder, P.; Reznek, R.; 
Oudkerk, M.; Mali, W., J Clin Oncol 2006, 24 (20), 3234-44. 
89. Von Schulthess, G. K.; Steinert, H. C.; Hany, T. F., Radiology 2006, 238 (2), 
405-22. 
90. Rohren, E. M.; Turkington, T. G.; Coleman, R. E., Radiology 2004, 231 (2), 
305-32. 
91. Mariani, G.; Bruselli, L.; Kuwert, T.; Kim, E.; Flotats, A.; Israel, O.; Dondi, M.; 
Watanabe, N., Eur J Nucl Med Mol I 2010, 37 (10), 1959-1985. 
92. Rosenthal, M. S.; Cullom, J.; Hawkins, W.; Moore, S. C.; Tsui, B. M. W.; 
Yester, M., J Nucl Med 1995, 36 (8), 1489-1513. 
93. Smith, S. V., Journal of Inorganic Biochemistry 2004, 98 (11), 1874-1901. 
94. Wolf, A. P., Clinical Neuropharmacology 1984, 7, S284. 
95. Snm What is PET. http://interactive.snm.org/index.cfm?PageID=972. 
  References 
240 | P a g e  
 
96. Young, H.; Baum, R.; Cremerius, U.; Herholz, K.; Hoekstra, O.; Lammertsma, 
A. A.; Pruim, J.; Price, P., European Journal of Cancer 1999, 35 (13), 1773-
1782. 
97. Young, H.; Baum, R.; Cremerius, U.; Herholz, K.; Hoekstra, O.; Lammertsma, 
A. A.; Pruim, J.; Price, P., Eur J Cancer 1999, 35 (13), 1773-82. 
98. Liu, X. D.; Laforest, R., Nucl Med Biol 2009, 36 (5), 551-559. 
99. Ido, T.; Wan, C. N.; Fowler, J. S.; Wolf, A. P., J Org Chem 1977, 42 (13), 2341-
2342. 
100. Medscape PET case cavalcade, Case X. 
http://www.medscape.com/viewarticle/477469&usg=__p-
irQ_NwoCS0djY6CR7LAtifQko=&h=579&w=400&sz=31&hl=en&start=19&z
oom=1&tbnid=NYDMXJU233iykM:&tbnh=134&tbnw=93&prev=/images%3F
q%3DFDG%2BPET%2Bimage%26hl%3Den%26sa%3DX%26rls%3Dcom.mic
rosoft:en-gb:IE-
SearchBox%26rlz%3D1I7GZAZ_en%26biw%3D1259%26bih%3D599%26tbs
%3Disch:10%2C485&itbs=1&iact=hc&vpx=332&vpy=234&dur=1938&hovh=
270&hovw=187&tx=107&ty=293&ei=pending&oei=s7_0TKyVHIGGhQeJ5rX
CBQ&esq=2&page=2&ndsp=19&ved=1t:429,r:14,s:19&biw=1259&bih=599. 
101. Mosconi, L.; Berti, V.; Glodzik, L.; Pupi, A.; De Santi, S.; De Leon, M. J., 
Journal of Alzheimer's Disease 2010, 20 (3), 843-854. 
102. Foster, N. L.; Heidebrink, J. L.; Clark, C. M.; Jagust, W. J.; Arnold, S. E.; 
Barbas, N. R.; Decarli, C. S.; Scott Turner, R.; Koeppe, R. A.; Higdon, R.; 
Minoshima, S., Brain 2007, 130 (10), 2616-2635. 
103. Johnson, K. A.; Dickerson, B. C., Neurology 2011, 77 (23), 2008-2009. 
104. Herholz, K.; Westwood, S.; Haense, C.; Dunn, G., J Nucl Med 2011, 52 (8), 
1218-1226. 
105. Zhou, J.; Greicius, M. D.; Gennatas, E. D.; Growdon, M. E.; Jang, J. Y.; 
Rabinovici, G. D.; Kramer, J. H.; Weiner, M.; Miller, B. L.; Seeley, W. W., 
Brain 2010, 133 (5), 1352-1367. 
106. Lin, K. J.; Hsu, W. C.; Hsiao, I. T.; Wey, S. P.; Jin, L. W.; Skovronsky, D.; Wai, 
Y. Y.; Chang, H. P.; Lo, C. W.; Yao, C. H.; Yen, T. C.; Kung, M. P., Nucl Med 
Biol 2010, 37 (4), 497-508. 
107. Lilly, E. FDA Approves Amyvid™ (Florbetapir F 18 Injection) for Use in 
Patients Being Evaluated for Alzheimer's Disease and Other Causes of Cognitive 
Decline. http://www.prnewswire.com/news-releases/fda-approves-amyvid-
  References 
241 | P a g e  
 
florbetapir-f-18-injection-for-use-in-patients-being-evaluated-for-alzheimers-
disease-and-other-causes-of-cognitive-decline-
146497155.html?utm_source=twitterfeed&utm_medium=twitter. 
108. Ametamey, S. M.; Samnick, S.; Leenders, K. L.; Vontobel, P.; Quack, G.; 
Parsons, C. G.; Schubiger, P. A., J Recept Signal Tr R 1999, 19 (1-4), 129-141. 
109. Robins, E. G.; Zhao, Y.; Khan, I.; Wilson, A.; Luthra, S. K.; Arstad, E., Bioorg 
Med Chem Lett 2010, 20 (5), 1749-1751. 
110. Labas, R.; Gilbert, G.; Nicole, O.; Dhilly, M.; Abbas, A.; Tirel, O.; Buisson, A.; 
Henry, J.; Barre, L.; Debruyne, D.; Sobrio, F., Eur J Med Chem 2011, 46 (6), 
2295-309. 
111. Hille, B., J Gen Physiol 1977, 69 (4), 497-515. 
112. Lagan, G.; Mclure, H. A., Current Anaesthesia & Critical Care 2004, 15 (4-5), 
247-254. 
113. Ruetsch, Y. a. B. T. B. A., Curr Top Med Chem 2001, 1, 175-182. 
114. Lima, M. S. D.; Soares, B. G. D. O.; Reisser, A. a. P.; Farrell, M., Addiction 
2002, 97 (8), 931-949. 
115. Tayama, M.; Solomon, S. B.; Glantz, S. A., Am J Physiol 1998, 274 (6 Pt 2), 
H2100-9. 
116. Langenfeld, H.; Weirich, J.; Kohler, C.; Kochsiek, K., J Cardiovasc Pharmacol 
1990, 15 (2), 338-45. 
117. Fiske, J. L.; Fomin, V. P.; Brown, M. L.; Duncan, R. L.; Sikes, R. A., Cancer 
and Metastasis Reviews 2006, 25 (3), 493-500. 
118. Hwang, D.; Noguchi, T., Tetrodotoxin Poisoning. In Advances in Food and 
Nutrition Research, Steve, L. T., Ed. Academic Press: 2007; Vol. Volume 52, pp 
141-236. 
119. Kishi, Y.; Aratani, M.; Fukuyama, T.; Nakatsubo, F.; Goto, T.; Inoue, S.; 
Tanino, H.; Sugiura, S.; Kakoi, H., J Am Chem Soc 1972, 94 (26), 9217-9219. 
120. Jover, E.; Massacrier, A.; Cau, P.; Martin, M. F.; Couraud, F., J Biol Chem 
1988, 263 (3), 1542-8. 
121. Lombet, A.; Bidard, J.-N.; Lazdunski, M., FEBS Letters 1987, 219 (2), 355-359. 
122. Lipkind, G. M.; Fozzard, H. A., Biophys J 1994, 66 (1), 1-13. 
123. Qu, Y.; Rogers, J.; Tanada, T.; Scheuer, T.; Catterall, W. A., P Natl Acad Sci 
USA 1995, 92 (25), 11839-11843. 
124. Vianna-Jorge, R.; Oliveira, C. F.; Ponte, C. G.; Suarez-Kurtz, G., Eur J 
Pharmacol 2001, 428 (1), 45-49. 
  References 
242 | P a g e  
 
125. Wanner, S. G.; Glossmann, H.; Knaus, H.-G.; Baker, R.; Parsons, W.; 
Rupprecht, K. M.; Brochu, R.; Cohen, C. J.; Schmalhofer, W.; Smith, M.; 
Warren, V.; Garcia, M. L.; Kaczorowski, G. J., Biochemistry-Us 1999, 38 (34), 
11137-11146. 
126. Palmer, R. A.; Potter, B. S.; Leach, M. J.; Jenkins, T. C.; Chowdhry, B. Z., 
MedChemComm 2010, 1 (1), 45-49. 
127. Shao, B.; Victory, S.; Ilyin, V. I.; Goehring, R. R.; Sun, Q.; Hogenkamp, D.; 
Hodges, D. D.; Islam, K.; Sha, D.; Zhang, C. W.; Nguyen, P.; Robledo, S.; 
Sakellaropoulos, G.; Carter, R. B., J Med Chem 2004, 47 (17), 4277-4285. 
128. Ramu, K.; Lam, G. N.; Hughes, H., Drug Metab Dispos 2000, 28 (10), 1153-
1161. 
129. Patel, S.; Gibson, R., Nucl Med Biol 2008, 35 (8), 805-15. 
130. Laruelle, M.; Slifstein, M.; Huang, Y., Mol Imaging Biol 2003, 5 (6), 363-75. 
131. Dimmock, J. R.; Puthucode, R. N.; Smith, J. M.; Hetherington, M.; Quail, J. W.; 
Pugazhenthi, U.; Lechler, T.; Stables, J. P., J Med Chem 1996, 39 (20), 3984-97. 
132. Akiko, O.; Katsuya, M.; Hideaki, O.; Noriyuki, Y., Synthetic Communications: 
An International Journal for Rapid Communication of Synthetic Organic 
Chemistry 2007, 37 (16), 2701 - 2715. 
133. Thomas, L.; Johannes, E.; Heinz, H. C., Nucl Med Biol 2002, 29 (2), 255-262. 
134. Stang, P. J., Angewandte Chemie International Edition in English 1992, 31 (3), 
274-285. 
135. Kamierczak, P.; Skulski, L., Synthesis 1995, 1995 (08), 1027,1032. 
136. Sperotto, E.; De Vries, J. G.; Van Klink, G. P. M.; Van Koten, G., Tetrahedron 
Letters 2007, 48 (41), 7366-7370. 
137. Glaser, M.; Årstad, E., Bioconjugate Chemistry 2007, 18 (3), 989-993. 
138. Constanti, A.; Bagetta, G.; Libri, V., Neuroscience 1993, 56 (4), 887-904. 
139. Bergman, J.; Solin, O., Nucl Med Biol 1997, 24 (7), 677-683. 
140. Toorongian, S. A.; Mulholland, G. K.; Jewett, D. M.; Bachelor, M. A.; Kilbourn, 
M. R., International Journal of Radiation Applications and Instrumentation. 
Part B. Nuclear Medicine and Biology 1990, 17 (3), 273-279. 
141. Arstad, E. L., Gb), 2009. 
142. Chirakal, R., Nucl Med Biol 1996, 23, 41-45. 
143. Nahmias, R. C. G. C. G. F. G. J. S. C., Nucl Med Biol 1996, 23, 41-45. 
  References 
243 | P a g e  
 
144. Coenen, H. H.; Elsinga, P. H.; Iwata, R.; Kilbourn, M. R.; Pillai, M. R. A.; 
Rajan, M. G. R.; Wagner, H. N.; Zaknun, J. J., Nucl Med Biol 2010, 37 (7), 727-
740. 
145. Blom, E.; Karimi, F.; Långström, B., Journal of Labelled Compounds and 
Radiopharmaceuticals 2009, 52 (12), 504-511. 
146. El Kazzouli, S.; Koubachi, J.; Berteina-Raboin, S.; Mouaddib, A.; Guillaumet, 
G., Tetrahedron Letters 2006, 47 (48), 8575-8577. 
147. Merritt, E. A.; Carneiro, V. M.; Silva, L. F., Jr.; Olofsson, B., J Org Chem 2010, 
75 (21), 7416-9. 
148. Papoutsi, I.; Spyroudis*, S.; Varvoglis*, A.; Raptopoulou, C. P., Tetrahedron 
1997, 53 (17), 6097-6112. 
149. Ludwig, T.; Ermert, J.; Coenen, H. H., Nucl Med Biol 2002, 29 (2), 255-262. 
150. Journal of Labelled Compounds and Radiopharmaceuticals 1997, 40 (1), 1-72. 
151. Pews, R. G.; Tsuno, Y.; Taft, R. W., J Am Chem Soc 1967, 89 (10), 2391-2396. 
152. Ermert, J.; Hocke, C.; Ludwig, T.; Gail, R.; Coenen, H. H., J Labelled Compd 
Rad 2004, 47 (7), 429-441. 
153. Berridge, M.; Crouzel, C.; Comar, D., J Labelled Compd Rad 1982, 19 (11-1), 
1639-1640. 
154. Lemaire, C.; Guillaume, M.; Christiaens, L.; Palmer, A. J.; Cantineau, R., Appl 
Radiat Isotopes 1987, 38 (12), 1033-1038. 
155. Karramkam, M.; Hinnen, F.; Bramoulle, Y.; Jubeau, S.; Dolle, F., J Labelled 
Compd Rad 2002, 45 (13), 1103-1113. 
156. Journal of Labelled Compounds and Radiopharmaceuticals 1995, 37 (6), 510-
612. 
157. Maeda, M.; Fukumura, T.; Kojima, M., Appl Radiat Isotopes 1987, 38 (4), 307-
310. 
158. Martin-Santamaria, S.; Carroll, M. A.; Carroll, C. M.; Carter, C. D.; Pike, V. W.; 
Rzepa, H. S.; Widdowson, D. A., Chemical Communications 2000,  (8), 649-
650. 
159. Shah, A.; W. Pike, V.; A. Widdowson, D., Journal of the Chemical Society, 
Perkin Transactions 1 1998,  (13), 2043-2046. 
160. Ermert, J.; Hocke, C.; Ludwig, T.; Gail, R.; Coenen, H. H., Journal of Labelled 
Compounds and Radiopharmaceuticals 2004, 47 (7), 429-441. 
161. W. Pike, V.; Butt, F.; Shah, A.; A. Widdowson, D., Journal of the Chemical 
Society, Perkin Transactions 1 1999,  (3), 245-248. 
  References 
244 | P a g e  
 
162. Barriga, S., Synlett 2001,  (4), 563-563. 
163. Hogenkamp, D., 6414011B1, 2002. 
164. Liu G., S. H. L., Szczepankiewicz B. G., Xin A., Zhao H., Serby M. D., Liu B., 
Liu, M., 2006. 
165. Elmaleh D. R., F. a. J., Shoup T. M.,, 2008. 
166. Royeck, M.; Horstmann, M.-T.; Remy, S.; Reitze, M.; Yaari, Y.; Beck, H., 
Journal of Neurophysiology 2008, 100 (4), 2361-2380. 
167. Whalley, B. J.; Wilkinson, J. D.; Williamson, E. M.; Constanti, A., Neuroscience 
Letters 2004, 365 (1), 58-63. 
168. Schwabe, K.; Ebert, U.; Löscher, W., Neuroscience 2004, 126 (3), 727-741. 
169. Sheldon, R. S.; Duff, H. J.; Thakore, E.; Hill, R. J., J Pharmacol Exp Ther 1994, 
268 (1), 187-94. 
170. Arstad, E., 2008/152109, 2008. 
171. Elsinga, P. H.; Kawamura, K.; Kobayashi, T.; Tsukada, H.; Senda, M.; 
Vaalburg, W.; Ishiwata, K., Synapse 2002, 43 (4), 259-267. 
172. Lu, S.-Y.; Chin, F. T.; Mccarron, J. A.; Pike, V. W., Journal of Labelled 
Compounds and Radiopharmaceuticals 2004, 47 (5), 289-297. 
173. Hara, T.; Kosaka, N.; Kishi, H., J Nucl Med 2002, 43 (2), 187-199. 
174. Bauman, A.; Piel, M.; Schirrmacher, R.; Rösch, F., Tetrahedron Lett 2003, 44 
(51), 9165-9167. 
175. Schmitz, A.; Shiue, C. Y.; Feng, Q.; Shiue, G. G.; Deng, S.; Pourdehnad, M. T.; 
Schirrmacher, R.; Vatamaniuk, M.; Doliba, N.; Matschinsky, F.; Wolf, B.; 
Rösch, F.; Naji, A.; Alavi, A. A., Nucl Med Biol 2004, 31 (4), 483-491. 
176. Hogenkamp, D. J., Upasani, C. A, Nguyen P.,, 2000. 
177. Block, D.; Coenen, H. H.; Stöcklin, G., Journal of Labelled Compounds and 
Radiopharmaceuticals 1987, 24 (9), 1029-1042. 
178. Hoigebazar, L.; Jeong, J. M.; Hong, M. K.; Kim, Y. J.; Lee, J. Y.; Shetty, D.; 
Lee, Y.-S.; Lee, D. S.; Chung, J.-K.; Lee, M. C., Bioorgan Med Chem 2011, 19 
(7), 2176-2181. 
179. Huang, Y.; Hwang, D. R.; Narendran, R.; Sudo, Y.; Chatterjee, R.; Bae, S. A.; 
Mawlawi, O.; Kegeles, L. S.; Wilson, A. A.; Kung, H. F.; Laruelle, M., J Cereb 
Blood Flow Metab 2002, 22 (11), 1377-98. 
180. Samnick, S.; Ametamey, S.; Leenders, K. L.; Vontobel, P.; Quack, G.; Parsons, 
C. G.; Neu, H.; Schubiger, P. A., Nucl Med Biol 1998, 25 (4), 323-30. 
181. Peterson, L. B.; Blagg, B. S., Bioorg Med Chem Lett 2010, 20 (13), 3957-60. 
  References 
245 | P a g e  
 
182. Evans, R. A., Australian Journal of Chemistry 2007, 60 (6), 384-395. 
183. Kolb, H. C.; Finn, M. G.; Sharpless, K. B., Angewandte Chemie International 
Edition 2001, 40 (11), 2004-2021. 
184. Hein, C. D.; Liu, X. M.; Wang, D., Pharm Res 2008, 25 (10), 2216-30. 
185. Kolb, H. C.; Finn, M. G.; Sharpless, K. B., Angew Chem Int Ed Engl 
2001, 40 (11), 2004-2021. 
186. Katz, E.; Willner, I., Angew Chem Int Ed Engl 2004, 43 (45), 6042-108. 
187. Straub, B. F., Chem Commun (Camb) 2007,  (37), 3868-70. 
188. Iddon, L.; Leyton, J.; Indrevoll, B.; Glaser, M.; Robins, E. G.; George, A. J. T.; 
Cuthbertson, A.; Luthra, S. K.; Aboagye, E. O., Bioorganic &amp; Medicinal 
Chemistry Letters 2011, 21 (10), 3122-3127. 
189. Djamgoz, M. B. A., Iubmb Life 2009, 61 (3), 298-298. 
190. Djamgoz, M. B. A.; Brackenbury, W. J.; Chioni, A. M.; Diss, J. K. J., Breast 
Cancer Res Tr 2007, 101 (2), 149-160. 
191. Grönroos, T.; Eskola, O.; Lehtiö, K.; Minn, H.; Marjamäki, P.; Bergman, J.; 
Haaparanta, M.; Forsback, S.; Solin, O., J Nucl Med 2001, 42 (9), 1397-1404. 
192. Brunner, M.; Langer, O.; Dobrozemsky, G.; Müller, U.; Zeitlinger, M.; 
Mitterhauser, M.; Wadsak, W.; Dudczak, R.; Kletter, K.; Müller, M., 
Antimicrobial Agents and Chemotherapy 2004, 48 (10), 3850-3857. 
193. Tang, G.; Wang, M.; Tang, X.; Luo, L.; Gan, M., Appl Radiat Isotopes 2003, 58 
(2), 219-225. 
194. Fraser, S. P.; Diss, J. K.; Chioni, A. M.; Mycielska, M. E.; Pan, H.; Yamaci, R. 
F.; Pani, F.; Siwy, Z.; Krasowska, M.; Grzywna, Z.; Brackenbury, W. J.; 
Theodorou, D.; Koyuturk, M.; Kaya, H.; Battaloglu, E.; De Bella, M. T.; Slade, 
M. J.; Tolhurst, R.; Palmieri, C.; Jiang, J.; Latchman, D. S.; Coombes, R. C.; 
Djamgoz, M. B., Clin Cancer Res 2005, 11 (15), 5381-9. 
195. In Vivo Biology Team, S. U., Hoppmann, S., Ed. 2012. 
196. Gottardis, M. M.; Robinson, S. P.; Jordan, V. C., Journal of Steroid 
Biochemistry 1988, 30 (1–6), 311-314. 
197. Letienne, R.; Bel, L.; Bessac, A. M.; Vacher, B.; Le Grand, B., Eur J Pharmacol 
2009, 624 (1-3), 16-22. 
198. Crill, W. E., Annu Rev Physiol 1996, 58, 349-62. 
199. Ju, Y. K.; Saint, D. A.; Gage, P. W., J Physiol 1996, 497 ( Pt 2), 337-47. 
200. Kunzelmann, K., J Membr Biol 2005, 205 (3), 159-73. 
  References 
246 | P a g e  
 
201. Hammarström, A.; Gage, P., European Biophysics Journal 2002, 31 (5), 323-
330. 
 
 
 
 
